id	sid	tid	token	lemma	pos
dpc-4194	1	1	dermatology	dermatology	NOUN
dpc-4194	1	2	:	:	PUNCT
dpc-4194	1	3	practical	practical	ADJ
dpc-4194	1	4	and	and	CCONJ
dpc-4194	1	5	conceptual	conceptual	ADJ
dpc-4194	1	6	original	original	ADJ
dpc-4194	1	7	article	article	NOUN
dpc-4194	1	8	|	|	ADV
dpc-4194	1	9	dermatol	dermatol	ADJ
dpc-4194	1	10	pract	pract	NOUN
dpc-4194	1	11	concept	concept	NOUN
dpc-4194	1	12	.	.	PUNCT
dpc-4194	2	1	2024;14(2):e2024052	2024;14(2):e2024052	NUM
dpc-4194	2	2	1	1	NUM
dpc-4194	2	3	bimekizumab	bimekizumab	NOUN
dpc-4194	2	4	for	for	ADP
dpc-4194	2	5	the	the	DET
dpc-4194	2	6	treatment	treatment	NOUN
dpc-4194	2	7	of	of	ADP
dpc-4194	2	8	plaque	plaque	NOUN
dpc-4194	2	9	psoriasis	psoriasis	NOUN
dpc-4194	2	10	with	with	ADP
dpc-4194	2	11	involvement	involvement	NOUN
dpc-4194	2	12	of	of	ADP
dpc-4194	2	13	genitalia	genitalia	NOUN
dpc-4194	2	14	:	:	PUNCT
dpc-4194	2	15	a	a	DET
dpc-4194	2	16	16	16	NUM
dpc-4194	2	17	-	-	PUNCT
dpc-4194	2	18	week	week	NOUN
dpc-4194	2	19	multicenter	multicenter	NOUN
dpc-4194	2	20	real	real	ADJ
dpc-4194	2	21	-	-	PUNCT
dpc-4194	2	22	world	world	NOUN
dpc-4194	2	23	experience	experience	NOUN
dpc-4194	2	24	—	—	PUNCT
dpc-4194	2	25	il	il	PROPN
dpc-4194	2	26	pso	pso	PROPN
dpc-4194	2	27	(	(	PUNCT
dpc-4194	2	28	italian	italian	ADJ
dpc-4194	2	29	landscape	landscape	NOUN
dpc-4194	2	30	psoriasis	psoriasis	NOUN
dpc-4194	2	31	)	)	PUNCT
dpc-4194	2	32	diego	diego	PROPN
dpc-4194	2	33	orsini1	orsini1	PROPN
dpc-4194	2	34	,	,	PUNCT
dpc-4194	2	35	piergiorgio	piergiorgio	PROPN
dpc-4194	2	36	malagoli2	malagoli2	PROPN
dpc-4194	2	37	,	,	PUNCT
dpc-4194	2	38	anna	anna	PROPN
dpc-4194	2	39	balato3	balato3	PROPN
dpc-4194	2	40	,	,	PUNCT
dpc-4194	2	41	luca	luca	PROPN
dpc-4194	2	42	bianchi4	bianchi4	PROPN
dpc-4194	2	43	,	,	PUNCT
dpc-4194	2	44	pina	pina	NOUN
dpc-4194	2	45	brianti5	brianti5	PROPN
dpc-4194	2	46	,	,	PUNCT
dpc-4194	2	47	dario	dario	PROPN
dpc-4194	2	48	 	 	SPACE
dpc-4194	2	49	buononato3	buononato3	PROPN
dpc-4194	2	50	,	,	PUNCT
dpc-4194	2	51	martina	martina	PROPN
dpc-4194	2	52	burlando6	burlando6	PROPN
dpc-4194	2	53	,	,	PUNCT
dpc-4194	2	54	giacomo	giacomo	NOUN
dpc-4194	2	55	caldarola7,8	caldarola7,8	PROPN
dpc-4194	2	56	,	,	PUNCT
dpc-4194	2	57	anna	anna	PROPN
dpc-4194	2	58	campanati9	campanati9	PROPN
dpc-4194	2	59	,	,	PUNCT
dpc-4194	2	60	elena	elena	PROPN
dpc-4194	2	61	 	 	SPACE
dpc-4194	2	62	campione4	campione4	PROPN
dpc-4194	2	63	,	,	PUNCT
dpc-4194	2	64	carlo	carlo	PROPN
dpc-4194	2	65	g.	g.	PROPN
dpc-4194	2	66	carrera10	carrera10	PROPN
dpc-4194	2	67	,	,	PUNCT
dpc-4194	2	68	andrea	andrea	PROPN
dpc-4194	2	69	carugno11,12	carugno11,12	PROPN
dpc-4194	2	70	,	,	PUNCT
dpc-4194	2	71	francesco	francesco	PROPN
dpc-4194	2	72	cusano13	cusano13	PROPN
dpc-4194	2	73	,	,	PUNCT
dpc-4194	2	74	paolo	paolo	PROPN
dpc-4194	2	75	 	 	SPACE
dpc-4194	2	76	dapavo14	dapavo14	PROPN
dpc-4194	2	77	,	,	PUNCT
dpc-4194	2	78	annunziata	annunziata	PROPN
dpc-4194	2	79	dattola15	dattola15	PROPN
dpc-4194	2	80	,	,	PUNCT
dpc-4194	2	81	clara	clara	PROPN
dpc-4194	2	82	de	de	PROPN
dpc-4194	2	83	simone7,8	simone7,8	PROPN
dpc-4194	2	84	,	,	PUNCT
dpc-4194	2	85	valentina	valentina	NOUN
dpc-4194	2	86	dini16	dini16	PROPN
dpc-4194	2	87	,	,	PUNCT
dpc-4194	2	88	maria	maria	PROPN
dpc-4194	2	89	 	 	SPACE
dpc-4194	2	90	esposito17	esposito17	PROPN
dpc-4194	2	91	,	,	PUNCT
dpc-4194	2	92	maria	maria	PROPN
dpc-4194	2	93	c.	c.	PROPN
dpc-4194	2	94	fargnoli17	fargnoli17	PROPN
dpc-4194	2	95	,	,	PUNCT
dpc-4194	2	96	francesca	francesca	PROPN
dpc-4194	2	97	m.	m.	PROPN
dpc-4194	2	98	gaiani2	gaiani2	PROPN
dpc-4194	2	99	,	,	PUNCT
dpc-4194	2	100	luigi	luigi	PROPN
dpc-4194	2	101	gargiulo18,19	gargiulo18,19	PROPN
dpc-4194	2	102	,	,	PUNCT
dpc-4194	2	103	paolo	paolo	NOUN
dpc-4194	2	104	 	 	SPACE
dpc-4194	2	105	gisondi20	gisondi20	NOUN
dpc-4194	2	106	,	,	PUNCT
dpc-4194	2	107	alessandro	alessandro	PROPN
dpc-4194	2	108	giunta4	giunta4	PROPN
dpc-4194	2	109	,	,	PUNCT
dpc-4194	2	110	luciano	luciano	PROPN
dpc-4194	2	111	ibba18,19	ibba18,19	PROPN
dpc-4194	2	112	,	,	PUNCT
dpc-4194	2	113	claudia	claudia	PROPN
dpc-4194	2	114	lasagni21	lasagni21	PROPN
dpc-4194	2	115	,	,	PUNCT
dpc-4194	2	116	francesco	francesco	PROPN
dpc-4194	2	117	 	 	SPACE
dpc-4194	2	118	loconsole22	loconsole22	PROPN
dpc-4194	2	119	,	,	PUNCT
dpc-4194	2	120	vincenzo	vincenzo	PROPN
dpc-4194	2	121	maione23	maione23	PROPN
dpc-4194	2	122	,	,	PUNCT
dpc-4194	2	123	edoardo	edoardo	PROPN
dpc-4194	2	124	mortato22	mortato22	NOUN
dpc-4194	2	125	,	,	PUNCT
dpc-4194	2	126	angelo	angelo	PROPN
dpc-4194	2	127	v.	v.	PROPN
dpc-4194	2	128	marzano10,24	marzano10,24	PROPN
dpc-4194	2	129	,	,	PUNCT
dpc-4194	2	130	martina	martina	PROPN
dpc-4194	2	131	maurelli20	maurelli20	PROPN
dpc-4194	2	132	,	,	PUNCT
dpc-4194	2	133	matteo	matteo	PROPN
dpc-4194	2	134	megna25	megna25	PROPN
dpc-4194	2	135	,	,	PUNCT
dpc-4194	2	136	santo	santo	PROPN
dpc-4194	2	137	r.	r.	PROPN
dpc-4194	2	138	mercuri5,26	mercuri5,26	PROPN
dpc-4194	2	139	,	,	PUNCT
dpc-4194	2	140	alessandra	alessandra	PROPN
dpc-4194	2	141	narcisi18	narcisi18	NOUN
dpc-4194	2	142	,	,	PUNCT
dpc-4194	2	143	annamaria	annamaria	VERB
dpc-4194	2	144	 	 	SPACE
dpc-4194	2	145	offidani10	offidani10	NOUN
dpc-4194	2	146	,	,	PUNCT
dpc-4194	2	147	giovanni	giovanni	PROPN
dpc-4194	2	148	paolino5	paolino5	PROPN
dpc-4194	2	149	,	,	PUNCT
dpc-4194	2	150	aurora	aurora	PROPN
dpc-4194	2	151	parodi6	parodi6	PROPN
dpc-4194	2	152	,	,	PUNCT
dpc-4194	2	153	giovanni	giovanni	PROPN
dpc-4194	2	154	pellacani15	pellacani15	NOUN
dpc-4194	2	155	,	,	PUNCT
dpc-4194	2	156	luca	luca	PROPN
dpc-4194	2	157	 	 	SPACE
dpc-4194	2	158	potestio25	potestio25	NOUN
dpc-4194	2	159	,	,	PUNCT
dpc-4194	2	160	pietro	pietro	NOUN
dpc-4194	2	161	quaglino14	quaglino14	PROPN
dpc-4194	2	162	,	,	PUNCT
dpc-4194	2	163	antonio	antonio	PROPN
dpc-4194	2	164	g.	g.	PROPN
dpc-4194	2	165	richetta15	richetta15	PROPN
dpc-4194	2	166	,	,	PUNCT
dpc-4194	2	167	francesca	francesca	PROPN
dpc-4194	2	168	romano27	romano27	NOUN
dpc-4194	2	169	,	,	PUNCT
dpc-4194	2	170	paolo	paolo	PROPN
dpc-4194	2	171	 	 	SPACE
dpc-4194	2	172	sena11	sena11	PROPN
dpc-4194	2	173	,	,	PUNCT
dpc-4194	2	174	marina	marina	PROPN
dpc-4194	2	175	venturini23	venturini23	PROPN
dpc-4194	2	176	,	,	PUNCT
dpc-4194	2	177	chiara	chiara	PROPN
dpc-4194	2	178	assorgi1,25	assorgi1,25	PROPN
dpc-4194	2	179	,	,	PUNCT
dpc-4194	2	180	antonio	antonio	PROPN
dpc-4194	2	181	costanzo18,19	costanzo18,19	ADJ
dpc-4194	2	182	1	1	NUM
dpc-4194	2	183	clinical	clinical	ADJ
dpc-4194	2	184	dermatology	dermatology	NOUN
dpc-4194	2	185	unit	unit	NOUN
dpc-4194	2	186	,	,	PUNCT
dpc-4194	2	187	san	san	PROPN
dpc-4194	2	188	gallicano	gallicano	PROPN
dpc-4194	2	189	dermatological	dermatological	PROPN
dpc-4194	2	190	institute	institute	NOUN
dpc-4194	2	191	irccs	irccs	PROPN
dpc-4194	2	192	,	,	PUNCT
dpc-4194	2	193	rome	rome	PROPN
dpc-4194	2	194	,	,	PUNCT
dpc-4194	2	195	italy	italy	PROPN
dpc-4194	2	196	2	2	NUM
dpc-4194	2	197	department	department	NOUN
dpc-4194	2	198	of	of	ADP
dpc-4194	2	199	dermatology	dermatology	NOUN
dpc-4194	2	200	,	,	PUNCT
dpc-4194	2	201	dermatology	dermatology	NOUN
dpc-4194	2	202	unit	unit	NOUN
dpc-4194	2	203	azienda	azienda	PROPN
dpc-4194	2	204	ospedaliera	ospedaliera	NOUN
dpc-4194	2	205	san	san	PROPN
dpc-4194	2	206	donato	donato	PROPN
dpc-4194	2	207	milanese	milanese	PROPN
dpc-4194	2	208	,	,	PUNCT
dpc-4194	2	209	milan	milan	PROPN
dpc-4194	2	210	,	,	PUNCT
dpc-4194	2	211	italy	italy	PROPN
dpc-4194	2	212	3	3	NUM
dpc-4194	2	213	dermatology	dermatology	NOUN
dpc-4194	2	214	unit	unit	NOUN
dpc-4194	2	215	,	,	PUNCT
dpc-4194	2	216	university	university	PROPN
dpc-4194	2	217	of	of	ADP
dpc-4194	2	218	campania	campania	PROPN
dpc-4194	2	219	l.	l.	PROPN
dpc-4194	2	220	vanvitelli	vanvitelli	PROPN
dpc-4194	2	221	,	,	PUNCT
dpc-4194	2	222	naples	naples	PROPN
dpc-4194	2	223	,	,	PUNCT
dpc-4194	2	224	italy	italy	PROPN
dpc-4194	2	225	4	4	NUM
dpc-4194	2	226	dermatology	dermatology	NOUN
dpc-4194	2	227	,	,	PUNCT
dpc-4194	2	228	department	department	NOUN
dpc-4194	2	229	of	of	ADP
dpc-4194	2	230	systems	system	NOUN
dpc-4194	2	231	medicine	medicine	NOUN
dpc-4194	2	232	,	,	PUNCT
dpc-4194	2	233	university	university	NOUN
dpc-4194	2	234	of	of	ADP
dpc-4194	2	235	rome	rome	PROPN
dpc-4194	2	236	tor	tor	PROPN
dpc-4194	2	237	vergata	vergata	PROPN
dpc-4194	2	238	,	,	PUNCT
dpc-4194	2	239	rome	rome	PROPN
dpc-4194	2	240	,	,	PUNCT
dpc-4194	2	241	italy	italy	PROPN
dpc-4194	2	242	5	5	NUM
dpc-4194	2	243	unit	unit	NOUN
dpc-4194	2	244	of	of	ADP
dpc-4194	2	245	dermatology	dermatology	NOUN
dpc-4194	2	246	and	and	CCONJ
dpc-4194	2	247	cosmetology	cosmetology	NOUN
dpc-4194	2	248	,	,	PUNCT
dpc-4194	2	249	irccs	ircc	VERB
dpc-4194	2	250	san	san	PROPN
dpc-4194	2	251	raffaele	raffaele	PROPN
dpc-4194	2	252	scientific	scientific	PROPN
dpc-4194	2	253	institute	institute	PROPN
dpc-4194	2	254	,	,	PUNCT
dpc-4194	2	255	milan	milan	PROPN
dpc-4194	2	256	,	,	PUNCT
dpc-4194	2	257	italy	italy	PROPN
dpc-4194	2	258	6	6	NUM
dpc-4194	2	259	section	section	NOUN
dpc-4194	2	260	of	of	ADP
dpc-4194	2	261	dermatology	dermatology	NOUN
dpc-4194	2	262	,	,	PUNCT
dpc-4194	2	263	department	department	NOUN
dpc-4194	2	264	of	of	ADP
dpc-4194	2	265	health	health	PROPN
dpc-4194	2	266	sciences	sciences	PROPN
dpc-4194	2	267	(	(	PUNCT
dpc-4194	2	268	dissal	dissal	NOUN
dpc-4194	2	269	)	)	PUNCT
dpc-4194	2	270	,	,	PUNCT
dpc-4194	2	271	irccs	ircc	VERB
dpc-4194	2	272	san	san	PROPN
dpc-4194	2	273	martino	martino	PROPN
dpc-4194	2	274	university	university	PROPN
dpc-4194	2	275	hospital	hospital	PROPN
dpc-4194	2	276	,	,	PUNCT
dpc-4194	2	277	genoa	genoa	PROPN
dpc-4194	2	278	,	,	PUNCT
dpc-4194	2	279	italy	italy	PROPN
dpc-4194	2	280	7	7	NUM
dpc-4194	2	281	section	section	NOUN
dpc-4194	2	282	of	of	ADP
dpc-4194	2	283	dermatology	dermatology	NOUN
dpc-4194	2	284	,	,	PUNCT
dpc-4194	2	285	department	department	NOUN
dpc-4194	2	286	of	of	ADP
dpc-4194	2	287	translational	translational	ADJ
dpc-4194	2	288	medicine	medicine	NOUN
dpc-4194	2	289	and	and	CCONJ
dpc-4194	2	290	surgery	surgery	NOUN
dpc-4194	2	291	,	,	PUNCT
dpc-4194	2	292	catholic	catholic	PROPN
dpc-4194	2	293	university	university	PROPN
dpc-4194	2	294	of	of	ADP
dpc-4194	2	295	the	the	DET
dpc-4194	2	296	sacred	sacred	ADJ
dpc-4194	2	297	heart	heart	NOUN
dpc-4194	2	298	,	,	PUNCT
dpc-4194	2	299	rome	rome	PROPN
dpc-4194	2	300	,	,	PUNCT
dpc-4194	2	301	italy	italy	PROPN
dpc-4194	2	302	8	8	NUM
dpc-4194	2	303	dermatology	dermatology	NOUN
dpc-4194	2	304	unit	unit	NOUN
dpc-4194	2	305	,	,	PUNCT
dpc-4194	2	306	agostino	agostino	PROPN
dpc-4194	2	307	gemelli	gemelli	PROPN
dpc-4194	2	308	university	university	PROPN
dpc-4194	2	309	polyclinic	polyclinic	PROPN
dpc-4194	2	310	foundation	foundation	PROPN
dpc-4194	2	311	,	,	PUNCT
dpc-4194	2	312	irccs	irccs	NOUN
dpc-4194	2	313	,	,	PUNCT
dpc-4194	2	314	rome	rome	PROPN
dpc-4194	2	315	,	,	PUNCT
dpc-4194	2	316	italy	italy	PROPN
dpc-4194	2	317	9	9	NUM
dpc-4194	2	318	department	department	NOUN
dpc-4194	2	319	of	of	ADP
dpc-4194	2	320	clinical	clinical	ADJ
dpc-4194	2	321	and	and	CCONJ
dpc-4194	2	322	molecular	molecular	ADJ
dpc-4194	2	323	sciences	science	NOUN
dpc-4194	2	324	dermatological	dermatological	ADJ
dpc-4194	2	325	clinic	clinic	NOUN
dpc-4194	2	326	,	,	PUNCT
dpc-4194	2	327	università	università	PROPN
dpc-4194	2	328	politecnica	politecnica	PROPN
dpc-4194	2	329	delle	delle	PROPN
dpc-4194	2	330	marche	marche	PROPN
dpc-4194	2	331	,	,	PUNCT
dpc-4194	2	332	ancona	ancona	PROPN
dpc-4194	2	333	,	,	PUNCT
dpc-4194	2	334	italy	italy	PROPN
dpc-4194	2	335	10	10	NUM
dpc-4194	2	336	dermatology	dermatology	NOUN
dpc-4194	2	337	unit	unit	NOUN
dpc-4194	2	338	,	,	PUNCT
dpc-4194	2	339	fondazione	fondazione	PROPN
dpc-4194	2	340	irccs	irccs	NOUN
dpc-4194	2	341	ca	can	AUX
dpc-4194	2	342	’	'	PUNCT
dpc-4194	2	343	granda	granda	PROPN
dpc-4194	2	344	ospedale	ospedale	PROPN
dpc-4194	2	345	maggiore	maggiore	PROPN
dpc-4194	2	346	policlinico	policlinico	PROPN
dpc-4194	2	347	,	,	PUNCT
dpc-4194	2	348	milan	milan	PROPN
dpc-4194	2	349	,	,	PUNCT
dpc-4194	2	350	italy	italy	PROPN
dpc-4194	2	351	11	11	NUM
dpc-4194	2	352	dermatology	dermatology	NOUN
dpc-4194	2	353	unit	unit	NOUN
dpc-4194	2	354	,	,	PUNCT
dpc-4194	2	355	asst	asst	NOUN
dpc-4194	2	356	papa	papa	NOUN
dpc-4194	2	357	giovanni	giovanni	PROPN
dpc-4194	2	358	xxiii	xxiii	PROPN
dpc-4194	2	359	hospital	hospital	PROPN
dpc-4194	2	360	,	,	PUNCT
dpc-4194	2	361	bergamo	bergamo	NOUN
dpc-4194	2	362	,	,	PUNCT
dpc-4194	2	363	italy	italy	PROPN
dpc-4194	2	364	12	12	NUM
dpc-4194	2	365	molecular	molecular	ADJ
dpc-4194	2	366	and	and	CCONJ
dpc-4194	2	367	translational	translational	ADJ
dpc-4194	2	368	medicine	medicine	NOUN
dpc-4194	2	369	(	(	PUNCT
dpc-4194	2	370	dimet	dimet	NOUN
dpc-4194	2	371	)	)	PUNCT
dpc-4194	2	372	,	,	PUNCT
dpc-4194	2	373	university	university	PROPN
dpc-4194	2	374	of	of	ADP
dpc-4194	2	375	milan	milan	PROPN
dpc-4194	2	376	-	-	PUNCT
dpc-4194	2	377	bicocca	bicocca	PROPN
dpc-4194	2	378	,	,	PUNCT
dpc-4194	2	379	milan	milan	PROPN
dpc-4194	2	380	,	,	PUNCT
dpc-4194	2	381	italy	italy	PROPN
dpc-4194	2	382	13	13	NUM
dpc-4194	2	383	department	department	PROPN
dpc-4194	2	384	of	of	ADP
dpc-4194	2	385	dermatology	dermatology	NOUN
dpc-4194	2	386	,	,	PUNCT
dpc-4194	2	387	gaetano	gaetano	PROPN
dpc-4194	2	388	rummo	rummo	PROPN
dpc-4194	2	389	hospital	hospital	PROPN
dpc-4194	2	390	,	,	PUNCT
dpc-4194	2	391	benevento	benevento	PROPN
dpc-4194	2	392	,	,	PUNCT
dpc-4194	2	393	italy	italy	PROPN
dpc-4194	2	394	14	14	NUM
dpc-4194	2	395	department	department	PROPN
dpc-4194	2	396	of	of	ADP
dpc-4194	2	397	biomedical	biomedical	ADJ
dpc-4194	2	398	science	science	NOUN
dpc-4194	2	399	and	and	CCONJ
dpc-4194	2	400	human	human	ADJ
dpc-4194	2	401	oncology	oncology	NOUN
dpc-4194	2	402	,	,	PUNCT
dpc-4194	2	403	second	second	ADJ
dpc-4194	2	404	dermatologic	dermatologic	ADJ
dpc-4194	2	405	clinic	clinic	NOUN
dpc-4194	2	406	,	,	PUNCT
dpc-4194	2	407	university	university	PROPN
dpc-4194	2	408	of	of	ADP
dpc-4194	2	409	turin	turin	PROPN
dpc-4194	2	410	,	,	PUNCT
dpc-4194	2	411	turin	turin	PROPN
dpc-4194	2	412	,	,	PUNCT
dpc-4194	2	413	italy	italy	PROPN
dpc-4194	2	414	15	15	NUM
dpc-4194	2	415	dermatology	dermatology	NOUN
dpc-4194	2	416	unit	unit	NOUN
dpc-4194	2	417	,	,	PUNCT
dpc-4194	2	418	department	department	NOUN
dpc-4194	2	419	of	of	ADP
dpc-4194	2	420	clinical	clinical	ADJ
dpc-4194	2	421	internal	internal	ADJ
dpc-4194	2	422	,	,	PUNCT
dpc-4194	2	423	anesthesiological	anesthesiological	ADJ
dpc-4194	2	424	and	and	CCONJ
dpc-4194	2	425	cardiovascular	cardiovascular	ADJ
dpc-4194	2	426	science	science	NOUN
dpc-4194	2	427	,	,	PUNCT
dpc-4194	2	428	university	university	NOUN
dpc-4194	2	429	of	of	ADP
dpc-4194	2	430	la	la	PROPN
dpc-4194	2	431	sapienza	sapienza	PROPN
dpc-4194	2	432	,	,	PUNCT
dpc-4194	2	433	rome	rome	PROPN
dpc-4194	2	434	,	,	PUNCT
dpc-4194	2	435	italy	italy	PROPN
dpc-4194	2	436	16	16	NUM
dpc-4194	2	437	dermatology	dermatology	NOUN
dpc-4194	2	438	unit	unit	NOUN
dpc-4194	2	439	,	,	PUNCT
dpc-4194	2	440	department	department	NOUN
dpc-4194	2	441	of	of	ADP
dpc-4194	2	442	clinical	clinical	ADJ
dpc-4194	2	443	and	and	CCONJ
dpc-4194	2	444	experimental	experimental	ADJ
dpc-4194	2	445	medicine	medicine	NOUN
dpc-4194	2	446	,	,	PUNCT
dpc-4194	2	447	ospedale	ospedale	PROPN
dpc-4194	2	448	santa	santa	PROPN
dpc-4194	2	449	chiara	chiara	PROPN
dpc-4194	2	450	,	,	PUNCT
dpc-4194	2	451	pisa	pisa	PROPN
dpc-4194	2	452	,	,	PUNCT
dpc-4194	2	453	italy	italy	PROPN
dpc-4194	2	454	17	17	NUM
dpc-4194	2	455	dermatology	dermatology	NOUN
dpc-4194	2	456	,	,	PUNCT
dpc-4194	2	457	department	department	NOUN
dpc-4194	2	458	of	of	ADP
dpc-4194	2	459	biotechnological	biotechnological	ADJ
dpc-4194	2	460	and	and	CCONJ
dpc-4194	2	461	applied	apply	VERB
dpc-4194	2	462	clinical	clinical	ADJ
dpc-4194	2	463	sciences	science	NOUN
dpc-4194	2	464	,	,	PUNCT
dpc-4194	2	465	university	university	NOUN
dpc-4194	2	466	of	of	ADP
dpc-4194	2	467	l’aquila	l’aquila	PROPN
dpc-4194	2	468	,	,	PUNCT
dpc-4194	2	469	l’aquila	l’aquila	PROPN
dpc-4194	2	470	,	,	PUNCT
dpc-4194	2	471	italy	italy	PROPN
dpc-4194	2	472	18	18	NUM
dpc-4194	2	473	dermatology	dermatology	NOUN
dpc-4194	2	474	unit	unit	NOUN
dpc-4194	2	475	,	,	PUNCT
dpc-4194	2	476	irccs	ircc	VERB
dpc-4194	2	477	humanitas	humanitas	NOUN
dpc-4194	2	478	research	research	NOUN
dpc-4194	2	479	hospital	hospital	NOUN
dpc-4194	2	480	,	,	PUNCT
dpc-4194	2	481	rozzano	rozzano	PROPN
dpc-4194	2	482	,	,	PUNCT
dpc-4194	2	483	milan	milan	PROPN
dpc-4194	2	484	,	,	PUNCT
dpc-4194	2	485	italy	italy	PROPN
dpc-4194	2	486	19	19	NUM
dpc-4194	2	487	department	department	PROPN
dpc-4194	2	488	of	of	ADP
dpc-4194	2	489	biomedical	biomedical	ADJ
dpc-4194	2	490	sciences	sciences	PROPN
dpc-4194	2	491	,	,	PUNCT
dpc-4194	2	492	humanitas	humanita	NOUN
dpc-4194	2	493	university	university	NOUN
dpc-4194	2	494	,	,	PUNCT
dpc-4194	2	495	pieve	pieve	PROPN
dpc-4194	2	496	emanuele	emanuele	PROPN
dpc-4194	2	497	,	,	PUNCT
dpc-4194	2	498	milan	milan	PROPN
dpc-4194	2	499	,	,	PUNCT
dpc-4194	2	500	italy	italy	PROPN
dpc-4194	2	501	20	20	NUM
dpc-4194	2	502	department	department	NOUN
dpc-4194	2	503	of	of	ADP
dpc-4194	2	504	medicine	medicine	NOUN
dpc-4194	2	505	,	,	PUNCT
dpc-4194	2	506	section	section	NOUN
dpc-4194	2	507	of	of	ADP
dpc-4194	2	508	dermatology	dermatology	NOUN
dpc-4194	2	509	and	and	CCONJ
dpc-4194	2	510	venereology	venereology	NOUN
dpc-4194	2	511	,	,	PUNCT
dpc-4194	2	512	university	university	NOUN
dpc-4194	2	513	of	of	ADP
dpc-4194	2	514	verona	verona	PROPN
dpc-4194	2	515	,	,	PUNCT
dpc-4194	2	516	verona	verona	PROPN
dpc-4194	2	517	,	,	PUNCT
dpc-4194	2	518	italy	italy	PROPN
dpc-4194	2	519	21	21	NUM
dpc-4194	2	520	dermatological	dermatological	ADJ
dpc-4194	2	521	clinic	clinic	NOUN
dpc-4194	2	522	,	,	PUNCT
dpc-4194	2	523	department	department	NOUN
dpc-4194	2	524	of	of	ADP
dpc-4194	2	525	specialized	specialized	ADJ
dpc-4194	2	526	medicine	medicine	NOUN
dpc-4194	2	527	,	,	PUNCT
dpc-4194	2	528	university	university	PROPN
dpc-4194	2	529	of	of	ADP
dpc-4194	2	530	modena	modena	PROPN
dpc-4194	2	531	,	,	PUNCT
dpc-4194	2	532	modena	modena	PROPN
dpc-4194	2	533	,	,	PUNCT
dpc-4194	2	534	italy	italy	PROPN
dpc-4194	2	535	22	22	NUM
dpc-4194	2	536	department	department	PROPN
dpc-4194	2	537	of	of	ADP
dpc-4194	2	538	dermatology	dermatology	NOUN
dpc-4194	2	539	,	,	PUNCT
dpc-4194	2	540	university	university	NOUN
dpc-4194	2	541	of	of	ADP
dpc-4194	2	542	bari	bari	NOUN
dpc-4194	2	543	,	,	PUNCT
dpc-4194	2	544	bari	bari	NOUN
dpc-4194	2	545	,	,	PUNCT
dpc-4194	2	546	italy	italy	PROPN
dpc-4194	2	547	23	23	NUM
dpc-4194	2	548	department	department	NOUN
dpc-4194	2	549	of	of	ADP
dpc-4194	2	550	dermatology	dermatology	NOUN
dpc-4194	2	551	,	,	PUNCT
dpc-4194	2	552	asst	asst	PROPN
dpc-4194	2	553	spedali	spedali	PROPN
dpc-4194	2	554	civili	civili	PROPN
dpc-4194	2	555	hospital	hospital	PROPN
dpc-4194	2	556	,	,	PUNCT
dpc-4194	2	557	brescia	brescia	PROPN
dpc-4194	2	558	,	,	PUNCT
dpc-4194	2	559	italy	italy	PROPN
dpc-4194	2	560	24	24	NUM
dpc-4194	2	561	department	department	PROPN
dpc-4194	2	562	of	of	ADP
dpc-4194	2	563	pathophysiology	pathophysiology	NOUN
dpc-4194	2	564	and	and	CCONJ
dpc-4194	2	565	transplantation	transplantation	NOUN
dpc-4194	2	566	,	,	PUNCT
dpc-4194	2	567	università	università	PROPN
dpc-4194	2	568	degli	degli	PROPN
dpc-4194	2	569	studi	studi	PROPN
dpc-4194	2	570	di	di	X
dpc-4194	2	571	milano	milano	PROPN
dpc-4194	2	572	,	,	PUNCT
dpc-4194	2	573	milan	milan	PROPN
dpc-4194	2	574	,	,	PUNCT
dpc-4194	2	575	italy	italy	PROPN
dpc-4194	2	576	25	25	NUM
dpc-4194	2	577	section	section	NOUN
dpc-4194	2	578	of	of	ADP
dpc-4194	2	579	dermatology	dermatology	NOUN
dpc-4194	2	580	,	,	PUNCT
dpc-4194	2	581	department	department	NOUN
dpc-4194	2	582	of	of	ADP
dpc-4194	2	583	clinical	clinical	ADJ
dpc-4194	2	584	medicine	medicine	NOUN
dpc-4194	2	585	and	and	CCONJ
dpc-4194	2	586	surgery	surgery	NOUN
dpc-4194	2	587	,	,	PUNCT
dpc-4194	2	588	university	university	NOUN
dpc-4194	2	589	of	of	ADP
dpc-4194	2	590	naples	naples	PROPN
dpc-4194	2	591	federico	federico	PROPN
dpc-4194	2	592	ii	ii	PROPN
dpc-4194	2	593	,	,	PUNCT
dpc-4194	2	594	naples	naples	PROPN
dpc-4194	2	595	,	,	PUNCT
dpc-4194	2	596	italy	italy	PROPN
dpc-4194	2	597	26	26	NUM
dpc-4194	2	598	università	università	PROPN
dpc-4194	2	599	vita	vita	PROPN
dpc-4194	2	600	-	-	PUNCT
dpc-4194	2	601	salute	salute	NOUN
dpc-4194	2	602	san	san	PROPN
dpc-4194	2	603	raffaele	raffaele	PROPN
dpc-4194	2	604	,	,	PUNCT
dpc-4194	2	605	milan	milan	PROPN
dpc-4194	2	606	,	,	PUNCT
dpc-4194	2	607	italy	italy	PROPN
dpc-4194	2	608	27	27	NUM
dpc-4194	2	609	dermatology	dermatology	NOUN
dpc-4194	2	610	unit	unit	NOUN
dpc-4194	2	611	,	,	PUNCT
dpc-4194	2	612	aorn	aorn	VERB
dpc-4194	2	613	“	"	PUNCT
dpc-4194	2	614	a.	a.	NOUN
dpc-4194	2	615	cardarelli	cardarelli	PROPN
dpc-4194	2	616	”	"	PUNCT
dpc-4194	2	617	,	,	PUNCT
dpc-4194	2	618	naples	naples	PROPN
dpc-4194	2	619	,	,	PUNCT
dpc-4194	2	620	italy	italy	PROPN
dpc-4194	2	621	2	2	NUM
dpc-4194	2	622	original	original	ADJ
dpc-4194	2	623	article	article	NOUN
dpc-4194	2	624	|	|	ADV
dpc-4194	2	625	dermatol	dermatol	ADJ
dpc-4194	2	626	pract	pract	NOUN
dpc-4194	2	627	concept	concept	NOUN
dpc-4194	2	628	.	.	PUNCT
dpc-4194	3	1	2024;14(2):e2024052	2024;14(2):e2024052	NUM
dpc-4194	3	2	key	key	ADJ
dpc-4194	3	3	words	word	NOUN
dpc-4194	3	4	:	:	PUNCT
dpc-4194	3	5	immonumodulatory	immonumodulatory	ADJ
dpc-4194	3	6	therapies	therapy	NOUN
dpc-4194	3	7	,	,	PUNCT
dpc-4194	3	8	inflammatory	inflammatory	ADJ
dpc-4194	3	9	skin	skin	NOUN
dpc-4194	3	10	diseases	disease	NOUN
dpc-4194	3	11	,	,	PUNCT
dpc-4194	3	12	psoriasis	psoriasis	NOUN
dpc-4194	3	13	,	,	PUNCT
dpc-4194	3	14	psoriasis	psoriasis	NOUN
dpc-4194	3	15	treatment	treatment	NOUN
dpc-4194	3	16	citation	citation	NOUN
dpc-4194	3	17	:	:	PUNCT
dpc-4194	3	18	orsini	orsini	PROPN
dpc-4194	3	19	d	d	PROPN
dpc-4194	3	20	,	,	PUNCT
dpc-4194	3	21	malagoli	malagoli	NOUN
dpc-4194	3	22	p	p	NOUN
dpc-4194	3	23	,	,	PUNCT
dpc-4194	3	24	balato	balato	NOUN
dpc-4194	3	25	a	a	PRON
dpc-4194	3	26	,	,	PUNCT
dpc-4194	3	27	et	et	PROPN
dpc-4194	3	28	al	al	PROPN
dpc-4194	3	29	.	.	PROPN
dpc-4194	3	30	bimekizumab	bimekizumab	PROPN
dpc-4194	3	31	for	for	ADP
dpc-4194	3	32	the	the	DET
dpc-4194	3	33	treatment	treatment	NOUN
dpc-4194	3	34	of	of	ADP
dpc-4194	3	35	plaque	plaque	NOUN
dpc-4194	3	36	psoriasis	psoriasis	NOUN
dpc-4194	3	37	with	with	ADP
dpc-4194	3	38	involvement	involvement	NOUN
dpc-4194	3	39	of	of	ADP
dpc-4194	3	40	genitalia	genitalia	NOUN
dpc-4194	3	41	:	:	PUNCT
dpc-4194	3	42	a	a	DET
dpc-4194	3	43	16	16	NUM
dpc-4194	3	44	-	-	PUNCT
dpc-4194	3	45	week	week	NOUN
dpc-4194	3	46	multicenter	multicenter	NOUN
dpc-4194	3	47	real	real	ADJ
dpc-4194	3	48	-	-	PUNCT
dpc-4194	3	49	world	world	NOUN
dpc-4194	3	50	experience	experience	NOUN
dpc-4194	3	51	—	—	PUNCT
dpc-4194	3	52	il	il	PROPN
dpc-4194	3	53	pso	pso	PROPN
dpc-4194	3	54	(	(	PUNCT
dpc-4194	3	55	italian	italian	ADJ
dpc-4194	3	56	landscape	landscape	NOUN
dpc-4194	3	57	psoriasis	psoriasis	NOUN
dpc-4194	3	58	)	)	PUNCT
dpc-4194	3	59	.	.	PUNCT
dpc-4194	4	1	dermatol	dermatol	NOUN
dpc-4194	4	2	pract	pract	PROPN
dpc-4194	4	3	concept	concept	NOUN
dpc-4194	4	4	.	.	PUNCT
dpc-4194	5	1	2024;14(2):e2024052	2024;14(2):e2024052	X
dpc-4194	5	2	.	.	PUNCT
dpc-4194	6	1	doi	doi	PROPN
dpc-4194	6	2	:	:	PUNCT
dpc-4194	6	3	https://doi.org/10.5826/dpc.1402a52	https://doi.org/10.5826/dpc.1402a52	PROPN
dpc-4194	6	4	accepted	accept	VERB
dpc-4194	6	5	:	:	PUNCT
dpc-4194	6	6	february	february	PROPN
dpc-4194	6	7	23	23	NUM
dpc-4194	6	8	,	,	PUNCT
dpc-4194	6	9	2024	2024	NUM
dpc-4194	6	10	;	;	PUNCT
dpc-4194	6	11	published	publish	VERB
dpc-4194	6	12	:	:	PUNCT
dpc-4194	7	1	april	april	PROPN
dpc-4194	7	2	2024	2024	NUM
dpc-4194	7	3	copyright	copyright	NOUN
dpc-4194	7	4	:	:	PUNCT
dpc-4194	7	5	©	©	PROPN
dpc-4194	7	6	2024	2024	NUM
dpc-4194	7	7	orsini	orsini	PROPN
dpc-4194	7	8	et	et	PROPN
dpc-4194	7	9	al	al	PROPN
dpc-4194	7	10	.	.	PUNCT
dpc-4194	8	1	this	this	PRON
dpc-4194	8	2	is	be	AUX
dpc-4194	8	3	an	an	DET
dpc-4194	8	4	open	open	ADJ
dpc-4194	8	5	-	-	PUNCT
dpc-4194	8	6	access	access	NOUN
dpc-4194	8	7	article	article	NOUN
dpc-4194	8	8	distributed	distribute	VERB
dpc-4194	8	9	under	under	ADP
dpc-4194	8	10	the	the	DET
dpc-4194	8	11	terms	term	NOUN
dpc-4194	8	12	of	of	ADP
dpc-4194	8	13	the	the	DET
dpc-4194	8	14	creative	creative	ADJ
dpc-4194	8	15	commons	common	NOUN
dpc-4194	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4194	8	17	license	license	NOUN
dpc-4194	8	18	(	(	PUNCT
dpc-4194	8	19	by	by	ADP
dpc-4194	8	20	-	-	PUNCT
dpc-4194	8	21	nc-4.0	nc-4.0	NOUN
dpc-4194	8	22	)	)	PUNCT
dpc-4194	8	23	,	,	PUNCT
dpc-4194	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4194	8	25	,	,	PUNCT
dpc-4194	8	26	which	which	PRON
dpc-4194	8	27	permits	permit	VERB
dpc-4194	8	28	unrestricted	unrestricted	ADJ
dpc-4194	8	29	noncommercial	noncommercial	ADJ
dpc-4194	8	30	use	use	NOUN
dpc-4194	8	31	,	,	PUNCT
dpc-4194	8	32	distribution	distribution	NOUN
dpc-4194	8	33	,	,	PUNCT
dpc-4194	8	34	and	and	CCONJ
dpc-4194	8	35	reproduction	reproduction	NOUN
dpc-4194	8	36	in	in	ADP
dpc-4194	8	37	any	any	DET
dpc-4194	8	38	medium	medium	NOUN
dpc-4194	8	39	,	,	PUNCT
dpc-4194	8	40	provided	provide	VERB
dpc-4194	8	41	the	the	DET
dpc-4194	8	42	original	original	ADJ
dpc-4194	8	43	authors	author	NOUN
dpc-4194	8	44	and	and	CCONJ
dpc-4194	8	45	source	source	NOUN
dpc-4194	8	46	are	be	AUX
dpc-4194	8	47	credited	credit	VERB
dpc-4194	8	48	.	.	PUNCT
dpc-4194	9	1	funding	funding	NOUN
dpc-4194	9	2	:	:	PUNCT
dpc-4194	9	3	none	none	NOUN
dpc-4194	9	4	.	.	PUNCT
dpc-4194	10	1	competing	compete	VERB
dpc-4194	10	2	interests	interest	NOUN
dpc-4194	10	3	:	:	PUNCT
dpc-4194	10	4	d.	d.	PROPN
dpc-4194	10	5	orsini	orsini	PROPN
dpc-4194	10	6	has	have	AUX
dpc-4194	10	7	been	be	AUX
dpc-4194	10	8	a	a	DET
dpc-4194	10	9	speaker	speaker	NOUN
dpc-4194	10	10	and/or	and/or	CCONJ
dpc-4194	10	11	consultant	consultant	NOUN
dpc-4194	10	12	for	for	ADP
dpc-4194	10	13	abbvie	abbvie	PROPN
dpc-4194	10	14	,	,	PUNCT
dpc-4194	10	15	leopharma	leopharma	PROPN
dpc-4194	10	16	,	,	PUNCT
dpc-4194	10	17	ucb	ucb	PROPN
dpc-4194	10	18	,	,	PUNCT
dpc-4194	10	19	bristol	bristol	PROPN
dpc-4194	10	20	-	-	PUNCT
dpc-4194	10	21	meyer	meyer	PROPN
dpc-4194	10	22	-	-	PUNCT
dpc-4194	10	23	squibb	squibb	PROPN
dpc-4194	10	24	and	and	CCONJ
dpc-4194	10	25	boehringeringelheim	boehringeringelheim	PROPN
dpc-4194	10	26	.	.	PUNCT
dpc-4194	11	1	p.	p.	NOUN
dpc-4194	11	2	malagoli	malagoli	NOUN
dpc-4194	11	3	has	have	AUX
dpc-4194	11	4	been	be	AUX
dpc-4194	11	5	a	a	DET
dpc-4194	11	6	speaker	speaker	NOUN
dpc-4194	11	7	for	for	ADP
dpc-4194	11	8	abbvie	abbvie	PROPN
dpc-4194	11	9	,	,	PUNCT
dpc-4194	11	10	lilly	lilly	PROPN
dpc-4194	11	11	,	,	PUNCT
dpc-4194	11	12	novartis	novartis	PROPN
dpc-4194	11	13	,	,	PUNCT
dpc-4194	11	14	janssen	janssen	NOUN
dpc-4194	11	15	-	-	PUNCT
dpc-4194	11	16	cilag	cilag	PROPN
dpc-4194	11	17	,	,	PUNCT
dpc-4194	11	18	celgene	celgene	NOUN
dpc-4194	11	19	,	,	PUNCT
dpc-4194	11	20	leopharma	leopharma	PROPN
dpc-4194	11	21	,	,	PUNCT
dpc-4194	11	22	and	and	CCONJ
dpc-4194	11	23	almirall	almirall	ADJ
dpc-4194	11	24	.	.	PUNCT
dpc-4194	12	1	a.	a.	NOUN
dpc-4194	12	2	balato	balato	PROPN
dpc-4194	12	3	has	have	AUX
dpc-4194	12	4	received	receive	VERB
dpc-4194	12	5	honoraria	honorarium	NOUN
dpc-4194	12	6	for	for	ADP
dpc-4194	12	7	participation	participation	NOUN
dpc-4194	12	8	in	in	ADP
dpc-4194	12	9	advisory	advisory	ADJ
dpc-4194	12	10	boards	board	NOUN
dpc-4194	12	11	,	,	PUNCT
dpc-4194	12	12	meetings	meeting	NOUN
dpc-4194	12	13	,	,	PUNCT
dpc-4194	12	14	or	or	CCONJ
dpc-4194	12	15	as	as	ADP
dpc-4194	12	16	speaker	speaker	NOUN
dpc-4194	12	17	for	for	ADP
dpc-4194	12	18	abbvie	abbvie	PROPN
dpc-4194	12	19	,	,	PUNCT
dpc-4194	12	20	celgene	celgene	NOUN
dpc-4194	12	21	,	,	PUNCT
dpc-4194	12	22	janssen	janssen	NOUN
dpc-4194	12	23	-	-	PUNCT
dpc-4194	12	24	cilag	cilag	PROPN
dpc-4194	12	25	,	,	PUNCT
dpc-4194	12	26	eli	eli	PROPN
dpc-4194	12	27	lilly	lilly	PROPN
dpc-4194	12	28	,	,	PUNCT
dpc-4194	12	29	novartis	novartis	PROPN
dpc-4194	12	30	pharma	pharma	PROPN
dpc-4194	12	31	,	,	PUNCT
dpc-4194	12	32	pfizer	pfizer	NOUN
dpc-4194	12	33	,	,	PUNCT
dpc-4194	12	34	sanofi	sanofi	PROPN
dpc-4194	12	35	-	-	PUNCT
dpc-4194	12	36	genzyme	genzyme	PROPN
dpc-4194	12	37	,	,	PUNCT
dpc-4194	12	38	and	and	CCONJ
dpc-4194	12	39	ucb	ucb	PROPN
dpc-4194	12	40	pharma	pharma	PROPN
dpc-4194	12	41	.	.	PUNCT
dpc-4194	13	1	l.	l.	PROPN
dpc-4194	13	2	bianchi	bianchi	PROPN
dpc-4194	13	3	has	have	AUX
dpc-4194	13	4	received	receive	VERB
dpc-4194	13	5	honoraria	honoraria	NOUN
dpc-4194	13	6	as	as	ADP
dpc-4194	13	7	a	a	DET
dpc-4194	13	8	speaker	speaker	NOUN
dpc-4194	13	9	or	or	CCONJ
dpc-4194	13	10	consultant	consultant	NOUN
dpc-4194	13	11	for	for	ADP
dpc-4194	13	12	abbvie	abbvie	PROPN
dpc-4194	13	13	,	,	PUNCT
dpc-4194	13	14	janssen	janssen	PROPN
dpc-4194	13	15	,	,	PUNCT
dpc-4194	13	16	almirall	almirall	ADJ
dpc-4194	13	17	eli	eli	PROPN
dpc-4194	13	18	-	-	PUNCT
dpc-4194	13	19	lilly	lilly	PROPN
dpc-4194	13	20	,	,	PUNCT
dpc-4194	13	21	leopharma	leopharma	PROPN
dpc-4194	13	22	,	,	PUNCT
dpc-4194	13	23	novartis	novartis	PROPN
dpc-4194	13	24	,	,	PUNCT
dpc-4194	13	25	sanofi	sanofi	NOUN
dpc-4194	13	26	,	,	PUNCT
dpc-4194	13	27	pfizer	pfizer	NOUN
dpc-4194	13	28	and	and	CCONJ
dpc-4194	13	29	ucb	ucb	PROPN
dpc-4194	13	30	pharma	pharma	PROPN
dpc-4194	13	31	.	.	PUNCT
dpc-4194	14	1	g.	g.	PROPN
dpc-4194	14	2	caldarola	caldarola	PROPN
dpc-4194	14	3	reports	report	VERB
dpc-4194	14	4	consulting	consult	VERB
dpc-4194	14	5	fees	fee	NOUN
dpc-4194	14	6	or	or	CCONJ
dpc-4194	14	7	honorarium	honorarium	NOUN
dpc-4194	14	8	and	and	CCONJ
dpc-4194	14	9	payment	payment	NOUN
dpc-4194	14	10	for	for	ADP
dpc-4194	14	11	lectures	lecture	NOUN
dpc-4194	14	12	from	from	ADP
dpc-4194	14	13	lilly	lilly	NOUN
dpc-4194	14	14	and	and	CCONJ
dpc-4194	14	15	novartis	novartis	PROPN
dpc-4194	14	16	.	.	PUNCT
dpc-4194	15	1	c.	c.	PROPN
dpc-4194	15	2	de	de	PROPN
dpc-4194	15	3	simone	simone	PROPN
dpc-4194	15	4	reports	report	VERB
dpc-4194	15	5	consulting	consulting	NOUN
dpc-4194	15	6	fees	fee	NOUN
dpc-4194	15	7	or	or	CCONJ
dpc-4194	15	8	honorarium	honorarium	NOUN
dpc-4194	15	9	from	from	ADP
dpc-4194	15	10	abbvie	abbvie	PROPN
dpc-4194	15	11	,	,	PUNCT
dpc-4194	15	12	amgen	amgen	PROPN
dpc-4194	15	13	,	,	PUNCT
dpc-4194	15	14	novartis	novartis	PROPN
dpc-4194	15	15	,	,	PUNCT
dpc-4194	15	16	celgene	celgene	NOUN
dpc-4194	15	17	,	,	PUNCT
dpc-4194	15	18	sanofi	sanofi	PROPN
dpc-4194	15	19	,	,	PUNCT
dpc-4194	15	20	ucb	ucb	PROPN
dpc-4194	15	21	pharma	pharma	PROPN
dpc-4194	15	22	,	,	PUNCT
dpc-4194	15	23	janssen	janssen	PROPN
dpc-4194	15	24	and	and	CCONJ
dpc-4194	15	25	lilly	lilly	PROPN
dpc-4194	15	26	and	and	CCONJ
dpc-4194	15	27	payment	payment	NOUN
dpc-4194	15	28	for	for	ADP
dpc-4194	15	29	lectures	lecture	NOUN
dpc-4194	15	30	from	from	ADP
dpc-4194	15	31	abbvie	abbvie	PROPN
dpc-4194	15	32	,	,	PUNCT
dpc-4194	15	33	lilly	lilly	PROPN
dpc-4194	15	34	,	,	PUNCT
dpc-4194	15	35	novartis	novartis	PROPN
dpc-4194	15	36	,	,	PUNCT
dpc-4194	15	37	ucb	ucb	PROPN
dpc-4194	15	38	pharma	pharma	PROPN
dpc-4194	15	39	,	,	PUNCT
dpc-4194	15	40	and	and	CCONJ
dpc-4194	15	41	celgene	celgene	NOUN
dpc-4194	15	42	.	.	PUNCT
dpc-4194	16	1	m.	m.	PROPN
dpc-4194	16	2	esposito	esposito	PROPN
dpc-4194	16	3	has	have	AUX
dpc-4194	16	4	served	serve	VERB
dpc-4194	16	5	as	as	ADP
dpc-4194	16	6	speaker	speaker	NOUN
dpc-4194	16	7	and/or	and/or	CCONJ
dpc-4194	16	8	consultant	consultant	NOUN
dpc-4194	16	9	for	for	ADP
dpc-4194	16	10	abbvie	abbvie	PROPN
dpc-4194	16	11	,	,	PUNCT
dpc-4194	16	12	almirall	almirall	ADJ
dpc-4194	16	13	,	,	PUNCT
dpc-4194	16	14	biogen	biogen	PROPN
dpc-4194	16	15	,	,	PUNCT
dpc-4194	16	16	celgene	celgene	NOUN
dpc-4194	16	17	,	,	PUNCT
dpc-4194	16	18	eli	eli	PROPN
dpc-4194	16	19	lilly	lilly	PROPN
dpc-4194	16	20	,	,	PUNCT
dpc-4194	16	21	janssen	janssen	PROPN
dpc-4194	16	22	,	,	PUNCT
dpc-4194	16	23	leo	leo	PROPN
dpc-4194	16	24	pharma	pharma	PROPN
dpc-4194	16	25	,	,	PUNCT
dpc-4194	16	26	novartis	novartis	PROPN
dpc-4194	16	27	,	,	PUNCT
dpc-4194	16	28	sanofi	sanofi	PROPN
dpc-4194	16	29	genzyme	genzyme	PROPN
dpc-4194	16	30	,	,	PUNCT
dpc-4194	16	31	ucb	ucb	PROPN
dpc-4194	16	32	.	.	PROPN
dpc-4194	16	33	m.	m.	PROPN
dpc-4194	16	34	c.	c.	PROPN
dpc-4194	16	35	fargnoli	fargnoli	PROPN
dpc-4194	16	36	has	have	AUX
dpc-4194	16	37	served	serve	VERB
dpc-4194	16	38	on	on	ADP
dpc-4194	16	39	advisory	advisory	ADJ
dpc-4194	16	40	boards	board	NOUN
dpc-4194	16	41	,	,	PUNCT
dpc-4194	16	42	received	receive	VERB
dpc-4194	16	43	honoraria	honorarium	NOUN
dpc-4194	16	44	for	for	ADP
dpc-4194	16	45	lectures	lecture	NOUN
dpc-4194	16	46	and	and	CCONJ
dpc-4194	16	47	research	research	NOUN
dpc-4194	16	48	grants	grant	NOUN
dpc-4194	16	49	from	from	ADP
dpc-4194	16	50	amgen	amgen	PROPN
dpc-4194	16	51	,	,	PUNCT
dpc-4194	16	52	almirall	almirall	ADJ
dpc-4194	16	53	,	,	PUNCT
dpc-4194	16	54	abbvie	abbvie	PROPN
dpc-4194	16	55	,	,	PUNCT
dpc-4194	16	56	bms	bms	PROPN
dpc-4194	16	57	,	,	PUNCT
dpc-4194	16	58	galderma	galderma	NOUN
dpc-4194	16	59	,	,	PUNCT
dpc-4194	16	60	kyowa	kyowa	PROPN
dpc-4194	16	61	kirin	kirin	PROPN
dpc-4194	16	62	,	,	PUNCT
dpc-4194	16	63	leo	leo	PROPN
dpc-4194	16	64	pharma	pharma	PROPN
dpc-4194	16	65	,	,	PUNCT
dpc-4194	16	66	pierre	pierre	PROPN
dpc-4194	16	67	fabre	fabre	PROPN
dpc-4194	16	68	,	,	PUNCT
dpc-4194	16	69	ucb	ucb	PROPN
dpc-4194	16	70	,	,	PUNCT
dpc-4194	16	71	lilly	lilly	PROPN
dpc-4194	16	72	,	,	PUNCT
dpc-4194	16	73	pfizer	pfizer	PROPN
dpc-4194	16	74	,	,	PUNCT
dpc-4194	16	75	janssen	janssen	PROPN
dpc-4194	16	76	,	,	PUNCT
dpc-4194	16	77	msd	msd	PROPN
dpc-4194	16	78	,	,	PUNCT
dpc-4194	16	79	novartis	novartis	PROPN
dpc-4194	16	80	,	,	PUNCT
dpc-4194	16	81	sanofi	sanofi	NOUN
dpc-4194	16	82	-	-	PUNCT
dpc-4194	16	83	regeneron	regeneron	PROPN
dpc-4194	16	84	,	,	PUNCT
dpc-4194	16	85	sun	sun	PROPN
dpc-4194	16	86	pharma	pharma	PROPN
dpc-4194	16	87	.	.	PUNCT
dpc-4194	17	1	p.	p.	NOUN
dpc-4194	17	2	gisondi	gisondi	NOUN
dpc-4194	17	3	has	have	AUX
dpc-4194	17	4	been	be	AUX
dpc-4194	17	5	a	a	DET
dpc-4194	17	6	consultant	consultant	NOUN
dpc-4194	17	7	and/or	and/or	CCONJ
dpc-4194	17	8	speaker	speaker	NOUN
dpc-4194	17	9	for	for	ADP
dpc-4194	17	10	abbvie	abbvie	PROPN
dpc-4194	17	11	,	,	PUNCT
dpc-4194	17	12	almirall	almirall	PROPN
dpc-4194	17	13	,	,	PUNCT
dpc-4194	17	14	amgen	amgen	PROPN
dpc-4194	17	15	,	,	PUNCT
dpc-4194	17	16	janssen	janssen	PROPN
dpc-4194	17	17	,	,	PUNCT
dpc-4194	17	18	leo	leo	PROPN
dpc-4194	17	19	-	-	PUNCT
dpc-4194	17	20	pharma	pharma	PROPN
dpc-4194	17	21	,	,	PUNCT
dpc-4194	17	22	eli	eli	PROPN
dpc-4194	17	23	-	-	PUNCT
dpc-4194	17	24	lilly	lilly	PROPN
dpc-4194	17	25	,	,	PUNCT
dpc-4194	17	26	novartis	novartis	PROPN
dpc-4194	17	27	,	,	PUNCT
dpc-4194	17	28	pierre	pierre	NOUN
dpc-4194	17	29	febre	febre	PROPN
dpc-4194	17	30	,	,	PUNCT
dpc-4194	17	31	sandoz	sandoz	PROPN
dpc-4194	17	32	,	,	PUNCT
dpc-4194	17	33	sanofi	sanofi	PROPN
dpc-4194	17	34	and	and	CCONJ
dpc-4194	17	35	ucb	ucb	PROPN
dpc-4194	17	36	.	.	PROPN
dpc-4194	18	1	m.	m.	NOUN
dpc-4194	18	2	burlando	burlando	PROPN
dpc-4194	18	3	has	have	AUX
dpc-4194	18	4	acted	act	VERB
dpc-4194	18	5	as	as	ADP
dpc-4194	18	6	a	a	DET
dpc-4194	18	7	speaker	speaker	NOUN
dpc-4194	18	8	and	and	CCONJ
dpc-4194	18	9	consultant	consultant	NOUN
dpc-4194	18	10	for	for	ADP
dpc-4194	18	11	abbvie	abbvie	PROPN
dpc-4194	18	12	,	,	PUNCT
dpc-4194	18	13	janssen	janssen	PROPN
dpc-4194	18	14	,	,	PUNCT
dpc-4194	18	15	amgen	amgen	PROPN
dpc-4194	18	16	,	,	PUNCT
dpc-4194	18	17	novartis	novartis	PROPN
dpc-4194	18	18	,	,	PUNCT
dpc-4194	18	19	eli	eli	PROPN
dpc-4194	18	20	lilly	lilly	PROPN
dpc-4194	18	21	,	,	PUNCT
dpc-4194	18	22	ucb	ucb	PROPN
dpc-4194	18	23	pharma	pharma	PROPN
dpc-4194	18	24	.	.	PUNCT
dpc-4194	19	1	c.	c.	PROPN
dpc-4194	19	2	g.	g.	PROPN
dpc-4194	19	3	carrera	carrera	PROPN
dpc-4194	19	4	has	have	AUX
dpc-4194	19	5	served	serve	VERB
dpc-4194	19	6	as	as	ADP
dpc-4194	19	7	a	a	DET
dpc-4194	19	8	board	board	NOUN
dpc-4194	19	9	participant	participant	NOUN
dpc-4194	19	10	or	or	CCONJ
dpc-4194	19	11	speaker	speaker	NOUN
dpc-4194	19	12	for	for	ADP
dpc-4194	19	13	abbvie	abbvie	PROPN
dpc-4194	19	14	,	,	PUNCT
dpc-4194	19	15	lilly	lilly	PROPN
dpc-4194	19	16	,	,	PUNCT
dpc-4194	19	17	janssen	janssen	PROPN
dpc-4194	19	18	,	,	PUNCT
dpc-4194	19	19	novartis	novartis	PROPN
dpc-4194	19	20	,	,	PUNCT
dpc-4194	19	21	celgene	celgene	NOUN
dpc-4194	19	22	,	,	PUNCT
dpc-4194	19	23	almirall	almirall	ADJ
dpc-4194	19	24	,	,	PUNCT
dpc-4194	19	25	and	and	CCONJ
dpc-4194	19	26	leopharma	leopharma	PROPN
dpc-4194	19	27	.	.	PUNCT
dpc-4194	20	1	p.	p.	NOUN
dpc-4194	20	2	dapavo	dapavo	PROPN
dpc-4194	20	3	has	have	AUX
dpc-4194	20	4	been	be	AUX
dpc-4194	20	5	a	a	DET
dpc-4194	20	6	speaker	speaker	NOUN
dpc-4194	20	7	for	for	ADP
dpc-4194	20	8	novartis	novartis	PROPN
dpc-4194	20	9	,	,	PUNCT
dpc-4194	20	10	abbvie	abbvie	PROPN
dpc-4194	20	11	,	,	PUNCT
dpc-4194	20	12	sanofi	sanofi	PROPN
dpc-4194	20	13	,	,	PUNCT
dpc-4194	20	14	ucb	ucb	PROPN
dpc-4194	20	15	,	,	PUNCT
dpc-4194	20	16	janssen	janssen	PROPN
dpc-4194	20	17	,	,	PUNCT
dpc-4194	20	18	lilly	lilly	PROPN
dpc-4194	20	19	,	,	PUNCT
dpc-4194	20	20	and	and	CCONJ
dpc-4194	20	21	leopharma	leopharma	PROPN
dpc-4194	20	22	.	.	PUNCT
dpc-4194	21	1	f.	f.	PROPN
dpc-4194	21	2	m.	m.	PROPN
dpc-4194	21	3	gaiani	gaiani	PROPN
dpc-4194	21	4	acted	act	VERB
dpc-4194	21	5	as	as	ADP
dpc-4194	21	6	a	a	DET
dpc-4194	21	7	speaker	speaker	NOUN
dpc-4194	21	8	or	or	CCONJ
dpc-4194	21	9	consultant	consultant	NOUN
dpc-4194	21	10	for	for	ADP
dpc-4194	21	11	novartis	novartis	PROPN
dpc-4194	21	12	,	,	PUNCT
dpc-4194	21	13	abbvie	abbvie	PROPN
dpc-4194	21	14	,	,	PUNCT
dpc-4194	21	15	eli	eli	PROPN
dpc-4194	21	16	lilly	lilly	PROPN
dpc-4194	21	17	,	,	PUNCT
dpc-4194	21	18	celgene	celgene	NOUN
dpc-4194	21	19	,	,	PUNCT
dpc-4194	21	20	leopharma	leopharma	PROPN
dpc-4194	21	21	,	,	PUNCT
dpc-4194	21	22	and	and	CCONJ
dpc-4194	21	23	almirall	almirall	ADJ
dpc-4194	21	24	.	.	PUNCT
dpc-4194	22	1	l.	l.	PROPN
dpc-4194	22	2	gargiulo	gargiulo	PROPN
dpc-4194	22	3	has	have	AUX
dpc-4194	22	4	been	be	AUX
dpc-4194	22	5	a	a	DET
dpc-4194	22	6	consultant	consultant	NOUN
dpc-4194	22	7	for	for	ADP
dpc-4194	22	8	almirall	almirall	ADJ
dpc-4194	22	9	a.	a.	PROPN
dpc-4194	22	10	giunta	giunta	PROPN
dpc-4194	22	11	received	receive	VERB
dpc-4194	22	12	grants	grant	NOUN
dpc-4194	22	13	or	or	CCONJ
dpc-4194	22	14	is	be	AUX
dpc-4194	22	15	an	an	DET
dpc-4194	22	16	investigator	investigator	NOUN
dpc-4194	22	17	for	for	ADP
dpc-4194	22	18	biogen	biogen	PROPN
dpc-4194	22	19	and	and	CCONJ
dpc-4194	22	20	lilly	lilly	PROPN
dpc-4194	22	21	;	;	PUNCT
dpc-4194	22	22	and	and	CCONJ
dpc-4194	22	23	is	be	AUX
dpc-4194	22	24	a	a	DET
dpc-4194	22	25	consultant	consultant	NOUN
dpc-4194	22	26	/	/	SYM
dpc-4194	22	27	advisory	advisory	ADJ
dpc-4194	22	28	board	board	NOUN
dpc-4194	22	29	/	/	SYM
dpc-4194	22	30	speaker	speaker	NOUN
dpc-4194	22	31	for	for	ADP
dpc-4194	22	32	abbvie	abbvie	PROPN
dpc-4194	22	33	,	,	PUNCT
dpc-4194	22	34	almirall	almirall	ADJ
dpc-4194	22	35	,	,	PUNCT
dpc-4194	22	36	celgene	celgene	NOUN
dpc-4194	22	37	,	,	PUNCT
dpc-4194	22	38	janssen	janssen	PROPN
dpc-4194	22	39	,	,	PUNCT
dpc-4194	22	40	leo	leo	PROPN
dpc-4194	22	41	pharma	pharma	PROPN
dpc-4194	22	42	,	,	PUNCT
dpc-4194	22	43	eli	eli	PROPN
dpc-4194	22	44	lilly	lilly	PROPN
dpc-4194	22	45	,	,	PUNCT
dpc-4194	22	46	merck	merck	PROPN
dpc-4194	22	47	sharpe	sharpe	PROPN
dpc-4194	22	48	dohme	dohme	PROPN
dpc-4194	22	49	,	,	PUNCT
dpc-4194	22	50	novartis	novartis	NOUN
dpc-4194	22	51	,	,	PUNCT
dpc-4194	22	52	pfizer	pfizer	PROPN
dpc-4194	22	53	,	,	PUNCT
dpc-4194	22	54	sandoz	sandoz	PROPN
dpc-4194	22	55	and	and	CCONJ
dpc-4194	22	56	ucb	ucb	PROPN
dpc-4194	22	57	.	.	PUNCT
dpc-4194	23	1	f.	f.	PROPN
dpc-4194	23	2	loconsole	loconsole	PROPN
dpc-4194	23	3	served	serve	VERB
dpc-4194	23	4	on	on	ADP
dpc-4194	23	5	advisory	advisory	ADJ
dpc-4194	23	6	boards	board	NOUN
dpc-4194	23	7	and/or	and/or	CCONJ
dpc-4194	23	8	received	receive	VERB
dpc-4194	23	9	honoraria	honorarium	NOUN
dpc-4194	23	10	for	for	ADP
dpc-4194	23	11	lectures	lecture	NOUN
dpc-4194	23	12	from	from	ADP
dpc-4194	23	13	abbvie	abbvie	PROPN
dpc-4194	23	14	,	,	PUNCT
dpc-4194	23	15	janssen	janssen	NOUN
dpc-4194	23	16	-	-	PUNCT
dpc-4194	23	17	cilag	cilag	PROPN
dpc-4194	23	18	,	,	PUNCT
dpc-4194	23	19	novartis	novartis	NOUN
dpc-4194	23	20	,	,	PUNCT
dpc-4194	23	21	lilly	lilly	PROPN
dpc-4194	23	22	,	,	PUNCT
dpc-4194	23	23	sanofi	sanofi	PROPN
dpc-4194	23	24	.	.	PUNCT
dpc-4194	24	1	a.	a.	PROPN
dpc-4194	24	2	v.	v.	ADP
dpc-4194	24	3	marzano	marzano	PROPN
dpc-4194	24	4	reports	report	NOUN
dpc-4194	24	5	consultancy	consultancy	NOUN
dpc-4194	24	6	/	/	SYM
dpc-4194	24	7	advisory	advisory	ADJ
dpc-4194	24	8	boards	board	NOUN
dpc-4194	24	9	disease	disease	NOUN
dpc-4194	24	10	-	-	PUNCT
dpc-4194	24	11	relevant	relevant	ADJ
dpc-4194	24	12	honoraria	honoraria	NOUN
dpc-4194	24	13	from	from	ADP
dpc-4194	24	14	abbvie	abbvie	PROPN
dpc-4194	24	15	,	,	PUNCT
dpc-4194	24	16	boehringer	boehringer	PROPN
dpc-4194	24	17	-	-	PUNCT
dpc-4194	24	18	ingelheim	ingelheim	PROPN
dpc-4194	24	19	,	,	PUNCT
dpc-4194	24	20	novartis	novartis	PROPN
dpc-4194	24	21	,	,	PUNCT
dpc-4194	24	22	pfizer	pfizer	NOUN
dpc-4194	24	23	,	,	PUNCT
dpc-4194	24	24	sanofi	sanofi	PROPN
dpc-4194	24	25	and	and	CCONJ
dpc-4194	24	26	ucb	ucb	PROPN
dpc-4194	24	27	.	.	PROPN
dpc-4194	24	28	m.	m.	PROPN
dpc-4194	24	29	megna	megna	PROPN
dpc-4194	24	30	acted	act	VERB
dpc-4194	24	31	as	as	ADP
dpc-4194	24	32	a	a	DET
dpc-4194	24	33	speaker	speaker	NOUN
dpc-4194	24	34	or	or	CCONJ
dpc-4194	24	35	consultant	consultant	NOUN
dpc-4194	24	36	for	for	ADP
dpc-4194	24	37	abbvie	abbvie	PROPN
dpc-4194	24	38	,	,	PUNCT
dpc-4194	24	39	eli	eli	PROPN
dpc-4194	24	40	lilly	lilly	PROPN
dpc-4194	24	41	,	,	PUNCT
dpc-4194	24	42	janssen	janssen	PROPN
dpc-4194	24	43	,	,	PUNCT
dpc-4194	24	44	leo	leo	PROPN
dpc-4194	24	45	-	-	PUNCT
dpc-4194	24	46	pharma	pharma	PROPN
dpc-4194	24	47	,	,	PUNCT
dpc-4194	24	48	ucb	ucb	PROPN
dpc-4194	24	49	and	and	CCONJ
dpc-4194	24	50	novartis	novartis	PROPN
dpc-4194	24	51	.	.	PUNCT
dpc-4194	25	1	a.	a.	PROPN
dpc-4194	25	2	narcisi	narcisi	PROPN
dpc-4194	25	3	has	have	AUX
dpc-4194	25	4	served	serve	VERB
dpc-4194	25	5	on	on	ADP
dpc-4194	25	6	advisory	advisory	ADJ
dpc-4194	25	7	boards	board	NOUN
dpc-4194	25	8	,	,	PUNCT
dpc-4194	25	9	received	receive	VERB
dpc-4194	25	10	honoraria	honorarium	NOUN
dpc-4194	25	11	for	for	ADP
dpc-4194	25	12	lectures	lecture	NOUN
dpc-4194	25	13	and	and	CCONJ
dpc-4194	25	14	research	research	NOUN
dpc-4194	25	15	grants	grant	NOUN
dpc-4194	25	16	from	from	ADP
dpc-4194	25	17	almirall	almirall	ADJ
dpc-4194	25	18	,	,	PUNCT
dpc-4194	25	19	abbvie	abbvie	PROPN
dpc-4194	25	20	,	,	PUNCT
dpc-4194	25	21	leo	leo	PROPN
dpc-4194	25	22	pharma	pharma	PROPN
dpc-4194	25	23	,	,	PUNCT
dpc-4194	25	24	celgene	celgene	NOUN
dpc-4194	25	25	,	,	PUNCT
dpc-4194	25	26	eli	eli	PROPN
dpc-4194	25	27	lilly	lilly	PROPN
dpc-4194	25	28	,	,	PUNCT
dpc-4194	25	29	janssen	janssen	PROPN
dpc-4194	25	30	,	,	PUNCT
dpc-4194	25	31	novartis	novartis	PROPN
dpc-4194	25	32	,	,	PUNCT
dpc-4194	25	33	sanofi‐genzyme	sanofi‐genzyme	NOUN
dpc-4194	25	34	,	,	PUNCT
dpc-4194	25	35	amgen	amgen	PROPN
dpc-4194	25	36	and	and	CCONJ
dpc-4194	25	37	boehringer	boehringer	PROPN
dpc-4194	25	38	ingelheim	ingelheim	PROPN
dpc-4194	25	39	.	.	PUNCT
dpc-4194	26	1	a.	a.	PROPN
dpc-4194	26	2	offidani	offidani	PROPN
dpc-4194	26	3	acted	act	VERB
dpc-4194	26	4	as	as	ADP
dpc-4194	26	5	a	a	DET
dpc-4194	26	6	speaker	speaker	NOUN
dpc-4194	26	7	and	and	CCONJ
dpc-4194	26	8	consultant	consultant	NOUN
dpc-4194	26	9	for	for	ADP
dpc-4194	26	10	abbvie	abbvie	PROPN
dpc-4194	26	11	,	,	PUNCT
dpc-4194	26	12	eli	eli	PROPN
dpc-4194	26	13	lilly	lilly	PROPN
dpc-4194	26	14	,	,	PUNCT
dpc-4194	26	15	novartis	novartis	PROPN
dpc-4194	26	16	,	,	PUNCT
dpc-4194	26	17	celgene	celgene	NOUN
dpc-4194	26	18	,	,	PUNCT
dpc-4194	26	19	sanofi	sanofi	NOUN
dpc-4194	26	20	,	,	PUNCT
dpc-4194	26	21	galderma	galderma	PROPN
dpc-4194	26	22	,	,	PUNCT
dpc-4194	26	23	leo	leo	PROPN
dpc-4194	26	24	pharma	pharma	PROPN
dpc-4194	26	25	,	,	PUNCT
dpc-4194	26	26	pierre	pierre	PROPN
dpc-4194	26	27	fabre	fabre	PROPN
dpc-4194	26	28	.	.	PROPN
dpc-4194	26	29	m.	m.	PROPN
dpc-4194	26	30	venturini	venturini	PROPN
dpc-4194	26	31	served	serve	VERB
dpc-4194	26	32	as	as	ADP
dpc-4194	26	33	a	a	DET
dpc-4194	26	34	speaker	speaker	NOUN
dpc-4194	26	35	or	or	CCONJ
dpc-4194	26	36	advisory	advisory	ADJ
dpc-4194	26	37	board	board	NOUN
dpc-4194	26	38	member	member	NOUN
dpc-4194	26	39	for	for	ADP
dpc-4194	26	40	abbvie	abbvie	PROPN
dpc-4194	26	41	,	,	PUNCT
dpc-4194	26	42	almirall	almirall	PROPN
dpc-4194	26	43	,	,	PUNCT
dpc-4194	26	44	amgen	amgen	PROPN
dpc-4194	26	45	,	,	PUNCT
dpc-4194	26	46	eli	eli	PROPN
dpc-4194	26	47	-	-	PUNCT
dpc-4194	26	48	lilly	lilly	PROPN
dpc-4194	26	49	,	,	PUNCT
dpc-4194	26	50	galderma	galderma	PROPN
dpc-4194	26	51	,	,	PUNCT
dpc-4194	26	52	leo	leo	PROPN
dpc-4194	26	53	pharma	pharma	PROPN
dpc-4194	26	54	,	,	PUNCT
dpc-4194	26	55	novartis	novartis	PROPN
dpc-4194	26	56	,	,	PUNCT
dpc-4194	26	57	pierre	pierre	PROPN
dpc-4194	26	58	fabre	fabre	PROPN
dpc-4194	26	59	and	and	CCONJ
dpc-4194	26	60	ucb	ucb	PROPN
dpc-4194	26	61	pharma	pharma	PROPN
dpc-4194	26	62	.	.	PUNCT
dpc-4194	27	1	a.	a.	PROPN
dpc-4194	27	2	costanzo	costanzo	PROPN
dpc-4194	27	3	has	have	AUX
dpc-4194	27	4	served	serve	VERB
dpc-4194	27	5	as	as	ADP
dpc-4194	27	6	an	an	DET
dpc-4194	27	7	advisory	advisory	ADJ
dpc-4194	27	8	board	board	NOUN
dpc-4194	27	9	member	member	NOUN
dpc-4194	27	10	,	,	PUNCT
dpc-4194	27	11	consultant	consultant	NOUN
dpc-4194	27	12	and	and	CCONJ
dpc-4194	27	13	has	have	AUX
dpc-4194	27	14	received	receive	VERB
dpc-4194	27	15	fees	fee	NOUN
dpc-4194	27	16	and	and	CCONJ
dpc-4194	27	17	speaker	speaker	NOUN
dpc-4194	27	18	’s	’s	PART
dpc-4194	27	19	honoraria	honoraria	NOUN
dpc-4194	27	20	or	or	CCONJ
dpc-4194	27	21	has	have	AUX
dpc-4194	27	22	participated	participate	VERB
dpc-4194	27	23	in	in	ADP
dpc-4194	27	24	clinical	clinical	ADJ
dpc-4194	27	25	trials	trial	NOUN
dpc-4194	27	26	for	for	ADP
dpc-4194	27	27	abbvie	abbvie	NOUN
dpc-4194	27	28	,	,	PUNCT
dpc-4194	27	29	almirall	almirall	ADJ
dpc-4194	27	30	,	,	PUNCT
dpc-4194	27	31	biogen	biogen	PROPN
dpc-4194	27	32	,	,	PUNCT
dpc-4194	27	33	leo	leo	PROPN
dpc-4194	27	34	pharma	pharma	PROPN
dpc-4194	27	35	,	,	PUNCT
dpc-4194	27	36	lilly	lilly	PROPN
dpc-4194	27	37	,	,	PUNCT
dpc-4194	27	38	janssen	janssen	PROPN
dpc-4194	27	39	,	,	PUNCT
dpc-4194	27	40	novartis	novartis	PROPN
dpc-4194	27	41	,	,	PUNCT
dpc-4194	27	42	pfizer	pfizer	NOUN
dpc-4194	27	43	,	,	PUNCT
dpc-4194	27	44	sanofi	sanofi	PROPN
dpc-4194	27	45	genzyme	genzyme	PROPN
dpc-4194	27	46	,	,	PUNCT
dpc-4194	27	47	and	and	CCONJ
dpc-4194	27	48	ucb	ucb	PROPN
dpc-4194	27	49	-	-	PUNCT
dpc-4194	27	50	pharma	pharma	PROPN
dpc-4194	27	51	.	.	PUNCT
dpc-4194	28	1	no	no	DET
dpc-4194	28	2	other	other	ADJ
dpc-4194	28	3	disclosures	disclosure	NOUN
dpc-4194	28	4	were	be	AUX
dpc-4194	28	5	reported	report	VERB
dpc-4194	28	6	.	.	PUNCT
dpc-4194	29	1	authorship	authorship	NOUN
dpc-4194	29	2	:	:	PUNCT
dpc-4194	29	3	all	all	DET
dpc-4194	29	4	authors	author	NOUN
dpc-4194	29	5	have	have	AUX
dpc-4194	29	6	contributed	contribute	VERB
dpc-4194	29	7	significantly	significantly	ADV
dpc-4194	29	8	to	to	ADP
dpc-4194	29	9	this	this	DET
dpc-4194	29	10	publication	publication	NOUN
dpc-4194	29	11	.	.	PUNCT
dpc-4194	30	1	corresponding	correspond	VERB
dpc-4194	30	2	author	author	NOUN
dpc-4194	30	3	:	:	PUNCT
dpc-4194	30	4	diego	diego	PROPN
dpc-4194	30	5	orsini	orsini	PROPN
dpc-4194	30	6	,	,	PUNCT
dpc-4194	30	7	md	md	PROPN
dpc-4194	30	8	,	,	PUNCT
dpc-4194	30	9	clinical	clinical	ADJ
dpc-4194	30	10	dermatology	dermatology	NOUN
dpc-4194	30	11	unit	unit	NOUN
dpc-4194	30	12	san	san	PROPN
dpc-4194	30	13	 	 	SPACE
dpc-4194	30	14	gallicano	gallicano	ADJ
dpc-4194	30	15	 	 	SPACE
dpc-4194	30	16	dermatological	dermatological	PROPN
dpc-4194	30	17	institute	institute	NOUN
dpc-4194	30	18	irccs	irccs	NOUN
dpc-4194	30	19	,	,	PUNCT
dpc-4194	30	20	00144	00144	NUM
dpc-4194	30	21	 	 	SPACE
dpc-4194	30	22	roma	roma	PROPN
dpc-4194	30	23	(	(	PUNCT
dpc-4194	30	24	rm	rm	PROPN
dpc-4194	30	25	)	)	PUNCT
dpc-4194	30	26	,	,	PUNCT
dpc-4194	30	27	italy	italy	PROPN
dpc-4194	30	28	.	.	PUNCT
dpc-4194	31	1	mail	mail	NOUN
dpc-4194	31	2	:	:	PUNCT
dpc-4194	31	3	diegorsini@gmail.com	diegorsini@gmail.com	X
dpc-4194	32	1	introduction	introduction	NOUN
dpc-4194	32	2	:	:	PUNCT
dpc-4194	32	3	genital	genital	ADJ
dpc-4194	32	4	involvement	involvement	NOUN
dpc-4194	32	5	is	be	AUX
dpc-4194	32	6	observed	observe	VERB
dpc-4194	32	7	in	in	ADP
dpc-4194	32	8	approximately	approximately	ADV
dpc-4194	32	9	60	60	NUM
dpc-4194	32	10	%	%	NOUN
dpc-4194	32	11	of	of	ADP
dpc-4194	32	12	patients	patient	NOUN
dpc-4194	32	13	with	with	ADP
dpc-4194	32	14	psoriasis	psoriasis	NOUN
dpc-4194	32	15	,	,	PUNCT
dpc-4194	32	16	presenting	present	VERB
dpc-4194	32	17	clinicians	clinician	NOUN
dpc-4194	32	18	with	with	ADP
dpc-4194	32	19	formidable	formidable	ADJ
dpc-4194	32	20	challenges	challenge	NOUN
dpc-4194	32	21	in	in	ADP
dpc-4194	32	22	treatment	treatment	NOUN
dpc-4194	32	23	.	.	PUNCT
dpc-4194	33	1	while	while	SCONJ
dpc-4194	33	2	new	new	ADJ
dpc-4194	33	3	biologic	biologic	NOUN
dpc-4194	33	4	drugs	drug	NOUN
dpc-4194	33	5	have	have	AUX
dpc-4194	33	6	emerged	emerge	VERB
dpc-4194	33	7	as	as	ADV
dpc-4194	33	8	safe	safe	ADJ
dpc-4194	33	9	and	and	CCONJ
dpc-4194	33	10	effective	effective	ADJ
dpc-4194	33	11	options	option	NOUN
dpc-4194	33	12	for	for	ADP
dpc-4194	33	13	managing	manage	VERB
dpc-4194	33	14	psoriasis	psoriasis	NOUN
dpc-4194	33	15	,	,	PUNCT
dpc-4194	33	16	their	their	PRON
dpc-4194	33	17	efficacy	efficacy	NOUN
dpc-4194	33	18	in	in	ADP
dpc-4194	33	19	challenging	challenge	VERB
dpc-4194	33	20	-	-	PUNCT
dpc-4194	33	21	to	to	ADP
dpc-4194	33	22	-	-	PUNCT
dpc-4194	33	23	treat	treat	NOUN
dpc-4194	33	24	areas	area	NOUN
dpc-4194	33	25	remains	remains	AUX
dpc-4194	33	26	inadequately	inadequately	ADV
dpc-4194	33	27	explored	explore	VERB
dpc-4194	33	28	.	.	PUNCT
dpc-4194	34	1	intriguingly	intriguingly	ADV
dpc-4194	34	2	,	,	PUNCT
dpc-4194	34	3	studies	study	NOUN
dpc-4194	34	4	have	have	AUX
dpc-4194	34	5	shown	show	VERB
dpc-4194	34	6	that	that	SCONJ
dpc-4194	34	7	interleukin	interleukin	NOUN
dpc-4194	34	8	(	(	PUNCT
dpc-4194	34	9	il)-17	il)-17	ADP
dpc-4194	34	10	inhibitors	inhibitor	NOUN
dpc-4194	34	11	exhibit	exhibit	VERB
dpc-4194	34	12	effectiveness	effectiveness	NOUN
dpc-4194	34	13	in	in	ADP
dpc-4194	34	14	addressing	address	VERB
dpc-4194	34	15	genital	genital	ADJ
dpc-4194	34	16	psoriasis	psoriasis	NOUN
dpc-4194	34	17	.	.	PUNCT
dpc-4194	35	1	objectives	objective	NOUN
dpc-4194	35	2	:	:	PUNCT
dpc-4194	35	3	we	we	PRON
dpc-4194	35	4	aimed	aim	VERB
dpc-4194	35	5	to	to	PART
dpc-4194	35	6	determine	determine	VERB
dpc-4194	35	7	the	the	DET
dpc-4194	35	8	effectiveness	effectiveness	NOUN
dpc-4194	35	9	profile	profile	NOUN
dpc-4194	35	10	of	of	ADP
dpc-4194	35	11	bimekizumab	bimekizumab	NOUN
dpc-4194	35	12	in	in	ADP
dpc-4194	35	13	patients	patient	NOUN
dpc-4194	35	14	affected	affect	VERB
dpc-4194	35	15	by	by	ADP
dpc-4194	35	16	moderate	moderate	ADJ
dpc-4194	35	17	-	-	PUNCT
dpc-4194	35	18	to	to	ADP
dpc-4194	35	19	-	-	PUNCT
dpc-4194	35	20	severe	severe	ADJ
dpc-4194	35	21	plaque	plaque	NOUN
dpc-4194	35	22	psoriasis	psoriasis	NOUN
dpc-4194	35	23	with	with	ADP
dpc-4194	35	24	involvement	involvement	NOUN
dpc-4194	35	25	of	of	ADP
dpc-4194	35	26	genitalia	genitalia	NOUN
dpc-4194	35	27	.	.	PUNCT
dpc-4194	36	1	methods	method	NOUN
dpc-4194	36	2	:	:	PUNCT
dpc-4194	36	3	bimekizumab	bimekizumab	ADV
dpc-4194	36	4	,	,	PUNCT
dpc-4194	36	5	a	a	DET
dpc-4194	36	6	dual	dual	ADJ
dpc-4194	36	7	inhibitor	inhibitor	NOUN
dpc-4194	36	8	of	of	ADP
dpc-4194	36	9	both	both	DET
dpc-4194	36	10	il-17a	il-17a	PROPN
dpc-4194	36	11	and	and	CCONJ
dpc-4194	36	12	il-17f	il-17f	NOUN
dpc-4194	36	13	,	,	PUNCT
dpc-4194	36	14	was	be	AUX
dpc-4194	36	15	the	the	DET
dpc-4194	36	16	focus	focus	NOUN
dpc-4194	36	17	of	of	ADP
dpc-4194	36	18	our	our	PRON
dpc-4194	36	19	16	16	NUM
dpc-4194	36	20	-	-	PUNCT
dpc-4194	36	21	week	week	NOUN
dpc-4194	36	22	study	study	NOUN
dpc-4194	36	23	,	,	PUNCT
dpc-4194	36	24	demonstrating	demonstrate	VERB
dpc-4194	36	25	highly	highly	ADV
dpc-4194	36	26	favorable	favorable	ADJ
dpc-4194	36	27	outcomes	outcome	NOUN
dpc-4194	36	28	for	for	ADP
dpc-4194	36	29	patients	patient	NOUN
dpc-4194	36	30	with	with	ADP
dpc-4194	36	31	genital	genital	ADJ
dpc-4194	36	32	psoriasis	psoriasis	NOUN
dpc-4194	36	33	.	.	PUNCT
dpc-4194	37	1	the	the	DET
dpc-4194	37	2	effectiveness	effectiveness	NOUN
dpc-4194	37	3	of	of	ADP
dpc-4194	37	4	bimekizumab	bimekizumab	NOUN
dpc-4194	37	5	was	be	AUX
dpc-4194	37	6	evaluated	evaluate	VERB
dpc-4194	37	7	in	in	ADP
dpc-4194	37	8	terms	term	NOUN
dpc-4194	37	9	of	of	ADP
dpc-4194	37	10	improvement	improvement	NOUN
dpc-4194	37	11	in	in	ADP
dpc-4194	37	12	static	static	ADJ
dpc-4194	37	13	physician	physician	NOUN
dpc-4194	37	14	global	global	ADJ
dpc-4194	37	15	assessment	assessment	NOUN
dpc-4194	37	16	of	of	ADP
dpc-4194	37	17	genitalia	genitalia	NOUN
dpc-4194	37	18	(	(	PUNCT
dpc-4194	37	19	spga	spga	NOUN
dpc-4194	37	20	-	-	PUNCT
dpc-4194	37	21	g	g	NOUN
dpc-4194	37	22	)	)	PUNCT
dpc-4194	37	23	and	and	CCONJ
dpc-4194	37	24	psoriasis	psoriasis	NOUN
dpc-4194	37	25	area	area	NOUN
dpc-4194	37	26	and	and	CCONJ
dpc-4194	37	27	severity	severity	NOUN
dpc-4194	37	28	index	index	NOUN
dpc-4194	37	29	.	.	PUNCT
dpc-4194	38	1	results	result	NOUN
dpc-4194	38	2	:	:	PUNCT
dpc-4194	38	3	sixty	sixty	NUM
dpc-4194	38	4	-	-	PUNCT
dpc-4194	38	5	five	five	NUM
dpc-4194	38	6	adult	adult	NOUN
dpc-4194	38	7	patients	patient	NOUN
dpc-4194	38	8	were	be	AUX
dpc-4194	38	9	enrolled	enrol	VERB
dpc-4194	38	10	.	.	PUNCT
dpc-4194	39	1	remarkably	remarkably	ADV
dpc-4194	39	2	,	,	PUNCT
dpc-4194	39	3	98.4	98.4	NUM
dpc-4194	39	4	%	%	NOUN
dpc-4194	39	5	of	of	ADP
dpc-4194	39	6	our	our	PRON
dpc-4194	39	7	participants	participant	NOUN
dpc-4194	39	8	achieved	achieve	VERB
dpc-4194	39	9	a	a	DET
dpc-4194	39	10	clear	clear	ADJ
dpc-4194	39	11	spga	spga	NOUN
dpc-4194	39	12	-	-	PUNCT
dpc-4194	39	13	g	g	NOUN
dpc-4194	39	14	score	score	NOUN
dpc-4194	39	15	(	(	PUNCT
dpc-4194	39	16	s	s	NOUN
dpc-4194	39	17	-	-	PUNCT
dpc-4194	39	18	pga	pga	NOUN
dpc-4194	39	19	-	-	PUNCT
dpc-4194	39	20	g	g	NOUN
dpc-4194	39	21	=	=	NOUN
dpc-4194	39	22	0	0	NUM
dpc-4194	39	23	)	)	PUNCT
dpc-4194	39	24	within	within	ADP
dpc-4194	39	25	16	16	NUM
dpc-4194	39	26	weeks	week	NOUN
dpc-4194	39	27	.	.	PUNCT
dpc-4194	40	1	moreover	moreover	ADV
dpc-4194	40	2	,	,	PUNCT
dpc-4194	40	3	consistent	consistent	ADJ
dpc-4194	40	4	improvements	improvement	NOUN
dpc-4194	40	5	were	be	AUX
dpc-4194	40	6	observed	observe	VERB
dpc-4194	40	7	in	in	ADP
dpc-4194	40	8	psoriasis	psoriasis	NOUN
dpc-4194	40	9	area	area	NOUN
dpc-4194	40	10	and	and	CCONJ
dpc-4194	40	11	severity	severity	NOUN
dpc-4194	40	12	index	index	NOUN
dpc-4194	40	13	scores	score	NOUN
dpc-4194	40	14	,	,	PUNCT
dpc-4194	40	15	accompanied	accompany	VERB
dpc-4194	40	16	by	by	ADP
dpc-4194	40	17	a	a	DET
dpc-4194	40	18	significant	significant	ADJ
dpc-4194	40	19	reduction	reduction	NOUN
dpc-4194	40	20	in	in	ADP
dpc-4194	40	21	the	the	DET
dpc-4194	40	22	mean	mean	ADJ
dpc-4194	40	23	dermatology	dermatology	NOUN
dpc-4194	40	24	life	life	NOUN
dpc-4194	40	25	quality	quality	NOUN
dpc-4194	40	26	index	index	NOUN
dpc-4194	40	27	,	,	PUNCT
dpc-4194	40	28	signifying	signify	VERB
dpc-4194	40	29	enhanced	enhanced	ADJ
dpc-4194	40	30	quality	quality	NOUN
dpc-4194	40	31	of	of	ADP
dpc-4194	40	32	life	life	NOUN
dpc-4194	40	33	.	.	PUNCT
dpc-4194	41	1	notably	notably	ADV
dpc-4194	41	2	,	,	PUNCT
dpc-4194	41	3	none	none	NOUN
dpc-4194	41	4	of	of	ADP
dpc-4194	41	5	the	the	DET
dpc-4194	41	6	patients	patient	NOUN
dpc-4194	41	7	reported	report	VERB
dpc-4194	41	8	a	a	DET
dpc-4194	41	9	severe	severe	ADJ
dpc-4194	41	10	impairment	impairment	NOUN
dpc-4194	41	11	in	in	ADP
dpc-4194	41	12	their	their	PRON
dpc-4194	41	13	quality	quality	NOUN
dpc-4194	41	14	of	of	ADP
dpc-4194	41	15	life	life	NOUN
dpc-4194	41	16	after	after	ADP
dpc-4194	41	17	16	16	NUM
dpc-4194	41	18	weeks	week	NOUN
dpc-4194	41	19	of	of	ADP
dpc-4194	41	20	treatment	treatment	NOUN
dpc-4194	41	21	.	.	PUNCT
dpc-4194	42	1	in	in	ADP
dpc-4194	42	2	our	our	PRON
dpc-4194	42	3	cohort	cohort	NOUN
dpc-4194	42	4	of	of	ADP
dpc-4194	42	5	65	65	NUM
dpc-4194	42	6	patients	patient	NOUN
dpc-4194	42	7	,	,	PUNCT
dpc-4194	42	8	subgroup	subgroup	NOUN
dpc-4194	42	9	analyses	analysis	NOUN
dpc-4194	42	10	unveiled	unveil	VERB
dpc-4194	42	11	that	that	SCONJ
dpc-4194	42	12	the	the	DET
dpc-4194	42	13	effectiveness	effectiveness	NOUN
dpc-4194	42	14	of	of	ADP
dpc-4194	42	15	bimekizumab	bimekizumab	NOUN
dpc-4194	42	16	remained	remain	VERB
dpc-4194	42	17	unaffected	unaffected	ADJ
dpc-4194	42	18	by	by	ADP
dpc-4194	42	19	prior	prior	ADJ
dpc-4194	42	20	exposure	exposure	NOUN
dpc-4194	42	21	to	to	ADP
dpc-4194	42	22	other	other	ADJ
dpc-4194	42	23	biologics	biologic	NOUN
dpc-4194	42	24	or	or	CCONJ
dpc-4194	42	25	by	by	ADP
dpc-4194	42	26	obesity	obesity	NOUN
dpc-4194	42	27	.	.	PUNCT
dpc-4194	43	1	conclusions	conclusion	NOUN
dpc-4194	43	2	:	:	PUNCT
dpc-4194	43	3	our	our	PRON
dpc-4194	43	4	initial	initial	ADJ
dpc-4194	43	5	findings	finding	NOUN
dpc-4194	43	6	suggest	suggest	VERB
dpc-4194	43	7	that	that	SCONJ
dpc-4194	43	8	bimekizumab	bimekizumab	NOUN
dpc-4194	43	9	may	may	AUX
dpc-4194	43	10	serve	serve	VERB
dpc-4194	43	11	as	as	ADP
dpc-4194	43	12	a	a	DET
dpc-4194	43	13	valuable	valuable	ADJ
dpc-4194	43	14	treatment	treatment	NOUN
dpc-4194	43	15	option	option	NOUN
dpc-4194	43	16	for	for	ADP
dpc-4194	43	17	genital	genital	ADJ
dpc-4194	43	18	psoriasis	psoriasis	NOUN
dpc-4194	43	19	.	.	PUNCT
dpc-4194	44	1	nevertheless	nevertheless	ADV
dpc-4194	44	2	,	,	PUNCT
dpc-4194	44	3	further	further	ADJ
dpc-4194	44	4	research	research	NOUN
dpc-4194	44	5	with	with	ADP
dpc-4194	44	6	larger	large	ADJ
dpc-4194	44	7	sample	sample	NOUN
dpc-4194	44	8	sizes	size	NOUN
dpc-4194	44	9	and	and	CCONJ
dpc-4194	44	10	longer	long	ADJ
dpc-4194	44	11	-	-	PUNCT
dpc-4194	44	12	term	term	NOUN
dpc-4194	44	13	follow	follow	NOUN
dpc-4194	44	14	-	-	PUNCT
dpc-4194	44	15	up	up	NOUN
dpc-4194	44	16	is	be	AUX
dpc-4194	44	17	imperative	imperative	ADJ
dpc-4194	44	18	to	to	PART
dpc-4194	44	19	conclusively	conclusively	ADV
dpc-4194	44	20	validate	validate	VERB
dpc-4194	44	21	these	these	DET
dpc-4194	44	22	results	result	NOUN
dpc-4194	44	23	.	.	PUNCT
dpc-4194	45	1	abstract	abstract	ADJ
dpc-4194	45	2	original	original	ADJ
dpc-4194	45	3	article	article	NOUN
dpc-4194	45	4	|	|	ADV
dpc-4194	45	5	dermatol	dermatol	ADJ
dpc-4194	45	6	pract	pract	NOUN
dpc-4194	45	7	concept	concept	NOUN
dpc-4194	45	8	.	.	PUNCT
dpc-4194	46	1	2024;14(2):e2024052	2024;14(2):e2024052	NUM
dpc-4194	46	2	3	3	NUM
dpc-4194	46	3	acknowledgements	acknowledgement	NOUN
dpc-4194	46	4	:	:	PUNCT
dpc-4194	46	5	editorial	editorial	ADJ
dpc-4194	46	6	assistance	assistance	NOUN
dpc-4194	46	7	was	be	AUX
dpc-4194	46	8	provided	provide	VERB
dpc-4194	46	9	by	by	ADP
dpc-4194	46	10	luca	luca	PROPN
dpc-4194	46	11	giacomelli	giacomelli	PROPN
dpc-4194	46	12	,	,	PUNCT
dpc-4194	46	13	phd	phd	NOUN
dpc-4194	46	14	,	,	PUNCT
dpc-4194	46	15	valeria	valeria	PROPN
dpc-4194	46	16	benedusi	benedusi	PROPN
dpc-4194	46	17	,	,	PUNCT
dpc-4194	46	18	phd	phd	NOUN
dpc-4194	46	19	,	,	PUNCT
dpc-4194	46	20	aashni	aashni	ADP
dpc-4194	46	21	shah	shah	PROPN
dpc-4194	46	22	and	and	CCONJ
dpc-4194	46	23	valentina	valentina	PROPN
dpc-4194	46	24	attanasio	attanasio	PROPN
dpc-4194	46	25	(	(	PUNCT
dpc-4194	46	26	polistudium	polistudium	PROPN
dpc-4194	46	27	srl	srl	PROPN
dpc-4194	46	28	,	,	PUNCT
dpc-4194	46	29	milan	milan	PROPN
dpc-4194	46	30	,	,	PUNCT
dpc-4194	46	31	italy	italy	PROPN
dpc-4194	46	32	)	)	PUNCT
dpc-4194	46	33	.	.	PUNCT
dpc-4194	47	1	this	this	DET
dpc-4194	47	2	assistance	assistance	NOUN
dpc-4194	47	3	was	be	AUX
dpc-4194	47	4	supported	support	VERB
dpc-4194	47	5	by	by	ADP
dpc-4194	47	6	internal	internal	ADJ
dpc-4194	47	7	funds	fund	NOUN
dpc-4194	47	8	.	.	PUNCT
dpc-4194	48	1	ethics	ethic	NOUN
dpc-4194	48	2	statement	statement	NOUN
dpc-4194	48	3	:	:	PUNCT
dpc-4194	48	4	institutional	institutional	ADJ
dpc-4194	48	5	review	review	NOUN
dpc-4194	48	6	board	board	NOUN
dpc-4194	48	7	approval	approval	NOUN
dpc-4194	48	8	was	be	AUX
dpc-4194	48	9	exempted	exempt	VERB
dpc-4194	48	10	as	as	SCONJ
dpc-4194	48	11	the	the	DET
dpc-4194	48	12	study	study	NOUN
dpc-4194	48	13	protocol	protocol	NOUN
dpc-4194	48	14	did	do	AUX
dpc-4194	48	15	not	not	PART
dpc-4194	48	16	deviate	deviate	VERB
dpc-4194	48	17	from	from	ADP
dpc-4194	48	18	standard	standard	ADJ
dpc-4194	48	19	clinical	clinical	ADJ
dpc-4194	48	20	practice	practice	NOUN
dpc-4194	48	21	.	.	PUNCT
dpc-4194	49	1	all	all	PRON
dpc-4194	49	2	included	include	VERB
dpc-4194	49	3	patients	patient	NOUN
dpc-4194	49	4	had	have	AUX
dpc-4194	49	5	provided	provide	VERB
dpc-4194	49	6	written	write	VERB
dpc-4194	49	7	consent	consent	NOUN
dpc-4194	49	8	for	for	ADP
dpc-4194	49	9	retrospective	retrospective	ADJ
dpc-4194	49	10	study	study	NOUN
dpc-4194	49	11	of	of	ADP
dpc-4194	49	12	data	datum	NOUN
dpc-4194	49	13	collected	collect	VERB
dpc-4194	49	14	during	during	ADP
dpc-4194	49	15	routine	routine	ADJ
dpc-4194	49	16	clinical	clinical	ADJ
dpc-4194	49	17	practice	practice	NOUN
dpc-4194	49	18	(	(	PUNCT
dpc-4194	49	19	demographics	demographic	NOUN
dpc-4194	49	20	,	,	PUNCT
dpc-4194	49	21	clinical	clinical	ADJ
dpc-4194	49	22	scores	score	NOUN
dpc-4194	49	23	)	)	PUNCT
dpc-4194	49	24	.	.	PUNCT
dpc-4194	50	1	the	the	DET
dpc-4194	50	2	study	study	NOUN
dpc-4194	50	3	was	be	AUX
dpc-4194	50	4	performed	perform	VERB
dpc-4194	50	5	in	in	ADP
dpc-4194	50	6	accordance	accordance	NOUN
dpc-4194	50	7	with	with	ADP
dpc-4194	50	8	the	the	DET
dpc-4194	50	9	helsinki	helsinki	PROPN
dpc-4194	50	10	declaration	declaration	NOUN
dpc-4194	50	11	of	of	ADP
dpc-4194	50	12	1964	1964	NUM
dpc-4194	50	13	and	and	CCONJ
dpc-4194	50	14	its	its	PRON
dpc-4194	50	15	later	later	ADJ
dpc-4194	50	16	amendments	amendment	NOUN
dpc-4194	50	17	.	.	PUNCT
dpc-4194	51	1	data	datum	NOUN
dpc-4194	51	2	collection	collection	NOUN
dpc-4194	51	3	and	and	CCONJ
dpc-4194	51	4	handling	handling	NOUN
dpc-4194	51	5	complied	comply	VERB
dpc-4194	51	6	with	with	ADP
dpc-4194	51	7	applicable	applicable	ADJ
dpc-4194	51	8	laws	law	NOUN
dpc-4194	51	9	,	,	PUNCT
dpc-4194	51	10	regulations	regulation	NOUN
dpc-4194	51	11	,	,	PUNCT
dpc-4194	51	12	and	and	CCONJ
dpc-4194	51	13	guidance	guidance	NOUN
dpc-4194	51	14	regarding	regard	VERB
dpc-4194	51	15	patient	patient	ADJ
dpc-4194	51	16	protection	protection	NOUN
dpc-4194	51	17	,	,	PUNCT
dpc-4194	51	18	including	include	VERB
dpc-4194	51	19	patient	patient	NOUN
dpc-4194	51	20	privacy	privacy	NOUN
dpc-4194	51	21	.	.	PUNCT
dpc-4194	52	1	introduction	introduction	NOUN
dpc-4194	52	2	genital	genital	ADJ
dpc-4194	52	3	involvement	involvement	NOUN
dpc-4194	52	4	occurs	occur	VERB
dpc-4194	52	5	in	in	ADP
dpc-4194	52	6	over	over	ADP
dpc-4194	52	7	60	60	NUM
dpc-4194	52	8	%	%	NOUN
dpc-4194	52	9	of	of	ADP
dpc-4194	52	10	psoriasis	psoriasis	NOUN
dpc-4194	52	11	patients	patient	NOUN
dpc-4194	52	12	throughout	throughout	ADP
dpc-4194	52	13	the	the	DET
dpc-4194	52	14	course	course	NOUN
dpc-4194	52	15	of	of	ADP
dpc-4194	52	16	their	their	PRON
dpc-4194	52	17	illness	illness	NOUN
dpc-4194	53	1	[	[	X
dpc-4194	53	2	1	1	NUM
dpc-4194	53	3	-	-	SYM
dpc-4194	53	4	3	3	NUM
dpc-4194	53	5	]	]	PUNCT
dpc-4194	53	6	.	.	PUNCT
dpc-4194	54	1	this	this	DET
dpc-4194	54	2	condition	condition	NOUN
dpc-4194	54	3	is	be	AUX
dpc-4194	54	4	associated	associate	VERB
dpc-4194	54	5	with	with	ADP
dpc-4194	54	6	a	a	DET
dpc-4194	54	7	major	major	ADJ
dpc-4194	54	8	impact	impact	NOUN
dpc-4194	54	9	to	to	ADP
dpc-4194	54	10	quality	quality	NOUN
dpc-4194	54	11	of	of	ADP
dpc-4194	54	12	life	life	NOUN
dpc-4194	54	13	(	(	PUNCT
dpc-4194	54	14	qol	qol	NOUN
dpc-4194	54	15	)	)	PUNCT
dpc-4194	54	16	,	,	PUNCT
dpc-4194	54	17	since	since	SCONJ
dpc-4194	54	18	it	it	PRON
dpc-4194	54	19	causes	cause	VERB
dpc-4194	54	20	intense	intense	ADJ
dpc-4194	54	21	burning	burning	NOUN
dpc-4194	54	22	and	and	CCONJ
dpc-4194	54	23	pruritus	pruritus	NOUN
dpc-4194	54	24	,	,	PUNCT
dpc-4194	54	25	and	and	CCONJ
dpc-4194	54	26	is	be	AUX
dpc-4194	54	27	associated	associate	VERB
dpc-4194	54	28	with	with	ADP
dpc-4194	54	29	embarrassment	embarrassment	NOUN
dpc-4194	54	30	in	in	ADP
dpc-4194	54	31	engaging	engage	VERB
dpc-4194	54	32	sexual	sexual	ADJ
dpc-4194	54	33	intercourses	intercourse	NOUN
dpc-4194	54	34	significantly	significantly	ADV
dpc-4194	54	35	impacting	impact	VERB
dpc-4194	54	36	their	their	PRON
dpc-4194	54	37	quality	quality	NOUN
dpc-4194	54	38	of	of	ADP
dpc-4194	54	39	life	life	NOUN
dpc-4194	54	40	[	[	X
dpc-4194	54	41	4	4	NUM
dpc-4194	54	42	-	-	SYM
dpc-4194	54	43	6	6	NUM
dpc-4194	54	44	]	]	PUNCT
dpc-4194	54	45	.	.	PUNCT
dpc-4194	55	1	nevertheless	nevertheless	ADV
dpc-4194	55	2	,	,	PUNCT
dpc-4194	55	3	genital	genital	ADJ
dpc-4194	55	4	psoriasis	psoriasis	NOUN
dpc-4194	55	5	is	be	AUX
dpc-4194	55	6	hardly	hardly	ADV
dpc-4194	55	7	diagnosed	diagnose	VERB
dpc-4194	55	8	in	in	ADP
dpc-4194	55	9	clinical	clinical	ADJ
dpc-4194	55	10	practice	practice	NOUN
dpc-4194	55	11	and	and	CCONJ
dpc-4194	55	12	its	its	PRON
dpc-4194	55	13	treatment	treatment	NOUN
dpc-4194	55	14	poses	pose	VERB
dpc-4194	55	15	challenges	challenge	NOUN
dpc-4194	55	16	due	due	ADP
dpc-4194	55	17	to	to	ADP
dpc-4194	55	18	its	its	PRON
dpc-4194	55	19	classification	classification	NOUN
dpc-4194	55	20	as	as	ADP
dpc-4194	55	21	a	a	DET
dpc-4194	55	22	‘	'	PUNCT
dpc-4194	55	23	difficult	difficult	ADJ
dpc-4194	55	24	to	to	PART
dpc-4194	55	25	-	-	PUNCT
dpc-4194	55	26	treat	treat	VERB
dpc-4194	55	27	’	'	PUNCT
dpc-4194	55	28	area	area	NOUN
dpc-4194	55	29	[	[	X
dpc-4194	55	30	7	7	NUM
dpc-4194	55	31	]	]	PUNCT
dpc-4194	55	32	.	.	PUNCT
dpc-4194	56	1	indeed	indeed	ADV
dpc-4194	56	2	,	,	PUNCT
dpc-4194	56	3	only	only	ADV
dpc-4194	56	4	40	40	NUM
dpc-4194	56	5	%	%	NOUN
dpc-4194	56	6	of	of	ADP
dpc-4194	56	7	patients	patient	NOUN
dpc-4194	56	8	reported	report	VERB
dpc-4194	56	9	to	to	PART
dpc-4194	56	10	have	have	AUX
dpc-4194	56	11	had	have	VERB
dpc-4194	56	12	a	a	DET
dpc-4194	56	13	previous	previous	ADJ
dpc-4194	56	14	examination	examination	NOUN
dpc-4194	56	15	of	of	ADP
dpc-4194	56	16	the	the	DET
dpc-4194	56	17	genital	genital	ADJ
dpc-4194	56	18	area	area	NOUN
dpc-4194	56	19	,	,	PUNCT
dpc-4194	56	20	and	and	CCONJ
dpc-4194	56	21	therefore	therefore	ADV
dpc-4194	56	22	treatment	treatment	NOUN
dpc-4194	56	23	is	be	AUX
dpc-4194	56	24	often	often	ADV
dpc-4194	56	25	initiated	initiate	VERB
dpc-4194	56	26	late	late	ADV
dpc-4194	56	27	[	[	X
dpc-4194	56	28	3	3	NUM
dpc-4194	56	29	]	]	PUNCT
dpc-4194	56	30	.	.	PUNCT
dpc-4194	57	1	topical	topical	ADJ
dpc-4194	57	2	treatments	treatment	NOUN
dpc-4194	57	3	,	,	PUNCT
dpc-4194	57	4	predominantly	predominantly	ADV
dpc-4194	57	5	corticosteroids	corticosteroid	NOUN
dpc-4194	57	6	,	,	PUNCT
dpc-4194	57	7	are	be	AUX
dpc-4194	57	8	the	the	DET
dpc-4194	57	9	initial	initial	ADJ
dpc-4194	57	10	choice	choice	NOUN
dpc-4194	57	11	for	for	ADP
dpc-4194	57	12	mild	mild	ADJ
dpc-4194	57	13	-	-	PUNCT
dpc-4194	57	14	to	to	ADP
dpc-4194	57	15	-	-	PUNCT
dpc-4194	57	16	moderate	moderate	ADJ
dpc-4194	57	17	genital	genital	ADJ
dpc-4194	57	18	psoriasis	psoriasis	NOUN
dpc-4194	57	19	[	[	X
dpc-4194	57	20	5	5	NUM
dpc-4194	57	21	]	]	PUNCT
dpc-4194	57	22	.	.	PUNCT
dpc-4194	58	1	however	however	ADV
dpc-4194	58	2	,	,	PUNCT
dpc-4194	58	3	the	the	DET
dpc-4194	58	4	long	long	ADJ
dpc-4194	58	5	-	-	PUNCT
dpc-4194	58	6	term	term	NOUN
dpc-4194	58	7	use	use	NOUN
dpc-4194	58	8	of	of	ADP
dpc-4194	58	9	corticosteroids	corticosteroid	NOUN
dpc-4194	58	10	is	be	AUX
dpc-4194	58	11	associated	associate	VERB
dpc-4194	58	12	with	with	ADP
dpc-4194	58	13	adverse	adverse	ADJ
dpc-4194	58	14	effects	effect	NOUN
dpc-4194	58	15	,	,	PUNCT
dpc-4194	58	16	and	and	CCONJ
dpc-4194	58	17	limited	limited	ADJ
dpc-4194	58	18	data	datum	NOUN
dpc-4194	58	19	exist	exist	VERB
dpc-4194	58	20	on	on	ADP
dpc-4194	58	21	the	the	DET
dpc-4194	58	22	efficacy	efficacy	NOUN
dpc-4194	58	23	of	of	ADP
dpc-4194	58	24	immunomodulators	immunomodulator	NOUN
dpc-4194	58	25	or	or	CCONJ
dpc-4194	58	26	vitamin	vitamin	NOUN
dpc-4194	58	27	d	d	NOUN
dpc-4194	58	28	derivatives	derivative	NOUN
dpc-4194	58	29	in	in	ADP
dpc-4194	58	30	this	this	DET
dpc-4194	58	31	context	context	NOUN
dpc-4194	59	1	[	[	X
dpc-4194	59	2	8	8	NUM
dpc-4194	59	3	]	]	PUNCT
dpc-4194	59	4	.	.	PUNCT
dpc-4194	60	1	systemic	systemic	ADJ
dpc-4194	60	2	treatments	treatment	NOUN
dpc-4194	60	3	are	be	AUX
dpc-4194	60	4	considered	consider	VERB
dpc-4194	60	5	for	for	ADP
dpc-4194	60	6	moderate	moderate	ADJ
dpc-4194	60	7	-	-	PUNCT
dpc-4194	60	8	to	to	ADP
dpc-4194	60	9	severe	severe	ADJ
dpc-4194	60	10	cases	case	NOUN
dpc-4194	60	11	,	,	PUNCT
dpc-4194	60	12	yet	yet	CCONJ
dpc-4194	60	13	evidence	evidence	NOUN
dpc-4194	60	14	for	for	ADP
dpc-4194	60	15	these	these	DET
dpc-4194	60	16	therapies	therapy	NOUN
dpc-4194	60	17	remains	remain	VERB
dpc-4194	60	18	limited	limited	ADJ
dpc-4194	60	19	[	[	PUNCT
dpc-4194	60	20	5,7	5,7	NUM
dpc-4194	60	21	-	-	SYM
dpc-4194	60	22	10	10	NUM
dpc-4194	60	23	]	]	PUNCT
dpc-4194	60	24	.	.	PUNCT
dpc-4194	61	1	monoclonal	monoclonal	NOUN
dpc-4194	61	2	antibodies	antibodie	VERB
dpc-4194	61	3	targeting	target	VERB
dpc-4194	61	4	key	key	ADJ
dpc-4194	61	5	cytokines	cytokine	NOUN
dpc-4194	61	6	in	in	ADP
dpc-4194	61	7	psoriasis	psoriasis	NOUN
dpc-4194	61	8	pathogenesis	pathogenesis	NOUN
dpc-4194	61	9	,	,	PUNCT
dpc-4194	61	10	primarily	primarily	ADV
dpc-4194	61	11	interleukin	interleukin	NOUN
dpc-4194	61	12	(	(	PUNCT
dpc-4194	61	13	il)-23	il)-23	PROPN
dpc-4194	61	14	and	and	CCONJ
dpc-4194	61	15	il-17a	il-17a	PROPN
dpc-4194	61	16	,	,	PUNCT
dpc-4194	61	17	have	have	AUX
dpc-4194	61	18	been	be	AUX
dpc-4194	61	19	developed	develop	VERB
dpc-4194	61	20	.	.	PUNCT
dpc-4194	62	1	while	while	SCONJ
dpc-4194	62	2	drugs	drug	NOUN
dpc-4194	62	3	like	like	ADP
dpc-4194	62	4	secukinumab	secukinumab	NOUN
dpc-4194	62	5	and	and	CCONJ
dpc-4194	62	6	ixekizumab	ixekizumab	NOUN
dpc-4194	62	7	target	target	PROPN
dpc-4194	62	8	il-17a	il-17a	PROPN
dpc-4194	62	9	,	,	PUNCT
dpc-4194	62	10	brodalumab	brodalumab	NOUN
dpc-4194	62	11	antagonizes	antagonize	VERB
dpc-4194	62	12	the	the	DET
dpc-4194	62	13	il-17a	il-17a	PROPN
dpc-4194	62	14	receptor	receptor	NOUN
dpc-4194	63	1	[	[	X
dpc-4194	63	2	11,12	11,12	NOUN
dpc-4194	63	3	]	]	PUNCT
dpc-4194	63	4	.	.	PUNCT
dpc-4194	64	1	ixekizumab	ixekizumab	NOUN
dpc-4194	64	2	has	have	AUX
dpc-4194	64	3	shown	show	VERB
dpc-4194	64	4	significant	significant	ADJ
dpc-4194	64	5	efficacy	efficacy	NOUN
dpc-4194	64	6	in	in	ADP
dpc-4194	64	7	treating	treat	VERB
dpc-4194	64	8	genital	genital	ADJ
dpc-4194	64	9	psoriasis	psoriasis	NOUN
dpc-4194	64	10	,	,	PUNCT
dpc-4194	64	11	providing	provide	VERB
dpc-4194	64	12	consistent	consistent	ADJ
dpc-4194	64	13	and	and	CCONJ
dpc-4194	64	14	lasting	lasting	ADJ
dpc-4194	64	15	improvements[7,10,13	improvements[7,10,13	NOUN
dpc-4194	64	16	-	-	SYM
dpc-4194	64	17	18	18	NUM
dpc-4194	64	18	]	]	PUNCT
dpc-4194	64	19	.	.	PUNCT
dpc-4194	65	1	recent	recent	ADJ
dpc-4194	65	2	research	research	NOUN
dpc-4194	65	3	has	have	AUX
dpc-4194	65	4	also	also	ADV
dpc-4194	65	5	emphasized	emphasize	VERB
dpc-4194	65	6	the	the	DET
dpc-4194	65	7	role	role	NOUN
dpc-4194	65	8	of	of	ADP
dpc-4194	65	9	il-17f	il-17f	NOUN
dpc-4194	65	10	,	,	PUNCT
dpc-4194	65	11	which	which	PRON
dpc-4194	65	12	exhibits	exhibit	VERB
dpc-4194	65	13	overlapping	overlap	VERB
dpc-4194	65	14	pro	pro	ADJ
dpc-4194	65	15	-	-	ADJ
dpc-4194	65	16	inflammatory	inflammatory	ADJ
dpc-4194	65	17	functions	function	NOUN
dpc-4194	65	18	with	with	ADP
dpc-4194	65	19	il-17a	il-17a	PROPN
dpc-4194	65	20	and	and	CCONJ
dpc-4194	65	21	is	be	AUX
dpc-4194	65	22	more	more	ADV
dpc-4194	65	23	abundant	abundant	ADJ
dpc-4194	65	24	in	in	ADP
dpc-4194	65	25	psoriatic	psoriatic	ADJ
dpc-4194	65	26	lesions	lesion	NOUN
dpc-4194	65	27	[	[	X
dpc-4194	65	28	19	19	NUM
dpc-4194	65	29	]	]	PUNCT
dpc-4194	65	30	.	.	PUNCT
dpc-4194	66	1	bimekizumab	bimekizumab	PROPN
dpc-4194	66	2	,	,	PUNCT
dpc-4194	66	3	a	a	DET
dpc-4194	66	4	humanized	humanize	VERB
dpc-4194	66	5	monoclonal	monoclonal	NOUN
dpc-4194	66	6	antibody	antibody	NOUN
dpc-4194	66	7	targeting	target	VERB
dpc-4194	66	8	both	both	CCONJ
dpc-4194	66	9	il-17a	il-17a	PROPN
dpc-4194	66	10	and	and	CCONJ
dpc-4194	66	11	il-17f	il-17f	NOUN
dpc-4194	66	12	,	,	PUNCT
dpc-4194	66	13	has	have	AUX
dpc-4194	66	14	gained	gain	VERB
dpc-4194	66	15	approval	approval	NOUN
dpc-4194	66	16	for	for	ADP
dpc-4194	66	17	moderate	moderate	ADJ
dpc-4194	66	18	-	-	PUNCT
dpc-4194	66	19	to	to	ADP
dpc-4194	66	20	-	-	PUNCT
dpc-4194	66	21	severe	severe	ADJ
dpc-4194	66	22	plaque	plaque	NOUN
dpc-4194	66	23	psoriasis	psoriasis	NOUN
dpc-4194	66	24	treatment	treatment	NOUN
dpc-4194	66	25	following	follow	VERB
dpc-4194	66	26	four	four	NUM
dpc-4194	66	27	successful	successful	ADJ
dpc-4194	66	28	phase	phase	NOUN
dpc-4194	66	29	-	-	PUNCT
dpc-4194	66	30	iii	iii	NOUN
dpc-4194	66	31	clinical	clinical	ADJ
dpc-4194	66	32	trials	trial	NOUN
dpc-4194	66	33	(	(	PUNCT
dpc-4194	66	34	be	be	AUX
dpc-4194	66	35	ready	ready	ADJ
dpc-4194	66	36	,	,	PUNCT
dpc-4194	66	37	be	be	AUX
dpc-4194	66	38	vivid	vivid	ADJ
dpc-4194	66	39	,	,	PUNCT
dpc-4194	66	40	be	be	AUX
dpc-4194	66	41	sure	sure	ADJ
dpc-4194	66	42	;	;	PUNCT
dpc-4194	66	43	be	be	AUX
dpc-4194	66	44	radiant	radiant	ADJ
dpc-4194	66	45	)	)	PUNCT
dpc-4194	66	46	demonstrating	demonstrate	VERB
dpc-4194	66	47	its	its	PRON
dpc-4194	66	48	superior	superior	ADJ
dpc-4194	66	49	efficacy	efficacy	NOUN
dpc-4194	66	50	compared	compare	VERB
dpc-4194	66	51	to	to	ADP
dpc-4194	66	52	placebo	placebo	NOUN
dpc-4194	66	53	,	,	PUNCT
dpc-4194	66	54	ustekinumab	ustekinumab	NOUN
dpc-4194	66	55	,	,	PUNCT
dpc-4194	66	56	adalimumab	adalimumab	NOUN
dpc-4194	66	57	,	,	PUNCT
dpc-4194	66	58	and	and	CCONJ
dpc-4194	66	59	secukinumab	secukinumab	NOUN
dpc-4194	66	60	[	[	X
dpc-4194	66	61	20	20	NUM
dpc-4194	66	62	-	-	SYM
dpc-4194	66	63	23	23	NUM
dpc-4194	66	64	]	]	PUNCT
dpc-4194	66	65	.	.	PUNCT
dpc-4194	67	1	despite	despite	SCONJ
dpc-4194	67	2	these	these	DET
dpc-4194	67	3	achievements	achievement	NOUN
dpc-4194	67	4	,	,	PUNCT
dpc-4194	67	5	real	real	ADJ
dpc-4194	67	6	-	-	PUNCT
dpc-4194	67	7	world	world	NOUN
dpc-4194	67	8	data	datum	NOUN
dpc-4194	67	9	on	on	ADP
dpc-4194	67	10	bimekizumab	bimekizumab	NOUN
dpc-4194	67	11	are	be	AUX
dpc-4194	67	12	limited	limit	VERB
dpc-4194	67	13	to	to	PART
dpc-4194	67	14	case	case	VERB
dpc-4194	67	15	reports	report	NOUN
dpc-4194	67	16	and	and	CCONJ
dpc-4194	67	17	a	a	DET
dpc-4194	67	18	recent	recent	ADJ
dpc-4194	67	19	retrospective	retrospective	ADJ
dpc-4194	67	20	multicenter	multicenter	NOUN
dpc-4194	67	21	study	study	NOUN
dpc-4194	67	22	by	by	ADP
dpc-4194	67	23	gargiulo	gargiulo	NOUN
dpc-4194	67	24	et	et	PROPN
dpc-4194	67	25	al	al	PROPN
dpc-4194	68	1	[	[	X
dpc-4194	68	2	24	24	NUM
dpc-4194	68	3	-	-	SYM
dpc-4194	68	4	26	26	NUM
dpc-4194	68	5	]	]	PUNCT
dpc-4194	68	6	.	.	PUNCT
dpc-4194	69	1	however	however	ADV
dpc-4194	69	2	,	,	PUNCT
dpc-4194	69	3	no	no	DET
dpc-4194	69	4	data	datum	NOUN
dpc-4194	69	5	are	be	AUX
dpc-4194	69	6	currently	currently	ADV
dpc-4194	69	7	available	available	ADJ
dpc-4194	69	8	regarding	regard	VERB
dpc-4194	69	9	the	the	DET
dpc-4194	69	10	effectiveness	effectiveness	NOUN
dpc-4194	69	11	of	of	ADP
dpc-4194	69	12	bimekizumab	bimekizumab	NOUN
dpc-4194	69	13	on	on	ADP
dpc-4194	69	14	difficult	difficult	ADJ
dpc-4194	69	15	-	-	PUNCT
dpc-4194	69	16	to	to	ADP
dpc-4194	69	17	-	-	PUNCT
dpc-4194	69	18	treat	treat	NOUN
dpc-4194	69	19	areas	area	NOUN
dpc-4194	69	20	,	,	PUNCT
dpc-4194	69	21	and	and	CCONJ
dpc-4194	69	22	genitalia	genitalia	NOUN
dpc-4194	69	23	in	in	ADP
dpc-4194	69	24	particular	particular	ADJ
dpc-4194	69	25	.	.	PUNCT
dpc-4194	70	1	given	give	VERB
dpc-4194	70	2	ixekizumab	ixekizumab	NOUN
dpc-4194	70	3	high	high	ADJ
dpc-4194	70	4	efficacy	efficacy	NOUN
dpc-4194	70	5	in	in	ADP
dpc-4194	70	6	treating	treat	VERB
dpc-4194	70	7	psoriatic	psoriatic	ADJ
dpc-4194	70	8	lesions	lesion	NOUN
dpc-4194	70	9	and	and	CCONJ
dpc-4194	70	10	the	the	DET
dpc-4194	70	11	increased	increase	VERB
dpc-4194	70	12	odds	odd	NOUN
dpc-4194	70	13	of	of	ADP
dpc-4194	70	14	genital	genital	ADJ
dpc-4194	70	15	psoriasis	psoriasis	NOUN
dpc-4194	70	16	clearance	clearance	NOUN
dpc-4194	70	17	with	with	ADP
dpc-4194	70	18	anti	anti	ADJ
dpc-4194	70	19	-	-	ADJ
dpc-4194	70	20	il-17a	il-17a	ADJ
dpc-4194	70	21	inhibitors	inhibitor	NOUN
dpc-4194	70	22	,	,	PUNCT
dpc-4194	70	23	as	as	SCONJ
dpc-4194	70	24	demonstrated	demonstrate	VERB
dpc-4194	70	25	in	in	ADP
dpc-4194	70	26	a	a	DET
dpc-4194	70	27	recent	recent	ADJ
dpc-4194	70	28	prospective	prospective	ADJ
dpc-4194	70	29	observational	observational	ADJ
dpc-4194	70	30	study	study	NOUN
dpc-4194	70	31	,	,	PUNCT
dpc-4194	70	32	coupled	couple	VERB
dpc-4194	70	33	with	with	ADP
dpc-4194	70	34	the	the	DET
dpc-4194	70	35	prevalence	prevalence	NOUN
dpc-4194	70	36	of	of	ADP
dpc-4194	70	37	il-17f	il-17f	NOUN
dpc-4194	70	38	in	in	ADP
dpc-4194	70	39	psoriatic	psoriatic	ADJ
dpc-4194	70	40	lesions	lesion	NOUN
dpc-4194	70	41	,	,	PUNCT
dpc-4194	70	42	we	we	PRON
dpc-4194	70	43	undertook	undertake	VERB
dpc-4194	70	44	this	this	DET
dpc-4194	70	45	study	study	NOUN
dpc-4194	70	46	to	to	PART
dpc-4194	70	47	explore	explore	VERB
dpc-4194	70	48	the	the	DET
dpc-4194	70	49	effectiveness	effectiveness	NOUN
dpc-4194	70	50	of	of	ADP
dpc-4194	70	51	bimekizumab	bimekizumab	NOUN
dpc-4194	70	52	specifically	specifically	ADV
dpc-4194	70	53	in	in	ADP
dpc-4194	70	54	this	this	DET
dpc-4194	70	55	challenging	challenge	VERB
dpc-4194	70	56	-	-	PUNCT
dpc-4194	70	57	to	to	ADP
dpc-4194	70	58	-	-	PUNCT
dpc-4194	70	59	treat	treat	VERB
dpc-4194	70	60	body	body	NOUN
dpc-4194	70	61	area	area	NOUN
dpc-4194	71	1	[	[	X
dpc-4194	71	2	19,27	19,27	NUM
dpc-4194	71	3	]	]	PUNCT
dpc-4194	71	4	.	.	PUNCT
dpc-4194	72	1	objectives	objective	NOUN
dpc-4194	72	2	in	in	ADP
dpc-4194	72	3	this	this	DET
dpc-4194	72	4	paper	paper	NOUN
dpc-4194	72	5	,	,	PUNCT
dpc-4194	72	6	we	we	PRON
dpc-4194	72	7	present	present	VERB
dpc-4194	72	8	the	the	DET
dpc-4194	72	9	results	result	NOUN
dpc-4194	72	10	of	of	ADP
dpc-4194	72	11	a	a	DET
dpc-4194	72	12	retrospective	retrospective	ADJ
dpc-4194	72	13	observational	observational	ADJ
dpc-4194	72	14	multicenter	multicenter	NOUN
dpc-4194	72	15	study	study	NOUN
dpc-4194	72	16	with	with	ADP
dpc-4194	72	17	a	a	DET
dpc-4194	72	18	16	16	NUM
dpc-4194	72	19	-	-	PUNCT
dpc-4194	72	20	week	week	NOUN
dpc-4194	72	21	follow	follow	NOUN
dpc-4194	72	22	-	-	PUNCT
dpc-4194	72	23	up	up	NOUN
dpc-4194	72	24	period	period	NOUN
dpc-4194	72	25	,	,	PUNCT
dpc-4194	72	26	aiming	aim	VERB
dpc-4194	72	27	to	to	PART
dpc-4194	72	28	assess	assess	VERB
dpc-4194	72	29	the	the	DET
dpc-4194	72	30	effectiveness	effectiveness	NOUN
dpc-4194	72	31	of	of	ADP
dpc-4194	72	32	bimekizumab	bimekizumab	NOUN
dpc-4194	72	33	in	in	ADP
dpc-4194	72	34	the	the	DET
dpc-4194	72	35	treatment	treatment	NOUN
dpc-4194	72	36	of	of	ADP
dpc-4194	72	37	genital	genital	ADJ
dpc-4194	72	38	psoriasis	psoriasis	NOUN
dpc-4194	72	39	.	.	PUNCT
dpc-4194	73	1	methods	method	NOUN
dpc-4194	73	2	this	this	PRON
dpc-4194	73	3	was	be	AUX
dpc-4194	73	4	a	a	DET
dpc-4194	73	5	retrospective	retrospective	ADJ
dpc-4194	73	6	,	,	PUNCT
dpc-4194	73	7	observational	observational	ADJ
dpc-4194	73	8	multicenter	multicenter	NOUN
dpc-4194	73	9	study	study	NOUN
dpc-4194	73	10	conducted	conduct	VERB
dpc-4194	73	11	at	at	ADP
dpc-4194	73	12	20	20	NUM
dpc-4194	73	13	italian	italian	ADJ
dpc-4194	73	14	dermatology	dermatology	NOUN
dpc-4194	73	15	clinics	clinic	NOUN
dpc-4194	73	16	,	,	PUNCT
dpc-4194	73	17	from	from	ADP
dpc-4194	73	18	january	january	PROPN
dpc-4194	73	19	2023	2023	NUM
dpc-4194	73	20	to	to	ADP
dpc-4194	73	21	august	august	PROPN
dpc-4194	73	22	2023	2023	NUM
dpc-4194	73	23	.	.	PUNCT
dpc-4194	74	1	consecutive	consecutive	ADJ
dpc-4194	74	2	adult	adult	NOUN
dpc-4194	74	3	(	(	PUNCT
dpc-4194	74	4	≥18	≥18	NUM
dpc-4194	74	5	years	year	NOUN
dpc-4194	74	6	)	)	PUNCT
dpc-4194	74	7	patients	patient	NOUN
dpc-4194	74	8	with	with	ADP
dpc-4194	74	9	moderate	moderate	ADJ
dpc-4194	74	10	-	-	PUNCT
dpc-4194	74	11	to	to	ADP
dpc-4194	74	12	-	-	PUNCT
dpc-4194	74	13	severe	severe	ADJ
dpc-4194	74	14	plaque	plaque	NOUN
dpc-4194	74	15	psoriasis	psoriasis	NOUN
dpc-4194	74	16	involving	involve	VERB
dpc-4194	74	17	the	the	DET
dpc-4194	74	18	genital	genital	ADJ
dpc-4194	74	19	area	area	NOUN
dpc-4194	74	20	were	be	AUX
dpc-4194	74	21	eligible	eligible	ADJ
dpc-4194	74	22	for	for	ADP
dpc-4194	74	23	inclusion	inclusion	NOUN
dpc-4194	74	24	in	in	ADP
dpc-4194	74	25	this	this	DET
dpc-4194	74	26	study	study	NOUN
dpc-4194	74	27	if	if	SCONJ
dpc-4194	74	28	they	they	PRON
dpc-4194	74	29	received	receive	VERB
dpc-4194	74	30	treatment	treatment	NOUN
dpc-4194	74	31	with	with	ADP
dpc-4194	74	32	bimekizumab	bimekizumab	NOUN
dpc-4194	74	33	.	.	PUNCT
dpc-4194	75	1	patients	patient	NOUN
dpc-4194	75	2	eligibility	eligibility	VERB
dpc-4194	75	3	for	for	ADP
dpc-4194	75	4	bimekizumab	bimekizumab	NOUN
dpc-4194	75	5	treatment	treatment	NOUN
dpc-4194	75	6	was	be	AUX
dpc-4194	75	7	assessed	assess	VERB
dpc-4194	75	8	in	in	ADP
dpc-4194	75	9	accordance	accordance	NOUN
dpc-4194	75	10	with	with	ADP
dpc-4194	75	11	the	the	DET
dpc-4194	75	12	italian	italian	ADJ
dpc-4194	75	13	guidelines	guideline	NOUN
dpc-4194	75	14	as	as	SCONJ
dpc-4194	75	15	outlined	outline	VERB
dpc-4194	75	16	by	by	ADP
dpc-4194	75	17	gisondi	gisondi	NOUN
dpc-4194	75	18	et	et	NOUN
dpc-4194	75	19	al	al	PROPN
dpc-4194	75	20	in	in	ADP
dpc-4194	75	21	2022	2022	NUM
dpc-4194	76	1	[	[	X
dpc-4194	76	2	28	28	NUM
dpc-4194	76	3	]	]	PUNCT
dpc-4194	76	4	.	.	PUNCT
dpc-4194	77	1	definition	definition	NOUN
dpc-4194	77	2	of	of	ADP
dpc-4194	77	3	genital	genital	ADJ
dpc-4194	77	4	involvement	involvement	NOUN
dpc-4194	77	5	to	to	PART
dpc-4194	77	6	differentiate	differentiate	VERB
dpc-4194	77	7	genital	genital	ADJ
dpc-4194	77	8	psoriasis	psoriasis	NOUN
dpc-4194	77	9	from	from	ADP
dpc-4194	77	10	inverse	inverse	ADJ
dpc-4194	77	11	psoriasis	psoriasis	NOUN
dpc-4194	77	12	,	,	PUNCT
dpc-4194	77	13	we	we	PRON
dpc-4194	77	14	defined	define	VERB
dpc-4194	77	15	genital	genital	ADJ
dpc-4194	77	16	involvement	involvement	NOUN
dpc-4194	77	17	based	base	VERB
dpc-4194	77	18	on	on	ADP
dpc-4194	77	19	specific	specific	ADJ
dpc-4194	77	20	anatomical	anatomical	ADJ
dpc-4194	77	21	regions	region	NOUN
dpc-4194	77	22	.	.	PUNCT
dpc-4194	78	1	for	for	ADP
dpc-4194	78	2	males	male	NOUN
dpc-4194	78	3	,	,	PUNCT
dpc-4194	78	4	genital	genital	ADJ
dpc-4194	78	5	involvement	involvement	NOUN
dpc-4194	78	6	encompassed	encompass	VERB
dpc-4194	78	7	lesions	lesion	NOUN
dpc-4194	78	8	on	on	ADP
dpc-4194	78	9	the	the	DET
dpc-4194	78	10	pubis	pubis	NOUN
dpc-4194	78	11	,	,	PUNCT
dpc-4194	78	12	shaft	shaft	NOUN
dpc-4194	78	13	,	,	PUNCT
dpc-4194	78	14	foreskin	foreskin	ADJ
dpc-4194	78	15	,	,	PUNCT
dpc-4194	78	16	glans	glan	NOUN
dpc-4194	78	17	,	,	PUNCT
dpc-4194	78	18	scrotum	scrotum	NOUN
dpc-4194	78	19	,	,	PUNCT
dpc-4194	78	20	and	and	CCONJ
dpc-4194	78	21	perineum	perineum	NOUN
dpc-4194	78	22	 	 	SPACE
dpc-4194	79	1	[	[	X
dpc-4194	79	2	7	7	NUM
dpc-4194	79	3	]	]	PUNCT
dpc-4194	79	4	.	.	PUNCT
dpc-4194	80	1	for	for	ADP
dpc-4194	80	2	females	female	NOUN
dpc-4194	80	3	,	,	PUNCT
dpc-4194	80	4	it	it	PRON
dpc-4194	80	5	included	include	VERB
dpc-4194	80	6	lesions	lesion	NOUN
dpc-4194	80	7	on	on	ADP
dpc-4194	80	8	the	the	DET
dpc-4194	80	9	mons	mon	NOUN
dpc-4194	80	10	pubis	pubis	NOUN
dpc-4194	80	11	,	,	PUNCT
dpc-4194	80	12	labia	labia	NOUN
dpc-4194	80	13	majora	majora	NOUN
dpc-4194	80	14	,	,	PUNCT
dpc-4194	80	15	labia	labia	NOUN
dpc-4194	80	16	minora	minora	NOUN
dpc-4194	80	17	,	,	PUNCT
dpc-4194	80	18	anterior	anterior	ADJ
dpc-4194	80	19	commissure	commissure	NOUN
dpc-4194	80	20	,	,	PUNCT
dpc-4194	80	21	interlabial	interlabial	ADJ
dpc-4194	80	22	groove	groove	NOUN
dpc-4194	80	23	,	,	PUNCT
dpc-4194	80	24	and	and	CCONJ
dpc-4194	80	25	perineum	perineum	NOUN
dpc-4194	81	1	[	[	X
dpc-4194	81	2	7	7	NUM
dpc-4194	81	3	]	]	PUNCT
dpc-4194	81	4	.	.	PUNCT
dpc-4194	82	1	patients	patient	NOUN
dpc-4194	82	2	with	with	ADP
dpc-4194	82	3	lesions	lesion	NOUN
dpc-4194	82	4	in	in	ADP
dpc-4194	82	5	the	the	DET
dpc-4194	82	6	inguinal	inguinal	ADJ
dpc-4194	82	7	folds	fold	NOUN
dpc-4194	82	8	and	and	CCONJ
dpc-4194	82	9	intergluteal	intergluteal	ADJ
dpc-4194	82	10	cleft	cleft	NOUN
dpc-4194	82	11	but	but	CCONJ
dpc-4194	82	12	without	without	ADP
dpc-4194	82	13	involvement	involvement	NOUN
dpc-4194	82	14	in	in	ADP
dpc-4194	82	15	the	the	DET
dpc-4194	82	16	aforementioned	aforementioned	ADJ
dpc-4194	82	17	anatomical	anatomical	ADJ
dpc-4194	82	18	sites	site	NOUN
dpc-4194	82	19	were	be	AUX
dpc-4194	82	20	excluded	exclude	VERB
dpc-4194	82	21	from	from	ADP
dpc-4194	82	22	the	the	DET
dpc-4194	82	23	study	study	NOUN
dpc-4194	82	24	[	[	X
dpc-4194	82	25	7	7	NUM
dpc-4194	82	26	]	]	PUNCT
dpc-4194	82	27	.	.	PUNCT
dpc-4194	83	1	all	all	DET
dpc-4194	83	2	patients	patient	NOUN
dpc-4194	83	3	received	receive	VERB
dpc-4194	83	4	bimekizumab	bimekizumab	NOUN
dpc-4194	83	5	in	in	ADP
dpc-4194	83	6	accordance	accordance	NOUN
dpc-4194	83	7	with	with	ADP
dpc-4194	83	8	the	the	DET
dpc-4194	83	9	summary	summary	NOUN
dpc-4194	83	10	of	of	ADP
dpc-4194	83	11	product	product	NOUN
dpc-4194	83	12	characteristics	characteristic	NOUN
dpc-4194	83	13	[	[	X
dpc-4194	83	14	29	29	NUM
dpc-4194	83	15	]	]	PUNCT
dpc-4194	83	16	.	.	PUNCT
dpc-4194	84	1	they	they	PRON
dpc-4194	84	2	were	be	AUX
dpc-4194	84	3	followed	follow	VERB
dpc-4194	84	4	up	up	ADP
dpc-4194	84	5	until	until	ADP
dpc-4194	84	6	week	week	NOUN
dpc-4194	84	7	16	16	NUM
dpc-4194	84	8	,	,	PUNCT
dpc-4194	84	9	receiving	receive	VERB
dpc-4194	84	10	two	two	NUM
dpc-4194	84	11	subcutaneous	subcutaneous	ADJ
dpc-4194	84	12	injections	injection	NOUN
dpc-4194	84	13	of	of	ADP
dpc-4194	84	14	160	160	NUM
dpc-4194	84	15	mg	mg	NOUN
dpc-4194	84	16	each	each	PRON
dpc-4194	84	17	at	at	ADP
dpc-4194	84	18	weeks	week	NOUN
dpc-4194	84	19	0	0	NUM
dpc-4194	84	20	,	,	PUNCT
dpc-4194	84	21	4	4	NUM
dpc-4194	84	22	,	,	PUNCT
dpc-4194	84	23	8	8	NUM
dpc-4194	84	24	,	,	PUNCT
dpc-4194	84	25	12	12	NUM
dpc-4194	84	26	,	,	PUNCT
dpc-4194	84	27	16	16	NUM
dpc-4194	85	1	[	[	X
dpc-4194	85	2	29	29	NUM
dpc-4194	85	3	]	]	PUNCT
dpc-4194	85	4	.	.	PUNCT
dpc-4194	86	1	no	no	DET
dpc-4194	86	2	concurrent	concurrent	ADJ
dpc-4194	86	3	topical	topical	ADJ
dpc-4194	86	4	or	or	CCONJ
dpc-4194	86	5	systemic	systemic	ADJ
dpc-4194	86	6	agents	agent	NOUN
dpc-4194	86	7	were	be	AUX
dpc-4194	86	8	administered	administer	VERB
dpc-4194	86	9	in	in	ADP
dpc-4194	86	10	conjunction	conjunction	NOUN
dpc-4194	86	11	with	with	ADP
dpc-4194	86	12	bimekizumab	bimekizumab	NOUN
dpc-4194	86	13	treatment	treatment	NOUN
dpc-4194	86	14	.	.	PUNCT
dpc-4194	87	1	ethical	ethical	ADJ
dpc-4194	87	2	considerations	consideration	NOUN
dpc-4194	87	3	this	this	DET
dpc-4194	87	4	study	study	NOUN
dpc-4194	87	5	adhered	adhere	VERB
dpc-4194	87	6	to	to	ADP
dpc-4194	87	7	established	establish	VERB
dpc-4194	87	8	clinical	clinical	ADJ
dpc-4194	87	9	standards	standard	NOUN
dpc-4194	87	10	and	and	CCONJ
dpc-4194	87	11	did	do	AUX
dpc-4194	87	12	not	not	PART
dpc-4194	87	13	require	require	VERB
dpc-4194	87	14	approval	approval	NOUN
dpc-4194	87	15	from	from	ADP
dpc-4194	87	16	the	the	DET
dpc-4194	87	17	institutional	institutional	ADJ
dpc-4194	87	18	review	review	NOUN
dpc-4194	87	19	board	board	NOUN
dpc-4194	87	20	.	.	PUNCT
dpc-4194	88	1	4	4	NUM
dpc-4194	88	2	original	original	ADJ
dpc-4194	88	3	article	article	NOUN
dpc-4194	88	4	|	|	ADV
dpc-4194	88	5	dermatol	dermatol	ADJ
dpc-4194	88	6	pract	pract	NOUN
dpc-4194	88	7	concept	concept	NOUN
dpc-4194	88	8	.	.	PUNCT
dpc-4194	89	1	2024;14(2):e2024052	2024;14(2):e2024052	NUM
dpc-4194	89	2	such	such	ADJ
dpc-4194	89	3	as	as	ADP
dpc-4194	89	4	obesity	obesity	NOUN
dpc-4194	89	5	,	,	PUNCT
dpc-4194	89	6	arterial	arterial	ADJ
dpc-4194	89	7	hypertension	hypertension	NOUN
dpc-4194	89	8	,	,	PUNCT
dpc-4194	89	9	cardiovascular	cardiovascular	ADJ
dpc-4194	89	10	disease	disease	NOUN
dpc-4194	89	11	,	,	PUNCT
dpc-4194	89	12	type	type	NOUN
dpc-4194	89	13	ii	ii	NOUN
dpc-4194	89	14	diabetes	diabetes	NOUN
dpc-4194	89	15	mellitus	mellitus	NOUN
dpc-4194	89	16	,	,	PUNCT
dpc-4194	89	17	and	and	CCONJ
dpc-4194	89	18	hyperlipidemia	hyperlipidemia	NOUN
dpc-4194	89	19	.	.	PUNCT
dpc-4194	90	1	interestingly	interestingly	ADV
dpc-4194	90	2	,	,	PUNCT
dpc-4194	90	3	19	19	NUM
dpc-4194	90	4	patients	patient	NOUN
dpc-4194	90	5	(	(	PUNCT
dpc-4194	90	6	29.2	29.2	NUM
dpc-4194	90	7	%	%	NOUN
dpc-4194	90	8	)	)	PUNCT
dpc-4194	90	9	had	have	AUX
dpc-4194	90	10	experienced	experience	VERB
dpc-4194	90	11	a	a	DET
dpc-4194	90	12	previous	previous	ADJ
dpc-4194	90	13	sars	sar	NOUN
dpc-4194	90	14	-	-	PUNCT
dpc-4194	90	15	cov-2	cov-2	NOUN
dpc-4194	90	16	infection	infection	NOUN
dpc-4194	90	17	.	.	PUNCT
dpc-4194	91	1	the	the	DET
dpc-4194	91	2	patients	patient	NOUN
dpc-4194	91	3	had	have	VERB
dpc-4194	91	4	a	a	DET
dpc-4194	91	5	mean	mean	ADJ
dpc-4194	91	6	history	history	NOUN
dpc-4194	91	7	of	of	ADP
dpc-4194	91	8	psoriasis	psoriasis	NOUN
dpc-4194	91	9	of	of	ADP
dpc-4194	91	10	13.9±11.3	13.9±11.3	NUM
dpc-4194	91	11	years	year	NOUN
dpc-4194	91	12	.	.	PUNCT
dpc-4194	92	1	at	at	ADP
dpc-4194	92	2	baseline	baseline	NOUN
dpc-4194	92	3	,	,	PUNCT
dpc-4194	92	4	the	the	DET
dpc-4194	92	5	mean	mean	ADJ
dpc-4194	92	6	pasi	pasi	NOUN
dpc-4194	92	7	was	be	AUX
dpc-4194	92	8	18.3±9.0	18.3±9.0	NUM
dpc-4194	92	9	,	,	PUNCT
dpc-4194	92	10	indicating	indicate	VERB
dpc-4194	92	11	the	the	DET
dpc-4194	92	12	severity	severity	NOUN
dpc-4194	92	13	of	of	ADP
dpc-4194	92	14	psoriasis	psoriasis	NOUN
dpc-4194	92	15	.	.	PUNCT
dpc-4194	93	1	dlqi	dlqi	VERB
dpc-4194	93	2	at	at	ADP
dpc-4194	93	3	baseline	baseline	PROPN
dpc-4194	93	4	had	have	VERB
dpc-4194	93	5	an	an	DET
dpc-4194	93	6	average	average	ADJ
dpc-4194	93	7	score	score	NOUN
dpc-4194	93	8	of	of	ADP
dpc-4194	93	9	17.1±8.8	17.1±8.8	NUM
dpc-4194	93	10	,	,	PUNCT
dpc-4194	93	11	highlighting	highlight	VERB
dpc-4194	93	12	a	a	DET
dpc-4194	93	13	substantial	substantial	ADJ
dpc-4194	93	14	impact	impact	NOUN
dpc-4194	93	15	on	on	ADP
dpc-4194	93	16	the	the	DET
dpc-4194	93	17	quality	quality	NOUN
dpc-4194	93	18	of	of	ADP
dpc-4194	93	19	life	life	NOUN
dpc-4194	93	20	for	for	ADP
dpc-4194	93	21	these	these	DET
dpc-4194	93	22	patients	patient	NOUN
dpc-4194	93	23	.	.	PUNCT
dpc-4194	94	1	fifty	fifty	NUM
dpc-4194	94	2	-	-	PUNCT
dpc-4194	94	3	one	one	NUM
dpc-4194	94	4	patients	patient	NOUN
dpc-4194	94	5	reported	report	VERB
dpc-4194	94	6	a	a	DET
dpc-4194	94	7	severe	severe	ADJ
dpc-4194	94	8	impairment	impairment	NOUN
dpc-4194	94	9	of	of	ADP
dpc-4194	94	10	their	their	PRON
dpc-4194	94	11	quality	quality	NOUN
dpc-4194	94	12	of	of	ADP
dpc-4194	94	13	life	life	NOUN
dpc-4194	94	14	,	,	PUNCT
dpc-4194	94	15	with	with	ADP
dpc-4194	94	16	a	a	DET
dpc-4194	94	17	dlqi	dlqi	ADJ
dpc-4194	94	18	score	score	NOUN
dpc-4194	94	19	of	of	ADP
dpc-4194	94	20	≥10	≥10	PROPN
dpc-4194	94	21	(	(	PUNCT
dpc-4194	94	22	81	81	NUM
dpc-4194	94	23	%	%	NOUN
dpc-4194	94	24	)	)	PUNCT
dpc-4194	94	25	.	.	PUNCT
dpc-4194	95	1	twenty	twenty	NUM
dpc-4194	95	2	-	-	PUNCT
dpc-4194	95	3	five	five	NUM
dpc-4194	95	4	patients	patient	NOUN
dpc-4194	95	5	had	have	AUX
dpc-4194	95	6	previously	previously	ADV
dpc-4194	95	7	failed	fail	VERB
dpc-4194	95	8	at	at	ADP
dpc-4194	95	9	least	least	ADV
dpc-4194	95	10	one	one	NUM
dpc-4194	95	11	biological	biological	ADJ
dpc-4194	95	12	therapy	therapy	NOUN
dpc-4194	95	13	(	(	PUNCT
dpc-4194	95	14	38.5	38.5	NUM
dpc-4194	95	15	%	%	NOUN
dpc-4194	95	16	)	)	PUNCT
dpc-4194	95	17	,	,	PUNCT
dpc-4194	95	18	while	while	SCONJ
dpc-4194	95	19	all	all	DET
dpc-4194	95	20	patients	patient	NOUN
dpc-4194	95	21	provided	provide	VERB
dpc-4194	95	22	written	write	VERB
dpc-4194	95	23	consent	consent	NOUN
dpc-4194	95	24	for	for	ADP
dpc-4194	95	25	the	the	DET
dpc-4194	95	26	retrospective	retrospective	ADJ
dpc-4194	95	27	collection	collection	NOUN
dpc-4194	95	28	of	of	ADP
dpc-4194	95	29	their	their	PRON
dpc-4194	95	30	anonymous	anonymous	ADJ
dpc-4194	95	31	data	datum	NOUN
dpc-4194	95	32	.	.	PUNCT
dpc-4194	96	1	the	the	DET
dpc-4194	96	2	research	research	NOUN
dpc-4194	96	3	was	be	AUX
dpc-4194	96	4	conducted	conduct	VERB
dpc-4194	96	5	in	in	ADP
dpc-4194	96	6	compliance	compliance	NOUN
dpc-4194	96	7	with	with	ADP
dpc-4194	96	8	the	the	DET
dpc-4194	96	9	helsinki	helsinki	PROPN
dpc-4194	96	10	declaration	declaration	NOUN
dpc-4194	96	11	of	of	ADP
dpc-4194	96	12	1964	1964	NUM
dpc-4194	96	13	and	and	CCONJ
dpc-4194	96	14	its	its	PRON
dpc-4194	96	15	subsequent	subsequent	ADJ
dpc-4194	96	16	amendments	amendment	NOUN
dpc-4194	96	17	.	.	PUNCT
dpc-4194	97	1	assessment	assessment	NOUN
dpc-4194	97	2	in	in	ADP
dpc-4194	97	3	accordance	accordance	NOUN
dpc-4194	97	4	with	with	ADP
dpc-4194	97	5	our	our	PRON
dpc-4194	97	6	institution	institution	NOUN
dpc-4194	97	7	standard	standard	ADJ
dpc-4194	97	8	protocol	protocol	NOUN
dpc-4194	97	9	,	,	PUNCT
dpc-4194	97	10	assessments	assessment	NOUN
dpc-4194	97	11	of	of	ADP
dpc-4194	97	12	effectiveness	effectiveness	NOUN
dpc-4194	97	13	and	and	CCONJ
dpc-4194	97	14	safety	safety	NOUN
dpc-4194	97	15	were	be	AUX
dpc-4194	97	16	conducted	conduct	VERB
dpc-4194	97	17	at	at	ADP
dpc-4194	97	18	baseline	baseline	NOUN
dpc-4194	97	19	,	,	PUNCT
dpc-4194	97	20	week	week	NOUN
dpc-4194	97	21	4	4	NUM
dpc-4194	97	22	,	,	PUNCT
dpc-4194	97	23	and	and	CCONJ
dpc-4194	97	24	week	week	NOUN
dpc-4194	97	25	16	16	NUM
dpc-4194	97	26	.	.	PUNCT
dpc-4194	98	1	during	during	ADP
dpc-4194	98	2	each	each	DET
dpc-4194	98	3	dermatological	dermatological	ADJ
dpc-4194	98	4	examination	examination	NOUN
dpc-4194	98	5	,	,	PUNCT
dpc-4194	98	6	the	the	DET
dpc-4194	98	7	following	follow	VERB
dpc-4194	98	8	parameters	parameter	NOUN
dpc-4194	98	9	were	be	AUX
dpc-4194	98	10	evaluated	evaluate	VERB
dpc-4194	98	11	:	:	PUNCT
dpc-4194	98	12	i.	i.	PROPN
dpc-4194	98	13	static	static	PROPN
dpc-4194	98	14	physician	physician	NOUN
dpc-4194	98	15	global	global	ADJ
dpc-4194	98	16	assessment	assessment	NOUN
dpc-4194	98	17	of	of	ADP
dpc-4194	98	18	genitalia	genitalia	NOUN
dpc-4194	98	19	(	(	PUNCT
dpc-4194	98	20	spga	spga	NOUN
dpc-4194	98	21	-	-	PUNCT
dpc-4194	98	22	g	g	NOUN
dpc-4194	98	23	):	):	PUNCT
dpc-4194	98	24	this	this	DET
dpc-4194	98	25	clinician	clinician	NOUN
dpc-4194	98	26	-	-	PUNCT
dpc-4194	98	27	reported	report	VERB
dpc-4194	98	28	outcome	outcome	NOUN
dpc-4194	98	29	measure	measure	NOUN
dpc-4194	98	30	,	,	PUNCT
dpc-4194	98	31	developed	develop	VERB
dpc-4194	98	32	specifically	specifically	ADV
dpc-4194	98	33	for	for	ADP
dpc-4194	98	34	grading	grade	VERB
dpc-4194	98	35	the	the	DET
dpc-4194	98	36	severity	severity	NOUN
dpc-4194	98	37	of	of	ADP
dpc-4194	98	38	genital	genital	ADJ
dpc-4194	98	39	psoriasis	psoriasis	NOUN
dpc-4194	98	40	,	,	PUNCT
dpc-4194	98	41	assesses	assesse	NOUN
dpc-4194	98	42	erythema	erythema	ADV
dpc-4194	98	43	,	,	PUNCT
dpc-4194	98	44	plaque	plaque	NOUN
dpc-4194	98	45	elevation	elevation	NOUN
dpc-4194	98	46	,	,	PUNCT
dpc-4194	98	47	and	and	CCONJ
dpc-4194	98	48	scaling	scale	VERB
dpc-4194	98	49	on	on	ADP
dpc-4194	98	50	a	a	DET
dpc-4194	98	51	6	6	NUM
dpc-4194	98	52	-	-	PUNCT
dpc-4194	98	53	point	point	NOUN
dpc-4194	98	54	scale	scale	NOUN
dpc-4194	98	55	(	(	PUNCT
dpc-4194	98	56	0	0	NUM
dpc-4194	98	57	:	:	PUNCT
dpc-4194	98	58	clear	clear	ADJ
dpc-4194	98	59	;	;	PUNCT
dpc-4194	98	60	5	5	NUM
dpc-4194	98	61	:	:	PUNCT
dpc-4194	98	62	very	very	ADV
dpc-4194	98	63	severe	severe	ADJ
dpc-4194	98	64	)	)	PUNCT
dpc-4194	99	1	[	[	X
dpc-4194	99	2	6	6	NUM
dpc-4194	99	3	]	]	PUNCT
dpc-4194	99	4	.	.	PUNCT
dpc-4194	100	1	ii	ii	PROPN
dpc-4194	100	2	.	.	PUNCT
dpc-4194	100	3	psoriasis	psoriasis	NOUN
dpc-4194	100	4	area	area	NOUN
dpc-4194	100	5	and	and	CCONJ
dpc-4194	100	6	severity	severity	NOUN
dpc-4194	100	7	index	index	NOUN
dpc-4194	100	8	(	(	PUNCT
dpc-4194	100	9	pasi	pasi	NOUN
dpc-4194	100	10	)	)	PUNCT
dpc-4194	100	11	score	score	NOUN
dpc-4194	100	12	:	:	PUNCT
dpc-4194	100	13	including	include	VERB
dpc-4194	100	14	pasi75	pasi75	NOUN
dpc-4194	100	15	,	,	PUNCT
dpc-4194	100	16	pasi90	pasi90	NOUN
dpc-4194	100	17	,	,	PUNCT
dpc-4194	100	18	and	and	CCONJ
dpc-4194	100	19	pasi100	pasi100	PROPN
dpc-4194	100	20	(	(	PUNCT
dpc-4194	100	21	percentages	percentage	NOUN
dpc-4194	100	22	of	of	ADP
dpc-4194	100	23	patients	patient	NOUN
dpc-4194	100	24	who	who	PRON
dpc-4194	100	25	achieved	achieve	VERB
dpc-4194	100	26	a	a	DET
dpc-4194	100	27	percentage	percentage	NOUN
dpc-4194	100	28	reduction	reduction	NOUN
dpc-4194	100	29	of	of	ADP
dpc-4194	100	30	75	75	NUM
dpc-4194	100	31	%	%	NOUN
dpc-4194	100	32	,	,	PUNCT
dpc-4194	100	33	90	90	NUM
dpc-4194	100	34	%	%	NOUN
dpc-4194	100	35	,	,	PUNCT
dpc-4194	100	36	and	and	CCONJ
dpc-4194	100	37	100	100	NUM
dpc-4194	100	38	%	%	NOUN
dpc-4194	100	39	from	from	ADP
dpc-4194	100	40	baseline	baseline	NOUN
dpc-4194	100	41	,	,	PUNCT
dpc-4194	100	42	respectively	respectively	ADV
dpc-4194	100	43	)	)	PUNCT
dpc-4194	100	44	.	.	PUNCT
dpc-4194	101	1	iii	iii	X
dpc-4194	101	2	.	.	NOUN
dpc-4194	101	3	proportion	proportion	NOUN
dpc-4194	101	4	of	of	ADP
dpc-4194	101	5	patients	patient	NOUN
dpc-4194	101	6	achieving	achieve	VERB
dpc-4194	101	7	an	an	DET
dpc-4194	101	8	absolute	absolute	ADJ
dpc-4194	101	9	pasi	pasi	NOUN
dpc-4194	101	10	of	of	ADP
dpc-4194	101	11	2	2	NUM
dpc-4194	101	12	 	 	SPACE
dpc-4194	101	13	or	or	CCONJ
dpc-4194	101	14	less	less	ADJ
dpc-4194	101	15	at	at	ADP
dpc-4194	101	16	each	each	DET
dpc-4194	101	17	visit	visit	NOUN
dpc-4194	101	18	.	.	PUNCT
dpc-4194	102	1	iv	iv	X
dpc-4194	102	2	.	.	PUNCT
dpc-4194	102	3	dermatology	dermatology	NOUN
dpc-4194	102	4	-	-	PUNCT
dpc-4194	102	5	life	life	NOUN
dpc-4194	102	6	-	-	PUNCT
dpc-4194	102	7	quality	quality	NOUN
dpc-4194	102	8	-	-	PUNCT
dpc-4194	102	9	index	index	NOUN
dpc-4194	102	10	(	(	PUNCT
dpc-4194	102	11	dlqi	dlqi	ADJ
dpc-4194	102	12	)	)	PUNCT
dpc-4194	102	13	.	.	PUNCT
dpc-4194	103	1	v.	v.	ADP
dpc-4194	103	2	percentage	percentage	NOUN
dpc-4194	103	3	of	of	ADP
dpc-4194	103	4	patients	patient	NOUN
dpc-4194	103	5	with	with	ADP
dpc-4194	103	6	dlqi≥10	dlqi≥10	PROPN
dpc-4194	103	7	(	(	PUNCT
dpc-4194	103	8	indicating	indicate	VERB
dpc-4194	103	9	a	a	DET
dpc-4194	103	10	severe	severe	ADJ
dpc-4194	103	11	impact	impact	NOUN
dpc-4194	103	12	on	on	ADP
dpc-4194	103	13	quality	quality	NOUN
dpc-4194	103	14	of	of	ADP
dpc-4194	103	15	life	life	NOUN
dpc-4194	103	16	)	)	PUNCT
dpc-4194	103	17	.	.	PUNCT
dpc-4194	104	1	data	datum	NOUN
dpc-4194	104	2	analysis	analysis	NOUN
dpc-4194	104	3	data	datum	NOUN
dpc-4194	104	4	analysis	analysis	NOUN
dpc-4194	104	5	was	be	AUX
dpc-4194	104	6	conducted	conduct	VERB
dpc-4194	104	7	utilizing	utilize	VERB
dpc-4194	104	8	descriptive	descriptive	ADJ
dpc-4194	104	9	statistics	statistic	NOUN
dpc-4194	104	10	.	.	PUNCT
dpc-4194	105	1	continuous	continuous	ADJ
dpc-4194	105	2	variables	variable	NOUN
dpc-4194	105	3	were	be	AUX
dpc-4194	105	4	presented	present	VERB
dpc-4194	105	5	as	as	ADP
dpc-4194	105	6	the	the	DET
dpc-4194	105	7	mean	mean	ADJ
dpc-4194	105	8	and	and	CCONJ
dpc-4194	105	9	standard	standard	ADJ
dpc-4194	105	10	deviation	deviation	NOUN
dpc-4194	105	11	(	(	PUNCT
dpc-4194	105	12	sd	sd	NOUN
dpc-4194	105	13	)	)	PUNCT
dpc-4194	105	14	,	,	PUNCT
dpc-4194	105	15	while	while	SCONJ
dpc-4194	105	16	categorical	categorical	ADJ
dpc-4194	105	17	variables	variable	NOUN
dpc-4194	105	18	were	be	AUX
dpc-4194	105	19	represented	represent	VERB
dpc-4194	105	20	as	as	ADP
dpc-4194	105	21	the	the	DET
dpc-4194	105	22	absolute	absolute	ADJ
dpc-4194	105	23	number	number	NOUN
dpc-4194	105	24	and	and	CCONJ
dpc-4194	105	25	percentage	percentage	NOUN
dpc-4194	105	26	.	.	PUNCT
dpc-4194	106	1	to	to	PART
dpc-4194	106	2	assess	assess	VERB
dpc-4194	106	3	differences	difference	NOUN
dpc-4194	106	4	between	between	ADP
dpc-4194	106	5	baseline	baseline	NOUN
dpc-4194	106	6	and	and	CCONJ
dpc-4194	106	7	follow	follow	VERB
dpc-4194	106	8	-	-	PUNCT
dpc-4194	106	9	up	up	ADP
dpc-4194	106	10	visits	visit	NOUN
dpc-4194	106	11	,	,	PUNCT
dpc-4194	106	12	the	the	DET
dpc-4194	106	13	wilcoxon	wilcoxon	ADJ
dpc-4194	106	14	matched	match	VERB
dpc-4194	106	15	-	-	PUNCT
dpc-4194	106	16	pair	pair	NOUN
dpc-4194	106	17	rank	rank	NOUN
dpc-4194	106	18	test	test	NOUN
dpc-4194	106	19	was	be	AUX
dpc-4194	106	20	employed	employ	VERB
dpc-4194	106	21	.	.	PUNCT
dpc-4194	107	1	a	a	DET
dpc-4194	107	2	p	p	NOUN
dpc-4194	107	3	value	value	NOUN
dpc-4194	107	4	less	less	ADJ
dpc-4194	107	5	than	than	ADP
dpc-4194	107	6	0.05	0.05	NUM
dpc-4194	107	7	was	be	AUX
dpc-4194	107	8	considered	consider	VERB
dpc-4194	107	9	statistically	statistically	ADV
dpc-4194	107	10	significant	significant	ADJ
dpc-4194	107	11	.	.	PUNCT
dpc-4194	108	1	subgroup	subgroup	NOUN
dpc-4194	108	2	analyses	analysis	NOUN
dpc-4194	108	3	were	be	AUX
dpc-4194	108	4	performed	perform	VERB
dpc-4194	108	5	to	to	PART
dpc-4194	108	6	assess	assess	VERB
dpc-4194	108	7	the	the	DET
dpc-4194	108	8	impact	impact	NOUN
dpc-4194	108	9	of	of	ADP
dpc-4194	108	10	previous	previous	ADJ
dpc-4194	108	11	exposure	exposure	NOUN
dpc-4194	108	12	to	to	ADP
dpc-4194	108	13	other	other	ADJ
dpc-4194	108	14	biologics	biologic	NOUN
dpc-4194	108	15	and	and	CCONJ
dpc-4194	108	16	the	the	DET
dpc-4194	108	17	presence	presence	NOUN
dpc-4194	108	18	of	of	ADP
dpc-4194	108	19	obesity	obesity	NOUN
dpc-4194	108	20	as	as	ADP
dpc-4194	108	21	a	a	DET
dpc-4194	108	22	comorbidity	comorbidity	NOUN
dpc-4194	108	23	on	on	ADP
dpc-4194	108	24	the	the	DET
dpc-4194	108	25	effectiveness	effectiveness	NOUN
dpc-4194	108	26	of	of	ADP
dpc-4194	108	27	bimekizumab	bimekizumab	NOUN
dpc-4194	108	28	.	.	PUNCT
dpc-4194	109	1	all	all	DET
dpc-4194	109	2	analyses	analysis	NOUN
dpc-4194	109	3	were	be	AUX
dpc-4194	109	4	carried	carry	VERB
dpc-4194	109	5	out	out	ADP
dpc-4194	109	6	using	use	VERB
dpc-4194	109	7	graphpad	graphpad	NOUN
dpc-4194	109	8	prism	prism	NOUN
dpc-4194	109	9	software	software	PROPN
dpc-4194	109	10	v8.0	v8.0	PROPN
dpc-4194	109	11	.	.	PUNCT
dpc-4194	110	1	results	result	VERB
dpc-4194	110	2	patient	patient	ADJ
dpc-4194	110	3	population	population	NOUN
dpc-4194	110	4	a	a	DET
dpc-4194	110	5	total	total	NOUN
dpc-4194	110	6	of	of	ADP
dpc-4194	110	7	65	65	NUM
dpc-4194	110	8	patients	patient	NOUN
dpc-4194	110	9	were	be	AUX
dpc-4194	110	10	enrolled	enrol	VERB
dpc-4194	110	11	in	in	ADP
dpc-4194	110	12	this	this	DET
dpc-4194	110	13	study	study	NOUN
dpc-4194	110	14	,	,	PUNCT
dpc-4194	110	15	with	with	ADP
dpc-4194	110	16	46	46	NUM
dpc-4194	110	17	of	of	ADP
dpc-4194	110	18	them	they	PRON
dpc-4194	110	19	being	be	AUX
dpc-4194	110	20	males	male	NOUN
dpc-4194	110	21	(	(	PUNCT
dpc-4194	110	22	70.8	70.8	NUM
dpc-4194	110	23	%	%	NOUN
dpc-4194	110	24	)	)	PUNCT
dpc-4194	110	25	.	.	PUNCT
dpc-4194	111	1	the	the	DET
dpc-4194	111	2	average	average	ADJ
dpc-4194	111	3	age	age	NOUN
dpc-4194	111	4	of	of	ADP
dpc-4194	111	5	the	the	DET
dpc-4194	111	6	patients	patient	NOUN
dpc-4194	111	7	was	be	AUX
dpc-4194	111	8	50.4±14.2	50.4±14.2	NUM
dpc-4194	111	9	years	year	NOUN
dpc-4194	111	10	.	.	PUNCT
dpc-4194	112	1	detailed	detailed	ADJ
dpc-4194	112	2	demographic	demographic	ADJ
dpc-4194	112	3	characteristics	characteristic	NOUN
dpc-4194	112	4	and	and	CCONJ
dpc-4194	112	5	clinical	clinical	ADJ
dpc-4194	112	6	features	feature	NOUN
dpc-4194	112	7	of	of	ADP
dpc-4194	112	8	all	all	DET
dpc-4194	112	9	patients	patient	NOUN
dpc-4194	112	10	at	at	ADP
dpc-4194	112	11	baseline	baseline	NOUN
dpc-4194	112	12	are	be	AUX
dpc-4194	112	13	presented	present	VERB
dpc-4194	112	14	in	in	ADP
dpc-4194	112	15	table	table	NOUN
dpc-4194	112	16	1	1	NUM
dpc-4194	112	17	.	.	PUNCT
dpc-4194	113	1	the	the	DET
dpc-4194	113	2	mean	mean	ADJ
dpc-4194	113	3	body	body	NOUN
dpc-4194	113	4	mass	mass	NOUN
dpc-4194	113	5	index	index	NOUN
dpc-4194	113	6	(	(	PUNCT
dpc-4194	113	7	bmi	bmi	PROPN
dpc-4194	113	8	)	)	PUNCT
dpc-4194	113	9	among	among	ADP
dpc-4194	113	10	the	the	DET
dpc-4194	113	11	patients	patient	NOUN
dpc-4194	113	12	was	be	AUX
dpc-4194	113	13	26.7±5.6	26.7±5.6	NUM
dpc-4194	113	14	kg	kg	NOUN
dpc-4194	113	15	/	/	SYM
dpc-4194	113	16	m²	m²	PROPN
dpc-4194	113	17	.	.	PUNCT
dpc-4194	114	1	fourteen	fourteen	NUM
dpc-4194	114	2	patients	patient	NOUN
dpc-4194	114	3	were	be	AUX
dpc-4194	114	4	obese	obese	ADJ
dpc-4194	114	5	(	(	PUNCT
dpc-4194	114	6	21.5	21.5	NUM
dpc-4194	114	7	%	%	NOUN
dpc-4194	114	8	)	)	PUNCT
dpc-4194	114	9	,	,	PUNCT
dpc-4194	114	10	with	with	ADP
dpc-4194	114	11	a	a	DET
dpc-4194	114	12	bmi	bmi	NOUN
dpc-4194	114	13	≥30	≥30	PROPN
dpc-4194	114	14	.	.	PUNCT
dpc-4194	115	1	additionally	additionally	ADV
dpc-4194	115	2	,	,	PUNCT
dpc-4194	115	3	6	6	NUM
dpc-4194	115	4	patients	patient	NOUN
dpc-4194	115	5	(	(	PUNCT
dpc-4194	115	6	9.2	9.2	NUM
dpc-4194	115	7	%	%	NOUN
dpc-4194	115	8	)	)	PUNCT
dpc-4194	115	9	had	have	VERB
dpc-4194	115	10	a	a	DET
dpc-4194	115	11	concomitant	concomitant	ADJ
dpc-4194	115	12	diagnosis	diagnosis	NOUN
dpc-4194	115	13	of	of	ADP
dpc-4194	115	14	psoriatic	psoriatic	ADJ
dpc-4194	115	15	arthritis	arthritis	NOUN
dpc-4194	115	16	.	.	PUNCT
dpc-4194	116	1	approximately	approximately	ADV
dpc-4194	116	2	3/4	3/4	NUM
dpc-4194	116	3	of	of	ADP
dpc-4194	116	4	the	the	DET
dpc-4194	116	5	patients	patient	NOUN
dpc-4194	116	6	(	(	PUNCT
dpc-4194	116	7	74.6	74.6	NUM
dpc-4194	116	8	%	%	NOUN
dpc-4194	116	9	)	)	PUNCT
dpc-4194	116	10	had	have	VERB
dpc-4194	116	11	at	at	ADV
dpc-4194	116	12	least	least	ADJ
dpc-4194	116	13	one	one	NUM
dpc-4194	116	14	cardio	cardio	NOUN
dpc-4194	116	15	-	-	PUNCT
dpc-4194	116	16	metabolic	metabolic	NOUN
dpc-4194	116	17	comorbidity	comorbidity	NOUN
dpc-4194	116	18	,	,	PUNCT
dpc-4194	116	19	which	which	PRON
dpc-4194	116	20	included	include	VERB
dpc-4194	116	21	conditions	condition	NOUN
dpc-4194	116	22	table	table	NOUN
dpc-4194	116	23	1	1	NUM
dpc-4194	116	24	.	.	PUNCT
dpc-4194	116	25	demographics	demographic	NOUN
dpc-4194	116	26	and	and	CCONJ
dpc-4194	116	27	general	general	ADJ
dpc-4194	116	28	clinical	clinical	ADJ
dpc-4194	116	29	characteristics	characteristic	NOUN
dpc-4194	116	30	of	of	ADP
dpc-4194	116	31	patients	patient	NOUN
dpc-4194	116	32	with	with	ADP
dpc-4194	116	33	genital	genital	ADJ
dpc-4194	116	34	psoriasis	psoriasis	NOUN
dpc-4194	116	35	at	at	ADP
dpc-4194	116	36	baseline	baseline	NOUN
dpc-4194	116	37	.	.	PUNCT
dpc-4194	117	1	characteristic	characteristic	ADJ
dpc-4194	117	2	all	all	DET
dpc-4194	117	3	patients	patient	NOUN
dpc-4194	117	4	(	(	PUNCT
dpc-4194	117	5	n	n	NOUN
dpc-4194	117	6	=	=	SYM
dpc-4194	117	7	65	65	NUM
dpc-4194	117	8	)	)	PUNCT
dpc-4194	117	9	age	age	NOUN
dpc-4194	117	10	(	(	PUNCT
dpc-4194	117	11	years	year	NOUN
dpc-4194	117	12	)	)	PUNCT
dpc-4194	117	13	50.4	50.4	NUM
dpc-4194	117	14	(	(	PUNCT
dpc-4194	117	15	14.2	14.2	NUM
dpc-4194	117	16	%	%	NOUN
dpc-4194	117	17	)	)	PUNCT
dpc-4194	117	18	male	male	ADJ
dpc-4194	117	19	sex	sex	NOUN
dpc-4194	117	20	46	46	NUM
dpc-4194	117	21	(	(	PUNCT
dpc-4194	117	22	70.8	70.8	NUM
dpc-4194	117	23	%	%	NOUN
dpc-4194	117	24	)	)	PUNCT
dpc-4194	117	25	bmi	bmi	NOUN
dpc-4194	117	26	(	(	PUNCT
dpc-4194	117	27	kg	kg	NOUN
dpc-4194	117	28	/	/	SYM
dpc-4194	117	29	m2	m2	PROPN
dpc-4194	117	30	)	)	PUNCT
dpc-4194	117	31	26.7	26.7	NUM
dpc-4194	117	32	(	(	PUNCT
dpc-4194	117	33	5.6	5.6	NUM
dpc-4194	117	34	%	%	NOUN
dpc-4194	117	35	)	)	PUNCT
dpc-4194	117	36	comorbidities	comorbiditie	NOUN
dpc-4194	117	37	•	•	ADP
dpc-4194	117	38	psoriatic	psoriatic	ADJ
dpc-4194	117	39	arthritis	arthritis	NOUN
dpc-4194	117	40	6	6	NUM
dpc-4194	117	41	(	(	PUNCT
dpc-4194	117	42	9.2	9.2	NUM
dpc-4194	117	43	%	%	NOUN
dpc-4194	117	44	)	)	PUNCT
dpc-4194	117	45	•	•	NOUN
dpc-4194	117	46	obesity	obesity	NOUN
dpc-4194	117	47	14	14	NUM
dpc-4194	117	48	(	(	PUNCT
dpc-4194	117	49	21.5	21.5	NUM
dpc-4194	117	50	%	%	NOUN
dpc-4194	117	51	)	)	PUNCT
dpc-4194	117	52	•	•	NOUN
dpc-4194	117	53	type	type	NOUN
dpc-4194	117	54	2	2	NUM
dpc-4194	117	55	diabetes	diabetes	NOUN
dpc-4194	117	56	5	5	NUM
dpc-4194	117	57	(	(	PUNCT
dpc-4194	117	58	7.7	7.7	NUM
dpc-4194	117	59	%	%	NOUN
dpc-4194	117	60	)	)	PUNCT
dpc-4194	117	61	•	•	NOUN
dpc-4194	117	62	hyperlipidemia	hyperlipidemia	NOUN
dpc-4194	117	63	10	10	NUM
dpc-4194	117	64	(	(	PUNCT
dpc-4194	117	65	15.4	15.4	NUM
dpc-4194	117	66	%	%	NOUN
dpc-4194	117	67	)	)	PUNCT
dpc-4194	117	68	•	•	NUM
dpc-4194	117	69	hypertension	hypertension	NOUN
dpc-4194	117	70	15	15	NUM
dpc-4194	117	71	(	(	PUNCT
dpc-4194	117	72	23.1	23.1	NUM
dpc-4194	117	73	%	%	NOUN
dpc-4194	117	74	)	)	PUNCT
dpc-4194	117	75	•	•	ADP
dpc-4194	117	76	cardiovascular	cardiovascular	ADJ
dpc-4194	117	77	diseases	disease	NOUN
dpc-4194	117	78	3	3	NUM
dpc-4194	117	79	(	(	PUNCT
dpc-4194	117	80	4.6	4.6	NUM
dpc-4194	117	81	%	%	NOUN
dpc-4194	117	82	)	)	PUNCT
dpc-4194	117	83	previous	previous	ADJ
dpc-4194	117	84	sars	sar	NOUN
dpc-4194	117	85	-	-	PUNCT
dpc-4194	117	86	cov-2	cov-2	PART
dpc-4194	117	87	infection	infection	NOUN
dpc-4194	117	88	19	19	NUM
dpc-4194	117	89	(	(	PUNCT
dpc-4194	117	90	29.2	29.2	NUM
dpc-4194	117	91	%	%	NOUN
dpc-4194	117	92	)	)	PUNCT
dpc-4194	118	1	mean	mean	VERB
dpc-4194	118	2	age	age	NOUN
dpc-4194	118	3	at	at	ADP
dpc-4194	118	4	baseline	baseline	PROPN
dpc-4194	118	5	(	(	PUNCT
dpc-4194	118	6	years	year	NOUN
dpc-4194	118	7	)	)	PUNCT
dpc-4194	118	8	48.2	48.2	NUM
dpc-4194	118	9	(	(	PUNCT
dpc-4194	118	10	14.9	14.9	NUM
dpc-4194	118	11	)	)	PUNCT
dpc-4194	118	12	mean	mean	VERB
dpc-4194	118	13	duration	duration	NOUN
dpc-4194	118	14	of	of	ADP
dpc-4194	118	15	psoriasis	psoriasis	NOUN
dpc-4194	118	16	(	(	PUNCT
dpc-4194	118	17	years	year	NOUN
dpc-4194	118	18	)	)	PUNCT
dpc-4194	118	19	13.9	13.9	NUM
dpc-4194	118	20	(	(	PUNCT
dpc-4194	118	21	11.3	11.3	NUM
dpc-4194	118	22	)	)	PUNCT
dpc-4194	118	23	psoriasis	psoriasis	NOUN
dpc-4194	118	24	on	on	ADP
dpc-4194	118	25	special	special	ADJ
dpc-4194	118	26	locations	location	NOUN
dpc-4194	118	27	•	•	ADV
dpc-4194	118	28	genital	genital	ADJ
dpc-4194	118	29	65	65	NUM
dpc-4194	118	30	(	(	PUNCT
dpc-4194	118	31	100	100	NUM
dpc-4194	118	32	%	%	NOUN
dpc-4194	118	33	)	)	PUNCT
dpc-4194	118	34	•	•	NUM
dpc-4194	118	35	scalp	scalp	NOUN
dpc-4194	118	36	48	48	NUM
dpc-4194	118	37	(	(	PUNCT
dpc-4194	118	38	73.8	73.8	NUM
dpc-4194	118	39	%	%	NOUN
dpc-4194	118	40	)	)	PUNCT
dpc-4194	118	41	•	•	NUM
dpc-4194	118	42	palmo	palmo	NOUN
dpc-4194	118	43	-	-	PUNCT
dpc-4194	118	44	plantar	plantar	NOUN
dpc-4194	118	45	19	19	NUM
dpc-4194	118	46	(	(	PUNCT
dpc-4194	118	47	29.2	29.2	NUM
dpc-4194	118	48	%	%	NOUN
dpc-4194	118	49	)	)	PUNCT
dpc-4194	118	50	•	•	NOUN
dpc-4194	118	51	nails	nail	NOUN
dpc-4194	118	52	25	25	NUM
dpc-4194	118	53	(	(	PUNCT
dpc-4194	118	54	38.5	38.5	NUM
dpc-4194	118	55	%	%	NOUN
dpc-4194	118	56	)	)	PUNCT
dpc-4194	119	1	mean	mean	PROPN
dpc-4194	119	2	pasi	pasi	NOUN
dpc-4194	119	3	at	at	ADP
dpc-4194	119	4	baselinea	baselinea	ADJ
dpc-4194	119	5	18.3	18.3	NUM
dpc-4194	119	6	(	(	PUNCT
dpc-4194	119	7	9.0	9.0	NUM
dpc-4194	119	8	%	%	NOUN
dpc-4194	119	9	)	)	PUNCT
dpc-4194	120	1	mean	mean	VERB
dpc-4194	120	2	dlqi	dlqi	ADJ
dpc-4194	120	3	at	at	ADP
dpc-4194	120	4	baseline	baseline	NOUN
dpc-4194	120	5	a	a	DET
dpc-4194	120	6	17.1	17.1	NUM
dpc-4194	120	7	(	(	PUNCT
dpc-4194	120	8	8.8	8.8	NUM
dpc-4194	120	9	%	%	NOUN
dpc-4194	120	10	)	)	PUNCT
dpc-4194	120	11	previous	previous	ADJ
dpc-4194	120	12	exposure	exposure	NOUN
dpc-4194	120	13	to	to	ADP
dpc-4194	120	14	biologics	biologic	NOUN
dpc-4194	120	15	25	25	NUM
dpc-4194	120	16	(	(	PUNCT
dpc-4194	120	17	38.5	38.5	NUM
dpc-4194	120	18	%	%	NOUN
dpc-4194	120	19	)	)	PUNCT
dpc-4194	120	20	adalimumab	adalimumab	NOUN
dpc-4194	120	21	12	12	NUM
dpc-4194	120	22	(	(	PUNCT
dpc-4194	120	23	18.5	18.5	NUM
dpc-4194	120	24	%	%	NOUN
dpc-4194	120	25	)	)	PUNCT
dpc-4194	120	26	brodalumab	brodalumab	NOUN
dpc-4194	120	27	1	1	NUM
dpc-4194	120	28	(	(	PUNCT
dpc-4194	120	29	1.5	1.5	NUM
dpc-4194	120	30	%	%	NOUN
dpc-4194	120	31	)	)	PUNCT
dpc-4194	120	32	ixekizumab	ixekizumab	NOUN
dpc-4194	120	33	2	2	NUM
dpc-4194	120	34	(	(	PUNCT
dpc-4194	120	35	3.1	3.1	NUM
dpc-4194	120	36	%	%	NOUN
dpc-4194	120	37	)	)	PUNCT
dpc-4194	120	38	risankizumab	risankizumab	NOUN
dpc-4194	120	39	2	2	NUM
dpc-4194	120	40	(	(	PUNCT
dpc-4194	120	41	3.1	3.1	NUM
dpc-4194	120	42	%	%	NOUN
dpc-4194	120	43	)	)	PUNCT
dpc-4194	120	44	secukinumab	secukinumab	NOUN
dpc-4194	120	45	9	9	NUM
dpc-4194	120	46	(	(	PUNCT
dpc-4194	120	47	13.8	13.8	NUM
dpc-4194	120	48	%	%	NOUN
dpc-4194	120	49	)	)	PUNCT
dpc-4194	120	50	tildrakizumab	tildrakizumab	NOUN
dpc-4194	120	51	1	1	NUM
dpc-4194	120	52	(	(	PUNCT
dpc-4194	120	53	1.5	1.5	NUM
dpc-4194	120	54	%	%	NOUN
dpc-4194	120	55	)	)	PUNCT
dpc-4194	120	56	ustekinumab	ustekinumab	NOUN
dpc-4194	120	57	3	3	NUM
dpc-4194	120	58	(	(	PUNCT
dpc-4194	120	59	4.6	4.6	NUM
dpc-4194	120	60	%	%	NOUN
dpc-4194	120	61	)	)	PUNCT
dpc-4194	120	62	bmi	bmi	NOUN
dpc-4194	120	63	=	=	SYM
dpc-4194	120	64	body	body	PROPN
dpc-4194	120	65	mass	mass	PROPN
dpc-4194	120	66	index	index	NOUN
dpc-4194	120	67	;	;	PUNCT
dpc-4194	120	68	dlqi	dlqi	ADJ
dpc-4194	120	69	=	=	SYM
dpc-4194	120	70	dermatology	dermatology	NOUN
dpc-4194	120	71	life	life	NOUN
dpc-4194	120	72	quality	quality	NOUN
dpc-4194	120	73	index	index	NOUN
dpc-4194	120	74	;	;	PUNCT
dpc-4194	120	75	pasi	pasi	NOUN
dpc-4194	120	76	:	:	PUNCT
dpc-4194	120	77	psoriasis	psoriasis	NOUN
dpc-4194	120	78	area	area	NOUN
dpc-4194	120	79	and	and	CCONJ
dpc-4194	120	80	severity	severity	NOUN
dpc-4194	120	81	index	index	NOUN
dpc-4194	120	82	.	.	PUNCT
dpc-4194	121	1	apasi	apasi	NOUN
dpc-4194	121	2	and	and	CCONJ
dpc-4194	121	3	dlqi	dlqi	ADJ
dpc-4194	121	4	scores	score	NOUN
dpc-4194	121	5	were	be	AUX
dpc-4194	121	6	available	available	ADJ
dpc-4194	121	7	for	for	ADP
dpc-4194	121	8	63	63	NUM
dpc-4194	121	9	patients	patient	NOUN
dpc-4194	121	10	at	at	ADP
dpc-4194	121	11	baseline	baseline	NOUN
dpc-4194	121	12	.	.	PUNCT
dpc-4194	122	1	continuous	continuous	ADJ
dpc-4194	122	2	variables	variable	NOUN
dpc-4194	122	3	were	be	AUX
dpc-4194	122	4	reported	report	VERB
dpc-4194	122	5	as	as	ADP
dpc-4194	122	6	mean	mean	NOUN
dpc-4194	122	7	(	(	PUNCT
dpc-4194	122	8	standard	standard	ADJ
dpc-4194	122	9	deviation	deviation	NOUN
dpc-4194	122	10	)	)	PUNCT
dpc-4194	122	11	,	,	PUNCT
dpc-4194	122	12	while	while	SCONJ
dpc-4194	122	13	categorical	categorical	ADJ
dpc-4194	122	14	variables	variable	NOUN
dpc-4194	122	15	were	be	AUX
dpc-4194	122	16	expressed	express	VERB
dpc-4194	122	17	as	as	ADP
dpc-4194	122	18	absolute	absolute	ADJ
dpc-4194	122	19	number	number	NOUN
dpc-4194	122	20	(	(	PUNCT
dpc-4194	122	21	percentage	percentage	NOUN
dpc-4194	122	22	)	)	PUNCT
dpc-4194	122	23	.	.	PUNCT
dpc-4194	123	1	original	original	ADJ
dpc-4194	123	2	article	article	NOUN
dpc-4194	123	3	|	|	ADV
dpc-4194	123	4	dermatol	dermatol	ADJ
dpc-4194	123	5	pract	pract	NOUN
dpc-4194	123	6	concept	concept	NOUN
dpc-4194	123	7	.	.	PUNCT
dpc-4194	124	1	2024;14(2):e2024052	2024;14(2):e2024052	NUM
dpc-4194	124	2	5	5	NUM
dpc-4194	124	3	pasi	pasi	NOUN
dpc-4194	124	4	improvement	improvement	NOUN
dpc-4194	124	5	at	at	ADP
dpc-4194	124	6	baseline	baseline	NOUN
dpc-4194	124	7	,	,	PUNCT
dpc-4194	124	8	pasi	pasi	NOUN
dpc-4194	124	9	was	be	AUX
dpc-4194	124	10	recorded	record	VERB
dpc-4194	124	11	for	for	ADP
dpc-4194	124	12	63	63	NUM
dpc-4194	124	13	patients	patient	NOUN
dpc-4194	124	14	,	,	PUNCT
dpc-4194	124	15	and	and	CCONJ
dpc-4194	124	16	61	61	NUM
dpc-4194	124	17	of	of	ADP
dpc-4194	124	18	them	they	PRON
dpc-4194	124	19	completed	complete	VERB
dpc-4194	124	20	16	16	NUM
dpc-4194	124	21	weeks	week	NOUN
dpc-4194	124	22	of	of	ADP
dpc-4194	124	23	follow	follow	NOUN
dpc-4194	124	24	-	-	PUNCT
dpc-4194	124	25	up	up	NOUN
dpc-4194	124	26	.	.	PUNCT
dpc-4194	125	1	in	in	ADP
dpc-4194	125	2	our	our	PRON
dpc-4194	125	3	study	study	NOUN
dpc-4194	125	4	,	,	PUNCT
dpc-4194	125	5	there	there	PRON
dpc-4194	125	6	was	be	VERB
dpc-4194	125	7	a	a	DET
dpc-4194	125	8	notable	notable	ADJ
dpc-4194	125	9	increase	increase	NOUN
dpc-4194	125	10	in	in	ADP
dpc-4194	125	11	the	the	DET
dpc-4194	125	12	percentage	percentage	NOUN
dpc-4194	125	13	of	of	ADP
dpc-4194	125	14	patients	patient	NOUN
dpc-4194	125	15	achieving	achieve	VERB
dpc-4194	125	16	pasi75	pasi75	NOUN
dpc-4194	125	17	,	,	PUNCT
dpc-4194	125	18	pasi90	pasi90	NOUN
dpc-4194	125	19	,	,	PUNCT
dpc-4194	125	20	and	and	CCONJ
dpc-4194	125	21	pasi100	pasi100	PROPN
dpc-4194	125	22	between	between	ADP
dpc-4194	125	23	the	the	DET
dpc-4194	125	24	4	4	NUM
dpc-4194	125	25	-	-	PUNCT
dpc-4194	125	26	week	week	NOUN
dpc-4194	125	27	and	and	CCONJ
dpc-4194	125	28	16	16	NUM
dpc-4194	125	29	-	-	PUNCT
dpc-4194	125	30	week	week	NOUN
dpc-4194	125	31	marks	mark	NOUN
dpc-4194	125	32	of	of	ADP
dpc-4194	125	33	bimekizumab	bimekizumab	NOUN
dpc-4194	125	34	treatment	treatment	NOUN
dpc-4194	125	35	(	(	PUNCT
dpc-4194	125	36	figure	figure	NOUN
dpc-4194	125	37	 	 	SPACE
dpc-4194	125	38	2	2	NUM
dpc-4194	125	39	)	)	PUNCT
dpc-4194	125	40	.	.	PUNCT
dpc-4194	126	1	specifically	specifically	ADV
dpc-4194	126	2	,	,	PUNCT
dpc-4194	126	3	pasi75	pasi75	NOUN
dpc-4194	126	4	was	be	AUX
dpc-4194	126	5	achieved	achieve	VERB
dpc-4194	126	6	by	by	ADP
dpc-4194	126	7	43	43	NUM
dpc-4194	126	8	patients	patient	NOUN
dpc-4194	126	9	after	after	ADP
dpc-4194	126	10	4	4	NUM
dpc-4194	126	11	weeks	week	NOUN
dpc-4194	126	12	(	(	PUNCT
dpc-4194	126	13	70.5	70.5	NUM
dpc-4194	126	14	%	%	NOUN
dpc-4194	126	15	)	)	PUNCT
dpc-4194	126	16	and	and	CCONJ
dpc-4194	126	17	by	by	ADP
dpc-4194	126	18	57	57	NUM
dpc-4194	126	19	patients	patient	NOUN
dpc-4194	126	20	after	after	ADP
dpc-4194	126	21	16	16	NUM
dpc-4194	126	22	weeks	week	NOUN
dpc-4194	126	23	(	(	PUNCT
dpc-4194	126	24	93.4	93.4	NUM
dpc-4194	126	25	%	%	NOUN
dpc-4194	126	26	)	)	PUNCT
dpc-4194	126	27	(	(	PUNCT
dpc-4194	126	28	figure	figure	NOUN
dpc-4194	126	29	 	 	SPACE
dpc-4194	126	30	2	2	NUM
dpc-4194	126	31	)	)	PUNCT
dpc-4194	126	32	.	.	PUNCT
dpc-4194	127	1	additionally	additionally	ADV
dpc-4194	127	2	,	,	PUNCT
dpc-4194	127	3	pasi90	pasi90	NOUN
dpc-4194	127	4	increased	increase	VERB
dpc-4194	127	5	from	from	ADP
dpc-4194	127	6	29	29	NUM
dpc-4194	127	7	patients	patient	NOUN
dpc-4194	127	8	at	at	ADP
dpc-4194	127	9	4	4	NUM
dpc-4194	127	10	weeks	week	NOUN
dpc-4194	127	11	(	(	PUNCT
dpc-4194	127	12	47.5	47.5	NUM
dpc-4194	127	13	%	%	NOUN
dpc-4194	127	14	)	)	PUNCT
dpc-4194	127	15	to	to	ADP
dpc-4194	127	16	48	48	NUM
dpc-4194	127	17	patients	patient	NOUN
dpc-4194	127	18	at	at	ADP
dpc-4194	127	19	16	16	NUM
dpc-4194	127	20	weeks	week	NOUN
dpc-4194	127	21	(	(	PUNCT
dpc-4194	127	22	78.7	78.7	NUM
dpc-4194	127	23	%	%	NOUN
dpc-4194	127	24	)	)	PUNCT
dpc-4194	127	25	.	.	PUNCT
dpc-4194	128	1	the	the	DET
dpc-4194	128	2	percentage	percentage	NOUN
dpc-4194	128	3	of	of	ADP
dpc-4194	128	4	patients	patient	NOUN
dpc-4194	128	5	achieving	achieve	VERB
dpc-4194	128	6	pasi100	pasi100	PROPN
dpc-4194	128	7	increased	increase	VERB
dpc-4194	128	8	from	from	ADP
dpc-4194	128	9	25	25	NUM
dpc-4194	128	10	at	at	ADP
dpc-4194	128	11	4	4	NUM
dpc-4194	128	12	weeks	week	NOUN
dpc-4194	128	13	(	(	PUNCT
dpc-4194	128	14	41	41	NUM
dpc-4194	128	15	%	%	NOUN
dpc-4194	128	16	)	)	PUNCT
dpc-4194	128	17	to	to	ADP
dpc-4194	128	18	42	42	NUM
dpc-4194	128	19	after	after	ADP
dpc-4194	128	20	16	16	NUM
dpc-4194	128	21	weeks	week	NOUN
dpc-4194	128	22	of	of	ADP
dpc-4194	128	23	treatment	treatment	NOUN
dpc-4194	128	24	(	(	PUNCT
dpc-4194	128	25	68.9	68.9	NUM
dpc-4194	128	26	%	%	NOUN
dpc-4194	128	27	)	)	PUNCT
dpc-4194	128	28	(	(	PUNCT
dpc-4194	128	29	figure	figure	NOUN
dpc-4194	128	30	2	2	NUM
dpc-4194	128	31	)	)	PUNCT
dpc-4194	128	32	.	.	PUNCT
dpc-4194	129	1	the	the	DET
dpc-4194	129	2	mean	mean	PROPN
dpc-4194	129	3	pasi	pasi	NOUN
dpc-4194	129	4	decreased	decrease	VERB
dpc-4194	129	5	significantly	significantly	ADV
dpc-4194	129	6	from	from	ADP
dpc-4194	129	7	18.3±9.0	18.3±9.0	NUM
dpc-4194	129	8	at	at	ADP
dpc-4194	129	9	baseline	baseline	NOUN
dpc-4194	129	10	to	to	ADP
dpc-4194	129	11	4.3±13	4.3±13	NUM
dpc-4194	129	12	after	after	ADP
dpc-4194	129	13	4	4	NUM
dpc-4194	129	14	weeks	week	NOUN
dpc-4194	129	15	of	of	ADP
dpc-4194	129	16	treatment	treatment	NOUN
dpc-4194	129	17	(	(	PUNCT
dpc-4194	129	18	p	p	X
dpc-4194	129	19	<	<	X
dpc-4194	129	20	0.001	0.001	NUM
dpc-4194	129	21	)	)	PUNCT
dpc-4194	129	22	and	and	CCONJ
dpc-4194	129	23	38	38	NUM
dpc-4194	129	24	patients	patient	NOUN
dpc-4194	129	25	were	be	AUX
dpc-4194	129	26	bio	bio	ADJ
dpc-4194	129	27	-	-	ADJ
dpc-4194	129	28	naive	naive	ADJ
dpc-4194	129	29	(	(	PUNCT
dpc-4194	129	30	61.5	61.5	NUM
dpc-4194	129	31	%	%	NOUN
dpc-4194	129	32	)	)	PUNCT
dpc-4194	129	33	(	(	PUNCT
dpc-4194	129	34	table	table	NOUN
dpc-4194	129	35	1	1	NUM
dpc-4194	129	36	)	)	PUNCT
dpc-4194	129	37	.	.	PUNCT
dpc-4194	130	1	a	a	DET
dpc-4194	130	2	significant	significant	ADJ
dpc-4194	130	3	proportion	proportion	NOUN
dpc-4194	130	4	of	of	ADP
dpc-4194	130	5	patients	patient	NOUN
dpc-4194	130	6	,	,	PUNCT
dpc-4194	130	7	specifically	specifically	ADV
dpc-4194	130	8	63	63	NUM
dpc-4194	130	9	out	out	ADP
dpc-4194	130	10	of	of	ADP
dpc-4194	130	11	65	65	NUM
dpc-4194	130	12	(	(	PUNCT
dpc-4194	130	13	96.9	96.9	NUM
dpc-4194	130	14	%	%	NOUN
dpc-4194	130	15	)	)	PUNCT
dpc-4194	130	16	,	,	PUNCT
dpc-4194	130	17	successfully	successfully	ADV
dpc-4194	130	18	completed	complete	VERB
dpc-4194	130	19	the	the	DET
dpc-4194	130	20	16	16	NUM
dpc-4194	130	21	-	-	PUNCT
dpc-4194	130	22	week	week	NOUN
dpc-4194	130	23	treatment	treatment	NOUN
dpc-4194	130	24	course	course	NOUN
dpc-4194	130	25	.	.	PUNCT
dpc-4194	131	1	the	the	DET
dpc-4194	131	2	remaining	remain	VERB
dpc-4194	131	3	patients	patient	NOUN
dpc-4194	131	4	were	be	AUX
dpc-4194	131	5	lost	lose	VERB
dpc-4194	131	6	to	to	PART
dpc-4194	131	7	follow	follow	VERB
dpc-4194	131	8	-	-	PUNCT
dpc-4194	131	9	up	up	NOUN
dpc-4194	131	10	.	.	PUNCT
dpc-4194	132	1	effectiveness	effectiveness	NOUN
dpc-4194	132	2	assessment	assessment	NOUN
dpc-4194	132	3	at	at	ADP
dpc-4194	132	4	baseline	baseline	NOUN
dpc-4194	132	5	,	,	PUNCT
dpc-4194	132	6	more	more	ADJ
dpc-4194	132	7	than	than	ADP
dpc-4194	132	8	half	half	NOUN
dpc-4194	132	9	of	of	ADP
dpc-4194	132	10	the	the	DET
dpc-4194	132	11	patients	patient	NOUN
dpc-4194	132	12	had	have	VERB
dpc-4194	132	13	a	a	DET
dpc-4194	132	14	moderate	moderate	ADJ
dpc-4194	132	15	to	to	PART
dpc-4194	132	16	-	-	PUNCT
dpc-4194	132	17	severe	severe	ADJ
dpc-4194	132	18	genital	genital	ADJ
dpc-4194	132	19	involvement	involvement	NOUN
dpc-4194	132	20	,	,	PUNCT
dpc-4194	132	21	defined	define	VERB
dpc-4194	132	22	as	as	ADP
dpc-4194	132	23	a	a	DET
dpc-4194	132	24	s	s	NOUN
dpc-4194	132	25	-	-	PUNCT
dpc-4194	132	26	pga	pga	NOUN
dpc-4194	132	27	-	-	PUNCT
dpc-4194	132	28	g	g	NOUN
dpc-4194	132	29	of	of	ADP
dpc-4194	132	30	3	3	NUM
dpc-4194	132	31	or	or	CCONJ
dpc-4194	132	32	more	more	ADJ
dpc-4194	132	33	(	(	PUNCT
dpc-4194	132	34	figure	figure	NOUN
dpc-4194	132	35	1	1	NUM
dpc-4194	132	36	and	and	CCONJ
dpc-4194	132	37	table	table	NOUN
dpc-4194	132	38	2	2	NUM
dpc-4194	132	39	)	)	PUNCT
dpc-4194	132	40	.	.	PUNCT
dpc-4194	133	1	among	among	ADP
dpc-4194	133	2	the	the	DET
dpc-4194	133	3	63	63	NUM
dpc-4194	133	4	patients	patient	NOUN
dpc-4194	133	5	evaluated	evaluate	VERB
dpc-4194	133	6	for	for	ADP
dpc-4194	133	7	spga	spga	NOUN
dpc-4194	133	8	-	-	PUNCT
dpc-4194	133	9	g	g	NOUN
dpc-4194	133	10	at	at	ADP
dpc-4194	133	11	the	the	DET
dpc-4194	133	12	4	4	NUM
dpc-4194	133	13	-	-	PUNCT
dpc-4194	133	14	week	week	NOUN
dpc-4194	133	15	mark	mark	NOUN
dpc-4194	133	16	,	,	PUNCT
dpc-4194	133	17	48	48	NUM
dpc-4194	133	18	patients	patient	NOUN
dpc-4194	133	19	achieved	achieve	VERB
dpc-4194	133	20	a	a	DET
dpc-4194	133	21	spga	spga	NOUN
dpc-4194	133	22	-	-	PUNCT
dpc-4194	133	23	g	g	NOUN
dpc-4194	133	24	score	score	NOUN
dpc-4194	133	25	of	of	ADP
dpc-4194	133	26	clear	clear	ADJ
dpc-4194	133	27	(	(	PUNCT
dpc-4194	133	28	76.2	76.2	NUM
dpc-4194	133	29	%	%	NOUN
dpc-4194	133	30	)	)	PUNCT
dpc-4194	133	31	,	,	PUNCT
dpc-4194	133	32	while	while	SCONJ
dpc-4194	133	33	11	11	NUM
dpc-4194	133	34	patients	patient	NOUN
dpc-4194	133	35	achieved	achieve	VERB
dpc-4194	133	36	a	a	DET
dpc-4194	133	37	score	score	NOUN
dpc-4194	133	38	of	of	ADP
dpc-4194	133	39	almost	almost	ADV
dpc-4194	133	40	clear	clear	ADJ
dpc-4194	133	41	(	(	PUNCT
dpc-4194	133	42	17.5	17.5	NUM
dpc-4194	133	43	%	%	NOUN
dpc-4194	133	44	)	)	PUNCT
dpc-4194	133	45	.	.	PUNCT
dpc-4194	134	1	impressively	impressively	ADV
dpc-4194	134	2	,	,	PUNCT
dpc-4194	134	3	at	at	ADP
dpc-4194	134	4	the	the	DET
dpc-4194	134	5	16	16	NUM
dpc-4194	134	6	-	-	PUNCT
dpc-4194	134	7	week	week	NOUN
dpc-4194	134	8	visit	visit	NOUN
dpc-4194	134	9	,	,	PUNCT
dpc-4194	134	10	98.4	98.4	NUM
dpc-4194	134	11	%	%	NOUN
dpc-4194	134	12	of	of	ADP
dpc-4194	134	13	the	the	DET
dpc-4194	134	14	assessed	assess	VERB
dpc-4194	134	15	patients	patient	NOUN
dpc-4194	134	16	had	have	AUX
dpc-4194	134	17	achieved	achieve	VERB
dpc-4194	134	18	a	a	DET
dpc-4194	134	19	spga	spga	NOUN
dpc-4194	134	20	-	-	PUNCT
dpc-4194	134	21	g	g	NOUN
dpc-4194	134	22	score	score	NOUN
dpc-4194	134	23	of	of	ADP
dpc-4194	134	24	clear	clear	ADJ
dpc-4194	134	25	,	,	PUNCT
dpc-4194	134	26	demonstrating	demonstrate	VERB
dpc-4194	134	27	the	the	DET
dpc-4194	134	28	remarkable	remarkable	ADJ
dpc-4194	134	29	efficacy	efficacy	NOUN
dpc-4194	134	30	of	of	ADP
dpc-4194	134	31	bimekizumab	bimekizumab	NOUN
dpc-4194	134	32	in	in	ADP
dpc-4194	134	33	clearing	clear	VERB
dpc-4194	134	34	genital	genital	ADJ
dpc-4194	134	35	psoriasis	psoriasis	NOUN
dpc-4194	134	36	(	(	PUNCT
dpc-4194	134	37	figure	figure	NOUN
dpc-4194	134	38	1	1	NUM
dpc-4194	134	39	,	,	PUNCT
dpc-4194	134	40	table	table	NOUN
dpc-4194	134	41	2	2	NUM
dpc-4194	134	42	)	)	PUNCT
dpc-4194	134	43	.	.	PUNCT
dpc-4194	135	1	figure	figure	NOUN
dpc-4194	135	2	1	1	NUM
dpc-4194	135	3	.	.	PUNCT
dpc-4194	136	1	static	static	ADJ
dpc-4194	136	2	genital	genital	ADJ
dpc-4194	136	3	pga	pga	NOUN
dpc-4194	136	4	score	score	NOUN
dpc-4194	136	5	(	(	PUNCT
dpc-4194	136	6	static	static	ADJ
dpc-4194	136	7	physician	physician	NOUN
dpc-4194	136	8	global	global	ADJ
dpc-4194	136	9	assessment	assessment	NOUN
dpc-4194	136	10	of	of	ADP
dpc-4194	136	11	genitalia	genitalia	NOUN
dpc-4194	136	12	,	,	PUNCT
dpc-4194	136	13	spga	spga	NOUN
dpc-4194	136	14	-	-	PUNCT
dpc-4194	136	15	g	g	NOUN
dpc-4194	136	16	)	)	PUNCT
dpc-4194	136	17	distribution	distribution	NOUN
dpc-4194	136	18	over	over	ADP
dpc-4194	136	19	time	time	NOUN
dpc-4194	136	20	.	.	PUNCT
dpc-4194	137	1	data	datum	NOUN
dpc-4194	137	2	were	be	AUX
dpc-4194	137	3	expressed	express	VERB
dpc-4194	137	4	as	as	ADP
dpc-4194	137	5	absolute	absolute	ADJ
dpc-4194	137	6	number	number	NOUN
dpc-4194	137	7	(	(	PUNCT
dpc-4194	137	8	percentage	percentage	NOUN
dpc-4194	137	9	)	)	PUNCT
dpc-4194	137	10	.	.	PUNCT
dpc-4194	138	1	table	table	NOUN
dpc-4194	138	2	2	2	NUM
dpc-4194	138	3	.	.	PUNCT
dpc-4194	139	1	static	static	ADJ
dpc-4194	139	2	genital	genital	ADJ
dpc-4194	139	3	pga	pga	NOUN
dpc-4194	139	4	score	score	NOUN
dpc-4194	139	5	(	(	PUNCT
dpc-4194	139	6	spga	spga	NOUN
dpc-4194	139	7	-	-	PUNCT
dpc-4194	139	8	g	g	NOUN
dpc-4194	139	9	)	)	PUNCT
dpc-4194	139	10	distribution	distribution	NOUN
dpc-4194	139	11	over	over	ADP
dpc-4194	139	12	time	time	NOUN
dpc-4194	139	13	.	.	PUNCT
dpc-4194	140	1	spga	spga	NOUN
dpc-4194	140	2	-	-	PUNCT
dpc-4194	140	3	g	g	NOUN
dpc-4194	140	4	baseline	baseline	NOUN
dpc-4194	140	5	(	(	PUNCT
dpc-4194	140	6	n	n	NOUN
dpc-4194	140	7	=	=	SYM
dpc-4194	140	8	65	65	NUM
dpc-4194	140	9	)	)	PUNCT
dpc-4194	140	10	4	4	NUM
dpc-4194	140	11	-	-	PUNCT
dpc-4194	140	12	week	week	NOUN
dpc-4194	140	13	visit	visit	NOUN
dpc-4194	140	14	(	(	PUNCT
dpc-4194	140	15	n	n	NOUN
dpc-4194	140	16	=	=	SYM
dpc-4194	140	17	63	63	NUM
dpc-4194	140	18	)	)	PUNCT
dpc-4194	140	19	16	16	NUM
dpc-4194	140	20	-	-	PUNCT
dpc-4194	140	21	week	week	NOUN
dpc-4194	140	22	visit	visit	NOUN
dpc-4194	140	23	(	(	PUNCT
dpc-4194	140	24	n	n	NOUN
dpc-4194	140	25	=	=	SYM
dpc-4194	140	26	63	63	NUM
dpc-4194	140	27	)	)	PUNCT
dpc-4194	140	28	clear	clear	ADJ
dpc-4194	140	29	48	48	NUM
dpc-4194	140	30	(	(	PUNCT
dpc-4194	140	31	76.2	76.2	NUM
dpc-4194	140	32	%	%	NOUN
dpc-4194	140	33	)	)	PUNCT
dpc-4194	140	34	62	62	NUM
dpc-4194	140	35	(	(	PUNCT
dpc-4194	140	36	98.4	98.4	NUM
dpc-4194	140	37	%	%	NOUN
dpc-4194	140	38	)	)	PUNCT
dpc-4194	140	39	almost	almost	ADV
dpc-4194	140	40	clear	clear	ADJ
dpc-4194	140	41	14	14	NUM
dpc-4194	140	42	(	(	PUNCT
dpc-4194	140	43	21.5	21.5	NUM
dpc-4194	140	44	%	%	NOUN
dpc-4194	140	45	)	)	PUNCT
dpc-4194	140	46	11	11	NUM
dpc-4194	140	47	(	(	PUNCT
dpc-4194	140	48	17.5	17.5	NUM
dpc-4194	140	49	%	%	NOUN
dpc-4194	140	50	)	)	PUNCT
dpc-4194	140	51	1	1	NUM
dpc-4194	140	52	(	(	PUNCT
dpc-4194	140	53	1.6	1.6	NUM
dpc-4194	140	54	%	%	NOUN
dpc-4194	140	55	)	)	PUNCT
dpc-4194	140	56	mild	mild	ADJ
dpc-4194	140	57	17	17	NUM
dpc-4194	140	58	(	(	PUNCT
dpc-4194	140	59	26.2	26.2	NUM
dpc-4194	140	60	%	%	NOUN
dpc-4194	140	61	)	)	PUNCT
dpc-4194	140	62	2	2	NUM
dpc-4194	140	63	(	(	PUNCT
dpc-4194	140	64	6.3	6.3	NUM
dpc-4194	140	65	%	%	NOUN
dpc-4194	140	66	)	)	PUNCT
dpc-4194	140	67	moderate	moderate	ADJ
dpc-4194	140	68	22	22	NUM
dpc-4194	140	69	(	(	PUNCT
dpc-4194	140	70	33.9	33.9	NUM
dpc-4194	140	71	%	%	NOUN
dpc-4194	140	72	)	)	PUNCT
dpc-4194	140	73	severe	severe	ADJ
dpc-4194	140	74	10	10	NUM
dpc-4194	140	75	(	(	PUNCT
dpc-4194	140	76	15.4	15.4	NUM
dpc-4194	140	77	%	%	NOUN
dpc-4194	140	78	)	)	PUNCT
dpc-4194	140	79	very	very	ADV
dpc-4194	140	80	severe	severe	ADJ
dpc-4194	140	81	2	2	NUM
dpc-4194	140	82	(	(	PUNCT
dpc-4194	140	83	3.1	3.1	NUM
dpc-4194	140	84	%	%	NOUN
dpc-4194	140	85	)	)	PUNCT
dpc-4194	140	86	spga	spga	NOUN
dpc-4194	140	87	-	-	PUNCT
dpc-4194	140	88	g	g	NOUN
dpc-4194	140	89	=	=	NOUN
dpc-4194	140	90	static	static	ADJ
dpc-4194	140	91	physician	physician	NOUN
dpc-4194	140	92	global	global	ADJ
dpc-4194	140	93	assessment	assessment	NOUN
dpc-4194	140	94	of	of	ADP
dpc-4194	140	95	genitalia	genitalia	NOUN
dpc-4194	140	96	.	.	PUNCT
dpc-4194	141	1	6	6	NUM
dpc-4194	141	2	original	original	ADJ
dpc-4194	141	3	article	article	NOUN
dpc-4194	141	4	|	|	ADV
dpc-4194	141	5	dermatol	dermatol	ADJ
dpc-4194	141	6	pract	pract	NOUN
dpc-4194	141	7	concept	concept	NOUN
dpc-4194	141	8	.	.	PUNCT
dpc-4194	142	1	2024;14(2):e2024052	2024;14(2):e2024052	NUM
dpc-4194	143	1	from	from	ADP
dpc-4194	143	2	51	51	NUM
dpc-4194	143	3	patients	patient	NOUN
dpc-4194	143	4	(	(	PUNCT
dpc-4194	143	5	81	81	NUM
dpc-4194	143	6	%	%	NOUN
dpc-4194	143	7	)	)	PUNCT
dpc-4194	143	8	at	at	ADP
dpc-4194	143	9	baseline	baseline	NOUN
dpc-4194	143	10	to	to	ADP
dpc-4194	143	11	5	5	NUM
dpc-4194	143	12	patients	patient	NOUN
dpc-4194	143	13	(	(	PUNCT
dpc-4194	143	14	8.3	8.3	NUM
dpc-4194	143	15	%	%	NOUN
dpc-4194	143	16	)	)	PUNCT
dpc-4194	143	17	after	after	ADP
dpc-4194	143	18	4	4	NUM
dpc-4194	143	19	weeks	week	NOUN
dpc-4194	143	20	of	of	ADP
dpc-4194	143	21	treatment	treatment	NOUN
dpc-4194	143	22	.	.	PUNCT
dpc-4194	144	1	none	none	NOUN
dpc-4194	144	2	of	of	ADP
dpc-4194	144	3	the	the	DET
dpc-4194	144	4	patients	patient	NOUN
dpc-4194	144	5	had	have	VERB
dpc-4194	144	6	a	a	DET
dpc-4194	144	7	dlqi≥10	dlqi≥10	ADJ
dpc-4194	144	8	after	after	ADP
dpc-4194	144	9	16	16	NUM
dpc-4194	144	10	weeks	week	NOUN
dpc-4194	144	11	of	of	ADP
dpc-4194	144	12	treatment	treatment	NOUN
dpc-4194	144	13	(	(	PUNCT
dpc-4194	144	14	table	table	NOUN
dpc-4194	144	15	3	3	NUM
dpc-4194	144	16	)	)	PUNCT
dpc-4194	144	17	.	.	PUNCT
dpc-4194	145	1	given	give	VERB
dpc-4194	145	2	the	the	DET
dpc-4194	145	3	impressive	impressive	ADJ
dpc-4194	145	4	response	response	NOUN
dpc-4194	145	5	of	of	ADP
dpc-4194	145	6	genital	genital	ADJ
dpc-4194	145	7	psoriasis	psoriasis	NOUN
dpc-4194	145	8	to	to	PART
dpc-4194	145	9	bimekizumab	bimekizumab	VERB
dpc-4194	145	10	in	in	ADP
dpc-4194	145	11	almost	almost	ADV
dpc-4194	145	12	all	all	PRON
dpc-4194	145	13	of	of	ADP
dpc-4194	145	14	our	our	PRON
dpc-4194	145	15	patient	patient	NOUN
dpc-4194	145	16	,	,	PUNCT
dpc-4194	145	17	in	in	ADP
dpc-4194	145	18	our	our	PRON
dpc-4194	145	19	study	study	NOUN
dpc-4194	145	20	we	we	PRON
dpc-4194	145	21	found	find	VERB
dpc-4194	145	22	no	no	DET
dpc-4194	145	23	significant	significant	ADJ
dpc-4194	145	24	impact	impact	NOUN
dpc-4194	145	25	of	of	ADP
dpc-4194	145	26	prior	prior	ADJ
dpc-4194	145	27	biologics	biologic	NOUN
dpc-4194	145	28	exposure	exposure	NOUN
dpc-4194	145	29	on	on	ADP
dpc-4194	145	30	the	the	DET
dpc-4194	145	31	improvement	improvement	NOUN
dpc-4194	145	32	of	of	ADP
dpc-4194	145	33	spga	spga	NOUN
dpc-4194	145	34	-	-	PUNCT
dpc-4194	145	35	g	g	NOUN
dpc-4194	145	36	or	or	CCONJ
dpc-4194	145	37	on	on	ADP
dpc-4194	145	38	the	the	DET
dpc-4194	145	39	likelihood	likelihood	NOUN
dpc-4194	145	40	of	of	ADP
dpc-4194	145	41	achieving	achieve	VERB
dpc-4194	145	42	pasi75	pasi75	NOUN
dpc-4194	145	43	,	,	PUNCT
dpc-4194	145	44	pasi90	pasi90	NOUN
dpc-4194	145	45	,	,	PUNCT
dpc-4194	145	46	or	or	CCONJ
dpc-4194	145	47	pasi100	pasi100	PROPN
dpc-4194	145	48	during	during	ADP
dpc-4194	145	49	the	the	DET
dpc-4194	145	50	study	study	NOUN
dpc-4194	145	51	(	(	PUNCT
dpc-4194	145	52	figure	figure	NOUN
dpc-4194	145	53	3	3	NUM
dpc-4194	145	54	)	)	PUNCT
dpc-4194	145	55	.	.	PUNCT
dpc-4194	146	1	similarly	similarly	ADV
dpc-4194	146	2	,	,	PUNCT
dpc-4194	146	3	the	the	DET
dpc-4194	146	4	presence	presence	NOUN
dpc-4194	146	5	of	of	ADP
dpc-4194	146	6	obesity	obesity	NOUN
dpc-4194	146	7	as	as	ADP
dpc-4194	146	8	a	a	DET
dpc-4194	146	9	comorbidity	comorbidity	NOUN
dpc-4194	146	10	did	do	AUX
dpc-4194	146	11	not	not	PART
dpc-4194	146	12	appear	appear	VERB
dpc-4194	146	13	to	to	PART
dpc-4194	146	14	have	have	VERB
dpc-4194	146	15	a	a	DET
dpc-4194	146	16	statistically	statistically	ADV
dpc-4194	146	17	significant	significant	ADJ
dpc-4194	146	18	effect	effect	NOUN
dpc-4194	146	19	on	on	ADP
dpc-4194	146	20	the	the	DET
dpc-4194	146	21	bimekizumab	bimekizumab	ADV
dpc-4194	146	22	-	-	PUNCT
dpc-4194	146	23	induced	induce	VERB
dpc-4194	146	24	improvement	improvement	NOUN
dpc-4194	146	25	of	of	ADP
dpc-4194	146	26	spga	spga	NOUN
dpc-4194	146	27	-	-	PUNCT
dpc-4194	146	28	g	g	NOUN
dpc-4194	146	29	values	value	NOUN
dpc-4194	146	30	.	.	PUNCT
dpc-4194	147	1	obesity	obesity	NOUN
dpc-4194	147	2	did	do	AUX
dpc-4194	147	3	not	not	PART
dpc-4194	147	4	significantly	significantly	ADV
dpc-4194	147	5	influence	influence	VERB
dpc-4194	147	6	the	the	DET
dpc-4194	147	7	likelihood	likelihood	NOUN
dpc-4194	147	8	of	of	ADP
dpc-4194	147	9	achieving	achieve	VERB
dpc-4194	147	10	pasi75	pasi75	NOUN
dpc-4194	147	11	,	,	PUNCT
dpc-4194	147	12	pasi90	pasi90	NOUN
dpc-4194	147	13	,	,	PUNCT
dpc-4194	147	14	or	or	CCONJ
dpc-4194	147	15	pasi100	pasi100	PROPN
dpc-4194	147	16	during	during	ADP
dpc-4194	147	17	the	the	DET
dpc-4194	147	18	study	study	NOUN
dpc-4194	147	19	(	(	PUNCT
dpc-4194	147	20	figure	figure	NOUN
dpc-4194	147	21	3	3	NUM
dpc-4194	147	22	)	)	PUNCT
dpc-4194	147	23	.	.	PUNCT
dpc-4194	148	1	these	these	DET
dpc-4194	148	2	findings	finding	NOUN
dpc-4194	148	3	suggest	suggest	VERB
dpc-4194	148	4	that	that	SCONJ
dpc-4194	148	5	bimekizumab	bimekizumab	NOUN
dpc-4194	148	6	is	be	AUX
dpc-4194	148	7	effective	effective	ADJ
dpc-4194	148	8	in	in	ADP
dpc-4194	148	9	improving	improve	VERB
dpc-4194	148	10	genital	genital	ADJ
dpc-4194	148	11	psoriasis	psoriasis	NOUN
dpc-4194	148	12	and	and	CCONJ
dpc-4194	148	13	associated	associate	VERB
dpc-4194	148	14	quality	quality	NOUN
dpc-4194	148	15	of	of	ADP
dpc-4194	148	16	life	life	NOUN
dpc-4194	148	17	,	,	PUNCT
dpc-4194	148	18	regardless	regardless	ADV
dpc-4194	148	19	of	of	ADP
dpc-4194	148	20	prior	prior	ADJ
dpc-4194	148	21	biologic	biologic	ADJ
dpc-4194	148	22	exposure	exposure	NOUN
dpc-4194	148	23	or	or	CCONJ
dpc-4194	148	24	the	the	DET
dpc-4194	148	25	presence	presence	NOUN
dpc-4194	148	26	of	of	ADP
dpc-4194	148	27	obesity	obesity	NOUN
dpc-4194	148	28	as	as	ADP
dpc-4194	148	29	a	a	DET
dpc-4194	148	30	comorbidity	comorbidity	NOUN
dpc-4194	148	31	.	.	PUNCT
dpc-4194	149	1	conclusions	conclusion	NOUN
dpc-4194	149	2	to	to	ADP
dpc-4194	149	3	date	date	NOUN
dpc-4194	149	4	,	,	PUNCT
dpc-4194	149	5	no	no	DET
dpc-4194	149	6	specific	specific	ADJ
dpc-4194	149	7	guidelines	guideline	NOUN
dpc-4194	149	8	are	be	AUX
dpc-4194	149	9	available	available	ADJ
dpc-4194	149	10	regarding	regard	VERB
dpc-4194	149	11	the	the	DET
dpc-4194	149	12	treatment	treatment	NOUN
dpc-4194	149	13	of	of	ADP
dpc-4194	149	14	genital	genital	ADJ
dpc-4194	149	15	psoriasis	psoriasis	NOUN
dpc-4194	149	16	with	with	ADP
dpc-4194	149	17	biological	biological	ADJ
dpc-4194	149	18	drugs	drug	NOUN
dpc-4194	149	19	.	.	PUNCT
dpc-4194	150	1	however	however	ADV
dpc-4194	150	2	,	,	PUNCT
dpc-4194	150	3	a	a	DET
dpc-4194	150	4	few	few	ADJ
dpc-4194	150	5	real	real	ADJ
dpc-4194	150	6	-	-	PUNCT
dpc-4194	150	7	world	world	NOUN
dpc-4194	150	8	experiences	experience	NOUN
dpc-4194	150	9	have	have	AUX
dpc-4194	150	10	been	be	AUX
dpc-4194	150	11	recently	recently	ADV
dpc-4194	150	12	was	be	AUX
dpc-4194	150	13	further	far	ADV
dpc-4194	150	14	reduced	reduce	VERB
dpc-4194	150	15	to	to	ADP
dpc-4194	150	16	1.1±3.5	1.1±3.5	NUM
dpc-4194	150	17	after	after	ADP
dpc-4194	150	18	16	16	NUM
dpc-4194	150	19	weeks	week	NOUN
dpc-4194	150	20	of	of	ADP
dpc-4194	150	21	therapy	therapy	NOUN
dpc-4194	150	22	(	(	PUNCT
dpc-4194	150	23	p	p	X
dpc-4194	150	24	<	<	X
dpc-4194	150	25	0.001	0.001	NUM
dpc-4194	150	26	)	)	PUNCT
dpc-4194	150	27	(	(	PUNCT
dpc-4194	150	28	table	table	NOUN
dpc-4194	150	29	3	3	NUM
dpc-4194	150	30	)	)	PUNCT
dpc-4194	150	31	.	.	PUNCT
dpc-4194	151	1	at	at	ADP
dpc-4194	151	2	baseline	baseline	NOUN
dpc-4194	151	3	,	,	PUNCT
dpc-4194	151	4	only	only	ADV
dpc-4194	151	5	1	1	NUM
dpc-4194	151	6	patient	patient	NOUN
dpc-4194	151	7	(	(	PUNCT
dpc-4194	151	8	1.6	1.6	NUM
dpc-4194	151	9	%	%	NOUN
dpc-4194	151	10	)	)	PUNCT
dpc-4194	151	11	had	have	VERB
dpc-4194	151	12	a	a	DET
dpc-4194	151	13	pasi	pasi	NOUN
dpc-4194	151	14	score	score	NOUN
dpc-4194	151	15	<	<	X
dpc-4194	151	16	2	2	NUM
dpc-4194	151	17	,	,	PUNCT
dpc-4194	151	18	while	while	SCONJ
dpc-4194	151	19	28	28	NUM
dpc-4194	151	20	patients	patient	NOUN
dpc-4194	151	21	(	(	PUNCT
dpc-4194	151	22	46.7	46.7	NUM
dpc-4194	151	23	%	%	NOUN
dpc-4194	151	24	)	)	PUNCT
dpc-4194	151	25	and	and	CCONJ
dpc-4194	151	26	47	47	NUM
dpc-4194	151	27	patients	patient	NOUN
dpc-4194	151	28	(	(	PUNCT
dpc-4194	151	29	78.3	78.3	NUM
dpc-4194	151	30	%	%	NOUN
dpc-4194	151	31	)	)	PUNCT
dpc-4194	151	32	had	have	VERB
dpc-4194	151	33	a	a	DET
dpc-4194	151	34	pasi	pasi	NOUN
dpc-4194	151	35	score	score	NOUN
dpc-4194	151	36	<	<	X
dpc-4194	151	37	2	2	NUM
dpc-4194	151	38	after	after	ADP
dpc-4194	151	39	4	4	NUM
dpc-4194	151	40	weeks	week	NOUN
dpc-4194	151	41	and	and	CCONJ
dpc-4194	151	42	16	16	NUM
dpc-4194	151	43	weeks	week	NOUN
dpc-4194	151	44	of	of	ADP
dpc-4194	151	45	treatment	treatment	NOUN
dpc-4194	151	46	,	,	PUNCT
dpc-4194	151	47	respectively	respectively	ADV
dpc-4194	151	48	(	(	PUNCT
dpc-4194	151	49	table	table	NOUN
dpc-4194	151	50	3	3	NUM
dpc-4194	151	51	)	)	PUNCT
dpc-4194	151	52	.	.	PUNCT
dpc-4194	152	1	dlqi	dlqi	ADJ
dpc-4194	152	2	improvement	improvement	NOUN
dpc-4194	152	3	at	at	ADP
dpc-4194	152	4	baseline	baseline	NOUN
dpc-4194	152	5	,	,	PUNCT
dpc-4194	152	6	dlqi	dlqi	ADJ
dpc-4194	152	7	scores	score	NOUN
dpc-4194	152	8	were	be	AUX
dpc-4194	152	9	available	available	ADJ
dpc-4194	152	10	for	for	ADP
dpc-4194	152	11	63	63	NUM
dpc-4194	152	12	patients	patient	NOUN
dpc-4194	152	13	and	and	CCONJ
dpc-4194	152	14	61	61	NUM
dpc-4194	152	15	of	of	ADP
dpc-4194	152	16	them	they	PRON
dpc-4194	152	17	had	have	VERB
dpc-4194	152	18	a	a	DET
dpc-4194	152	19	4and	4and	NUM
dpc-4194	152	20	16	16	NUM
dpc-4194	152	21	-	-	PUNCT
dpc-4194	152	22	week	week	NOUN
dpc-4194	152	23	follow	follow	NOUN
dpc-4194	152	24	-	-	PUNCT
dpc-4194	152	25	up	up	NOUN
dpc-4194	152	26	.	.	PUNCT
dpc-4194	153	1	the	the	DET
dpc-4194	153	2	rapid	rapid	ADJ
dpc-4194	153	3	improvement	improvement	NOUN
dpc-4194	153	4	in	in	ADP
dpc-4194	153	5	pasi	pasi	NOUN
dpc-4194	153	6	scores	score	NOUN
dpc-4194	153	7	was	be	AUX
dpc-4194	153	8	paralleled	parallel	VERB
dpc-4194	153	9	by	by	ADP
dpc-4194	153	10	a	a	DET
dpc-4194	153	11	decrease	decrease	NOUN
dpc-4194	153	12	in	in	ADP
dpc-4194	153	13	the	the	DET
dpc-4194	153	14	mean	mean	ADJ
dpc-4194	153	15	dlqi	dlqi	NOUN
dpc-4194	153	16	throughout	throughout	ADP
dpc-4194	153	17	the	the	DET
dpc-4194	153	18	study	study	NOUN
dpc-4194	153	19	period	period	NOUN
dpc-4194	153	20	(	(	PUNCT
dpc-4194	153	21	table	table	NOUN
dpc-4194	153	22	3	3	NUM
dpc-4194	153	23	)	)	PUNCT
dpc-4194	153	24	.	.	PUNCT
dpc-4194	154	1	the	the	DET
dpc-4194	154	2	dlqi	dlqi	NOUN
dpc-4194	154	3	,	,	PUNCT
dpc-4194	154	4	which	which	PRON
dpc-4194	154	5	was	be	AUX
dpc-4194	154	6	17.1±8.8	17.1±8.8	NUM
dpc-4194	154	7	at	at	ADP
dpc-4194	154	8	baseline	baseline	NOUN
dpc-4194	154	9	,	,	PUNCT
dpc-4194	154	10	significantly	significantly	ADV
dpc-4194	154	11	improved	improve	VERB
dpc-4194	154	12	to	to	ADP
dpc-4194	154	13	2.9±4	2.9±4	NUM
dpc-4194	154	14	at	at	ADP
dpc-4194	154	15	4	4	NUM
dpc-4194	154	16	weeks	week	NOUN
dpc-4194	154	17	(	(	PUNCT
dpc-4194	154	18	p	p	X
dpc-4194	154	19	<	<	X
dpc-4194	154	20	0.001	0.001	NUM
dpc-4194	154	21	,	,	PUNCT
dpc-4194	154	22	paired	pair	VERB
dpc-4194	154	23	sample	sample	NOUN
dpc-4194	154	24	t	t	NOUN
dpc-4194	154	25	-	-	PUNCT
dpc-4194	154	26	test	test	NOUN
dpc-4194	154	27	)	)	PUNCT
dpc-4194	154	28	and	and	CCONJ
dpc-4194	154	29	further	far	ADV
dpc-4194	154	30	dropped	drop	VERB
dpc-4194	154	31	to	to	ADP
dpc-4194	154	32	0.5±1.4	0.5±1.4	NOUN
dpc-4194	154	33	at	at	ADP
dpc-4194	154	34	16	16	NUM
dpc-4194	154	35	weeks	week	NOUN
dpc-4194	154	36	(	(	PUNCT
dpc-4194	154	37	p	p	X
dpc-4194	154	38	<	<	X
dpc-4194	154	39	0.001	0.001	NUM
dpc-4194	154	40	,	,	PUNCT
dpc-4194	154	41	paired	pair	VERB
dpc-4194	154	42	sample	sample	NOUN
dpc-4194	154	43	t	t	NOUN
dpc-4194	154	44	-	-	PUNCT
dpc-4194	154	45	test	test	NOUN
dpc-4194	154	46	)	)	PUNCT
dpc-4194	154	47	.	.	PUNCT
dpc-4194	155	1	the	the	DET
dpc-4194	155	2	number	number	NOUN
dpc-4194	155	3	of	of	ADP
dpc-4194	155	4	patients	patient	NOUN
dpc-4194	155	5	reporting	report	VERB
dpc-4194	155	6	severe	severe	ADJ
dpc-4194	155	7	impairment	impairment	NOUN
dpc-4194	155	8	of	of	ADP
dpc-4194	155	9	quality	quality	NOUN
dpc-4194	155	10	of	of	ADP
dpc-4194	155	11	life	life	NOUN
dpc-4194	155	12	(	(	PUNCT
dpc-4194	155	13	dlqi	dlqi	ADJ
dpc-4194	155	14	≥10	≥10	ADJ
dpc-4194	155	15	)	)	PUNCT
dpc-4194	155	16	decreased	decrease	VERB
dpc-4194	155	17	table	table	NOUN
dpc-4194	155	18	3	3	NUM
dpc-4194	155	19	.	.	PUNCT
dpc-4194	155	20	mean	mean	ADJ
dpc-4194	155	21	pasi	pasi	NOUN
dpc-4194	155	22	and	and	CCONJ
dpc-4194	155	23	dlqi	dlqi	NOUN
dpc-4194	155	24	,	,	PUNCT
dpc-4194	155	25	percentage	percentage	NOUN
dpc-4194	155	26	of	of	ADP
dpc-4194	155	27	patients	patient	NOUN
dpc-4194	155	28	with	with	ADP
dpc-4194	155	29	pasi≤2	pasi≤2	PROPN
dpc-4194	155	30	,	,	PUNCT
dpc-4194	155	31	and	and	CCONJ
dpc-4194	155	32	percentage	percentage	NOUN
dpc-4194	155	33	with	with	ADP
dpc-4194	155	34	dlqi≥10	dlqi≥10	ADJ
dpc-4194	155	35	over	over	ADP
dpc-4194	155	36	time	time	NOUN
dpc-4194	155	37	.	.	PUNCT
dpc-4194	156	1	time	time	NOUN
dpc-4194	156	2	point	point	NOUN
dpc-4194	156	3	mean	mean	NOUN
dpc-4194	156	4	pasi	pasi	X
dpc-4194	156	5	pasi≤2	pasi≤2	PROPN
dpc-4194	156	6	baseline	baseline	VERB
dpc-4194	156	7	18.3	18.3	NUM
dpc-4194	156	8	(	(	PUNCT
dpc-4194	156	9	9.0	9.0	NUM
dpc-4194	156	10	)	)	PUNCT
dpc-4194	156	11	4	4	NUM
dpc-4194	156	12	weeks	week	NOUN
dpc-4194	156	13	4.3	4.3	NUM
dpc-4194	156	14	(	(	PUNCT
dpc-4194	156	15	13.0	13.0	NUM
dpc-4194	156	16	)	)	SYM
dpc-4194	156	17	28	28	NUM
dpc-4194	156	18	(	(	PUNCT
dpc-4194	156	19	46.7	46.7	NUM
dpc-4194	156	20	%	%	NOUN
dpc-4194	156	21	)	)	PUNCT
dpc-4194	156	22	16	16	NUM
dpc-4194	156	23	weeks	week	NOUN
dpc-4194	156	24	1.1	1.1	NUM
dpc-4194	156	25	(	(	PUNCT
dpc-4194	156	26	3.5	3.5	NUM
dpc-4194	156	27	)	)	PUNCT
dpc-4194	156	28	47	47	NUM
dpc-4194	156	29	(	(	PUNCT
dpc-4194	156	30	78.3	78.3	NUM
dpc-4194	156	31	%	%	NOUN
dpc-4194	156	32	)	)	PUNCT
dpc-4194	156	33	time	time	NOUN
dpc-4194	156	34	point	point	NOUN
dpc-4194	156	35	mean	mean	INTJ
dpc-4194	156	36	dlqi	dlqi	PROPN
dpc-4194	156	37	dlqi	dlqi	PROPN
dpc-4194	156	38	≥	≥	PROPN
dpc-4194	156	39	10	10	NUM
dpc-4194	156	40	baseline	baseline	NOUN
dpc-4194	156	41	17.1	17.1	NUM
dpc-4194	156	42	(	(	PUNCT
dpc-4194	156	43	8.8	8.8	NUM
dpc-4194	156	44	)	)	PUNCT
dpc-4194	156	45	51	51	NUM
dpc-4194	156	46	(	(	PUNCT
dpc-4194	156	47	81.0	81.0	NUM
dpc-4194	156	48	%	%	NOUN
dpc-4194	156	49	)	)	PUNCT
dpc-4194	156	50	4	4	NUM
dpc-4194	156	51	weeks	week	NOUN
dpc-4194	156	52	2.9	2.9	NUM
dpc-4194	156	53	(	(	PUNCT
dpc-4194	156	54	4.0	4.0	NUM
dpc-4194	156	55	)	)	SYM
dpc-4194	156	56	5	5	NUM
dpc-4194	156	57	(	(	PUNCT
dpc-4194	156	58	8.3	8.3	NUM
dpc-4194	156	59	%	%	NOUN
dpc-4194	156	60	)	)	PUNCT
dpc-4194	156	61	16	16	NUM
dpc-4194	156	62	weeks	week	NOUN
dpc-4194	156	63	0.5	0.5	NUM
dpc-4194	156	64	(	(	PUNCT
dpc-4194	156	65	1.4	1.4	NUM
dpc-4194	156	66	)	)	PUNCT
dpc-4194	156	67	0	0	NUM
dpc-4194	156	68	pasi	pasi	NOUN
dpc-4194	156	69	and	and	CCONJ
dpc-4194	156	70	dlqi	dlqi	ADJ
dpc-4194	156	71	scores	score	NOUN
dpc-4194	156	72	were	be	AUX
dpc-4194	156	73	available	available	ADJ
dpc-4194	156	74	for	for	ADP
dpc-4194	156	75	63	63	NUM
dpc-4194	156	76	patients	patient	NOUN
dpc-4194	156	77	at	at	ADP
dpc-4194	156	78	baseline	baseline	NOUN
dpc-4194	156	79	and	and	CCONJ
dpc-4194	156	80	for	for	ADP
dpc-4194	156	81	61	61	NUM
dpc-4194	156	82	patients	patient	NOUN
dpc-4194	156	83	at	at	ADP
dpc-4194	156	84	weeks	week	NOUN
dpc-4194	156	85	4	4	NUM
dpc-4194	156	86	and	and	CCONJ
dpc-4194	156	87	16	16	NUM
dpc-4194	156	88	.	.	PUNCT
dpc-4194	157	1	dlqi	dlqi	VERB
dpc-4194	157	2	=	=	PUNCT
dpc-4194	157	3	dermatology	dermatology	NOUN
dpc-4194	157	4	life	life	NOUN
dpc-4194	157	5	quality	quality	NOUN
dpc-4194	157	6	index	index	NOUN
dpc-4194	157	7	;	;	PUNCT
dpc-4194	157	8	pasi	pasi	NOUN
dpc-4194	157	9	:	:	PUNCT
dpc-4194	157	10	psoriasis	psoriasis	NOUN
dpc-4194	157	11	area	area	NOUN
dpc-4194	157	12	and	and	CCONJ
dpc-4194	157	13	severity	severity	NOUN
dpc-4194	157	14	index	index	NOUN
dpc-4194	157	15	.	.	PUNCT
dpc-4194	158	1	figure	figure	NOUN
dpc-4194	158	2	3	3	NUM
dpc-4194	158	3	.	.	PUNCT
dpc-4194	159	1	(	(	PUNCT
dpc-4194	159	2	a	a	X
dpc-4194	159	3	)	)	PUNCT
dpc-4194	159	4	patients	patient	NOUN
dpc-4194	159	5	achieving	achieve	VERB
dpc-4194	159	6	psoriasis	psoriasis	NOUN
dpc-4194	159	7	area	area	NOUN
dpc-4194	159	8	and	and	CCONJ
dpc-4194	159	9	severity	severity	NOUN
dpc-4194	159	10	index	index	NOUN
dpc-4194	159	11	(	(	PUNCT
dpc-4194	159	12	pasi	pasi	NOUN
dpc-4194	159	13	)	)	PUNCT
dpc-4194	159	14	75	75	NUM
dpc-4194	159	15	,	,	PUNCT
dpc-4194	159	16	pasi90	pasi90	NOUN
dpc-4194	159	17	and	and	CCONJ
dpc-4194	159	18	pasi100	pasi100	PROPN
dpc-4194	159	19	during	during	ADP
dpc-4194	159	20	treatment	treatment	NOUN
dpc-4194	159	21	in	in	ADP
dpc-4194	159	22	relation	relation	NOUN
dpc-4194	159	23	to	to	ADP
dpc-4194	159	24	previous	previous	ADJ
dpc-4194	159	25	exposure	exposure	NOUN
dpc-4194	159	26	to	to	ADP
dpc-4194	159	27	biologic	biologic	NOUN
dpc-4194	159	28	therapy	therapy	NOUN
dpc-4194	159	29	.	.	PUNCT
dpc-4194	160	1	(	(	PUNCT
dpc-4194	160	2	b	b	X
dpc-4194	160	3	)	)	PUNCT
dpc-4194	160	4	percentage	percentage	NOUN
dpc-4194	160	5	of	of	ADP
dpc-4194	160	6	patients	patient	NOUN
dpc-4194	160	7	achieving	achieve	VERB
dpc-4194	160	8	pasi	pasi	NOUN
dpc-4194	160	9	75	75	NUM
dpc-4194	160	10	,	,	PUNCT
dpc-4194	160	11	pasi90	pasi90	NOUN
dpc-4194	160	12	and	and	CCONJ
dpc-4194	160	13	pasi	pasi	NOUN
dpc-4194	160	14	100	100	NUM
dpc-4194	160	15	over	over	ADP
dpc-4194	160	16	time	time	NOUN
dpc-4194	160	17	in	in	ADP
dpc-4194	160	18	relation	relation	NOUN
dpc-4194	160	19	to	to	ADP
dpc-4194	160	20	the	the	DET
dpc-4194	160	21	presence	presence	NOUN
dpc-4194	160	22	of	of	ADP
dpc-4194	160	23	obesity	obesity	NOUN
dpc-4194	160	24	as	as	ADP
dpc-4194	160	25	a	a	DET
dpc-4194	160	26	comorbidity	comorbidity	NOUN
dpc-4194	160	27	.	.	PUNCT
dpc-4194	161	1	pasi75	pasi75	NOUN
dpc-4194	161	2	,	,	PUNCT
dpc-4194	161	3	at	at	ADP
dpc-4194	161	4	least	least	ADJ
dpc-4194	161	5	a	a	DET
dpc-4194	161	6	75	75	NUM
dpc-4194	161	7	%	%	NOUN
dpc-4194	161	8	improvement	improvement	NOUN
dpc-4194	161	9	from	from	ADP
dpc-4194	161	10	baseline	baseline	NOUN
dpc-4194	161	11	in	in	ADP
dpc-4194	161	12	pasi	pasi	NOUN
dpc-4194	161	13	;	;	PUNCT
dpc-4194	161	14	pasi90	pasi90	NOUN
dpc-4194	161	15	,	,	PUNCT
dpc-4194	161	16	at	at	ADP
dpc-4194	161	17	least	least	ADJ
dpc-4194	161	18	a	a	DET
dpc-4194	161	19	90	90	NUM
dpc-4194	161	20	%	%	NOUN
dpc-4194	161	21	improvement	improvement	NOUN
dpc-4194	161	22	from	from	ADP
dpc-4194	161	23	baseline	baseline	NOUN
dpc-4194	161	24	in	in	ADP
dpc-4194	161	25	pasi	pasi	NOUN
dpc-4194	161	26	.	.	PUNCT
dpc-4194	162	1	pasi100	pasi100	PROPN
dpc-4194	162	2	,	,	PUNCT
dpc-4194	162	3	100	100	NUM
dpc-4194	162	4	%	%	NOUN
dpc-4194	162	5	improvement	improvement	NOUN
dpc-4194	162	6	from	from	ADP
dpc-4194	162	7	baseline	baseline	NOUN
dpc-4194	162	8	in	in	ADP
dpc-4194	162	9	pasi	pasi	PROPN
dpc-4194	162	10	.	.	PUNCT
dpc-4194	163	1	pasi	pasi	PROPN
dpc-4194	163	2	score	score	PROPN
dpc-4194	163	3	was	be	AUX
dpc-4194	163	4	available	available	ADJ
dpc-4194	163	5	for	for	ADP
dpc-4194	163	6	63	63	NUM
dpc-4194	163	7	patients	patient	NOUN
dpc-4194	163	8	at	at	ADP
dpc-4194	163	9	baseline	baseline	NOUN
dpc-4194	163	10	and	and	CCONJ
dpc-4194	163	11	for	for	ADP
dpc-4194	163	12	61	61	NUM
dpc-4194	163	13	patients	patient	NOUN
dpc-4194	163	14	at	at	ADP
dpc-4194	163	15	weeks	week	NOUN
dpc-4194	163	16	4	4	NUM
dpc-4194	163	17	and	and	CCONJ
dpc-4194	163	18	16	16	NUM
dpc-4194	163	19	.	.	PUNCT
dpc-4194	164	1	figure	figure	NOUN
dpc-4194	164	2	2	2	NUM
dpc-4194	164	3	.	.	NOUN
dpc-4194	164	4	percentage	percentage	NOUN
dpc-4194	164	5	of	of	ADP
dpc-4194	164	6	patients	patient	NOUN
dpc-4194	164	7	achieving	achieve	VERB
dpc-4194	164	8	psoriasis	psoriasis	NOUN
dpc-4194	164	9	area	area	NOUN
dpc-4194	164	10	and	and	CCONJ
dpc-4194	164	11	severity	severity	NOUN
dpc-4194	164	12	index	index	NOUN
dpc-4194	164	13	(	(	PUNCT
dpc-4194	164	14	pasi	pasi	NOUN
dpc-4194	164	15	)	)	PUNCT
dpc-4194	164	16	75	75	NUM
dpc-4194	164	17	,	,	PUNCT
dpc-4194	164	18	pasi90	pasi90	NOUN
dpc-4194	164	19	and	and	CCONJ
dpc-4194	164	20	pasi	pasi	NOUN
dpc-4194	164	21	100	100	NUM
dpc-4194	164	22	over	over	ADP
dpc-4194	164	23	time	time	NOUN
dpc-4194	164	24	.	.	PUNCT
dpc-4194	165	1	baseline	baseline	PROPN
dpc-4194	165	2	,	,	PUNCT
dpc-4194	165	3	n	n	PROPN
dpc-4194	165	4	=	=	SYM
dpc-4194	165	5	63	63	NUM
dpc-4194	165	6	;	;	PUNCT
dpc-4194	165	7	week	week	NOUN
dpc-4194	165	8	4	4	NUM
dpc-4194	165	9	,	,	PUNCT
dpc-4194	165	10	n	n	NOUN
dpc-4194	165	11	=	=	SYM
dpc-4194	165	12	61	61	NUM
dpc-4194	165	13	;	;	PUNCT
dpc-4194	165	14	week	week	NOUN
dpc-4194	165	15	16	16	NUM
dpc-4194	165	16	,	,	PUNCT
dpc-4194	165	17	n	n	PROPN
dpc-4194	165	18	=	=	SYM
dpc-4194	165	19	61	61	NUM
dpc-4194	165	20	;	;	PUNCT
dpc-4194	165	21	;	;	PUNCT
dpc-4194	165	22	pasi75	pasi75	NOUN
dpc-4194	165	23	,	,	PUNCT
dpc-4194	165	24	at	at	ADP
dpc-4194	165	25	least	least	ADJ
dpc-4194	165	26	a	a	DET
dpc-4194	165	27	75	75	NUM
dpc-4194	165	28	%	%	NOUN
dpc-4194	165	29	improvement	improvement	NOUN
dpc-4194	165	30	from	from	ADP
dpc-4194	165	31	baseline	baseline	NOUN
dpc-4194	165	32	in	in	ADP
dpc-4194	165	33	pasi	pasi	NOUN
dpc-4194	165	34	;	;	PUNCT
dpc-4194	165	35	pasi90	pasi90	NOUN
dpc-4194	165	36	,	,	PUNCT
dpc-4194	165	37	at	at	ADP
dpc-4194	165	38	least	least	ADJ
dpc-4194	165	39	a	a	DET
dpc-4194	165	40	90	90	NUM
dpc-4194	165	41	%	%	NOUN
dpc-4194	165	42	improvement	improvement	NOUN
dpc-4194	165	43	from	from	ADP
dpc-4194	165	44	baseline	baseline	NOUN
dpc-4194	165	45	in	in	ADP
dpc-4194	165	46	pasi	pasi	NOUN
dpc-4194	165	47	.	.	PUNCT
dpc-4194	166	1	pasi100	pasi100	PROPN
dpc-4194	166	2	,	,	PUNCT
dpc-4194	166	3	100	100	NUM
dpc-4194	166	4	%	%	NOUN
dpc-4194	166	5	improvement	improvement	NOUN
dpc-4194	166	6	from	from	ADP
dpc-4194	166	7	baseline	baseline	NOUN
dpc-4194	166	8	in	in	ADP
dpc-4194	166	9	pasi	pasi	PROPN
dpc-4194	166	10	.	.	PUNCT
dpc-4194	167	1	pasi	pasi	PROPN
dpc-4194	167	2	score	score	PROPN
dpc-4194	167	3	was	be	AUX
dpc-4194	167	4	available	available	ADJ
dpc-4194	167	5	for	for	ADP
dpc-4194	167	6	63	63	NUM
dpc-4194	167	7	patients	patient	NOUN
dpc-4194	167	8	at	at	ADP
dpc-4194	167	9	baseline	baseline	NOUN
dpc-4194	167	10	and	and	CCONJ
dpc-4194	167	11	for	for	ADP
dpc-4194	167	12	61	61	NUM
dpc-4194	167	13	patients	patient	NOUN
dpc-4194	167	14	at	at	ADP
dpc-4194	167	15	weeks	week	NOUN
dpc-4194	167	16	4	4	NUM
dpc-4194	167	17	and	and	CCONJ
dpc-4194	167	18	16	16	NUM
dpc-4194	167	19	.	.	PUNCT
dpc-4194	168	1	original	original	ADJ
dpc-4194	168	2	article	article	NOUN
dpc-4194	168	3	|	|	ADV
dpc-4194	168	4	dermatol	dermatol	ADJ
dpc-4194	168	5	pract	pract	NOUN
dpc-4194	168	6	concept	concept	NOUN
dpc-4194	168	7	.	.	PUNCT
dpc-4194	169	1	2024;14(2):e2024052	2024;14(2):e2024052	NUM
dpc-4194	169	2	7	7	NUM
dpc-4194	169	3	compared	compare	VERB
dpc-4194	169	4	to	to	ADP
dpc-4194	169	5	biologically	biologically	ADV
dpc-4194	169	6	experienced	experienced	ADJ
dpc-4194	169	7	individuals	individual	NOUN
dpc-4194	169	8	,	,	PUNCT
dpc-4194	169	9	our	our	PRON
dpc-4194	169	10	study	study	NOUN
dpc-4194	169	11	did	do	AUX
dpc-4194	169	12	not	not	PART
dpc-4194	169	13	find	find	VERB
dpc-4194	169	14	significant	significant	ADJ
dpc-4194	169	15	differences	difference	NOUN
dpc-4194	169	16	in	in	ADP
dpc-4194	169	17	how	how	SCONJ
dpc-4194	169	18	patients	patient	NOUN
dpc-4194	169	19	responded	respond	VERB
dpc-4194	169	20	to	to	ADP
dpc-4194	169	21	bimekizumab	bimekizumab	NOUN
dpc-4194	169	22	treatment	treatment	NOUN
dpc-4194	169	23	,	,	PUNCT
dpc-4194	169	24	regardless	regardless	ADV
dpc-4194	169	25	of	of	ADP
dpc-4194	169	26	their	their	PRON
dpc-4194	169	27	prior	prior	ADJ
dpc-4194	169	28	exposure	exposure	NOUN
dpc-4194	169	29	to	to	ADP
dpc-4194	169	30	biologics	biologic	NOUN
dpc-4194	169	31	[	[	X
dpc-4194	169	32	32	32	NUM
dpc-4194	169	33	-	-	SYM
dpc-4194	169	34	35	35	NUM
dpc-4194	169	35	]	]	PUNCT
dpc-4194	169	36	.	.	PUNCT
dpc-4194	170	1	previous	previous	ADJ
dpc-4194	170	2	research	research	NOUN
dpc-4194	170	3	has	have	AUX
dpc-4194	170	4	shown	show	VERB
dpc-4194	170	5	a	a	DET
dpc-4194	170	6	direct	direct	ADJ
dpc-4194	170	7	correlation	correlation	NOUN
dpc-4194	170	8	between	between	ADP
dpc-4194	170	9	bmi	bmi	NOUN
dpc-4194	170	10	and	and	CCONJ
dpc-4194	170	11	psoriasis	psoriasis	NOUN
dpc-4194	170	12	prevalence	prevalence	NOUN
dpc-4194	170	13	and	and	CCONJ
dpc-4194	170	14	severity	severity	NOUN
dpc-4194	170	15	,	,	PUNCT
dpc-4194	170	16	along	along	ADP
dpc-4194	170	17	with	with	ADP
dpc-4194	170	18	evidence	evidence	NOUN
dpc-4194	170	19	that	that	SCONJ
dpc-4194	170	20	psoriasis	psoriasis	NOUN
dpc-4194	170	21	symptoms	symptom	NOUN
dpc-4194	170	22	improve	improve	VERB
dpc-4194	170	23	with	with	ADP
dpc-4194	170	24	weight	weight	NOUN
dpc-4194	170	25	reduction	reduction	NOUN
dpc-4194	170	26	and	and	CCONJ
dpc-4194	170	27	increased	increase	VERB
dpc-4194	170	28	physical	physical	ADJ
dpc-4194	170	29	activity	activity	NOUN
dpc-4194	170	30	[	[	X
dpc-4194	170	31	36	36	NUM
dpc-4194	170	32	-	-	SYM
dpc-4194	170	33	41	41	NUM
dpc-4194	170	34	]	]	PUNCT
dpc-4194	170	35	.	.	PUNCT
dpc-4194	171	1	it	it	PRON
dpc-4194	171	2	is	be	AUX
dpc-4194	171	3	worth	worth	ADJ
dpc-4194	171	4	noting	note	VERB
dpc-4194	171	5	that	that	SCONJ
dpc-4194	171	6	many	many	ADJ
dpc-4194	171	7	anti	anti	ADJ
dpc-4194	171	8	-	-	ADJ
dpc-4194	171	9	tnfα	tnfα	ADJ
dpc-4194	171	10	biologic	biologic	NOUN
dpc-4194	171	11	treatments	treatment	NOUN
dpc-4194	171	12	for	for	ADP
dpc-4194	171	13	psoriasis	psoriasis	NOUN
dpc-4194	171	14	have	have	AUX
dpc-4194	171	15	shown	show	VERB
dpc-4194	171	16	better	well	ADJ
dpc-4194	171	17	outcomes	outcome	NOUN
dpc-4194	171	18	in	in	ADP
dpc-4194	171	19	individuals	individual	NOUN
dpc-4194	171	20	with	with	ADP
dpc-4194	171	21	normal	normal	ADJ
dpc-4194	171	22	or	or	CCONJ
dpc-4194	171	23	slightly	slightly	ADV
dpc-4194	171	24	higher	high	ADJ
dpc-4194	171	25	body	body	NOUN
dpc-4194	171	26	weight	weight	NOUN
dpc-4194	171	27	compared	compare	VERB
dpc-4194	171	28	to	to	ADP
dpc-4194	171	29	those	those	PRON
dpc-4194	171	30	who	who	PRON
dpc-4194	171	31	are	be	AUX
dpc-4194	171	32	obese	obese	ADJ
dpc-4194	171	33	[	[	X
dpc-4194	171	34	39	39	NUM
dpc-4194	171	35	]	]	PUNCT
dpc-4194	171	36	.	.	PUNCT
dpc-4194	172	1	similarly	similarly	ADV
dpc-4194	172	2	,	,	PUNCT
dpc-4194	172	3	il-17	il-17	ADV
dpc-4194	172	4	inhibitors	inhibitor	NOUN
dpc-4194	172	5	like	like	ADP
dpc-4194	172	6	secukinumab	secukinumab	NOUN
dpc-4194	172	7	,	,	PUNCT
dpc-4194	172	8	ixekizumab	ixekizumab	NOUN
dpc-4194	172	9	,	,	PUNCT
dpc-4194	172	10	and	and	CCONJ
dpc-4194	172	11	brodalumab	brodalumab	NOUN
dpc-4194	172	12	,	,	PUNCT
dpc-4194	172	13	while	while	SCONJ
dpc-4194	172	14	generally	generally	ADV
dpc-4194	172	15	highly	highly	ADV
dpc-4194	172	16	effective	effective	ADJ
dpc-4194	172	17	regardless	regardless	ADV
dpc-4194	172	18	of	of	ADP
dpc-4194	172	19	body	body	NOUN
dpc-4194	172	20	weight	weight	NOUN
dpc-4194	172	21	,	,	PUNCT
dpc-4194	172	22	tend	tend	VERB
dpc-4194	172	23	to	to	PART
dpc-4194	172	24	yield	yield	VERB
dpc-4194	172	25	a	a	DET
dpc-4194	172	26	more	more	ADV
dpc-4194	172	27	favorable	favorable	ADJ
dpc-4194	172	28	response	response	NOUN
dpc-4194	172	29	in	in	ADP
dpc-4194	172	30	patients	patient	NOUN
dpc-4194	172	31	with	with	ADP
dpc-4194	172	32	normal	normal	ADJ
dpc-4194	172	33	body	body	NOUN
dpc-4194	172	34	weight	weight	NOUN
dpc-4194	172	35	compared	compare	VERB
dpc-4194	172	36	to	to	ADP
dpc-4194	172	37	those	those	PRON
dpc-4194	172	38	who	who	PRON
dpc-4194	172	39	are	be	AUX
dpc-4194	172	40	overweight	overweight	ADJ
dpc-4194	172	41	or	or	CCONJ
dpc-4194	172	42	obese	obese	ADJ
dpc-4194	173	1	[	[	X
dpc-4194	173	2	3942	3942	NUM
dpc-4194	173	3	]	]	PUNCT
dpc-4194	173	4	.	.	PUNCT
dpc-4194	174	1	our	our	PRON
dpc-4194	174	2	findings	finding	NOUN
dpc-4194	174	3	did	do	AUX
dpc-4194	174	4	not	not	PART
dpc-4194	174	5	align	align	VERB
dpc-4194	174	6	with	with	ADP
dpc-4194	174	7	these	these	DET
dpc-4194	174	8	associations	association	NOUN
dpc-4194	174	9	,	,	PUNCT
dpc-4194	174	10	as	as	SCONJ
dpc-4194	174	11	it	it	PRON
dpc-4194	174	12	did	do	AUX
dpc-4194	174	13	not	not	PART
dpc-4194	174	14	reveal	reveal	VERB
dpc-4194	174	15	significant	significant	ADJ
dpc-4194	174	16	differences	difference	NOUN
dpc-4194	174	17	in	in	ADP
dpc-4194	174	18	treatment	treatment	NOUN
dpc-4194	174	19	response	response	NOUN
dpc-4194	174	20	to	to	ADP
dpc-4194	174	21	bimekizumab	bimekizumab	NOUN
dpc-4194	174	22	between	between	ADP
dpc-4194	174	23	obese	obese	ADJ
dpc-4194	174	24	and	and	CCONJ
dpc-4194	174	25	non	non	ADJ
dpc-4194	174	26	-	-	ADJ
dpc-4194	174	27	obese	obese	ADJ
dpc-4194	174	28	patients	patient	NOUN
dpc-4194	174	29	.	.	PUNCT
dpc-4194	175	1	the	the	DET
dpc-4194	175	2	absence	absence	NOUN
dpc-4194	175	3	of	of	ADP
dpc-4194	175	4	a	a	DET
dpc-4194	175	5	statistically	statistically	ADV
dpc-4194	175	6	significant	significant	ADJ
dpc-4194	175	7	difference	difference	NOUN
dpc-4194	175	8	in	in	ADP
dpc-4194	175	9	the	the	DET
dpc-4194	175	10	response	response	NOUN
dpc-4194	175	11	to	to	ADP
dpc-4194	175	12	bimekizumab	bimekizumab	NOUN
dpc-4194	175	13	between	between	ADP
dpc-4194	175	14	non	non	ADJ
dpc-4194	175	15	-	-	ADJ
dpc-4194	175	16	obese	obese	ADJ
dpc-4194	175	17	and	and	CCONJ
dpc-4194	175	18	obese	obese	ADJ
dpc-4194	175	19	patients	patient	NOUN
dpc-4194	175	20	in	in	ADP
dpc-4194	175	21	our	our	PRON
dpc-4194	175	22	study	study	NOUN
dpc-4194	175	23	could	could	AUX
dpc-4194	175	24	be	be	AUX
dpc-4194	175	25	attributed	attribute	VERB
dpc-4194	175	26	to	to	ADP
dpc-4194	175	27	the	the	DET
dpc-4194	175	28	relatively	relatively	ADV
dpc-4194	175	29	small	small	ADJ
dpc-4194	175	30	sample	sample	NOUN
dpc-4194	175	31	size	size	NOUN
dpc-4194	175	32	.	.	PUNCT
dpc-4194	176	1	additionally	additionally	ADV
dpc-4194	176	2	,	,	PUNCT
dpc-4194	176	3	it	it	PRON
dpc-4194	176	4	is	be	AUX
dpc-4194	176	5	worth	worth	ADJ
dpc-4194	176	6	considering	consider	VERB
dpc-4194	176	7	that	that	SCONJ
dpc-4194	176	8	the	the	DET
dpc-4194	176	9	superior	superior	ADJ
dpc-4194	176	10	efficacy	efficacy	NOUN
dpc-4194	176	11	of	of	ADP
dpc-4194	176	12	bimekizumab	bimekizumab	NOUN
dpc-4194	176	13	,	,	PUNCT
dpc-4194	176	14	which	which	PRON
dpc-4194	176	15	inhibits	inhibit	VERB
dpc-4194	176	16	both	both	DET
dpc-4194	176	17	il17a	il17a	PROPN
dpc-4194	176	18	and	and	CCONJ
dpc-4194	176	19	il17f	il17f	PRON
dpc-4194	176	20	,	,	PUNCT
dpc-4194	176	21	in	in	ADP
dpc-4194	176	22	treating	treat	VERB
dpc-4194	176	23	psoriatic	psoriatic	ADJ
dpc-4194	176	24	patients	patient	NOUN
dpc-4194	176	25	compared	compare	VERB
dpc-4194	176	26	to	to	ADP
dpc-4194	176	27	secukinumab	secukinumab	NOUN
dpc-4194	176	28	,	,	PUNCT
dpc-4194	176	29	which	which	PRON
dpc-4194	176	30	only	only	ADV
dpc-4194	176	31	inhibits	inhibit	VERB
dpc-4194	176	32	il-17a	il-17a	PROPN
dpc-4194	176	33	,	,	PUNCT
dpc-4194	176	34	might	might	AUX
dpc-4194	176	35	have	have	AUX
dpc-4194	176	36	lessened	lessen	VERB
dpc-4194	176	37	the	the	DET
dpc-4194	176	38	impact	impact	NOUN
dpc-4194	176	39	of	of	ADP
dpc-4194	176	40	obesity	obesity	NOUN
dpc-4194	176	41	[	[	X
dpc-4194	176	42	23	23	NUM
dpc-4194	176	43	]	]	PUNCT
dpc-4194	176	44	.	.	PUNCT
dpc-4194	177	1	however	however	ADV
dpc-4194	177	2	,	,	PUNCT
dpc-4194	177	3	this	this	DET
dpc-4194	177	4	hypothesis	hypothesis	NOUN
dpc-4194	177	5	contrasts	contrast	VERB
dpc-4194	177	6	with	with	ADP
dpc-4194	177	7	the	the	DET
dpc-4194	177	8	fact	fact	NOUN
dpc-4194	177	9	that	that	SCONJ
dpc-4194	177	10	brodalumab	brodalumab	NOUN
dpc-4194	177	11	,	,	PUNCT
dpc-4194	177	12	which	which	PRON
dpc-4194	177	13	blocks	block	VERB
dpc-4194	177	14	the	the	DET
dpc-4194	177	15	il-1	il-1	ADJ
dpc-4194	177	16	receptor	receptor	NOUN
dpc-4194	177	17	a	a	PRON
dpc-4194	177	18	and	and	CCONJ
dpc-4194	177	19	inhibits	inhibit	VERB
dpc-4194	177	20	the	the	DET
dpc-4194	177	21	biological	biological	ADJ
dpc-4194	177	22	activity	activity	NOUN
dpc-4194	177	23	of	of	ADP
dpc-4194	177	24	il-17a	il-17a	PROPN
dpc-4194	177	25	,	,	PUNCT
dpc-4194	177	26	il-17f	il-17f	NOUN
dpc-4194	177	27	,	,	PUNCT
dpc-4194	177	28	il-17e	il-17e	NOUN
dpc-4194	177	29	,	,	PUNCT
dpc-4194	177	30	and	and	CCONJ
dpc-4194	177	31	il-17c	il-17c	PROPN
dpc-4194	177	32	,	,	PUNCT
dpc-4194	177	33	has	have	AUX
dpc-4194	177	34	shown	show	VERB
dpc-4194	177	35	greater	great	ADJ
dpc-4194	177	36	effectiveness	effectiveness	NOUN
dpc-4194	177	37	in	in	ADP
dpc-4194	177	38	nonobese	nonobese	ADJ
dpc-4194	177	39	psoriatic	psoriatic	ADJ
dpc-4194	177	40	patients	patient	NOUN
dpc-4194	177	41	in	in	ADP
dpc-4194	177	42	various	various	ADJ
dpc-4194	177	43	studies	study	NOUN
dpc-4194	177	44	[	[	X
dpc-4194	177	45	12,34,43	12,34,43	NUM
dpc-4194	177	46	]	]	PUNCT
dpc-4194	177	47	.	.	PUNCT
dpc-4194	178	1	the	the	DET
dpc-4194	178	2	study	study	NOUN
dpc-4194	178	3	does	do	AUX
dpc-4194	178	4	have	have	VERB
dpc-4194	178	5	several	several	ADJ
dpc-4194	178	6	limitations	limitation	NOUN
dpc-4194	178	7	that	that	PRON
dpc-4194	178	8	should	should	AUX
dpc-4194	178	9	be	be	AUX
dpc-4194	178	10	acknowledged	acknowledge	VERB
dpc-4194	178	11	.	.	PUNCT
dpc-4194	179	1	first	first	ADV
dpc-4194	179	2	,	,	PUNCT
dpc-4194	179	3	the	the	DET
dpc-4194	179	4	study	study	NOUN
dpc-4194	179	5	enrolled	enrol	VERB
dpc-4194	179	6	a	a	DET
dpc-4194	179	7	relatively	relatively	ADV
dpc-4194	179	8	small	small	ADJ
dpc-4194	179	9	number	number	NOUN
dpc-4194	179	10	of	of	ADP
dpc-4194	179	11	patients	patient	NOUN
dpc-4194	179	12	,	,	PUNCT
dpc-4194	179	13	underscoring	underscore	VERB
dpc-4194	179	14	the	the	DET
dpc-4194	179	15	need	need	NOUN
dpc-4194	179	16	for	for	ADP
dpc-4194	179	17	further	further	ADJ
dpc-4194	179	18	research	research	NOUN
dpc-4194	179	19	to	to	PART
dpc-4194	179	20	assess	assess	VERB
dpc-4194	179	21	the	the	DET
dpc-4194	179	22	long	long	ADJ
dpc-4194	179	23	-	-	PUNCT
dpc-4194	179	24	term	term	NOUN
dpc-4194	179	25	optimal	optimal	ADJ
dpc-4194	179	26	management	management	NOUN
dpc-4194	179	27	of	of	ADP
dpc-4194	179	28	genital	genital	ADJ
dpc-4194	179	29	psoriasis	psoriasis	NOUN
dpc-4194	179	30	patients	patient	NOUN
dpc-4194	179	31	in	in	ADP
dpc-4194	179	32	real	real	ADJ
dpc-4194	179	33	-	-	PUNCT
dpc-4194	179	34	life	life	NOUN
dpc-4194	179	35	settings	setting	NOUN
dpc-4194	179	36	.	.	PUNCT
dpc-4194	180	1	additionally	additionally	ADV
dpc-4194	180	2	,	,	PUNCT
dpc-4194	180	3	the	the	DET
dpc-4194	180	4	study	study	NOUN
dpc-4194	180	5	did	do	AUX
dpc-4194	180	6	not	not	PART
dpc-4194	180	7	include	include	VERB
dpc-4194	180	8	an	an	DET
dpc-4194	180	9	active	active	ADJ
dpc-4194	180	10	comparator	comparator	NOUN
dpc-4194	180	11	,	,	PUNCT
dpc-4194	180	12	which	which	PRON
dpc-4194	180	13	could	could	AUX
dpc-4194	180	14	have	have	AUX
dpc-4194	180	15	been	be	AUX
dpc-4194	180	16	ixekizumab	ixekizumab	VERB
dpc-4194	180	17	,	,	PUNCT
dpc-4194	180	18	to	to	PART
dpc-4194	180	19	provide	provide	VERB
dpc-4194	180	20	a	a	DET
dpc-4194	180	21	more	more	ADV
dpc-4194	180	22	comprehensive	comprehensive	ADJ
dpc-4194	180	23	comparison	comparison	NOUN
dpc-4194	180	24	.	.	PUNCT
dpc-4194	181	1	furthermore	furthermore	ADV
dpc-4194	181	2	,	,	PUNCT
dpc-4194	181	3	it	it	PRON
dpc-4194	181	4	is	be	AUX
dpc-4194	181	5	worth	worth	ADJ
dpc-4194	181	6	noting	note	VERB
dpc-4194	181	7	that	that	SCONJ
dpc-4194	181	8	73	73	NUM
dpc-4194	181	9	%	%	NOUN
dpc-4194	181	10	of	of	ADP
dpc-4194	181	11	the	the	DET
dpc-4194	181	12	study	study	NOUN
dpc-4194	181	13	population	population	NOUN
dpc-4194	181	14	consisted	consist	VERB
dpc-4194	181	15	of	of	ADP
dpc-4194	181	16	men	man	NOUN
dpc-4194	181	17	,	,	PUNCT
dpc-4194	181	18	even	even	ADV
dpc-4194	181	19	though	though	SCONJ
dpc-4194	181	20	genital	genital	ADJ
dpc-4194	181	21	psoriasis	psoriasis	NOUN
dpc-4194	181	22	is	be	AUX
dpc-4194	181	23	somewhat	somewhat	ADV
dpc-4194	181	24	more	more	ADV
dpc-4194	181	25	common	common	ADJ
dpc-4194	181	26	in	in	ADP
dpc-4194	181	27	male	male	NOUN
dpc-4194	181	28	compared	compare	VERB
dpc-4194	181	29	to	to	ADP
dpc-4194	181	30	female	female	ADJ
dpc-4194	181	31	psoriasis	psoriasis	NOUN
dpc-4194	181	32	patients	patient	NOUN
dpc-4194	181	33	,	,	PUNCT
dpc-4194	181	34	as	as	SCONJ
dpc-4194	181	35	reported	report	VERB
dpc-4194	181	36	in	in	ADP
dpc-4194	181	37	previous	previous	ADJ
dpc-4194	181	38	studies	study	NOUN
dpc-4194	181	39	[	[	X
dpc-4194	181	40	44	44	NUM
dpc-4194	181	41	]	]	PUNCT
dpc-4194	181	42	.	.	PUNCT
dpc-4194	182	1	moreover	moreover	ADV
dpc-4194	182	2	,	,	PUNCT
dpc-4194	182	3	the	the	DET
dpc-4194	182	4	study	study	NOUN
dpc-4194	182	5	assessed	assess	VERB
dpc-4194	182	6	treatment	treatment	NOUN
dpc-4194	182	7	response	response	NOUN
dpc-4194	182	8	only	only	ADV
dpc-4194	182	9	up	up	ADP
dpc-4194	182	10	to	to	ADP
dpc-4194	182	11	the	the	DET
dpc-4194	182	12	16	16	NUM
dpc-4194	182	13	-	-	PUNCT
dpc-4194	182	14	week	week	NOUN
dpc-4194	182	15	mark	mark	NOUN
dpc-4194	182	16	and	and	CCONJ
dpc-4194	182	17	only	only	ADV
dpc-4194	182	18	a	a	DET
dpc-4194	182	19	18.5	18.5	NUM
dpc-4194	182	20	%	%	NOUN
dpc-4194	182	21	of	of	ADP
dpc-4194	182	22	patients	patient	NOUN
dpc-4194	182	23	had	have	VERB
dpc-4194	182	24	a	a	DET
dpc-4194	182	25	severe	severe	ADJ
dpc-4194	182	26	or	or	CCONJ
dpc-4194	182	27	very	very	ADV
dpc-4194	182	28	severe	severe	ADJ
dpc-4194	182	29	genital	genital	ADJ
dpc-4194	182	30	psoriasis	psoriasis	NOUN
dpc-4194	182	31	.	.	PUNCT
dpc-4194	183	1	investigating	investigate	VERB
dpc-4194	183	2	the	the	DET
dpc-4194	183	3	long	long	ADJ
dpc-4194	183	4	-	-	PUNCT
dpc-4194	183	5	term	term	NOUN
dpc-4194	183	6	impact	impact	NOUN
dpc-4194	183	7	of	of	ADP
dpc-4194	183	8	bimekizumab	bimekizumab	NOUN
dpc-4194	183	9	on	on	ADP
dpc-4194	183	10	genital	genital	ADJ
dpc-4194	183	11	symptoms	symptom	NOUN
dpc-4194	183	12	and	and	CCONJ
dpc-4194	183	13	sexual	sexual	ADJ
dpc-4194	183	14	activity	activity	NOUN
dpc-4194	183	15	is	be	AUX
dpc-4194	183	16	crucial	crucial	ADJ
dpc-4194	183	17	,	,	PUNCT
dpc-4194	183	18	as	as	SCONJ
dpc-4194	183	19	the	the	DET
dpc-4194	183	20	effects	effect	NOUN
dpc-4194	183	21	of	of	ADP
dpc-4194	183	22	treatment	treatment	NOUN
dpc-4194	183	23	on	on	ADP
dpc-4194	183	24	sexual	sexual	ADJ
dpc-4194	183	25	activity	activity	NOUN
dpc-4194	183	26	within	within	ADP
dpc-4194	183	27	a	a	DET
dpc-4194	183	28	relationship	relationship	NOUN
dpc-4194	183	29	may	may	AUX
dpc-4194	183	30	take	take	VERB
dpc-4194	183	31	longer	long	ADJ
dpc-4194	183	32	to	to	PART
dpc-4194	183	33	become	become	VERB
dpc-4194	183	34	evident	evident	ADJ
dpc-4194	183	35	in	in	ADP
dpc-4194	183	36	some	some	DET
dpc-4194	183	37	cases	case	NOUN
dpc-4194	183	38	.	.	PUNCT
dpc-4194	184	1	the	the	DET
dpc-4194	184	2	involvement	involvement	NOUN
dpc-4194	184	3	of	of	ADP
dpc-4194	184	4	difficult	difficult	ADJ
dpc-4194	184	5	-	-	PUNCT
dpc-4194	184	6	to	to	ADP
dpc-4194	184	7	-	-	PUNCT
dpc-4194	184	8	treat	treat	NOUN
dpc-4194	184	9	areas	area	NOUN
dpc-4194	184	10	can	can	AUX
dpc-4194	184	11	severely	severely	ADV
dpc-4194	184	12	impact	impact	VERB
dpc-4194	184	13	the	the	DET
dpc-4194	184	14	patients	patient	NOUN
dpc-4194	184	15	quality	quality	NOUN
dpc-4194	184	16	of	of	ADP
dpc-4194	184	17	life	life	NOUN
dpc-4194	184	18	and	and	CCONJ
dpc-4194	184	19	,	,	PUNCT
dpc-4194	184	20	in	in	ADP
dpc-4194	184	21	this	this	DET
dpc-4194	184	22	context	context	NOUN
dpc-4194	184	23	,	,	PUNCT
dpc-4194	184	24	both	both	CCONJ
dpc-4194	184	25	anti	anti	ADJ
dpc-4194	184	26	-	-	NOUN
dpc-4194	184	27	il-23	il-23	ADJ
dpc-4194	184	28	and	and	CCONJ
dpc-4194	184	29	anti	anti	ADJ
dpc-4194	184	30	-	-	ADJ
dpc-4194	184	31	il-17	il-17	PRON
dpc-4194	184	32	drugs	drug	NOUN
dpc-4194	184	33	have	have	AUX
dpc-4194	184	34	shown	show	VERB
dpc-4194	184	35	promising	promising	ADJ
dpc-4194	184	36	data	datum	NOUN
dpc-4194	185	1	[	[	X
dpc-4194	185	2	45,46	45,46	NOUN
dpc-4194	185	3	]	]	PUNCT
dpc-4194	185	4	.	.	PUNCT
dpc-4194	186	1	the	the	DET
dpc-4194	186	2	role	role	NOUN
dpc-4194	186	3	of	of	ADP
dpc-4194	186	4	bimekizumab	bimekizumab	NOUN
dpc-4194	186	5	in	in	ADP
dpc-4194	186	6	this	this	DET
dpc-4194	186	7	setting	setting	NOUN
dpc-4194	186	8	has	have	AUX
dpc-4194	186	9	not	not	PART
dpc-4194	186	10	published	publish	VERB
dpc-4194	186	11	on	on	ADP
dpc-4194	186	12	the	the	DET
dpc-4194	186	13	role	role	NOUN
dpc-4194	186	14	of	of	ADP
dpc-4194	186	15	anti	anti	ADJ
dpc-4194	186	16	-	-	NOUN
dpc-4194	186	17	il-23	il-23	ADJ
dpc-4194	186	18	and	and	CCONJ
dpc-4194	186	19	anti	anti	ADJ
dpc-4194	186	20	-	-	ADJ
dpc-4194	186	21	il17a	il17a	ADJ
dpc-4194	186	22	drugs	drug	NOUN
dpc-4194	186	23	[	[	X
dpc-4194	186	24	16,30	16,30	NUM
dpc-4194	186	25	]	]	PUNCT
dpc-4194	186	26	.	.	PUNCT
dpc-4194	187	1	real	real	ADJ
dpc-4194	187	2	-	-	PUNCT
dpc-4194	187	3	world	world	NOUN
dpc-4194	187	4	evidence	evidence	NOUN
dpc-4194	187	5	on	on	ADP
dpc-4194	187	6	the	the	DET
dpc-4194	187	7	effectiveness	effectiveness	NOUN
dpc-4194	187	8	of	of	ADP
dpc-4194	187	9	bimekizumab	bimekizumab	NOUN
dpc-4194	187	10	in	in	ADP
dpc-4194	187	11	this	this	DET
dpc-4194	187	12	subset	subset	NOUN
dpc-4194	187	13	of	of	ADP
dpc-4194	187	14	patients	patient	NOUN
dpc-4194	187	15	are	be	AUX
dpc-4194	187	16	extremely	extremely	ADV
dpc-4194	187	17	limited	limited	ADJ
dpc-4194	187	18	.	.	PUNCT
dpc-4194	188	1	when	when	SCONJ
dpc-4194	188	2	examining	examine	VERB
dpc-4194	188	3	our	our	PRON
dpc-4194	188	4	study	study	NOUN
dpc-4194	188	5	population	population	NOUN
dpc-4194	188	6	at	at	ADP
dpc-4194	188	7	baseline	baseline	NOUN
dpc-4194	188	8	,	,	PUNCT
dpc-4194	188	9	we	we	PRON
dpc-4194	188	10	observed	observe	VERB
dpc-4194	188	11	similarities	similarity	NOUN
dpc-4194	188	12	in	in	ADP
dpc-4194	188	13	their	their	PRON
dpc-4194	188	14	characteristics	characteristic	NOUN
dpc-4194	188	15	when	when	SCONJ
dpc-4194	188	16	compared	compare	VERB
dpc-4194	188	17	to	to	ADP
dpc-4194	188	18	the	the	DET
dpc-4194	188	19	participants	participant	NOUN
dpc-4194	188	20	in	in	ADP
dpc-4194	188	21	phase-3	phase-3	NUM
dpc-4194	188	22	clinical	clinical	ADJ
dpc-4194	188	23	trials	trial	NOUN
dpc-4194	188	24	evaluating	evaluate	VERB
dpc-4194	188	25	bimekizumab	bimekizumab	NOUN
dpc-4194	188	26	in	in	ADP
dpc-4194	188	27	psoriatic	psoriatic	ADJ
dpc-4194	188	28	patients	patient	NOUN
dpc-4194	188	29	[	[	X
dpc-4194	188	30	20	20	NUM
dpc-4194	188	31	-	-	SYM
dpc-4194	188	32	23	23	NUM
dpc-4194	188	33	]	]	PUNCT
dpc-4194	188	34	.	.	PUNCT
dpc-4194	189	1	one	one	NUM
dpc-4194	189	2	notable	notable	ADJ
dpc-4194	189	3	exception	exception	NOUN
dpc-4194	189	4	was	be	AUX
dpc-4194	189	5	the	the	DET
dpc-4194	189	6	lower	low	ADJ
dpc-4194	189	7	mean	mean	ADJ
dpc-4194	189	8	pasi	pasi	NOUN
dpc-4194	189	9	at	at	ADP
dpc-4194	189	10	baseline	baseline	NOUN
dpc-4194	189	11	in	in	ADP
dpc-4194	189	12	our	our	PRON
dpc-4194	189	13	study	study	NOUN
dpc-4194	189	14	.	.	PUNCT
dpc-4194	190	1	this	this	DET
dpc-4194	190	2	discrepancy	discrepancy	NOUN
dpc-4194	190	3	can	can	AUX
dpc-4194	190	4	be	be	AUX
dpc-4194	190	5	attributed	attribute	VERB
dpc-4194	190	6	to	to	ADP
dpc-4194	190	7	the	the	DET
dpc-4194	190	8	stringent	stringent	ADJ
dpc-4194	190	9	inclusion	inclusion	NOUN
dpc-4194	190	10	criteria	criterion	NOUN
dpc-4194	190	11	typically	typically	ADV
dpc-4194	190	12	employed	employ	VERB
dpc-4194	190	13	in	in	ADP
dpc-4194	190	14	clinical	clinical	ADJ
dpc-4194	190	15	trials	trial	NOUN
dpc-4194	190	16	.	.	PUNCT
dpc-4194	191	1	of	of	ADP
dpc-4194	191	2	particular	particular	ADJ
dpc-4194	191	3	interest	interest	NOUN
dpc-4194	191	4	,	,	PUNCT
dpc-4194	191	5	our	our	PRON
dpc-4194	191	6	patients	patient	NOUN
dpc-4194	191	7	exhibited	exhibit	VERB
dpc-4194	191	8	a	a	DET
dpc-4194	191	9	higher	high	ADJ
dpc-4194	191	10	mean	mean	NOUN
dpc-4194	191	11	dlqi	dlqi	NOUN
dpc-4194	191	12	compared	compare	VERB
dpc-4194	191	13	to	to	ADP
dpc-4194	191	14	those	those	PRON
dpc-4194	191	15	involved	involve	VERB
dpc-4194	191	16	in	in	ADP
dpc-4194	191	17	the	the	DET
dpc-4194	191	18	aforementioned	aforementioned	ADJ
dpc-4194	191	19	trials	trial	NOUN
dpc-4194	191	20	,	,	PUNCT
dpc-4194	191	21	underscoring	underscore	VERB
dpc-4194	191	22	the	the	DET
dpc-4194	191	23	substantial	substantial	ADJ
dpc-4194	191	24	impact	impact	NOUN
dpc-4194	191	25	of	of	ADP
dpc-4194	191	26	psoriasis	psoriasis	NOUN
dpc-4194	191	27	on	on	ADP
dpc-4194	191	28	our	our	PRON
dpc-4194	191	29	patients	patient	NOUN
dpc-4194	191	30	quality	quality	NOUN
dpc-4194	191	31	of	of	ADP
dpc-4194	191	32	life	life	NOUN
dpc-4194	191	33	[	[	X
dpc-4194	191	34	20	20	NUM
dpc-4194	191	35	-	-	SYM
dpc-4194	191	36	23	23	NUM
dpc-4194	191	37	]	]	PUNCT
dpc-4194	191	38	.	.	PUNCT
dpc-4194	192	1	the	the	DET
dpc-4194	192	2	data	datum	NOUN
dpc-4194	192	3	presented	present	VERB
dpc-4194	192	4	in	in	ADP
dpc-4194	192	5	our	our	PRON
dpc-4194	192	6	study	study	NOUN
dpc-4194	192	7	highlight	highlight	VERB
dpc-4194	192	8	the	the	DET
dpc-4194	192	9	remarkable	remarkable	ADJ
dpc-4194	192	10	effectiveness	effectiveness	NOUN
dpc-4194	192	11	of	of	ADP
dpc-4194	192	12	bimekizumab	bimekizumab	NOUN
dpc-4194	192	13	in	in	ADP
dpc-4194	192	14	the	the	DET
dpc-4194	192	15	treatment	treatment	NOUN
dpc-4194	192	16	of	of	ADP
dpc-4194	192	17	genital	genital	ADJ
dpc-4194	192	18	psoriasis	psoriasis	NOUN
dpc-4194	192	19	.	.	PUNCT
dpc-4194	193	1	we	we	PRON
dpc-4194	193	2	observed	observe	VERB
dpc-4194	193	3	rapid	rapid	ADJ
dpc-4194	193	4	and	and	CCONJ
dpc-4194	193	5	significant	significant	ADJ
dpc-4194	193	6	improvements	improvement	NOUN
dpc-4194	193	7	in	in	ADP
dpc-4194	193	8	the	the	DET
dpc-4194	193	9	severity	severity	NOUN
dpc-4194	193	10	of	of	ADP
dpc-4194	193	11	genital	genital	ADJ
dpc-4194	193	12	psoriasis	psoriasis	NOUN
dpc-4194	193	13	,	,	PUNCT
dpc-4194	193	14	as	as	SCONJ
dpc-4194	193	15	measured	measure	VERB
dpc-4194	193	16	by	by	ADP
dpc-4194	193	17	the	the	DET
dpc-4194	193	18	spga	spga	NOUN
dpc-4194	193	19	-	-	PUNCT
dpc-4194	193	20	g	g	NOUN
dpc-4194	193	21	score	score	NOUN
dpc-4194	193	22	,	,	PUNCT
dpc-4194	193	23	with	with	ADP
dpc-4194	193	24	98.4	98.4	NUM
dpc-4194	193	25	%	%	NOUN
dpc-4194	193	26	of	of	ADP
dpc-4194	193	27	patients	patient	NOUN
dpc-4194	193	28	achieving	achieve	VERB
dpc-4194	193	29	a	a	DET
dpc-4194	193	30	clear	clear	ADJ
dpc-4194	193	31	spga	spga	NOUN
dpc-4194	193	32	-	-	PUNCT
dpc-4194	193	33	g	g	NOUN
dpc-4194	193	34	score	score	NOUN
dpc-4194	193	35	after	after	ADP
dpc-4194	193	36	just	just	ADV
dpc-4194	193	37	16	16	NUM
dpc-4194	193	38	weeks	week	NOUN
dpc-4194	193	39	of	of	ADP
dpc-4194	193	40	treatment	treatment	NOUN
dpc-4194	193	41	.	.	PUNCT
dpc-4194	194	1	compared	compare	VERB
dpc-4194	194	2	with	with	ADP
dpc-4194	194	3	ixekizumab	ixekizumab	NOUN
dpc-4194	194	4	,	,	PUNCT
dpc-4194	194	5	the	the	DET
dpc-4194	194	6	only	only	ADJ
dpc-4194	194	7	biological	biological	ADJ
dpc-4194	194	8	treatment	treatment	NOUN
dpc-4194	194	9	specifically	specifically	ADV
dpc-4194	194	10	approved	approve	VERB
dpc-4194	194	11	for	for	ADP
dpc-4194	194	12	genital	genital	ADJ
dpc-4194	194	13	psoriasis	psoriasis	NOUN
dpc-4194	194	14	treatment	treatment	NOUN
dpc-4194	194	15	,	,	PUNCT
dpc-4194	194	16	we	we	PRON
dpc-4194	194	17	observed	observe	VERB
dpc-4194	194	18	better	well	ADJ
dpc-4194	194	19	clinical	clinical	ADJ
dpc-4194	194	20	responses	response	NOUN
dpc-4194	194	21	at	at	ADP
dpc-4194	194	22	week	week	NOUN
dpc-4194	194	23	16	16	NUM
dpc-4194	195	1	[	[	X
dpc-4194	195	2	31	31	NUM
dpc-4194	195	3	]	]	PUNCT
dpc-4194	195	4	.	.	PUNCT
dpc-4194	196	1	as	as	ADP
dpc-4194	196	2	a	a	DET
dpc-4194	196	3	matter	matter	NOUN
dpc-4194	196	4	of	of	ADP
dpc-4194	196	5	fact	fact	NOUN
dpc-4194	196	6	,	,	PUNCT
dpc-4194	196	7	the	the	DET
dpc-4194	196	8	study	study	NOUN
dpc-4194	196	9	on	on	ADP
dpc-4194	196	10	ixekizumab	ixekizumab	NOUN
dpc-4194	196	11	by	by	ADP
dpc-4194	196	12	guenther	guenther	PROPN
dpc-4194	196	13	et	et	PROPN
dpc-4194	196	14	al	al	PROPN
dpc-4194	196	15	showed	show	VERB
dpc-4194	196	16	that	that	SCONJ
dpc-4194	196	17	75	75	NUM
dpc-4194	196	18	%	%	NOUN
dpc-4194	196	19	of	of	ADP
dpc-4194	196	20	patients	patient	NOUN
dpc-4194	196	21	achieved	achieve	VERB
dpc-4194	196	22	a	a	DET
dpc-4194	196	23	clear	clear	ADJ
dpc-4194	196	24	or	or	CCONJ
dpc-4194	196	25	almost	almost	ADV
dpc-4194	196	26	clear	clear	ADJ
dpc-4194	196	27	spga	spga	NOUN
dpc-4194	196	28	-	-	PUNCT
dpc-4194	196	29	g	g	NOUN
dpc-4194	196	30	score	score	NOUN
dpc-4194	196	31	after	after	ADP
dpc-4194	196	32	52	52	NUM
dpc-4194	196	33	weeks	week	NOUN
dpc-4194	196	34	of	of	ADP
dpc-4194	196	35	treatment	treatment	NOUN
dpc-4194	196	36	,	,	PUNCT
dpc-4194	196	37	with	with	ADP
dpc-4194	196	38	60	60	NUM
dpc-4194	196	39	%	%	NOUN
dpc-4194	196	40	achieving	achieve	VERB
dpc-4194	196	41	complete	complete	ADJ
dpc-4194	196	42	clearance	clearance	NOUN
dpc-4194	197	1	[	[	X
dpc-4194	197	2	10	10	NUM
dpc-4194	197	3	]	]	PUNCT
dpc-4194	197	4	.	.	PUNCT
dpc-4194	198	1	similarly	similarly	ADV
dpc-4194	198	2	,	,	PUNCT
dpc-4194	198	3	sotirou	sotirou	PROPN
dpc-4194	198	4	et	et	PROPN
dpc-4194	198	5	al	al	PROPN
dpc-4194	198	6	achieved	achieve	VERB
dpc-4194	198	7	a	a	DET
dpc-4194	198	8	spga	spga	NOUN
dpc-4194	198	9	-	-	PUNCT
dpc-4194	198	10	g	g	NOUN
dpc-4194	198	11	score	score	NOUN
dpc-4194	198	12	of	of	ADP
dpc-4194	198	13	almost	almost	ADV
dpc-4194	198	14	clear	clear	ADJ
dpc-4194	198	15	or	or	CCONJ
dpc-4194	198	16	clear	clear	ADJ
dpc-4194	198	17	in	in	ADP
dpc-4194	198	18	68.8	68.8	NUM
dpc-4194	198	19	%	%	NOUN
dpc-4194	198	20	and	and	CCONJ
dpc-4194	198	21	93.8	93.8	NUM
dpc-4194	198	22	%	%	NOUN
dpc-4194	198	23	of	of	ADP
dpc-4194	198	24	patients	patient	NOUN
dpc-4194	198	25	treated	treat	VERB
dpc-4194	198	26	with	with	ADP
dpc-4194	198	27	ixekizumab	ixekizumab	NOUN
dpc-4194	198	28	at	at	ADP
dpc-4194	198	29	weeks	week	NOUN
dpc-4194	198	30	16	16	NUM
dpc-4194	198	31	and	and	CCONJ
dpc-4194	198	32	24	24	NUM
dpc-4194	198	33	,	,	PUNCT
dpc-4194	198	34	respectively	respectively	ADV
dpc-4194	198	35	[	[	X
dpc-4194	198	36	16	16	NUM
dpc-4194	198	37	]	]	PUNCT
dpc-4194	198	38	.	.	PUNCT
dpc-4194	199	1	these	these	DET
dpc-4194	199	2	findings	finding	NOUN
dpc-4194	199	3	suggest	suggest	VERB
dpc-4194	199	4	that	that	SCONJ
dpc-4194	199	5	bimekizumab	bimekizumab	NOUN
dpc-4194	199	6	may	may	AUX
dpc-4194	199	7	lead	lead	VERB
dpc-4194	199	8	to	to	ADP
dpc-4194	199	9	a	a	DET
dpc-4194	199	10	more	more	ADV
dpc-4194	199	11	rapid	rapid	ADJ
dpc-4194	199	12	and	and	CCONJ
dpc-4194	199	13	effective	effective	ADJ
dpc-4194	199	14	improvement	improvement	NOUN
dpc-4194	199	15	in	in	ADP
dpc-4194	199	16	genital	genital	ADJ
dpc-4194	199	17	psoriasis	psoriasis	NOUN
dpc-4194	199	18	compared	compare	VERB
dpc-4194	199	19	to	to	ADP
dpc-4194	199	20	ixekizumab	ixekizumab	NOUN
dpc-4194	199	21	,	,	PUNCT
dpc-4194	199	22	but	but	CCONJ
dpc-4194	199	23	head	head	NOUN
dpc-4194	199	24	-	-	PUNCT
dpc-4194	199	25	to	to	ADP
dpc-4194	199	26	-	-	PUNCT
dpc-4194	199	27	head	head	NOUN
dpc-4194	199	28	comparison	comparison	NOUN
dpc-4194	199	29	studies	study	NOUN
dpc-4194	199	30	are	be	AUX
dpc-4194	199	31	needed	need	VERB
dpc-4194	199	32	to	to	PART
dpc-4194	199	33	confirm	confirm	VERB
dpc-4194	199	34	this	this	DET
dpc-4194	199	35	observation	observation	NOUN
dpc-4194	199	36	.	.	PUNCT
dpc-4194	200	1	our	our	PRON
dpc-4194	200	2	findings	finding	NOUN
dpc-4194	200	3	could	could	AUX
dpc-4194	200	4	also	also	ADV
dpc-4194	200	5	be	be	AUX
dpc-4194	200	6	partially	partially	ADV
dpc-4194	200	7	explained	explain	VERB
dpc-4194	200	8	with	with	ADP
dpc-4194	200	9	a	a	DET
dpc-4194	200	10	moderate	moderate	ADJ
dpc-4194	200	11	severity	severity	NOUN
dpc-4194	200	12	of	of	ADP
dpc-4194	200	13	genital	genital	ADJ
dpc-4194	200	14	psoriasis	psoriasis	NOUN
dpc-4194	200	15	in	in	ADP
dpc-4194	200	16	our	our	PRON
dpc-4194	200	17	cohort	cohort	NOUN
dpc-4194	200	18	,	,	PUNCT
dpc-4194	200	19	as	as	SCONJ
dpc-4194	200	20	one	one	NUM
dpc-4194	200	21	third	third	NOUN
dpc-4194	200	22	of	of	ADP
dpc-4194	200	23	the	the	DET
dpc-4194	200	24	patients	patient	NOUN
dpc-4194	200	25	had	have	VERB
dpc-4194	200	26	a	a	DET
dpc-4194	200	27	s	s	NOUN
dpc-4194	200	28	-	-	PUNCT
dpc-4194	200	29	pga	pga	NOUN
dpc-4194	200	30	-	-	PUNCT
dpc-4194	200	31	g	g	NOUN
dpc-4194	200	32	of	of	ADP
dpc-4194	200	33	3	3	NUM
dpc-4194	200	34	,	,	PUNCT
dpc-4194	200	35	as	as	SCONJ
dpc-4194	200	36	shown	show	VERB
dpc-4194	200	37	in	in	ADP
dpc-4194	200	38	table	table	NOUN
dpc-4194	200	39	2	2	NUM
dpc-4194	200	40	.	.	PUNCT
dpc-4194	201	1	in	in	ADP
dpc-4194	201	2	comparison	comparison	NOUN
dpc-4194	201	3	to	to	ADP
dpc-4194	201	4	the	the	DET
dpc-4194	201	5	results	result	NOUN
dpc-4194	201	6	from	from	ADP
dpc-4194	201	7	randomized	randomized	ADJ
dpc-4194	201	8	clinical	clinical	ADJ
dpc-4194	201	9	trials	trial	NOUN
dpc-4194	201	10	with	with	ADP
dpc-4194	201	11	bimekizumab	bimekizumab	NOUN
dpc-4194	201	12	,	,	PUNCT
dpc-4194	201	13	our	our	PRON
dpc-4194	201	14	study	study	NOUN
dpc-4194	201	15	demonstrated	demonstrate	VERB
dpc-4194	201	16	comparable	comparable	ADJ
dpc-4194	201	17	or	or	CCONJ
dpc-4194	201	18	slightly	slightly	ADV
dpc-4194	201	19	superior	superior	ADJ
dpc-4194	201	20	rates	rate	NOUN
dpc-4194	201	21	of	of	ADP
dpc-4194	201	22	improvement	improvement	NOUN
dpc-4194	201	23	in	in	ADP
dpc-4194	201	24	key	key	ADJ
dpc-4194	201	25	psoriasis	psoriasis	NOUN
dpc-4194	201	26	severity	severity	NOUN
dpc-4194	201	27	measures	measure	NOUN
dpc-4194	201	28	,	,	PUNCT
dpc-4194	201	29	including	include	VERB
dpc-4194	201	30	pasi75	pasi75	NOUN
dpc-4194	201	31	,	,	PUNCT
dpc-4194	201	32	pasi90	pasi90	NOUN
dpc-4194	201	33	,	,	PUNCT
dpc-4194	201	34	and	and	CCONJ
dpc-4194	201	35	pasi100	pasi100	PROPN
dpc-4194	201	36	,	,	PUNCT
dpc-4194	201	37	at	at	ADP
dpc-4194	201	38	both	both	CCONJ
dpc-4194	201	39	the	the	DET
dpc-4194	201	40	4	4	NUM
dpc-4194	201	41	-	-	PUNCT
dpc-4194	201	42	week	week	NOUN
dpc-4194	201	43	and	and	CCONJ
dpc-4194	201	44	16	16	NUM
dpc-4194	201	45	-	-	PUNCT
dpc-4194	201	46	week	week	NOUN
dpc-4194	201	47	time	time	NOUN
dpc-4194	201	48	points	point	NOUN
dpc-4194	201	49	[	[	X
dpc-4194	201	50	23	23	NUM
dpc-4194	201	51	]	]	PUNCT
dpc-4194	201	52	.	.	PUNCT
dpc-4194	202	1	specifically	specifically	ADV
dpc-4194	202	2	,	,	PUNCT
dpc-4194	202	3	at	at	ADP
dpc-4194	202	4	the	the	DET
dpc-4194	202	5	4	4	NUM
dpc-4194	202	6	-	-	PUNCT
dpc-4194	202	7	week	week	NOUN
dpc-4194	202	8	mark	mark	NOUN
dpc-4194	202	9	,	,	PUNCT
dpc-4194	202	10	our	our	PRON
dpc-4194	202	11	study	study	NOUN
dpc-4194	202	12	showed	show	VERB
dpc-4194	202	13	higher	high	ADJ
dpc-4194	202	14	rates	rate	NOUN
dpc-4194	202	15	of	of	ADP
dpc-4194	202	16	patients	patient	NOUN
dpc-4194	202	17	achieving	achieve	VERB
dpc-4194	202	18	pasi100	pasi100	PROPN
dpc-4194	202	19	response	response	NOUN
dpc-4194	202	20	compared	compare	VERB
dpc-4194	202	21	to	to	ADP
dpc-4194	202	22	those	those	PRON
dpc-4194	202	23	reported	report	VERB
dpc-4194	202	24	in	in	ADP
dpc-4194	202	25	clinical	clinical	ADJ
dpc-4194	202	26	trials	trial	NOUN
dpc-4194	202	27	[	[	X
dpc-4194	202	28	20	20	NUM
dpc-4194	202	29	-	-	SYM
dpc-4194	202	30	23	23	NUM
dpc-4194	202	31	]	]	PUNCT
dpc-4194	202	32	.	.	PUNCT
dpc-4194	203	1	by	by	ADP
dpc-4194	203	2	the	the	DET
dpc-4194	203	3	16	16	NUM
dpc-4194	203	4	-	-	PUNCT
dpc-4194	203	5	week	week	NOUN
dpc-4194	203	6	time	time	NOUN
dpc-4194	203	7	point	point	NOUN
dpc-4194	203	8	,	,	PUNCT
dpc-4194	203	9	the	the	DET
dpc-4194	203	10	rates	rate	NOUN
dpc-4194	203	11	of	of	ADP
dpc-4194	203	12	improvement	improvement	NOUN
dpc-4194	203	13	in	in	ADP
dpc-4194	203	14	pasi	pasi	NOUN
dpc-4194	203	15	scores	score	NOUN
dpc-4194	203	16	in	in	ADP
dpc-4194	203	17	our	our	PRON
dpc-4194	203	18	study	study	NOUN
dpc-4194	203	19	were	be	AUX
dpc-4194	203	20	very	very	ADV
dpc-4194	203	21	similar	similar	ADJ
dpc-4194	203	22	to	to	ADP
dpc-4194	203	23	those	those	PRON
dpc-4194	203	24	reported	report	VERB
dpc-4194	203	25	in	in	ADP
dpc-4194	203	26	the	the	DET
dpc-4194	203	27	clinical	clinical	ADJ
dpc-4194	203	28	trials	trial	NOUN
dpc-4194	203	29	.	.	PUNCT
dpc-4194	204	1	in	in	ADP
dpc-4194	204	2	terms	term	NOUN
dpc-4194	204	3	of	of	ADP
dpc-4194	204	4	how	how	SCONJ
dpc-4194	204	5	bimekizumab	bimekizumab	NOUN
dpc-4194	204	6	treatment	treatment	NOUN
dpc-4194	204	7	affected	affect	VERB
dpc-4194	204	8	the	the	DET
dpc-4194	204	9	well	well	ADV
dpc-4194	204	10	-	-	PUNCT
dpc-4194	204	11	being	being	NOUN
dpc-4194	204	12	of	of	ADP
dpc-4194	204	13	patients	patient	NOUN
dpc-4194	204	14	,	,	PUNCT
dpc-4194	204	15	it	it	PRON
dpc-4194	204	16	is	be	AUX
dpc-4194	204	17	worth	worth	ADJ
dpc-4194	204	18	noting	note	VERB
dpc-4194	204	19	that	that	SCONJ
dpc-4194	204	20	after	after	ADP
dpc-4194	204	21	16	16	NUM
dpc-4194	204	22	weeks	week	NOUN
dpc-4194	204	23	,	,	PUNCT
dpc-4194	204	24	all	all	DET
dpc-4194	204	25	individuals	individual	NOUN
dpc-4194	204	26	reported	report	VERB
dpc-4194	204	27	that	that	SCONJ
dpc-4194	204	28	their	their	PRON
dpc-4194	204	29	psoriasis	psoriasis	NOUN
dpc-4194	204	30	was	be	AUX
dpc-4194	204	31	no	no	ADV
dpc-4194	204	32	longer	long	ADV
dpc-4194	204	33	having	have	VERB
dpc-4194	204	34	a	a	DET
dpc-4194	204	35	negative	negative	ADJ
dpc-4194	204	36	impact	impact	NOUN
dpc-4194	204	37	on	on	ADP
dpc-4194	204	38	their	their	PRON
dpc-4194	204	39	quality	quality	NOUN
dpc-4194	204	40	of	of	ADP
dpc-4194	204	41	life	life	NOUN
dpc-4194	204	42	.	.	PUNCT
dpc-4194	205	1	in	in	ADP
dpc-4194	205	2	contrast	contrast	NOUN
dpc-4194	205	3	to	to	ADP
dpc-4194	205	4	earlier	early	ADJ
dpc-4194	205	5	research	research	NOUN
dpc-4194	205	6	,	,	PUNCT
dpc-4194	205	7	which	which	PRON
dpc-4194	205	8	suggested	suggest	VERB
dpc-4194	205	9	that	that	SCONJ
dpc-4194	205	10	treatment	treatment	NOUN
dpc-4194	205	11	responses	response	NOUN
dpc-4194	205	12	were	be	AUX
dpc-4194	205	13	better	well	ADJ
dpc-4194	205	14	in	in	ADP
dpc-4194	205	15	biologically	biologically	ADV
dpc-4194	205	16	naive	naive	ADJ
dpc-4194	205	17	(	(	PUNCT
dpc-4194	205	18	patients	patient	NOUN
dpc-4194	205	19	who	who	PRON
dpc-4194	205	20	had	have	AUX
dpc-4194	205	21	not	not	PART
dpc-4194	205	22	previously	previously	ADV
dpc-4194	205	23	received	receive	VERB
dpc-4194	205	24	biologic	biologic	NOUN
dpc-4194	205	25	treatments	treatment	NOUN
dpc-4194	205	26	)	)	PUNCT
dpc-4194	205	27	8	8	NUM
dpc-4194	205	28	original	original	ADJ
dpc-4194	205	29	article	article	NOUN
dpc-4194	205	30	|	|	ADV
dpc-4194	205	31	dermatol	dermatol	ADJ
dpc-4194	205	32	pract	pract	NOUN
dpc-4194	205	33	concept	concept	NOUN
dpc-4194	205	34	.	.	PUNCT
dpc-4194	206	1	2024;14(2):e2024052	2024;14(2):e2024052	NUM
dpc-4194	206	2	2022;36(4):e277	2022;36(4):e277	NOUN
dpc-4194	206	3	-	-	PUNCT
dpc-4194	206	4	e279	e279	PROPN
dpc-4194	206	5	.	.	PUNCT
dpc-4194	206	6	doi	doi	NOUN
dpc-4194	206	7	:	:	PUNCT
dpc-4194	206	8	10.1111	10.1111	NUM
dpc-4194	206	9	/	/	SYM
dpc-4194	206	10	jdv.17836	jdv.17836	PROPN
dpc-4194	206	11	.	.	PUNCT
dpc-4194	207	1	pmid	pmid	NOUN
dpc-4194	207	2	:	:	PUNCT
dpc-4194	207	3	34812561	34812561	NUM
dpc-4194	207	4	.	.	PUNCT
dpc-4194	208	1	pmcid	pmcid	NOUN
dpc-4194	208	2	:	:	PUNCT
dpc-4194	208	3	pmc9299771	pmc9299771	NOUN
dpc-4194	208	4	.	.	PUNCT
dpc-4194	209	1	7	7	X
dpc-4194	209	2	.	.	X
dpc-4194	209	3	calianno	calianno	PROPN
dpc-4194	209	4	g	g	PROPN
dpc-4194	209	5	,	,	PUNCT
dpc-4194	209	6	esposito	esposito	PROPN
dpc-4194	209	7	m	m	PROPN
dpc-4194	209	8	,	,	PUNCT
dpc-4194	209	9	fidanza	fidanza	X
dpc-4194	209	10	r	r	NOUN
dpc-4194	209	11	,	,	PUNCT
dpc-4194	209	12	palmieri	palmieri	PROPN
dpc-4194	209	13	m	m	PROPN
dpc-4194	209	14	,	,	PUNCT
dpc-4194	209	15	fargnoli	fargnoli	PROPN
dpc-4194	209	16	mc	mc	PROPN
dpc-4194	209	17	.	.	PROPN
dpc-4194	209	18	ixekizumab	ixekizumab	NOUN
dpc-4194	209	19	improves	improve	VERB
dpc-4194	209	20	disease	disease	NOUN
dpc-4194	209	21	severity	severity	NOUN
dpc-4194	209	22	,	,	PUNCT
dpc-4194	209	23	clinical	clinical	ADJ
dpc-4194	209	24	symptoms	symptom	NOUN
dpc-4194	209	25	and	and	CCONJ
dpc-4194	209	26	quality	quality	NOUN
dpc-4194	209	27	of	of	ADP
dpc-4194	209	28	life	life	NOUN
dpc-4194	209	29	in	in	ADP
dpc-4194	209	30	patients	patient	NOUN
dpc-4194	209	31	with	with	ADP
dpc-4194	209	32	genital	genital	ADJ
dpc-4194	209	33	psoriasis	psoriasis	NOUN
dpc-4194	209	34	:	:	PUNCT
dpc-4194	209	35	a	a	DET
dpc-4194	209	36	24	24	NUM
dpc-4194	209	37	-	-	PUNCT
dpc-4194	209	38	week	week	NOUN
dpc-4194	209	39	real	real	ADJ
dpc-4194	209	40	-	-	PUNCT
dpc-4194	209	41	life	life	NOUN
dpc-4194	209	42	experience	experience	NOUN
dpc-4194	209	43	.	.	PUNCT
dpc-4194	210	1	dermatol	dermatol	NOUN
dpc-4194	210	2	ther	ther	ADV
dpc-4194	210	3	.	.	PUNCT
dpc-4194	211	1	2021;34(4):e14993	2021;34(4):e14993	X
dpc-4194	211	2	.	.	PUNCT
dpc-4194	212	1	doi	doi	NOUN
dpc-4194	212	2	:	:	PUNCT
dpc-4194	212	3	10.1111	10.1111	NUM
dpc-4194	212	4	/dth.14993	/dth.14993	NOUN
dpc-4194	212	5	.	.	PUNCT
dpc-4194	213	1	pmid	pmid	NOUN
dpc-4194	213	2	:	:	PUNCT
dpc-4194	213	3	34029442	34029442	NUM
dpc-4194	213	4	.	.	PUNCT
dpc-4194	214	1	8	8	X
dpc-4194	214	2	.	.	PUNCT
dpc-4194	215	1	hong	hong	PROPN
dpc-4194	215	2	jj	jj	PROPN
dpc-4194	215	3	,	,	PUNCT
dpc-4194	215	4	mosca	mosca	PROPN
dpc-4194	215	5	ml	ml	PROPN
dpc-4194	215	6	,	,	PUNCT
dpc-4194	215	7	hadeler	hadeler	PROPN
dpc-4194	215	8	ek	ek	PROPN
dpc-4194	215	9	,	,	PUNCT
dpc-4194	215	10	brownstone	brownstone	NOUN
dpc-4194	215	11	nd	nd	PRON
dpc-4194	215	12	,	,	PUNCT
dpc-4194	215	13	bhutani	bhutani	PROPN
dpc-4194	215	14	t	t	PROPN
dpc-4194	215	15	,	,	PUNCT
dpc-4194	215	16	liao	liao	PROPN
dpc-4194	215	17	wj	wj	PROPN
dpc-4194	215	18	.	.	PUNCT
dpc-4194	216	1	genital	genital	ADJ
dpc-4194	216	2	and	and	CCONJ
dpc-4194	216	3	inverse	inverse	ADJ
dpc-4194	216	4	/	/	SYM
dpc-4194	216	5	intertriginous	intertriginous	ADJ
dpc-4194	216	6	psoriasis	psoriasis	NOUN
dpc-4194	216	7	:	:	PUNCT
dpc-4194	216	8	an	an	DET
dpc-4194	216	9	updated	update	VERB
dpc-4194	216	10	review	review	NOUN
dpc-4194	216	11	of	of	ADP
dpc-4194	216	12	therapies	therapy	NOUN
dpc-4194	216	13	and	and	CCONJ
dpc-4194	216	14	recommendations	recommendation	NOUN
dpc-4194	216	15	for	for	ADP
dpc-4194	216	16	practical	practical	ADJ
dpc-4194	216	17	management	management	NOUN
dpc-4194	216	18	.	.	PUNCT
dpc-4194	217	1	dermatol	dermatol	NOUN
dpc-4194	217	2	ther	ther	ADV
dpc-4194	217	3	(	(	PUNCT
dpc-4194	217	4	heidelb	heidelb	NOUN
dpc-4194	217	5	)	)	PUNCT
dpc-4194	217	6	.	.	PUNCT
dpc-4194	218	1	2021;11(3):833	2021;11(3):833	NUM
dpc-4194	218	2	-	-	SYM
dpc-4194	218	3	844	844	NUM
dpc-4194	218	4	.	.	PUNCT
dpc-4194	219	1	doi	doi	NOUN
dpc-4194	219	2	:	:	PUNCT
dpc-4194	219	3	10.1007	10.1007	NUM
dpc-4194	219	4	/	/	SYM
dpc-4194	219	5	s13555	s13555	PROPN
dpc-4194	219	6	-	-	PUNCT
dpc-4194	219	7	021	021	NUM
dpc-4194	219	8	-	-	PUNCT
dpc-4194	219	9	00536	00536	NUM
dpc-4194	219	10	-	-	PUNCT
dpc-4194	219	11	6	6	NUM
dpc-4194	219	12	.	.	PUNCT
dpc-4194	220	1	pmid	pmid	NOUN
dpc-4194	220	2	:	:	PUNCT
dpc-4194	220	3	33914293	33914293	NUM
dpc-4194	220	4	.	.	PUNCT
dpc-4194	221	1	pmcid	pmcid	ADJ
dpc-4194	221	2	:	:	PUNCT
dpc-4194	221	3	pmc8163914	pmc8163914	NOUN
dpc-4194	221	4	.	.	PUNCT
dpc-4194	222	1	9	9	X
dpc-4194	222	2	.	.	X
dpc-4194	222	3	beck	beck	PROPN
dpc-4194	222	4	km	km	PROPN
dpc-4194	222	5	,	,	PUNCT
dpc-4194	222	6	yang	yang	PROPN
dpc-4194	222	7	ej	ej	PROPN
dpc-4194	222	8	,	,	PUNCT
dpc-4194	222	9	sanchez	sanchez	PROPN
dpc-4194	222	10	i	i	PROPN
dpc-4194	222	11	m	m	PROPN
dpc-4194	222	12	,	,	PUNCT
dpc-4194	222	13	liao	liao	PROPN
dpc-4194	222	14	w.	w.	PROPN
dpc-4194	222	15	treatment	treatment	NOUN
dpc-4194	222	16	of	of	ADP
dpc-4194	222	17	genital	genital	ADJ
dpc-4194	222	18	psoriasis	psoriasis	NOUN
dpc-4194	222	19	:	:	PUNCT
dpc-4194	222	20	a	a	DET
dpc-4194	222	21	systematic	systematic	ADJ
dpc-4194	222	22	review	review	NOUN
dpc-4194	222	23	.	.	PUNCT
dpc-4194	223	1	dermatol	dermatol	NOUN
dpc-4194	223	2	ther	ther	ADV
dpc-4194	223	3	(	(	PUNCT
dpc-4194	223	4	heidelb	heidelb	NOUN
dpc-4194	223	5	)	)	PUNCT
dpc-4194	223	6	.	.	PUNCT
dpc-4194	224	1	2018;8(4):509	2018;8(4):509	NUM
dpc-4194	224	2	-	-	SYM
dpc-4194	224	3	525	525	NUM
dpc-4194	224	4	.	.	PUNCT
dpc-4194	225	1	doi	doi	NOUN
dpc-4194	225	2	:	:	PUNCT
dpc-4194	225	3	10.1007	10.1007	NUM
dpc-4194	225	4	/	/	SYM
dpc-4194	225	5	s13555	s13555	PROPN
dpc-4194	225	6	-	-	PUNCT
dpc-4194	225	7	018	018	NUM
dpc-4194	225	8	-	-	PUNCT
dpc-4194	225	9	0257	0257	NUM
dpc-4194	225	10	-	-	PUNCT
dpc-4194	225	11	y.	y.	NOUN
dpc-4194	225	12	pmid	pmid	PROPN
dpc-4194	225	13	:	:	PUNCT
dpc-4194	225	14	30145740	30145740	NUM
dpc-4194	225	15	.	.	PUNCT
dpc-4194	226	1	pmcid	pmcid	NOUN
dpc-4194	226	2	:	:	PUNCT
dpc-4194	226	3	pmc6261118	pmc6261118	ADJ
dpc-4194	226	4	.	.	PUNCT
dpc-4194	227	1	10	10	NUM
dpc-4194	227	2	.	.	PUNCT
dpc-4194	227	3	guenther	guenther	PROPN
dpc-4194	227	4	l	l	PROPN
dpc-4194	227	5	,	,	PUNCT
dpc-4194	227	6	potts	potts	PROPN
dpc-4194	227	7	bleakman	bleakman	PROPN
dpc-4194	227	8	a	a	PROPN
dpc-4194	227	9	,	,	PUNCT
dpc-4194	227	10	weisman	weisman	PROPN
dpc-4194	227	11	j	j	PROPN
dpc-4194	227	12	,	,	PUNCT
dpc-4194	227	13	et	et	PROPN
dpc-4194	227	14	al	al	PROPN
dpc-4194	227	15	.	.	PROPN
dpc-4194	227	16	ixekizumab	ixekizumab	NOUN
dpc-4194	227	17	results	result	NOUN
dpc-4194	227	18	in	in	ADP
dpc-4194	227	19	persistent	persistent	ADJ
dpc-4194	227	20	clinical	clinical	ADJ
dpc-4194	227	21	improvement	improvement	NOUN
dpc-4194	227	22	in	in	ADP
dpc-4194	227	23	moderate	moderate	ADJ
dpc-4194	227	24	-	-	PUNCT
dpc-4194	227	25	to	to	ADP
dpc-4194	227	26	severe	severe	ADJ
dpc-4194	227	27	genital	genital	ADJ
dpc-4194	227	28	psoriasis	psoriasis	NOUN
dpc-4194	227	29	during	during	ADP
dpc-4194	227	30	a	a	DET
dpc-4194	227	31	52	52	NUM
dpc-4194	227	32	week	week	NOUN
dpc-4194	227	33	,	,	PUNCT
dpc-4194	227	34	randomized	randomize	VERB
dpc-4194	227	35	,	,	PUNCT
dpc-4194	227	36	placebo	placebo	NOUN
dpc-4194	227	37	-	-	PUNCT
dpc-4194	227	38	controlled	control	VERB
dpc-4194	227	39	,	,	PUNCT
dpc-4194	227	40	phase	phase	NOUN
dpc-4194	227	41	3	3	NUM
dpc-4194	227	42	clinical	clinical	ADJ
dpc-4194	227	43	trial	trial	NOUN
dpc-4194	227	44	.	.	PUNCT
dpc-4194	228	1	acta	acta	PROPN
dpc-4194	228	2	derm	derm	PROPN
dpc-4194	228	3	venereol	venereol	NOUN
dpc-4194	228	4	.	.	PUNCT
dpc-4194	229	1	2020;100(1):adv00006	2020;100(1):adv00006	X
dpc-4194	229	2	.	.	PUNCT
dpc-4194	229	3	doi	doi	PROPN
dpc-4194	229	4	:	:	PUNCT
dpc-4194	229	5	10.2340/00015555	10.2340/00015555	NUM
dpc-4194	229	6	-	-	SYM
dpc-4194	229	7	3353	3353	NUM
dpc-4194	229	8	.	.	PUNCT
dpc-4194	230	1	pmid	pmid	NOUN
dpc-4194	230	2	:	:	PUNCT
dpc-4194	230	3	31620802	31620802	NUM
dpc-4194	230	4	.	.	PUNCT
dpc-4194	231	1	pmcid	pmcid	NOUN
dpc-4194	231	2	:	:	PUNCT
dpc-4194	231	3	pmc9128873	pmc9128873	PROPN
dpc-4194	231	4	.	.	PUNCT
dpc-4194	232	1	11	11	NUM
dpc-4194	232	2	.	.	PUNCT
dpc-4194	233	1	armstrong	armstrong	PROPN
dpc-4194	233	2	aw	aw	INTJ
dpc-4194	233	3	,	,	PUNCT
dpc-4194	233	4	read	read	VERB
dpc-4194	233	5	c.	c.	PROPN
dpc-4194	233	6	pathophysiology	pathophysiology	NOUN
dpc-4194	233	7	,	,	PUNCT
dpc-4194	233	8	clinical	clinical	ADJ
dpc-4194	233	9	presentation	presentation	NOUN
dpc-4194	233	10	,	,	PUNCT
dpc-4194	233	11	and	and	CCONJ
dpc-4194	233	12	treatment	treatment	NOUN
dpc-4194	233	13	of	of	ADP
dpc-4194	233	14	psoriasis	psoriasis	NOUN
dpc-4194	233	15	:	:	PUNCT
dpc-4194	233	16	a	a	DET
dpc-4194	233	17	review	review	NOUN
dpc-4194	233	18	.	.	PUNCT
dpc-4194	234	1	jama	jama	PROPN
dpc-4194	234	2	.	.	PUNCT
dpc-4194	235	1	2020;323(19):19451960	2020;323(19):19451960	X
dpc-4194	235	2	.	.	PUNCT
dpc-4194	236	1	doi	doi	NOUN
dpc-4194	236	2	:	:	PUNCT
dpc-4194	236	3	10.1001	10.1001	NUM
dpc-4194	236	4	/	/	SYM
dpc-4194	236	5	jama.2020.4006	jama.2020.4006	PROPN
dpc-4194	236	6	.	.	PUNCT
dpc-4194	237	1	pmid	pmid	NOUN
dpc-4194	237	2	:	:	PUNCT
dpc-4194	237	3	32427307	32427307	NUM
dpc-4194	237	4	.	.	PUNCT
dpc-4194	238	1	12	12	NUM
dpc-4194	238	2	.	.	PUNCT
dpc-4194	239	1	gargiulo	gargiulo	PROPN
dpc-4194	239	2	l	l	NOUN
dpc-4194	239	3	,	,	PUNCT
dpc-4194	239	4	ibba	ibba	ADJ
dpc-4194	239	5	l	l	NOUN
dpc-4194	239	6	,	,	PUNCT
dpc-4194	239	7	malagoli	malagoli	NOUN
dpc-4194	239	8	p	p	NOUN
dpc-4194	239	9	,	,	PUNCT
dpc-4194	239	10	et	et	PROPN
dpc-4194	239	11	al	al	PROPN
dpc-4194	239	12	.	.	PROPN
dpc-4194	239	13	brodalumab	brodalumab	PROPN
dpc-4194	239	14	for	for	ADP
dpc-4194	239	15	the	the	DET
dpc-4194	239	16	treatment	treatment	NOUN
dpc-4194	239	17	of	of	ADP
dpc-4194	239	18	plaque	plaque	NOUN
dpc-4194	239	19	psoriasis	psoriasis	NOUN
dpc-4194	239	20	in	in	ADP
dpc-4194	239	21	a	a	DET
dpc-4194	239	22	real	real	ADJ
dpc-4194	239	23	-	-	PUNCT
dpc-4194	239	24	life	life	NOUN
dpc-4194	239	25	setting	setting	NOUN
dpc-4194	239	26	:	:	PUNCT
dpc-4194	239	27	a	a	DET
dpc-4194	239	28	3	3	NUM
dpc-4194	239	29	years	year	NOUN
dpc-4194	239	30	multicenter	multicenter	NOUN
dpc-4194	239	31	retrospective	retrospective	ADJ
dpc-4194	239	32	study	study	NOUN
dpc-4194	239	33	-	-	PUNCT
dpc-4194	239	34	il	il	PROPN
dpc-4194	239	35	pso	pso	PROPN
dpc-4194	239	36	(	(	PUNCT
dpc-4194	239	37	italian	italian	ADJ
dpc-4194	239	38	landscape	landscape	NOUN
dpc-4194	239	39	psoriasis	psoriasis	NOUN
dpc-4194	239	40	)	)	PUNCT
dpc-4194	239	41	.	.	PUNCT
dpc-4194	240	1	front	front	PROPN
dpc-4194	240	2	med	med	PROPN
dpc-4194	240	3	(	(	PUNCT
dpc-4194	240	4	lausanne	lausanne	PROPN
dpc-4194	240	5	)	)	PUNCT
dpc-4194	240	6	.	.	PUNCT
dpc-4194	241	1	2023;10:1196966	2023;10:1196966	X
dpc-4194	241	2	.	.	X
dpc-4194	241	3	doi	doi	NOUN
dpc-4194	241	4	:	:	PUNCT
dpc-4194	241	5	10.3389	10.3389	NUM
dpc-4194	241	6	/fmed.2023.1196966	/fmed.2023.1196966	NOUN
dpc-4194	241	7	.	.	PUNCT
dpc-4194	242	1	pmid	pmid	NOUN
dpc-4194	242	2	:	:	PUNCT
dpc-4194	242	3	37469659	37469659	NUM
dpc-4194	242	4	.	.	PUNCT
dpc-4194	243	1	pmcid	pmcid	NOUN
dpc-4194	243	2	:	:	PUNCT
dpc-4194	243	3	pmc10352451	pmc10352451	NOUN
dpc-4194	243	4	.	.	PUNCT
dpc-4194	244	1	13	13	NUM
dpc-4194	244	2	.	.	X
dpc-4194	244	3	yosipovitch	yosipovitch	PROPN
dpc-4194	244	4	g	g	PROPN
dpc-4194	244	5	,	,	PUNCT
dpc-4194	244	6	foley	foley	PROPN
dpc-4194	244	7	p	p	PROPN
dpc-4194	244	8	,	,	PUNCT
dpc-4194	244	9	ryan	ryan	PROPN
dpc-4194	244	10	c	c	AUX
dpc-4194	244	11	,	,	PUNCT
dpc-4194	244	12	et	et	PROPN
dpc-4194	244	13	al	al	PROPN
dpc-4194	244	14	.	.	PROPN
dpc-4194	244	15	ixekizumab	ixekizumab	PROPN
dpc-4194	244	16	improved	improve	VERB
dpc-4194	244	17	patient	patient	NOUN
dpc-4194	244	18	-	-	PUNCT
dpc-4194	244	19	reported	report	VERB
dpc-4194	244	20	genital	genital	ADJ
dpc-4194	244	21	psoriasis	psoriasis	NOUN
dpc-4194	244	22	symptoms	symptom	NOUN
dpc-4194	244	23	and	and	CCONJ
dpc-4194	244	24	impact	impact	NOUN
dpc-4194	244	25	of	of	ADP
dpc-4194	244	26	symptoms	symptom	NOUN
dpc-4194	244	27	on	on	ADP
dpc-4194	244	28	sexual	sexual	ADJ
dpc-4194	244	29	activity	activity	NOUN
dpc-4194	244	30	vs	vs	ADP
dpc-4194	244	31	placebo	placebo	NOUN
dpc-4194	244	32	in	in	ADP
dpc-4194	244	33	a	a	DET
dpc-4194	244	34	randomized	randomized	ADJ
dpc-4194	244	35	,	,	PUNCT
dpc-4194	244	36	double	double	ADJ
dpc-4194	244	37	-	-	PUNCT
dpc-4194	244	38	blind	blind	ADJ
dpc-4194	244	39	study	study	NOUN
dpc-4194	244	40	.	.	PUNCT
dpc-4194	245	1	j	j	PROPN
dpc-4194	245	2	sex	sex	PROPN
dpc-4194	245	3	med	med	PROPN
dpc-4194	245	4	.	.	PUNCT
dpc-4194	246	1	2018;15(11):1645	2018;15(11):1645	NUM
dpc-4194	246	2	-	-	SYM
dpc-4194	246	3	1652	1652	NUM
dpc-4194	246	4	.	.	PUNCT
dpc-4194	247	1	doi	doi	NOUN
dpc-4194	247	2	:	:	PUNCT
dpc-4194	247	3	10.1016	10.1016	NUM
dpc-4194	247	4	/	/	SYM
dpc-4194	247	5	j.jsxm.2018.09.004	j.jsxm.2018.09.004	NOUN
dpc-4194	247	6	.	.	PUNCT
dpc-4194	248	1	pmid	pmid	NOUN
dpc-4194	248	2	:	:	PUNCT
dpc-4194	248	3	30415816	30415816	NUM
dpc-4194	248	4	.	.	PUNCT
dpc-4194	249	1	14	14	NUM
dpc-4194	249	2	.	.	PUNCT
dpc-4194	250	1	merola	merola	PROPN
dpc-4194	250	2	jf	jf	PROPN
dpc-4194	250	3	,	,	PUNCT
dpc-4194	250	4	ghislain	ghislain	PROPN
dpc-4194	250	5	pd	pd	PROPN
dpc-4194	250	6	,	,	PUNCT
dpc-4194	250	7	dauendorffer	dauendorffer	VERB
dpc-4194	250	8	jnet	jnet	PROPN
dpc-4194	250	9	al	al	PROPN
dpc-4194	250	10	.	.	PROPN
dpc-4194	250	11	ixekizumab	ixekizumab	NOUN
dpc-4194	250	12	improves	improve	VERB
dpc-4194	250	13	secondary	secondary	ADJ
dpc-4194	250	14	lesional	lesional	ADJ
dpc-4194	250	15	signs	sign	NOUN
dpc-4194	250	16	,	,	PUNCT
dpc-4194	250	17	pain	pain	NOUN
dpc-4194	250	18	and	and	CCONJ
dpc-4194	250	19	sexual	sexual	ADJ
dpc-4194	250	20	health	health	NOUN
dpc-4194	250	21	in	in	ADP
dpc-4194	250	22	patients	patient	NOUN
dpc-4194	250	23	with	with	ADP
dpc-4194	250	24	moderate	moderate	ADJ
dpc-4194	250	25	-	-	PUNCT
dpc-4194	250	26	to	to	ADP
dpc-4194	250	27	-	-	PUNCT
dpc-4194	250	28	severe	severe	ADJ
dpc-4194	250	29	genital	genital	ADJ
dpc-4194	250	30	psoriasis	psoriasis	NOUN
dpc-4194	250	31	.	.	PUNCT
dpc-4194	251	1	j	j	PROPN
dpc-4194	251	2	eur	eur	PROPN
dpc-4194	251	3	acad	acad	PROPN
dpc-4194	251	4	dermatol	dermatol	NOUN
dpc-4194	251	5	venereol	venereol	NOUN
dpc-4194	251	6	.	.	PUNCT
dpc-4194	252	1	2020;34(6):1257	2020;34(6):1257	NOUN
dpc-4194	252	2	-	-	SYM
dpc-4194	252	3	1262	1262	NUM
dpc-4194	252	4	.	.	PUNCT
dpc-4194	253	1	doi	doi	NOUN
dpc-4194	253	2	:	:	PUNCT
dpc-4194	253	3	10.1111	10.1111	NUM
dpc-4194	253	4	/	/	SYM
dpc-4194	253	5	jdv	jdv	NOUN
dpc-4194	253	6	.16181	.16181	PROPN
dpc-4194	253	7	.	.	PUNCT
dpc-4194	254	1	pmid	pmid	NOUN
dpc-4194	254	2	:	:	PUNCT
dpc-4194	254	3	31919919	31919919	NUM
dpc-4194	254	4	.	.	PUNCT
dpc-4194	255	1	pmcid	pmcid	NOUN
dpc-4194	255	2	:	:	PUNCT
dpc-4194	255	3	pmc7318177	pmc7318177	ADJ
dpc-4194	255	4	.	.	PUNCT
dpc-4194	256	1	15	15	X
dpc-4194	256	2	.	.	PUNCT
dpc-4194	256	3	yeh	yeh	PROPN
dpc-4194	256	4	cp	cp	PROPN
dpc-4194	256	5	,	,	PUNCT
dpc-4194	256	6	huang	huang	PROPN
dpc-4194	256	7	yw	yw	PROPN
dpc-4194	256	8	,	,	PUNCT
dpc-4194	256	9	tsai	tsai	PROPN
dpc-4194	256	10	tf	tf	PROPN
dpc-4194	256	11	.	.	PUNCT
dpc-4194	256	12	comparison	comparison	NOUN
dpc-4194	256	13	of	of	ADP
dpc-4194	256	14	the	the	DET
dpc-4194	256	15	relative	relative	ADJ
dpc-4194	256	16	efficacy	efficacy	NOUN
dpc-4194	256	17	of	of	ADP
dpc-4194	256	18	different	different	ADJ
dpc-4194	256	19	biologics	biologic	NOUN
dpc-4194	256	20	in	in	ADP
dpc-4194	256	21	different	different	ADJ
dpc-4194	256	22	body	body	NOUN
dpc-4194	256	23	areas	area	NOUN
dpc-4194	256	24	in	in	ADP
dpc-4194	256	25	patients	patient	NOUN
dpc-4194	256	26	with	with	ADP
dpc-4194	256	27	moderate	moderate	ADJ
dpc-4194	256	28	to	to	ADP
dpc-4194	256	29	severe	severe	ADJ
dpc-4194	256	30	psoriasis	psoriasis	NOUN
dpc-4194	256	31	receiving	receive	VERB
dpc-4194	256	32	biologics	biologic	NOUN
dpc-4194	256	33	and	and	CCONJ
dpc-4194	256	34	tofacitinib	tofacitinib	NOUN
dpc-4194	256	35	in	in	ADP
dpc-4194	256	36	phase	phase	NOUN
dpc-4194	256	37	3	3	NUM
dpc-4194	256	38	randomized	randomize	VERB
dpc-4194	256	39	controlled	control	VERB
dpc-4194	256	40	trials	trial	NOUN
dpc-4194	256	41	:	:	PUNCT
dpc-4194	256	42	a	a	DET
dpc-4194	256	43	15	15	NUM
dpc-4194	256	44	-	-	PUNCT
dpc-4194	256	45	year	year	NOUN
dpc-4194	256	46	single	single	ADJ
dpc-4194	256	47	-	-	PUNCT
dpc-4194	256	48	center	center	NOUN
dpc-4194	256	49	experience	experience	NOUN
dpc-4194	256	50	.	.	PUNCT
dpc-4194	257	1	expert	expert	NOUN
dpc-4194	257	2	rev	rev	PROPN
dpc-4194	257	3	clin	clin	PROPN
dpc-4194	257	4	pharmacol	pharmacol	PROPN
dpc-4194	257	5	.	.	PUNCT
dpc-4194	258	1	2022;15(7):887	2022;15(7):887	NUM
dpc-4194	258	2	-	-	SYM
dpc-4194	258	3	895	895	NUM
dpc-4194	258	4	.	.	PUNCT
dpc-4194	258	5	doi	doi	NOUN
dpc-4194	258	6	:	:	PUNCT
dpc-4194	258	7	10.1080/17512433.2022.2103538	10.1080/17512433.2022.2103538	NUM
dpc-4194	258	8	.	.	PUNCT
dpc-4194	259	1	pmid	pmid	NOUN
dpc-4194	259	2	:	:	PUNCT
dpc-4194	259	3	35848067	35848067	NUM
dpc-4194	259	4	.	.	PUNCT
dpc-4194	260	1	16	16	NUM
dpc-4194	260	2	.	.	PUNCT
dpc-4194	261	1	sotiriou	sotiriou	PROPN
dpc-4194	261	2	e	e	NOUN
dpc-4194	261	3	,	,	PUNCT
dpc-4194	261	4	bakirtzi	bakirtzi	VERB
dpc-4194	261	5	k	k	NOUN
dpc-4194	261	6	,	,	PUNCT
dpc-4194	261	7	papadimitriou	papadimitriou	VERB
dpc-4194	261	8	i	i	PRON
dpc-4194	261	9	,	,	PUNCT
dpc-4194	261	10	et	et	PROPN
dpc-4194	261	11	al	al	PROPN
dpc-4194	261	12	.	.	PUNCT
dpc-4194	262	1	a	a	DET
dpc-4194	262	2	head	head	NOUN
dpc-4194	262	3	-	-	PUNCT
dpc-4194	262	4	to	to	ADP
dpc-4194	262	5	-	-	PUNCT
dpc-4194	262	6	head	head	NOUN
dpc-4194	262	7	comparison	comparison	NOUN
dpc-4194	262	8	of	of	ADP
dpc-4194	262	9	risankizumab	risankizumab	NOUN
dpc-4194	262	10	and	and	CCONJ
dpc-4194	262	11	ixekizumab	ixekizumab	NOUN
dpc-4194	262	12	for	for	ADP
dpc-4194	262	13	genital	genital	ADJ
dpc-4194	262	14	psoriasis	psoriasis	NOUN
dpc-4194	262	15	:	:	PUNCT
dpc-4194	262	16	a	a	DET
dpc-4194	262	17	real	real	ADJ
dpc-4194	262	18	-	-	PUNCT
dpc-4194	262	19	life	life	NOUN
dpc-4194	262	20	,	,	PUNCT
dpc-4194	262	21	24	24	NUM
dpc-4194	262	22	-	-	PUNCT
dpc-4194	262	23	week	week	NOUN
dpc-4194	262	24	,	,	PUNCT
dpc-4194	262	25	prospective	prospective	ADJ
dpc-4194	262	26	study	study	NOUN
dpc-4194	262	27	.	.	PUNCT
dpc-4194	263	1	j	j	PROPN
dpc-4194	263	2	eur	eur	PROPN
dpc-4194	263	3	acad	acad	PROPN
dpc-4194	263	4	dermatol	dermatol	NOUN
dpc-4194	263	5	venereol	venereol	NOUN
dpc-4194	263	6	.	.	PUNCT
dpc-4194	264	1	2022;36(5):e359	2022;36(5):e359	NOUN
dpc-4194	264	2	-	-	PUNCT
dpc-4194	264	3	e361	e361	PROPN
dpc-4194	264	4	.	.	PUNCT
dpc-4194	265	1	doi	doi	NOUN
dpc-4194	265	2	:	:	PUNCT
dpc-4194	265	3	10.1111	10.1111	NUM
dpc-4194	265	4	/	/	SYM
dpc-4194	265	5	jdv.17880	jdv.17880	NUM
dpc-4194	265	6	.	.	PUNCT
dpc-4194	266	1	pmid	pmid	NOUN
dpc-4194	266	2	:	:	PUNCT
dpc-4194	266	3	34923693	34923693	NUM
dpc-4194	266	4	.	.	PUNCT
dpc-4194	267	1	17	17	NUM
dpc-4194	267	2	.	.	PUNCT
dpc-4194	268	1	ryan	ryan	PROPN
dpc-4194	268	2	c	c	PROPN
dpc-4194	268	3	,	,	PUNCT
dpc-4194	268	4	menter	menter	X
dpc-4194	268	5	a	a	NOUN
dpc-4194	268	6	,	,	PUNCT
dpc-4194	268	7	guenther	guenther	PROPN
dpc-4194	268	8	l	l	PROPN
dpc-4194	268	9	,	,	PUNCT
dpc-4194	268	10	et	et	PROPN
dpc-4194	268	11	al	al	PROPN
dpc-4194	268	12	.	.	PROPN
dpc-4194	268	13	efficacy	efficacy	NOUN
dpc-4194	268	14	and	and	CCONJ
dpc-4194	268	15	safety	safety	NOUN
dpc-4194	268	16	of	of	ADP
dpc-4194	268	17	ixekizumab	ixekizumab	NOUN
dpc-4194	268	18	in	in	ADP
dpc-4194	268	19	a	a	DET
dpc-4194	268	20	randomized	randomized	ADJ
dpc-4194	268	21	,	,	PUNCT
dpc-4194	268	22	double	double	ADJ
dpc-4194	268	23	-	-	PUNCT
dpc-4194	268	24	blinded	blind	VERB
dpc-4194	268	25	,	,	PUNCT
dpc-4194	268	26	placebo	placebo	NOUN
dpc-4194	268	27	-	-	PUNCT
dpc-4194	268	28	controlled	control	VERB
dpc-4194	268	29	phase	phase	NOUN
dpc-4194	268	30	iiib	iiib	NOUN
dpc-4194	268	31	study	study	NOUN
dpc-4194	268	32	of	of	ADP
dpc-4194	268	33	patients	patient	NOUN
dpc-4194	268	34	with	with	ADP
dpc-4194	268	35	moderate	moderate	ADJ
dpc-4194	268	36	-	-	PUNCT
dpc-4194	268	37	to	to	ADP
dpc-4194	268	38	-	-	PUNCT
dpc-4194	268	39	severe	severe	ADJ
dpc-4194	268	40	genital	genital	ADJ
dpc-4194	268	41	psoriasis	psoriasis	NOUN
dpc-4194	268	42	.	.	PUNCT
dpc-4194	269	1	br	br	PROPN
dpc-4194	269	2	j	j	PROPN
dpc-4194	269	3	dermatol	dermatol	NOUN
dpc-4194	269	4	.	.	PUNCT
dpc-4194	270	1	2018;179(4):844	2018;179(4):844	NUM
dpc-4194	270	2	-	-	SYM
dpc-4194	270	3	852	852	NUM
dpc-4194	270	4	.	.	PUNCT
dpc-4194	271	1	doi	doi	NOUN
dpc-4194	271	2	:	:	PUNCT
dpc-4194	271	3	10.1111/	10.1111/	NUM
dpc-4194	271	4	bjd.16736	bjd.16736	PROPN
dpc-4194	271	5	..	..	PUNCT
dpc-4194	271	6	pmid	pmid	NOUN
dpc-4194	271	7	:	:	PUNCT
dpc-4194	271	8	29747232	29747232	NUM
dpc-4194	271	9	.	.	PUNCT
dpc-4194	272	1	18	18	NUM
dpc-4194	272	2	.	.	PUNCT
dpc-4194	272	3	soung	soung	PROPN
dpc-4194	272	4	j	j	PROPN
dpc-4194	272	5	,	,	PUNCT
dpc-4194	272	6	jennifer	jennifer	PROPN
dpc-4194	272	7	cc	cc	PROPN
dpc-4194	272	8	,	,	PUNCT
dpc-4194	272	9	gooderham	gooderham	PROPN
dpc-4194	272	10	m.	m.	NOUN
dpc-4194	272	11	33054	33054	NUM
dpc-4194	272	12	improvement	improvement	NOUN
dpc-4194	272	13	in	in	ADP
dpc-4194	272	14	touch	touch	NOUN
dpc-4194	272	15	avoidance	avoidance	NOUN
dpc-4194	272	16	in	in	ADP
dpc-4194	272	17	patients	patient	NOUN
dpc-4194	272	18	with	with	ADP
dpc-4194	272	19	genital	genital	ADJ
dpc-4194	272	20	psoriasis	psoriasis	NOUN
dpc-4194	272	21	treated	treat	VERB
dpc-4194	272	22	with	with	ADP
dpc-4194	272	23	ixekizumab	ixekizumab	NOUN
dpc-4194	272	24	:	:	PUNCT
dpc-4194	272	25	52	52	NUM
dpc-4194	272	26	-	-	PUNCT
dpc-4194	272	27	week	week	NOUN
dpc-4194	272	28	results	result	NOUN
dpc-4194	272	29	of	of	ADP
dpc-4194	272	30	a	a	DET
dpc-4194	272	31	phase	phase	NOUN
dpc-4194	272	32	3	3	NUM
dpc-4194	272	33	clinical	clinical	ADJ
dpc-4194	272	34	trial	trial	NOUN
dpc-4194	272	35	in	in	ADP
dpc-4194	272	36	patients	patient	NOUN
dpc-4194	272	37	with	with	ADP
dpc-4194	272	38	moderate	moderate	ADJ
dpc-4194	272	39	-	-	PUNCT
dpc-4194	272	40	to	to	ADP
dpc-4194	272	41	-	-	PUNCT
dpc-4194	272	42	severe	severe	ADJ
dpc-4194	272	43	genital	genital	ADJ
dpc-4194	272	44	psoriasis	psoriasis	NOUN
dpc-4194	272	45	(	(	PUNCT
dpc-4194	272	46	ixora	ixora	NOUN
dpc-4194	272	47	-	-	PUNCT
dpc-4194	272	48	q	q	NOUN
dpc-4194	272	49	)	)	PUNCT
dpc-4194	272	50	.	.	PUNCT
dpc-4194	273	1	been	be	AUX
dpc-4194	273	2	explored	explore	VERB
dpc-4194	273	3	yet	yet	ADV
dpc-4194	273	4	,	,	PUNCT
dpc-4194	273	5	thus	thus	ADV
dpc-4194	273	6	our	our	PRON
dpc-4194	273	7	study	study	NOUN
dpc-4194	273	8	provides	provide	VERB
dpc-4194	273	9	initial	initial	ADJ
dpc-4194	273	10	real	real	ADJ
dpc-4194	273	11	-	-	PUNCT
dpc-4194	273	12	world	world	NOUN
dpc-4194	273	13	data	datum	NOUN
dpc-4194	273	14	,	,	PUNCT
dpc-4194	273	15	even	even	ADV
dpc-4194	273	16	though	though	SCONJ
dpc-4194	273	17	they	they	PRON
dpc-4194	273	18	are	be	AUX
dpc-4194	273	19	limited	limit	VERB
dpc-4194	273	20	by	by	ADP
dpc-4194	273	21	a	a	DET
dpc-4194	273	22	small	small	ADJ
dpc-4194	273	23	sample	sample	NOUN
dpc-4194	273	24	size	size	NOUN
dpc-4194	273	25	and	and	CCONJ
dpc-4194	273	26	a	a	DET
dpc-4194	273	27	relatively	relatively	ADV
dpc-4194	273	28	short	short	ADJ
dpc-4194	273	29	observation	observation	NOUN
dpc-4194	273	30	period	period	NOUN
dpc-4194	273	31	.	.	PUNCT
dpc-4194	274	1	in	in	ADP
dpc-4194	274	2	this	this	DET
dpc-4194	274	3	study	study	NOUN
dpc-4194	274	4	,	,	PUNCT
dpc-4194	274	5	a	a	DET
dpc-4194	274	6	16	16	NUM
dpc-4194	274	7	-	-	PUNCT
dpc-4194	274	8	week	week	NOUN
dpc-4194	274	9	course	course	NOUN
dpc-4194	274	10	of	of	ADP
dpc-4194	274	11	bimekizumab	bimekizumab	NOUN
dpc-4194	274	12	treatment	treatment	NOUN
dpc-4194	274	13	demonstrated	demonstrate	VERB
dpc-4194	274	14	highly	highly	ADV
dpc-4194	274	15	favorable	favorable	ADJ
dpc-4194	274	16	outcomes	outcome	NOUN
dpc-4194	274	17	for	for	ADP
dpc-4194	274	18	patients	patient	NOUN
dpc-4194	274	19	with	with	ADP
dpc-4194	274	20	genital	genital	ADJ
dpc-4194	274	21	psoriasis	psoriasis	NOUN
dpc-4194	274	22	.	.	PUNCT
dpc-4194	275	1	notably	notably	ADV
dpc-4194	275	2	,	,	PUNCT
dpc-4194	275	3	98.4	98.4	NUM
dpc-4194	275	4	%	%	NOUN
dpc-4194	275	5	of	of	ADP
dpc-4194	275	6	patients	patient	NOUN
dpc-4194	275	7	achieved	achieve	VERB
dpc-4194	275	8	a	a	DET
dpc-4194	275	9	clear	clear	ADJ
dpc-4194	275	10	spga	spga	NOUN
dpc-4194	275	11	-	-	PUNCT
dpc-4194	275	12	g	g	NOUN
dpc-4194	275	13	score	score	NOUN
dpc-4194	275	14	within	within	ADP
dpc-4194	275	15	16	16	NUM
dpc-4194	275	16	weeks	week	NOUN
dpc-4194	275	17	of	of	ADP
dpc-4194	275	18	treatment	treatment	NOUN
dpc-4194	275	19	,	,	PUNCT
dpc-4194	275	20	and	and	CCONJ
dpc-4194	275	21	there	there	PRON
dpc-4194	275	22	were	be	VERB
dpc-4194	275	23	consistent	consistent	ADJ
dpc-4194	275	24	improvements	improvement	NOUN
dpc-4194	275	25	in	in	ADP
dpc-4194	275	26	pasi	pasi	NOUN
dpc-4194	275	27	scores	score	NOUN
dpc-4194	275	28	over	over	ADP
dpc-4194	275	29	the	the	DET
dpc-4194	275	30	4	4	NUM
dpc-4194	275	31	to	to	PART
dpc-4194	275	32	16	16	NUM
dpc-4194	275	33	-	-	PUNCT
dpc-4194	275	34	week	week	NOUN
dpc-4194	275	35	treatment	treatment	NOUN
dpc-4194	275	36	period	period	NOUN
dpc-4194	275	37	.	.	PUNCT
dpc-4194	276	1	furthermore	furthermore	ADV
dpc-4194	276	2	,	,	PUNCT
dpc-4194	276	3	the	the	DET
dpc-4194	276	4	study	study	NOUN
dpc-4194	276	5	revealed	reveal	VERB
dpc-4194	276	6	a	a	DET
dpc-4194	276	7	significant	significant	ADJ
dpc-4194	276	8	reduction	reduction	NOUN
dpc-4194	276	9	in	in	ADP
dpc-4194	276	10	the	the	DET
dpc-4194	276	11	mean	mean	ADJ
dpc-4194	276	12	dlqi	dlqi	NOUN
dpc-4194	276	13	score	score	NOUN
dpc-4194	276	14	,	,	PUNCT
dpc-4194	276	15	indicating	indicate	VERB
dpc-4194	276	16	an	an	DET
dpc-4194	276	17	improvement	improvement	NOUN
dpc-4194	276	18	in	in	ADP
dpc-4194	276	19	patients	patient	NOUN
dpc-4194	276	20	quality	quality	NOUN
dpc-4194	276	21	of	of	ADP
dpc-4194	276	22	life	life	NOUN
dpc-4194	276	23	.	.	PUNCT
dpc-4194	277	1	noteworthy	noteworthy	ADJ
dpc-4194	277	2	is	be	AUX
dpc-4194	277	3	the	the	DET
dpc-4194	277	4	low	low	ADJ
dpc-4194	277	5	number	number	NOUN
dpc-4194	277	6	of	of	ADP
dpc-4194	277	7	patients	patient	NOUN
dpc-4194	277	8	reporting	report	VERB
dpc-4194	277	9	severe	severe	ADJ
dpc-4194	277	10	impairment	impairment	NOUN
dpc-4194	277	11	in	in	ADP
dpc-4194	277	12	quality	quality	NOUN
dpc-4194	277	13	of	of	ADP
dpc-4194	277	14	life	life	NOUN
dpc-4194	277	15	(	(	PUNCT
dpc-4194	277	16	dlqi	dlqi	PROPN
dpc-4194	277	17	≥10	≥10	PROPN
dpc-4194	277	18	)	)	PUNCT
dpc-4194	277	19	after	after	ADP
dpc-4194	277	20	only	only	ADV
dpc-4194	277	21	four	four	NUM
dpc-4194	277	22	weeks	week	NOUN
dpc-4194	277	23	of	of	ADP
dpc-4194	277	24	treatment	treatment	NOUN
dpc-4194	277	25	,	,	PUNCT
dpc-4194	277	26	with	with	ADP
dpc-4194	277	27	none	none	NOUN
dpc-4194	277	28	experiencing	experience	VERB
dpc-4194	277	29	this	this	DET
dpc-4194	277	30	level	level	NOUN
dpc-4194	277	31	of	of	ADP
dpc-4194	277	32	impairment	impairment	NOUN
dpc-4194	277	33	by	by	ADP
dpc-4194	277	34	the	the	DET
dpc-4194	277	35	end	end	NOUN
dpc-4194	277	36	of	of	ADP
dpc-4194	277	37	the	the	DET
dpc-4194	277	38	16	16	NUM
dpc-4194	277	39	-	-	PUNCT
dpc-4194	277	40	week	week	NOUN
dpc-4194	277	41	period	period	NOUN
dpc-4194	277	42	.	.	PUNCT
dpc-4194	278	1	contrary	contrary	ADJ
dpc-4194	278	2	to	to	ADP
dpc-4194	278	3	some	some	DET
dpc-4194	278	4	existing	exist	VERB
dpc-4194	278	5	literature	literature	NOUN
dpc-4194	278	6	,	,	PUNCT
dpc-4194	278	7	our	our	PRON
dpc-4194	278	8	study	study	NOUN
dpc-4194	278	9	did	do	AUX
dpc-4194	278	10	not	not	PART
dpc-4194	278	11	observe	observe	VERB
dpc-4194	278	12	differences	difference	NOUN
dpc-4194	278	13	on	on	ADP
dpc-4194	278	14	the	the	DET
dpc-4194	278	15	effectiveness	effectiveness	NOUN
dpc-4194	278	16	of	of	ADP
dpc-4194	278	17	bimekizumab	bimekizumab	NOUN
dpc-4194	278	18	between	between	ADP
dpc-4194	278	19	bio	bio	PROPN
dpc-4194	278	20	-	-	PROPN
dpc-4194	278	21	naïve	naïve	ADJ
dpc-4194	278	22	and	and	CCONJ
dpc-4194	278	23	bio	bio	ADV
dpc-4194	278	24	-	-	ADJ
dpc-4194	278	25	experienced	experience	VERB
dpc-4194	278	26	subgroups	subgroup	NOUN
dpc-4194	278	27	or	or	CCONJ
dpc-4194	278	28	between	between	ADP
dpc-4194	278	29	non	non	ADJ
dpc-4194	278	30	-	-	ADJ
dpc-4194	278	31	obese	obese	ADJ
dpc-4194	278	32	and	and	CCONJ
dpc-4194	278	33	obese	obese	ADJ
dpc-4194	278	34	patient	patient	ADJ
dpc-4194	278	35	groups	group	NOUN
dpc-4194	278	36	.	.	PUNCT
dpc-4194	279	1	it	it	PRON
dpc-4194	279	2	is	be	AUX
dpc-4194	279	3	important	important	ADJ
dpc-4194	279	4	to	to	PART
dpc-4194	279	5	acknowledge	acknowledge	VERB
dpc-4194	279	6	the	the	DET
dpc-4194	279	7	limitations	limitation	NOUN
dpc-4194	279	8	of	of	ADP
dpc-4194	279	9	our	our	PRON
dpc-4194	279	10	study	study	NOUN
dpc-4194	279	11	,	,	PUNCT
dpc-4194	279	12	primarily	primarily	ADV
dpc-4194	279	13	the	the	DET
dpc-4194	279	14	relatively	relatively	ADV
dpc-4194	279	15	small	small	ADJ
dpc-4194	279	16	cohort	cohort	NOUN
dpc-4194	279	17	size	size	NOUN
dpc-4194	279	18	,	,	PUNCT
dpc-4194	279	19	which	which	PRON
dpc-4194	279	20	may	may	AUX
dpc-4194	279	21	have	have	AUX
dpc-4194	279	22	influenced	influence	VERB
dpc-4194	279	23	these	these	DET
dpc-4194	279	24	findings	finding	NOUN
dpc-4194	279	25	.	.	PUNCT
dpc-4194	280	1	in	in	ADP
dpc-4194	280	2	summary	summary	NOUN
dpc-4194	280	3	,	,	PUNCT
dpc-4194	280	4	our	our	PRON
dpc-4194	280	5	preliminary	preliminary	ADJ
dpc-4194	280	6	findings	finding	NOUN
dpc-4194	280	7	are	be	AUX
dpc-4194	280	8	promising	promise	VERB
dpc-4194	280	9	and	and	CCONJ
dpc-4194	280	10	suggest	suggest	VERB
dpc-4194	280	11	that	that	SCONJ
dpc-4194	280	12	bimekizumab	bimekizumab	PROPN
dpc-4194	280	13	holds	hold	VERB
dpc-4194	280	14	great	great	ADJ
dpc-4194	280	15	potential	potential	NOUN
dpc-4194	280	16	as	as	ADP
dpc-4194	280	17	a	a	DET
dpc-4194	280	18	treatment	treatment	NOUN
dpc-4194	280	19	option	option	NOUN
dpc-4194	280	20	for	for	ADP
dpc-4194	280	21	genital	genital	ADJ
dpc-4194	280	22	psoriasis	psoriasis	NOUN
dpc-4194	280	23	.	.	PUNCT
dpc-4194	281	1	however	however	ADV
dpc-4194	281	2	,	,	PUNCT
dpc-4194	281	3	further	further	ADJ
dpc-4194	281	4	research	research	NOUN
dpc-4194	281	5	with	with	ADP
dpc-4194	281	6	larger	large	ADJ
dpc-4194	281	7	sample	sample	NOUN
dpc-4194	281	8	sizes	size	NOUN
dpc-4194	281	9	and	and	CCONJ
dpc-4194	281	10	longer	long	ADJ
dpc-4194	281	11	-	-	PUNCT
dpc-4194	281	12	term	term	NOUN
dpc-4194	281	13	follow	follow	NOUN
dpc-4194	281	14	-	-	PUNCT
dpc-4194	281	15	up	up	NOUN
dpc-4194	281	16	is	be	AUX
dpc-4194	281	17	essential	essential	ADJ
dpc-4194	281	18	to	to	PART
dpc-4194	281	19	validate	validate	VERB
dpc-4194	281	20	these	these	DET
dpc-4194	281	21	results	result	NOUN
dpc-4194	281	22	conclusively	conclusively	ADV
dpc-4194	281	23	.	.	PUNCT
dpc-4194	282	1	references	reference	NOUN
dpc-4194	282	2	1	1	NUM
dpc-4194	282	3	.	.	PUNCT
dpc-4194	282	4	meeuwis	meeuwis	PROPN
dpc-4194	282	5	kap	kap	PROPN
dpc-4194	282	6	,	,	PUNCT
dpc-4194	282	7	potts	potts	PROPN
dpc-4194	282	8	bleakman	bleakman	PROPN
dpc-4194	282	9	a	a	PROPN
dpc-4194	282	10	,	,	PUNCT
dpc-4194	282	11	van	van	PROPN
dpc-4194	282	12	de	de	X
dpc-4194	282	13	kerkhof	kerkhof	PROPN
dpc-4194	282	14	pcm	pcm	PROPN
dpc-4194	282	15	,	,	PUNCT
dpc-4194	282	16	et	et	NOUN
dpc-4194	282	17	  	  	SPACE
dpc-4194	282	18	al	al	PROPN
dpc-4194	282	19	.	.	PUNCT
dpc-4194	283	1	prevalence	prevalence	NOUN
dpc-4194	283	2	of	of	ADP
dpc-4194	283	3	genital	genital	ADJ
dpc-4194	283	4	psoriasis	psoriasis	NOUN
dpc-4194	283	5	in	in	ADP
dpc-4194	283	6	patients	patient	NOUN
dpc-4194	283	7	with	with	ADP
dpc-4194	283	8	psoriasis	psoriasis	NOUN
dpc-4194	283	9	.	.	PUNCT
dpc-4194	284	1	j	j	PROPN
dpc-4194	284	2	dermatolog	dermatolog	PROPN
dpc-4194	284	3	treat	treat	NOUN
dpc-4194	284	4	.	.	PUNCT
dpc-4194	285	1	2018;29(8):754	2018;29(8):754	NUM
dpc-4194	285	2	-	-	SYM
dpc-4194	285	3	760	760	NUM
dpc-4194	285	4	.	.	PUNCT
dpc-4194	285	5	doi	doi	NOUN
dpc-4194	285	6	:	:	PUNCT
dpc-4194	285	7	10.1080	10.1080	NUM
dpc-4194	285	8	/09546634.2018.1453125	/09546634.2018.1453125	SYM
dpc-4194	285	9	.	.	PUNCT
dpc-4194	286	1	pmid	pmid	NOUN
dpc-4194	286	2	:	:	PUNCT
dpc-4194	286	3	29565190	29565190	NUM
dpc-4194	286	4	.	.	PUNCT
dpc-4194	287	1	2	2	X
dpc-4194	287	2	.	.	X
dpc-4194	287	3	staubach	staubach	PROPN
dpc-4194	287	4	p	p	X
dpc-4194	287	5	,	,	PUNCT
dpc-4194	287	6	plavic	plavic	PROPN
dpc-4194	287	7	-	-	PUNCT
dpc-4194	287	8	radeka	radeka	PROPN
dpc-4194	287	9	n	n	NOUN
dpc-4194	287	10	,	,	PUNCT
dpc-4194	287	11	peveling	peveling	NOUN
dpc-4194	287	12	-	-	PUNCT
dpc-4194	287	13	oberhag	oberhag	NOUN
dpc-4194	287	14	a	a	PRON
dpc-4194	287	15	,	,	PUNCT
dpc-4194	287	16	et	et	PROPN
dpc-4194	287	17	al	al	PROPN
dpc-4194	287	18	.	.	PROPN
dpc-4194	287	19	high	high	ADJ
dpc-4194	287	20	prevalence	prevalence	NOUN
dpc-4194	287	21	and	and	CCONJ
dpc-4194	287	22	little	little	ADJ
dpc-4194	287	23	awareness	awareness	NOUN
dpc-4194	287	24	in	in	ADP
dpc-4194	287	25	patients	patient	NOUN
dpc-4194	287	26	with	with	ADP
dpc-4194	287	27	chronic	chronic	ADJ
dpc-4194	287	28	inflammatory	inflammatory	ADJ
dpc-4194	287	29	skin	skin	NOUN
dpc-4194	287	30	diseases	disease	NOUN
dpc-4194	287	31	and	and	CCONJ
dpc-4194	287	32	genital	genital	ADJ
dpc-4194	287	33	involvement	involvement	NOUN
dpc-4194	287	34	.	.	PUNCT
dpc-4194	288	1	j	j	PROPN
dpc-4194	288	2	dtsch	dtsch	PROPN
dpc-4194	288	3	dermatol	dermatol	NOUN
dpc-4194	288	4	ges	ges	PROPN
dpc-4194	288	5	.	.	PROPN
dpc-4194	288	6	2021;19(10):1443	2021;19(10):1443	NUM
dpc-4194	288	7	-	-	SYM
dpc-4194	288	8	1448	1448	NUM
dpc-4194	288	9	.	.	PUNCT
dpc-4194	289	1	doi	doi	NOUN
dpc-4194	289	2	:	:	PUNCT
dpc-4194	289	3	10.1111	10.1111	NUM
dpc-4194	289	4	/	/	SYM
dpc-4194	289	5	ddg.14437	ddg.14437	PROPN
dpc-4194	289	6	.	.	PUNCT
dpc-4194	290	1	pmid	pmid	NOUN
dpc-4194	290	2	:	:	PUNCT
dpc-4194	290	3	34396689	34396689	NUM
dpc-4194	290	4	.	.	PUNCT
dpc-4194	291	1	3	3	X
dpc-4194	291	2	.	.	X
dpc-4194	291	3	larsabal	larsabal	PROPN
dpc-4194	291	4	m	m	PROPN
dpc-4194	291	5	,	,	PUNCT
dpc-4194	291	6	ly	ly	PROPN
dpc-4194	291	7	s	s	PROPN
dpc-4194	291	8	,	,	PUNCT
dpc-4194	291	9	sbidian	sbidian	PROPN
dpc-4194	291	10	e	e	NOUN
dpc-4194	291	11	,	,	PUNCT
dpc-4194	291	12	et	et	PROPN
dpc-4194	291	13	al	al	PROPN
dpc-4194	291	14	.	.	PROPN
dpc-4194	291	15	genipso	genipso	PROPN
dpc-4194	291	16	:	:	PUNCT
dpc-4194	291	17	a	a	DET
dpc-4194	291	18	french	french	ADJ
dpc-4194	291	19	prospective	prospective	ADJ
dpc-4194	291	20	study	study	NOUN
dpc-4194	291	21	assessing	assess	VERB
dpc-4194	291	22	instantaneous	instantaneous	ADJ
dpc-4194	291	23	prevalence	prevalence	NOUN
dpc-4194	291	24	,	,	PUNCT
dpc-4194	291	25	clinical	clinical	ADJ
dpc-4194	291	26	features	feature	NOUN
dpc-4194	291	27	and	and	CCONJ
dpc-4194	291	28	impact	impact	NOUN
dpc-4194	291	29	on	on	ADP
dpc-4194	291	30	quality	quality	NOUN
dpc-4194	291	31	of	of	ADP
dpc-4194	291	32	life	life	NOUN
dpc-4194	291	33	of	of	ADP
dpc-4194	291	34	genital	genital	ADJ
dpc-4194	291	35	psoriasis	psoriasis	NOUN
dpc-4194	291	36	among	among	ADP
dpc-4194	291	37	patients	patient	NOUN
dpc-4194	291	38	consulting	consult	VERB
dpc-4194	291	39	for	for	ADP
dpc-4194	291	40	psoriasis	psoriasis	NOUN
dpc-4194	291	41	.	.	PUNCT
dpc-4194	292	1	br	br	PROPN
dpc-4194	292	2	j	j	PROPN
dpc-4194	292	3	dermatol	dermatol	NOUN
dpc-4194	292	4	.	.	PUNCT
dpc-4194	293	1	2019;180(3):647	2019;180(3):647	NUM
dpc-4194	293	2	-	-	SYM
dpc-4194	293	3	656	656	NUM
dpc-4194	293	4	.	.	PUNCT
dpc-4194	294	1	doi	doi	NOUN
dpc-4194	294	2	:	:	PUNCT
dpc-4194	294	3	10.1111	10.1111	NUM
dpc-4194	294	4	/	/	SYM
dpc-4194	294	5	bjd.17147	bjd.17147	PROPN
dpc-4194	294	6	.	.	PUNCT
dpc-4194	295	1	pmid	pmid	NOUN
dpc-4194	295	2	:	:	PUNCT
dpc-4194	295	3	30188572	30188572	NUM
dpc-4194	295	4	.	.	PUNCT
dpc-4194	296	1	4	4	X
dpc-4194	296	2	.	.	X
dpc-4194	296	3	yang	yang	PROPN
dpc-4194	296	4	ej	ej	PROPN
dpc-4194	296	5	,	,	PUNCT
dpc-4194	296	6	beck	beck	PROPN
dpc-4194	296	7	km	km	PROPN
dpc-4194	296	8	,	,	PUNCT
dpc-4194	296	9	sanchez	sanchez	PROPN
dpc-4194	297	1	i	i	PRON
dpc-4194	297	2	m	m	PROPN
dpc-4194	297	3	,	,	PUNCT
dpc-4194	297	4	koo	koo	PROPN
dpc-4194	297	5	j	j	PROPN
dpc-4194	297	6	,	,	PUNCT
dpc-4194	297	7	liao	liao	PROPN
dpc-4194	297	8	w.	w.	PROPN
dpc-4194	298	1	the	the	DET
dpc-4194	298	2	impact	impact	NOUN
dpc-4194	298	3	of	of	ADP
dpc-4194	298	4	genital	genital	ADJ
dpc-4194	298	5	psoriasis	psoriasis	NOUN
dpc-4194	298	6	on	on	ADP
dpc-4194	298	7	quality	quality	NOUN
dpc-4194	298	8	of	of	ADP
dpc-4194	298	9	life	life	NOUN
dpc-4194	298	10	:	:	PUNCT
dpc-4194	298	11	a	a	DET
dpc-4194	298	12	systematic	systematic	ADJ
dpc-4194	298	13	review	review	NOUN
dpc-4194	298	14	.	.	PUNCT
dpc-4194	299	1	psoriasis	psoriasis	NOUN
dpc-4194	299	2	(	(	PUNCT
dpc-4194	299	3	auckl	auckl	NOUN
dpc-4194	299	4	)	)	PUNCT
dpc-4194	299	5	.	.	PUNCT
dpc-4194	300	1	2018;8:41	2018;8:41	NUM
dpc-4194	300	2	-	-	SYM
dpc-4194	300	3	47	47	NUM
dpc-4194	300	4	.	.	PUNCT
dpc-4194	301	1	doi	doi	NOUN
dpc-4194	301	2	:	:	PUNCT
dpc-4194	301	3	10.2147	10.2147	NUM
dpc-4194	301	4	/	/	SYM
dpc-4194	301	5	ptt.s169389	ptt.s169389	NOUN
dpc-4194	301	6	.	.	PUNCT
dpc-4194	302	1	pmid	pmid	NOUN
dpc-4194	302	2	:	:	PUNCT
dpc-4194	302	3	30214891	30214891	NUM
dpc-4194	302	4	.	.	PUNCT
dpc-4194	303	1	pmcid	pmcid	NOUN
dpc-4194	303	2	:	:	PUNCT
dpc-4194	303	3	pmc6118254	pmc6118254	NOUN
dpc-4194	303	4	.	.	PUNCT
dpc-4194	304	1	5	5	X
dpc-4194	304	2	.	.	X
dpc-4194	304	3	kelly	kelly	PROPN
dpc-4194	304	4	a	a	PROPN
dpc-4194	304	5	,	,	PUNCT
dpc-4194	304	6	ryan	ryan	PROPN
dpc-4194	304	7	c.	c.	PROPN
dpc-4194	304	8	genital	genital	ADJ
dpc-4194	304	9	psoriasis	psoriasis	NOUN
dpc-4194	304	10	:	:	PUNCT
dpc-4194	304	11	impact	impact	NOUN
dpc-4194	304	12	on	on	ADP
dpc-4194	304	13	quality	quality	NOUN
dpc-4194	304	14	of	of	ADP
dpc-4194	304	15	life	life	NOUN
dpc-4194	304	16	and	and	CCONJ
dpc-4194	304	17	treatment	treatment	NOUN
dpc-4194	304	18	options	option	NOUN
dpc-4194	304	19	.	.	PUNCT
dpc-4194	305	1	am	be	AUX
dpc-4194	305	2	j	j	PROPN
dpc-4194	305	3	clin	clin	PROPN
dpc-4194	305	4	dermatol	dermatol	NOUN
dpc-4194	305	5	.	.	PUNCT
dpc-4194	306	1	2019;20(5):639	2019;20(5):639	NUM
dpc-4194	306	2	-	-	PUNCT
dpc-4194	306	3	646	646	NUM
dpc-4194	306	4	.	.	PUNCT
dpc-4194	307	1	doi	doi	NOUN
dpc-4194	307	2	:	:	PUNCT
dpc-4194	307	3	10.1007	10.1007	NUM
dpc-4194	307	4	/	/	SYM
dpc-4194	307	5	s40257	s40257	NOUN
dpc-4194	307	6	-	-	PUNCT
dpc-4194	307	7	019	019	NUM
dpc-4194	307	8	-	-	PUNCT
dpc-4194	307	9	00447	00447	NUM
dpc-4194	307	10	-	-	PUNCT
dpc-4194	307	11	5	5	NUM
dpc-4194	307	12	.	.	PUNCT
dpc-4194	308	1	pmid	pmid	NOUN
dpc-4194	308	2	:	:	PUNCT
dpc-4194	308	3	31313079	31313079	NUM
dpc-4194	308	4	.	.	PUNCT
dpc-4194	309	1	6	6	NUM
dpc-4194	309	2	.	.	X
dpc-4194	309	3	ryan	ryan	PROPN
dpc-4194	309	4	c	c	PROPN
dpc-4194	309	5	,	,	PUNCT
dpc-4194	309	6	guenther	guenther	PROPN
dpc-4194	309	7	l	l	PROPN
dpc-4194	309	8	,	,	PUNCT
dpc-4194	309	9	foley	foley	PROPN
dpc-4194	309	10	p	p	X
dpc-4194	309	11	,	,	PUNCT
dpc-4194	309	12	et	et	PROPN
dpc-4194	309	13	al	al	PROPN
dpc-4194	309	14	.	.	PROPN
dpc-4194	309	15	ixekizumab	ixekizumab	NOUN
dpc-4194	309	16	provides	provide	VERB
dpc-4194	309	17	persistent	persistent	ADJ
dpc-4194	309	18	improvements	improvement	NOUN
dpc-4194	309	19	in	in	ADP
dpc-4194	309	20	health	health	NOUN
dpc-4194	309	21	-	-	PUNCT
dpc-4194	309	22	related	relate	VERB
dpc-4194	309	23	quality	quality	NOUN
dpc-4194	309	24	of	of	ADP
dpc-4194	309	25	life	life	NOUN
dpc-4194	309	26	and	and	CCONJ
dpc-4194	309	27	the	the	DET
dpc-4194	309	28	sexual	sexual	ADJ
dpc-4194	309	29	impact	impact	NOUN
dpc-4194	309	30	associated	associate	VERB
dpc-4194	309	31	with	with	ADP
dpc-4194	309	32	moderate	moderate	ADJ
dpc-4194	309	33	-	-	PUNCT
dpc-4194	309	34	to	to	ADP
dpc-4194	309	35	-	-	PUNCT
dpc-4194	309	36	severe	severe	ADJ
dpc-4194	309	37	genital	genital	ADJ
dpc-4194	309	38	psoriasis	psoriasis	NOUN
dpc-4194	309	39	in	in	ADP
dpc-4194	309	40	adult	adult	NOUN
dpc-4194	309	41	patients	patient	NOUN
dpc-4194	309	42	during	during	ADP
dpc-4194	309	43	a	a	DET
dpc-4194	309	44	52	52	NUM
dpc-4194	309	45	-	-	PUNCT
dpc-4194	309	46	week	week	NOUN
dpc-4194	309	47	,	,	PUNCT
dpc-4194	309	48	randomised	randomise	VERB
dpc-4194	309	49	,	,	PUNCT
dpc-4194	309	50	placebo	placebo	NOUN
dpc-4194	309	51	controlled	control	VERB
dpc-4194	309	52	,	,	PUNCT
dpc-4194	309	53	phase	phase	NOUN
dpc-4194	309	54	3	3	NUM
dpc-4194	309	55	clinical	clinical	ADJ
dpc-4194	309	56	trial	trial	NOUN
dpc-4194	309	57	.	.	PUNCT
dpc-4194	310	1	j	j	PROPN
dpc-4194	310	2	eur	eur	PROPN
dpc-4194	310	3	acad	acad	PROPN
dpc-4194	310	4	dermatol	dermatol	NOUN
dpc-4194	310	5	venereol	venereol	NOUN
dpc-4194	310	6	.	.	PUNCT
dpc-4194	311	1	original	original	ADJ
dpc-4194	311	2	article	article	NOUN
dpc-4194	311	3	|	|	ADV
dpc-4194	311	4	dermatol	dermatol	ADJ
dpc-4194	311	5	pract	pract	NOUN
dpc-4194	311	6	concept	concept	NOUN
dpc-4194	311	7	.	.	PUNCT
dpc-4194	312	1	2024;14(2):e2024052	2024;14(2):e2024052	NUM
dpc-4194	312	2	9	9	NUM
dpc-4194	312	3	pso	pso	NOUN
dpc-4194	312	4	(	(	PUNCT
dpc-4194	312	5	italian	italian	ADJ
dpc-4194	312	6	landscape	landscape	NOUN
dpc-4194	312	7	psoriasis	psoriasis	NOUN
dpc-4194	312	8	)	)	PUNCT
dpc-4194	312	9	.	.	PUNCT
dpc-4194	313	1	j	j	PROPN
dpc-4194	313	2	eur	eur	PROPN
dpc-4194	313	3	acad	acad	PROPN
dpc-4194	313	4	dermatol	dermatol	NOUN
dpc-4194	313	5	venereol	venereol	NOUN
dpc-4194	313	6	.	.	PUNCT
dpc-4194	314	1	2024;38(1):e113	2024;38(1):e113	PROPN
dpc-4194	314	2	-	-	PUNCT
dpc-4194	314	3	e116	e116	PROPN
dpc-4194	314	4	.	.	PUNCT
dpc-4194	314	5	doi	doi	NOUN
dpc-4194	314	6	:	:	PUNCT
dpc-4194	314	7	10.1111	10.1111	NUM
dpc-4194	314	8	/	/	SYM
dpc-4194	314	9	jdv.19464	jdv.19464	PROPN
dpc-4194	314	10	..	..	PUNCT
dpc-4194	314	11	pmid	pmid	NOUN
dpc-4194	314	12	:	:	PUNCT
dpc-4194	314	13	37611277	37611277	NUM
dpc-4194	314	14	.	.	PUNCT
dpc-4194	315	1	33	33	NUM
dpc-4194	315	2	.	.	NOUN
dpc-4194	315	3	mastorino	mastorino	PROPN
dpc-4194	315	4	l	l	PROPN
dpc-4194	315	5	,	,	PUNCT
dpc-4194	315	6	castelli	castelli	PROPN
dpc-4194	315	7	f	f	PROPN
dpc-4194	315	8	,	,	PUNCT
dpc-4194	315	9	stroppiana	stroppiana	PROPN
dpc-4194	315	10	e	e	PROPN
dpc-4194	315	11	,	,	PUNCT
dpc-4194	315	12	et	et	PROPN
dpc-4194	315	13	al	al	PROPN
dpc-4194	315	14	.	.	PROPN
dpc-4194	315	15	risankizumab	risankizumab	PROPN
dpc-4194	315	16	shows	show	VERB
dpc-4194	315	17	faster	fast	ADJ
dpc-4194	315	18	response	response	NOUN
dpc-4194	315	19	in	in	ADP
dpc-4194	315	20	bio	bio	PROPN
dpc-4194	315	21	naïve	naïve	PROPN
dpc-4194	315	22	than	than	ADP
dpc-4194	315	23	in	in	ADP
dpc-4194	315	24	bio	bio	ADJ
dpc-4194	315	25	-	-	ADJ
dpc-4194	315	26	experienced	experienced	ADJ
dpc-4194	315	27	psoriatic	psoriatic	ADJ
dpc-4194	315	28	patients	patient	NOUN
dpc-4194	315	29	.	.	PUNCT
dpc-4194	316	1	j	j	PROPN
dpc-4194	316	2	eur	eur	PROPN
dpc-4194	316	3	acad	acad	PROPN
dpc-4194	316	4	dermatol	dermatol	NOUN
dpc-4194	316	5	venereol	venereol	NOUN
dpc-4194	316	6	.	.	PUNCT
dpc-4194	317	1	2022;36(10):e838	2022;36(10):e838	NUM
dpc-4194	317	2	-	-	SYM
dpc-4194	317	3	e841	e841	PROPN
dpc-4194	317	4	.	.	PUNCT
dpc-4194	318	1	doi	doi	NOUN
dpc-4194	318	2	:	:	PUNCT
dpc-4194	318	3	10.1111	10.1111	NUM
dpc-4194	318	4	/	/	SYM
dpc-4194	318	5	jdv.18314	jdv.18314	PROPN
dpc-4194	318	6	.	.	PUNCT
dpc-4194	319	1	pmid	pmid	NOUN
dpc-4194	319	2	:	:	PUNCT
dpc-4194	319	3	35686942	35686942	NUM
dpc-4194	319	4	.	.	PUNCT
dpc-4194	320	1	34	34	NUM
dpc-4194	320	2	.	.	PUNCT
dpc-4194	320	3	mastorino	mastorino	PROPN
dpc-4194	320	4	l	l	PROPN
dpc-4194	320	5	,	,	PUNCT
dpc-4194	320	6	cariti	cariti	PROPN
dpc-4194	320	7	c	c	NOUN
dpc-4194	320	8	,	,	PUNCT
dpc-4194	320	9	susca	susca	PROPN
dpc-4194	320	10	s	s	PROPN
dpc-4194	320	11	,	,	PUNCT
dpc-4194	320	12	et	et	PROPN
dpc-4194	320	13	al	al	PROPN
dpc-4194	320	14	.	.	PROPN
dpc-4194	320	15	brodalumab	brodalumab	PROPN
dpc-4194	320	16	efficacy	efficacy	NOUN
dpc-4194	320	17	in	in	ADP
dpc-4194	320	18	bionaïve	bionaïve	NOUN
dpc-4194	320	19	psoriasis	psoriasis	NOUN
dpc-4194	320	20	patients	patient	NOUN
dpc-4194	320	21	:	:	PUNCT
dpc-4194	320	22	real	real	ADJ
dpc-4194	320	23	-	-	PUNCT
dpc-4194	320	24	life	life	NOUN
dpc-4194	320	25	experience	experience	NOUN
dpc-4194	320	26	of	of	ADP
dpc-4194	320	27	202	202	NUM
dpc-4194	320	28	subjects	subject	NOUN
dpc-4194	320	29	up	up	ADP
dpc-4194	320	30	to	to	ADP
dpc-4194	320	31	48	48	NUM
dpc-4194	320	32	weeks	week	NOUN
dpc-4194	320	33	.	.	PUNCT
dpc-4194	321	1	j	j	PROPN
dpc-4194	321	2	dermatolog	dermatolog	PROPN
dpc-4194	321	3	treat	treat	NOUN
dpc-4194	321	4	.	.	PUNCT
dpc-4194	322	1	2022;33(8):3211	2022;33(8):3211	NUM
dpc-4194	322	2	-	-	SYM
dpc-4194	322	3	3213	3213	NUM
dpc-4194	322	4	.	.	PUNCT
dpc-4194	323	1	doi	doi	NOUN
dpc-4194	323	2	:	:	PUNCT
dpc-4194	323	3	10.1080/09546634.2022.2125265	10.1080/09546634.2022.2125265	NUM
dpc-4194	323	4	.	.	PUNCT
dpc-4194	324	1	pmid	pmid	NOUN
dpc-4194	324	2	:	:	PUNCT
dpc-4194	324	3	36103200	36103200	NUM
dpc-4194	324	4	.	.	PUNCT
dpc-4194	325	1	35	35	NUM
dpc-4194	325	2	.	.	PUNCT
dpc-4194	326	1	gargiulo	gargiulo	PROPN
dpc-4194	326	2	l	l	NOUN
dpc-4194	326	3	,	,	PUNCT
dpc-4194	326	4	ibba	ibba	ADJ
dpc-4194	326	5	l	l	NOUN
dpc-4194	326	6	,	,	PUNCT
dpc-4194	326	7	pavia	pavia	PROPN
dpc-4194	326	8	g	g	NOUN
dpc-4194	326	9	,	,	PUNCT
dpc-4194	326	10	et	et	PROPN
dpc-4194	326	11	al	al	PROPN
dpc-4194	326	12	.	.	PUNCT
dpc-4194	327	1	real	real	ADJ
dpc-4194	327	2	-	-	PUNCT
dpc-4194	327	3	life	life	NOUN
dpc-4194	327	4	effectiveness	effectiveness	NOUN
dpc-4194	327	5	and	and	CCONJ
dpc-4194	327	6	safety	safety	NOUN
dpc-4194	327	7	of	of	ADP
dpc-4194	327	8	risankizumab	risankizumab	NOUN
dpc-4194	327	9	in	in	ADP
dpc-4194	327	10	131	131	NUM
dpc-4194	327	11	patients	patient	NOUN
dpc-4194	327	12	affected	affect	VERB
dpc-4194	327	13	by	by	ADP
dpc-4194	327	14	moderate	moderate	ADJ
dpc-4194	327	15	-	-	PUNCT
dpc-4194	327	16	to	to	ADP
dpc-4194	327	17	-	-	PUNCT
dpc-4194	327	18	severe	severe	ADJ
dpc-4194	327	19	plaque	plaque	NOUN
dpc-4194	327	20	psoriasis	psoriasis	NOUN
dpc-4194	327	21	:	:	PUNCT
dpc-4194	327	22	a	a	DET
dpc-4194	327	23	52	52	NUM
dpc-4194	327	24	-	-	PUNCT
dpc-4194	327	25	week	week	NOUN
dpc-4194	327	26	retrospective	retrospective	ADJ
dpc-4194	327	27	study	study	NOUN
dpc-4194	327	28	.	.	PUNCT
dpc-4194	328	1	dermatol	dermatol	NOUN
dpc-4194	328	2	ther	ther	ADV
dpc-4194	328	3	(	(	PUNCT
dpc-4194	328	4	heidelb	heidelb	NOUN
dpc-4194	328	5	)	)	PUNCT
dpc-4194	328	6	.	.	PUNCT
dpc-4194	329	1	2022;12(10):2309	2022;12(10):2309	NUM
dpc-4194	329	2	-	-	SYM
dpc-4194	329	3	2324	2324	NUM
dpc-4194	329	4	.	.	PUNCT
dpc-4194	330	1	doi	doi	NOUN
dpc-4194	330	2	:	:	PUNCT
dpc-4194	330	3	10.1007	10.1007	NUM
dpc-4194	330	4	/	/	SYM
dpc-4194	330	5	s13555	s13555	PROPN
dpc-4194	330	6	-	-	PUNCT
dpc-4194	330	7	02200795	02200795	NUM
dpc-4194	330	8	-	-	PUNCT
dpc-4194	330	9	x.	x.	NOUN
dpc-4194	330	10	pmid	pmid	PROPN
dpc-4194	330	11	:	:	PUNCT
dpc-4194	330	12	36063283	36063283	NUM
dpc-4194	330	13	.	.	PUNCT
dpc-4194	331	1	pmcid	pmcid	NOUN
dpc-4194	331	2	:	:	PUNCT
dpc-4194	331	3	pmc9443623	pmc9443623	VERB
dpc-4194	331	4	.	.	PUNCT
dpc-4194	332	1	36	36	NUM
dpc-4194	332	2	.	.	PUNCT
dpc-4194	333	1	ko	ko	PROPN
dpc-4194	333	2	sh	sh	PROPN
dpc-4194	333	3	,	,	PUNCT
dpc-4194	333	4	chi	chi	PROPN
dpc-4194	333	5	cc	cc	PROPN
dpc-4194	333	6	,	,	PUNCT
dpc-4194	333	7	yeh	yeh	PROPN
dpc-4194	333	8	ml	ml	PROPN
dpc-4194	333	9	,	,	PUNCT
dpc-4194	333	10	wang	wang	PROPN
dpc-4194	333	11	sh	sh	PROPN
dpc-4194	333	12	,	,	PUNCT
dpc-4194	333	13	tsai	tsai	PROPN
dpc-4194	333	14	ys	ys	PROPN
dpc-4194	333	15	,	,	PUNCT
dpc-4194	333	16	hsu	hsu	PROPN
dpc-4194	333	17	my	my	PRON
dpc-4194	333	18	.	.	PUNCT
dpc-4194	333	19	lifestyle	lifestyle	NOUN
dpc-4194	333	20	changes	change	NOUN
dpc-4194	333	21	for	for	ADP
dpc-4194	333	22	treating	treat	VERB
dpc-4194	333	23	psoriasis	psoriasis	NOUN
dpc-4194	333	24	.	.	PUNCT
dpc-4194	334	1	cochrane	cochrane	NOUN
dpc-4194	334	2	database	database	PROPN
dpc-4194	334	3	syst	syst	PROPN
dpc-4194	334	4	rev	rev	PROPN
dpc-4194	334	5	.	.	PROPN
dpc-4194	335	1	2019;7(7):cd011972	2019;7(7):cd011972	NUM
dpc-4194	335	2	.	.	PUNCT
dpc-4194	335	3	doi	doi	PROPN
dpc-4194	335	4	:	:	PUNCT
dpc-4194	336	1	10.1002/14651858.cd011972	10.1002/14651858.cd011972	NUM
dpc-4194	336	2	.	.	PUNCT
dpc-4194	337	1	pub2	pub2	PROPN
dpc-4194	337	2	.	.	PUNCT
dpc-4194	338	1	pmid	pmid	NOUN
dpc-4194	338	2	:	:	PUNCT
dpc-4194	338	3	31309536	31309536	NUM
dpc-4194	338	4	.	.	PUNCT
dpc-4194	339	1	pmcid	pmcid	NOUN
dpc-4194	339	2	:	:	PUNCT
dpc-4194	339	3	pmc6629583	pmc6629583	NOUN
dpc-4194	339	4	.	.	PUNCT
dpc-4194	340	1	37	37	NUM
dpc-4194	340	2	.	.	PUNCT
dpc-4194	341	1	ogawa	ogawa	PROPN
dpc-4194	341	2	k	k	PROPN
dpc-4194	341	3	,	,	PUNCT
dpc-4194	341	4	stuart	stuart	PROPN
dpc-4194	341	5	pe	pe	PROPN
dpc-4194	341	6	,	,	PUNCT
dpc-4194	341	7	tsoi	tsoi	PROPN
dpc-4194	341	8	lc	lc	PROPN
dpc-4194	341	9	,	,	PUNCT
dpc-4194	341	10	et	et	PROPN
dpc-4194	341	11	al	al	PROPN
dpc-4194	341	12	.	.	PUNCT
dpc-4194	342	1	a	a	DET
dpc-4194	342	2	transethnic	transethnic	ADJ
dpc-4194	342	3	mendelian	mendelian	ADJ
dpc-4194	342	4	randomization	randomization	NOUN
dpc-4194	342	5	study	study	NOUN
dpc-4194	342	6	identifies	identify	VERB
dpc-4194	342	7	causality	causality	NOUN
dpc-4194	342	8	of	of	ADP
dpc-4194	342	9	obesity	obesity	NOUN
dpc-4194	342	10	on	on	ADP
dpc-4194	342	11	risk	risk	NOUN
dpc-4194	342	12	of	of	ADP
dpc-4194	342	13	psoriasis	psoriasis	NOUN
dpc-4194	342	14	.	.	PUNCT
dpc-4194	343	1	j	j	PROPN
dpc-4194	343	2	invest	invest	VERB
dpc-4194	343	3	dermatol	dermatol	NOUN
dpc-4194	343	4	.	.	PUNCT
dpc-4194	344	1	2019;139(6):1397	2019;139(6):1397	NUM
dpc-4194	344	2	-	-	SYM
dpc-4194	344	3	1400	1400	NUM
dpc-4194	344	4	.	.	PUNCT
dpc-4194	345	1	doi	doi	NOUN
dpc-4194	345	2	:	:	PUNCT
dpc-4194	345	3	10.1016	10.1016	NUM
dpc-4194	345	4	/j.jid.2018.11.023	/j.jid.2018.11.023	PROPN
dpc-4194	345	5	.	.	PUNCT
dpc-4194	346	1	pmid	pmid	NOUN
dpc-4194	346	2	:	:	PUNCT
dpc-4194	346	3	30528826	30528826	NUM
dpc-4194	346	4	.	.	PUNCT
dpc-4194	347	1	pmcid	pmcid	NOUN
dpc-4194	347	2	:	:	PUNCT
dpc-4194	347	3	pmc7028352	pmc7028352	ADJ
dpc-4194	347	4	.	.	PUNCT
dpc-4194	348	1	38	38	NUM
dpc-4194	348	2	.	.	PUNCT
dpc-4194	349	1	jensen	jensen	PROPN
dpc-4194	349	2	p	p	PROPN
dpc-4194	349	3	,	,	PUNCT
dpc-4194	349	4	skov	skov	NOUN
dpc-4194	349	5	l.	l.	NOUN
dpc-4194	349	6	psoriasis	psoriasis	NOUN
dpc-4194	349	7	and	and	CCONJ
dpc-4194	349	8	obesity	obesity	NOUN
dpc-4194	349	9	.	.	PUNCT
dpc-4194	350	1	dermatology	dermatology	NOUN
dpc-4194	350	2	.	.	PUNCT
dpc-4194	351	1	2016	2016	NUM
dpc-4194	351	2	;	;	PUNCT
dpc-4194	351	3	232(6):633	232(6):633	NUM
dpc-4194	351	4	-	-	SYM
dpc-4194	351	5	639	639	NUM
dpc-4194	351	6	.	.	PUNCT
dpc-4194	352	1	doi	doi	NOUN
dpc-4194	352	2	:	:	PUNCT
dpc-4194	352	3	10.1159/000455840	10.1159/000455840	NUM
dpc-4194	352	4	.	.	PUNCT
dpc-4194	353	1	pmid	pmid	NOUN
dpc-4194	353	2	:	:	PUNCT
dpc-4194	353	3	28226326	28226326	NUM
dpc-4194	353	4	.	.	PUNCT
dpc-4194	354	1	39	39	NUM
dpc-4194	354	2	.	.	PUNCT
dpc-4194	355	1	kaushik	kaushik	PROPN
dpc-4194	355	2	sb	sb	PROPN
dpc-4194	355	3	,	,	PUNCT
dpc-4194	355	4	lebwohl	lebwohl	VERB
dpc-4194	355	5	mg	mg	PROPN
dpc-4194	355	6	.	.	PUNCT
dpc-4194	356	1	psoriasis	psoriasis	NOUN
dpc-4194	356	2	:	:	PUNCT
dpc-4194	356	3	which	which	DET
dpc-4194	356	4	therapy	therapy	NOUN
dpc-4194	356	5	for	for	ADP
dpc-4194	356	6	which	which	PRON
dpc-4194	356	7	patient	patient	NOUN
dpc-4194	356	8	:	:	PUNCT
dpc-4194	356	9	psoriasis	psoriasis	NOUN
dpc-4194	356	10	comorbidities	comorbiditie	NOUN
dpc-4194	356	11	and	and	CCONJ
dpc-4194	356	12	preferred	preferred	ADJ
dpc-4194	356	13	systemic	systemic	ADJ
dpc-4194	356	14	agents	agent	NOUN
dpc-4194	356	15	.	.	PUNCT
dpc-4194	357	1	j	j	PROPN
dpc-4194	357	2	am	be	AUX
dpc-4194	357	3	acad	acad	ADJ
dpc-4194	357	4	dermatol	dermatol	NOUN
dpc-4194	357	5	.	.	PUNCT
dpc-4194	358	1	2019;80(1):27	2019;80(1):27	NUM
dpc-4194	358	2	-	-	SYM
dpc-4194	358	3	40	40	NUM
dpc-4194	358	4	.	.	PUNCT
dpc-4194	359	1	doi	doi	NOUN
dpc-4194	359	2	:	:	PUNCT
dpc-4194	359	3	10.1016	10.1016	NUM
dpc-4194	359	4	/	/	SYM
dpc-4194	359	5	j.jaad	j.jaad	ADJ
dpc-4194	359	6	.2018.06.057	.2018.06.057	PROPN
dpc-4194	359	7	.	.	PUNCT
dpc-4194	360	1	pmid	pmid	NOUN
dpc-4194	360	2	:	:	PUNCT
dpc-4194	360	3	30017705	30017705	NUM
dpc-4194	360	4	.	.	PUNCT
dpc-4194	361	1	40	40	NUM
dpc-4194	361	2	.	.	PUNCT
dpc-4194	362	1	polo	polo	PROPN
dpc-4194	362	2	tcf	tcf	PROPN
dpc-4194	362	3	,	,	PUNCT
dpc-4194	362	4	corrente	corrente	PROPN
dpc-4194	362	5	je	je	PROPN
dpc-4194	362	6	,	,	PUNCT
dpc-4194	362	7	miot	miot	PROPN
dpc-4194	362	8	ldb	ldb	PROPN
dpc-4194	362	9	,	,	PUNCT
dpc-4194	362	10	papini	papini	PROPN
dpc-4194	362	11	sj	sj	PROPN
dpc-4194	362	12	,	,	PUNCT
dpc-4194	362	13	miot	miot	NOUN
dpc-4194	362	14	ha	ha	INTJ
dpc-4194	362	15	.	.	PUNCT
dpc-4194	362	16	dietary	dietary	ADJ
dpc-4194	362	17	patterns	pattern	NOUN
dpc-4194	362	18	of	of	ADP
dpc-4194	362	19	patients	patient	NOUN
dpc-4194	362	20	with	with	ADP
dpc-4194	362	21	psoriasis	psoriasis	NOUN
dpc-4194	362	22	at	at	ADP
dpc-4194	362	23	a	a	DET
dpc-4194	362	24	public	public	ADJ
dpc-4194	362	25	healthcare	healthcare	NOUN
dpc-4194	362	26	institution	institution	NOUN
dpc-4194	362	27	in	in	ADP
dpc-4194	362	28	brazil	brazil	PROPN
dpc-4194	362	29	.	.	PUNCT
dpc-4194	363	1	an	an	DET
dpc-4194	363	2	bras	bras	NOUN
dpc-4194	363	3	dermatol	dermatol	NOUN
dpc-4194	363	4	.	.	PUNCT
dpc-4194	364	1	2020;95(4):452	2020;95(4):452	NOUN
dpc-4194	364	2	-	-	SYM
dpc-4194	364	3	458	458	NUM
dpc-4194	364	4	.	.	PUNCT
dpc-4194	365	1	doi	doi	NOUN
dpc-4194	365	2	:	:	PUNCT
dpc-4194	365	3	10.1016	10.1016	NUM
dpc-4194	365	4	/	/	SYM
dpc-4194	365	5	j	j	PROPN
dpc-4194	365	6	.abd.2020.02.002	.abd.2020.02.002	PUNCT
dpc-4194	365	7	.	.	PUNCT
dpc-4194	366	1	pmid	pmid	NOUN
dpc-4194	366	2	:	:	PUNCT
dpc-4194	366	3	32471756	32471756	NUM
dpc-4194	366	4	.	.	PUNCT
dpc-4194	367	1	pmcid	pmcid	NOUN
dpc-4194	367	2	:	:	PUNCT
dpc-4194	367	3	pmc7335888	pmc7335888	NOUN
dpc-4194	367	4	.	.	PUNCT
dpc-4194	368	1	41	41	NUM
dpc-4194	368	2	.	.	PUNCT
dpc-4194	369	1	paroutoglou	paroutoglou	PROPN
dpc-4194	369	2	k	k	PROPN
dpc-4194	369	3	,	,	PUNCT
dpc-4194	369	4	papadavid	papadavid	NOUN
dpc-4194	369	5	e	e	NOUN
dpc-4194	369	6	,	,	PUNCT
dpc-4194	369	7	christodoulatos	christodoulatos	PROPN
dpc-4194	369	8	gs	gs	NOUN
dpc-4194	369	9	,	,	PUNCT
dpc-4194	369	10	dalamaga	dalamaga	NOUN
dpc-4194	369	11	m.	m.	NOUN
dpc-4194	369	12	deciphering	decipher	VERB
dpc-4194	369	13	the	the	DET
dpc-4194	369	14	association	association	NOUN
dpc-4194	369	15	between	between	ADP
dpc-4194	369	16	psoriasis	psoriasis	NOUN
dpc-4194	369	17	and	and	CCONJ
dpc-4194	369	18	obesity	obesity	NOUN
dpc-4194	369	19	:	:	PUNCT
dpc-4194	369	20	current	current	ADJ
dpc-4194	369	21	evidence	evidence	NOUN
dpc-4194	369	22	and	and	CCONJ
dpc-4194	369	23	treatment	treatment	NOUN
dpc-4194	369	24	considerations	consideration	NOUN
dpc-4194	369	25	.	.	PUNCT
dpc-4194	370	1	curr	curr	PROPN
dpc-4194	370	2	obes	obes	PROPN
dpc-4194	370	3	rep	rep	PROPN
dpc-4194	370	4	.	.	PROPN
dpc-4194	370	5	2020;9(3):165	2020;9(3):165	PROPN
dpc-4194	370	6	-	-	PUNCT
dpc-4194	370	7	178	178	NUM
dpc-4194	370	8	.	.	PUNCT
dpc-4194	371	1	doi	doi	NOUN
dpc-4194	371	2	:	:	PUNCT
dpc-4194	371	3	10.1007	10.1007	NUM
dpc-4194	371	4	/	/	SYM
dpc-4194	371	5	s13679	s13679	NOUN
dpc-4194	371	6	-	-	PUNCT
dpc-4194	371	7	020	020	NUM
dpc-4194	371	8	-	-	PUNCT
dpc-4194	371	9	00380	00380	NUM
dpc-4194	371	10	-	-	PUNCT
dpc-4194	371	11	3	3	NUM
dpc-4194	371	12	.	.	PUNCT
dpc-4194	372	1	pmid	pmid	NOUN
dpc-4194	372	2	:	:	PUNCT
dpc-4194	372	3	32418186	32418186	NUM
dpc-4194	372	4	.	.	PUNCT
dpc-4194	373	1	42	42	NUM
dpc-4194	373	2	.	.	PUNCT
dpc-4194	374	1	zafiriou	zafiriou	NOUN
dpc-4194	374	2	e	e	NOUN
dpc-4194	374	3	,	,	PUNCT
dpc-4194	374	4	daponte	daponte	PROPN
dpc-4194	374	5	ai	ai	PROPN
dpc-4194	374	6	,	,	PUNCT
dpc-4194	374	7	siokas	siokas	ADJ
dpc-4194	374	8	v	v	NOUN
dpc-4194	374	9	,	,	PUNCT
dpc-4194	374	10	tsigalou	tsigalou	ADP
dpc-4194	374	11	c	c	PROPN
dpc-4194	374	12	,	,	PUNCT
dpc-4194	374	13	dardiotis	dardiotis	PROPN
dpc-4194	374	14	e	e	PROPN
dpc-4194	374	15	,	,	PUNCT
dpc-4194	374	16	bogdanos	bogdanos	PROPN
dpc-4194	374	17	dp	dp	PROPN
dpc-4194	374	18	.	.	PUNCT
dpc-4194	374	19	depression	depression	NOUN
dpc-4194	374	20	and	and	CCONJ
dpc-4194	374	21	obesity	obesity	NOUN
dpc-4194	374	22	in	in	ADP
dpc-4194	374	23	patients	patient	NOUN
dpc-4194	374	24	with	with	ADP
dpc-4194	374	25	psoriasis	psoriasis	NOUN
dpc-4194	374	26	and	and	CCONJ
dpc-4194	374	27	psoriatic	psoriatic	ADJ
dpc-4194	374	28	arthritis	arthritis	NOUN
dpc-4194	374	29	:	:	PUNCT
dpc-4194	374	30	is	be	AUX
dpc-4194	374	31	il-17	il-17	ADV
dpc-4194	374	32	-	-	PUNCT
dpc-4194	374	33	mediated	mediate	VERB
dpc-4194	374	34	immune	immune	ADJ
dpc-4194	374	35	dysregulation	dysregulation	NOUN
dpc-4194	374	36	the	the	DET
dpc-4194	374	37	connecting	connect	VERB
dpc-4194	374	38	link	link	NOUN
dpc-4194	374	39	?	?	PUNCT
dpc-4194	375	1	front	front	ADJ
dpc-4194	375	2	immunol	immunol	NOUN
dpc-4194	375	3	.	.	PUNCT
dpc-4194	376	1	2021;12:699848	2021;12:699848	X
dpc-4194	376	2	.	.	PUNCT
dpc-4194	376	3	doi	doi	NOUN
dpc-4194	376	4	:	:	PUNCT
dpc-4194	376	5	10.3389	10.3389	NUM
dpc-4194	376	6	/	/	SYM
dpc-4194	376	7	fimmu.2021.699848	fimmu.2021.699848	NOUN
dpc-4194	376	8	.	.	PUNCT
dpc-4194	377	1	pmid	pmid	NOUN
dpc-4194	377	2	:	:	PUNCT
dpc-4194	377	3	34367160	34367160	NUM
dpc-4194	377	4	.	.	PUNCT
dpc-4194	378	1	pmcid	pmcid	ADJ
dpc-4194	378	2	:	:	PUNCT
dpc-4194	378	3	pmc8334867	pmc8334867	NOUN
dpc-4194	378	4	.	.	PUNCT
dpc-4194	379	1	43	43	NUM
dpc-4194	379	2	.	.	PUNCT
dpc-4194	380	1	blair	blair	PROPN
dpc-4194	380	2	ha	ha	PROPN
dpc-4194	380	3	.	.	PROPN
dpc-4194	380	4	brodalumab	brodalumab	PROPN
dpc-4194	380	5	:	:	PUNCT
dpc-4194	380	6	a	a	DET
dpc-4194	380	7	review	review	NOUN
dpc-4194	380	8	in	in	ADP
dpc-4194	380	9	moderate	moderate	ADJ
dpc-4194	380	10	to	to	ADP
dpc-4194	380	11	severe	severe	ADJ
dpc-4194	380	12	plaque	plaque	NOUN
dpc-4194	380	13	psoriasis	psoriasis	NOUN
dpc-4194	380	14	.	.	PUNCT
dpc-4194	381	1	drugs	drug	NOUN
dpc-4194	381	2	.	.	PUNCT
dpc-4194	382	1	2018;78(4):495	2018;78(4):495	NUM
dpc-4194	382	2	-	-	PUNCT
dpc-4194	382	3	504	504	NUM
dpc-4194	382	4	.	.	PUNCT
dpc-4194	383	1	doi	doi	NOUN
dpc-4194	383	2	:	:	PUNCT
dpc-4194	383	3	10.1007	10.1007	NUM
dpc-4194	383	4	/	/	SYM
dpc-4194	383	5	s40265	s40265	NOUN
dpc-4194	383	6	-018	-018	NOUN
dpc-4194	383	7	-	-	PUNCT
dpc-4194	383	8	0888	0888	NUM
dpc-4194	383	9	-	-	SYM
dpc-4194	383	10	4	4	NUM
dpc-4194	383	11	.	.	PUNCT
dpc-4194	384	1	pmid	pmid	NOUN
dpc-4194	384	2	:	:	PUNCT
dpc-4194	384	3	29516365	29516365	NUM
dpc-4194	384	4	.	.	X
dpc-4194	385	1	44	44	NUM
dpc-4194	385	2	.	.	PUNCT
dpc-4194	385	3	meeuwis	meeuwis	PROPN
dpc-4194	385	4	ka	ka	PROPN
dpc-4194	385	5	,	,	PUNCT
dpc-4194	385	6	de	de	X
dpc-4194	385	7	hullu	hullu	PROPN
dpc-4194	385	8	ja	ja	PROPN
dpc-4194	385	9	,	,	PUNCT
dpc-4194	385	10	massuger	massuger	PROPN
dpc-4194	385	11	lf	lf	PROPN
dpc-4194	385	12	,	,	PUNCT
dpc-4194	385	13	van	van	PROPN
dpc-4194	385	14	de	de	X
dpc-4194	385	15	kerkhof	kerkhof	PROPN
dpc-4194	385	16	pc	pc	NOUN
dpc-4194	385	17	,	,	PUNCT
dpc-4194	385	18	van	van	PROPN
dpc-4194	385	19	rossum	rossum	PROPN
dpc-4194	385	20	mm	mm	PROPN
dpc-4194	385	21	.	.	PUNCT
dpc-4194	385	22	genital	genital	ADJ
dpc-4194	385	23	psoriasis	psoriasis	NOUN
dpc-4194	385	24	:	:	PUNCT
dpc-4194	385	25	a	a	DET
dpc-4194	385	26	systematic	systematic	ADJ
dpc-4194	385	27	literature	literature	NOUN
dpc-4194	385	28	review	review	NOUN
dpc-4194	385	29	on	on	ADP
dpc-4194	385	30	this	this	DET
dpc-4194	385	31	hidden	hide	VERB
dpc-4194	385	32	skin	skin	NOUN
dpc-4194	385	33	disease	disease	NOUN
dpc-4194	385	34	.	.	PUNCT
dpc-4194	386	1	acta	acta	PROPN
dpc-4194	386	2	derm	derm	PROPN
dpc-4194	386	3	venereol	venereol	NOUN
dpc-4194	386	4	.	.	PUNCT
dpc-4194	387	1	2011;91(1):5	2011;91(1):5	NUM
dpc-4194	387	2	-	-	SYM
dpc-4194	387	3	11	11	NUM
dpc-4194	387	4	.	.	PUNCT
dpc-4194	388	1	doi	doi	NOUN
dpc-4194	388	2	:	:	PUNCT
dpc-4194	388	3	10.2340/00015555	10.2340/00015555	NUM
dpc-4194	388	4	-	-	SYM
dpc-4194	388	5	0988	0988	NUM
dpc-4194	388	6	.	.	PUNCT
dpc-4194	389	1	pmid	pmid	NOUN
dpc-4194	389	2	:	:	PUNCT
dpc-4194	389	3	20927490	20927490	NUM
dpc-4194	389	4	.	.	PUNCT
dpc-4194	390	1	45	45	NUM
dpc-4194	390	2	.	.	PUNCT
dpc-4194	391	1	cortese	cortese	PROPN
dpc-4194	391	2	a	a	PRON
dpc-4194	391	3	,	,	PUNCT
dpc-4194	391	4	gargiulo	gargiulo	ADJ
dpc-4194	391	5	l	l	NOUN
dpc-4194	391	6	,	,	PUNCT
dpc-4194	391	7	ibba	ibba	ADJ
dpc-4194	391	8	l	l	NOUN
dpc-4194	391	9	,	,	PUNCT
dpc-4194	391	10	et	et	PROPN
dpc-4194	391	11	al	al	PROPN
dpc-4194	391	12	.	.	PUNCT
dpc-4194	392	1	anti	anti	PROPN
dpc-4194	392	2	-	-	ADJ
dpc-4194	392	3	interleukin-17	interleukin-17	ADJ
dpc-4194	392	4	and	and	CCONJ
dpc-4194	392	5	anti	anti	ADJ
dpc-4194	392	6	-	-	ADJ
dpc-4194	392	7	interleukin-23	interleukin-23	ADJ
dpc-4194	392	8	biologic	biologic	NOUN
dpc-4194	392	9	drugs	drug	NOUN
dpc-4194	392	10	for	for	ADP
dpc-4194	392	11	genital	genital	ADJ
dpc-4194	392	12	psoriasis	psoriasis	NOUN
dpc-4194	392	13	:	:	PUNCT
dpc-4194	392	14	a	a	DET
dpc-4194	392	15	single	single	ADJ
dpc-4194	392	16	center	center	NOUN
dpc-4194	392	17	retrospective	retrospective	ADJ
dpc-4194	392	18	comparative	comparative	ADJ
dpc-4194	392	19	study	study	NOUN
dpc-4194	392	20	.	.	PUNCT
dpc-4194	393	1	dermatol	dermatol	NOUN
dpc-4194	393	2	reports	report	NOUN
dpc-4194	393	3	.	.	PUNCT
dpc-4194	394	1	2023	2023	NUM
dpc-4194	394	2	;	;	PUNCT
dpc-4194	394	3	15(3):9692	15(3):9692	NUM
dpc-4194	394	4	.	.	PUNCT
dpc-4194	394	5	doi	doi	NOUN
dpc-4194	394	6	:	:	PUNCT
dpc-4194	394	7	10.4081	10.4081	NUM
dpc-4194	394	8	/	/	SYM
dpc-4194	394	9	dr.2023.9692	dr.2023.9692	NOUN
dpc-4194	394	10	.	.	PUNCT
dpc-4194	395	1	pmid	pmid	NOUN
dpc-4194	395	2	:	:	PUNCT
dpc-4194	395	3	37790655	37790655	NUM
dpc-4194	395	4	.	.	PUNCT
dpc-4194	396	1	pmcid	pmcid	NOUN
dpc-4194	396	2	:	:	PUNCT
dpc-4194	396	3	pmc10543193	pmc10543193	NOUN
dpc-4194	396	4	.	.	PUNCT
dpc-4194	397	1	46	46	NUM
dpc-4194	397	2	.	.	PUNCT
dpc-4194	397	3	trovato	trovato	PROPN
dpc-4194	397	4	e	e	PROPN
dpc-4194	397	5	,	,	PUNCT
dpc-4194	397	6	cortonesi	cortonesi	VERB
dpc-4194	397	7	g	g	PROPN
dpc-4194	397	8	,	,	PUNCT
dpc-4194	397	9	orsini	orsini	PROPN
dpc-4194	397	10	c	c	PROPN
dpc-4194	397	11	,	,	PUNCT
dpc-4194	397	12	et	et	PROPN
dpc-4194	397	13	al	al	PROPN
dpc-4194	397	14	.	.	PUNCT
dpc-4194	398	1	anti	anti	ADJ
dpc-4194	398	2	-	-	ADJ
dpc-4194	398	3	il23for	il23for	ADV
dpc-4194	398	4	nail	nail	NOUN
dpc-4194	398	5	psoriasis	psoriasis	NOUN
dpc-4194	398	6	in	in	ADP
dpc-4194	398	7	real	real	ADJ
dpc-4194	398	8	life	life	NOUN
dpc-4194	398	9	:	:	PUNCT
dpc-4194	398	10	results	result	NOUN
dpc-4194	398	11	of	of	ADP
dpc-4194	398	12	efficacy	efficacy	NOUN
dpc-4194	398	13	and	and	CCONJ
dpc-4194	398	14	safety	safety	NOUN
dpc-4194	398	15	during	during	ADP
dpc-4194	398	16	a	a	DET
dpc-4194	398	17	52	52	NUM
dpc-4194	398	18	-	-	PUNCT
dpc-4194	398	19	week	week	NOUN
dpc-4194	398	20	period	period	NOUN
dpc-4194	398	21	.	.	PUNCT
dpc-4194	399	1	dermatol	dermatol	NOUN
dpc-4194	399	2	ther	ther	ADV
dpc-4194	399	3	.	.	PUNCT
dpc-4194	400	1	2022;35(7):e15506	2022;35(7):e15506	NUM
dpc-4194	400	2	.	.	PUNCT
dpc-4194	401	1	doi	doi	NOUN
dpc-4194	401	2	:	:	PUNCT
dpc-4194	401	3	10.1111	10.1111	NUM
dpc-4194	401	4	/	/	SYM
dpc-4194	401	5	dth	dth	ADJ
dpc-4194	401	6	.15506	.15506	NOUN
dpc-4194	401	7	.	.	PUNCT
dpc-4194	402	1	pmid	pmid	NOUN
dpc-4194	402	2	:	:	PUNCT
dpc-4194	402	3	35411578	35411578	NUM
dpc-4194	402	4	.	.	PUNCT
dpc-4194	403	1	journal	journal	NOUN
dpc-4194	403	2	of	of	ADP
dpc-4194	403	3	the	the	DET
dpc-4194	403	4	american	american	PROPN
dpc-4194	403	5	academy	academy	PROPN
dpc-4194	403	6	of	of	ADP
dpc-4194	403	7	dermatology	dermatology	NOUN
dpc-4194	403	8	.	.	PUNCT
dpc-4194	404	1	2022;87(3	2022;87(3	NUM
dpc-4194	404	2	)	)	PUNCT
dpc-4194	404	3	ab69	ab69	PROPN
dpc-4194	404	4	.	.	PUNCT
dpc-4194	405	1	doi	doi	NOUN
dpc-4194	405	2	:	:	PUNCT
dpc-4194	405	3	10.1016	10.1016	NUM
dpc-4194	405	4	/	/	SYM
dpc-4194	405	5	j.jaad.2022.06.309	j.jaad.2022.06.309	PROPN
dpc-4194	405	6	.	.	PROPN
dpc-4194	406	1	19	19	NUM
dpc-4194	406	2	.	.	PUNCT
dpc-4194	407	1	kolbinger	kolbinger	PROPN
dpc-4194	407	2	f	f	PROPN
dpc-4194	407	3	,	,	PUNCT
dpc-4194	407	4	loesche	loesche	NOUN
dpc-4194	407	5	c	c	X
dpc-4194	407	6	,	,	PUNCT
dpc-4194	407	7	valentin	valentin	PROPN
dpc-4194	407	8	ma	ma	PROPN
dpc-4194	407	9	,	,	PUNCT
dpc-4194	407	10	et	et	PROPN
dpc-4194	407	11	al	al	PROPN
dpc-4194	407	12	.	.	PUNCT
dpc-4194	408	1	β	β	X
dpc-4194	408	2	-	-	PUNCT
dpc-4194	408	3	defensin	defensin	ADJ
dpc-4194	408	4	2	2	NUM
dpc-4194	408	5	is	be	AUX
dpc-4194	408	6	a	a	DET
dpc-4194	408	7	responsive	responsive	ADJ
dpc-4194	408	8	biomarker	biomarker	NOUN
dpc-4194	408	9	of	of	ADP
dpc-4194	408	10	il-17a	il-17a	PROPN
dpc-4194	408	11	-	-	PUNCT
dpc-4194	408	12	driven	drive	VERB
dpc-4194	408	13	skin	skin	NOUN
dpc-4194	408	14	pathology	pathology	NOUN
dpc-4194	408	15	in	in	ADP
dpc-4194	408	16	patients	patient	NOUN
dpc-4194	408	17	with	with	ADP
dpc-4194	408	18	psoriasis	psoriasis	NOUN
dpc-4194	408	19	.	.	PUNCT
dpc-4194	409	1	j	j	PROPN
dpc-4194	409	2	allergy	allergy	PROPN
dpc-4194	409	3	clin	clin	PROPN
dpc-4194	409	4	immunol	immunol	PROPN
dpc-4194	409	5	.	.	PUNCT
dpc-4194	410	1	2017;139(3):923	2017;139(3):923	NUM
dpc-4194	410	2	-	-	PUNCT
dpc-4194	410	3	932.e8	932.e8	NOUN
dpc-4194	410	4	.	.	PUNCT
dpc-4194	410	5	doi	doi	NOUN
dpc-4194	410	6	:	:	PUNCT
dpc-4194	410	7	10.1016	10.1016	NUM
dpc-4194	410	8	/	/	SYM
dpc-4194	410	9	j.jaci.2016.06.038	j.jaci.2016.06.038	PROPN
dpc-4194	410	10	.	.	PUNCT
dpc-4194	411	1	pmid	pmid	NOUN
dpc-4194	411	2	:	:	PUNCT
dpc-4194	411	3	27502297	27502297	NUM
dpc-4194	411	4	.	.	PUNCT
dpc-4194	412	1	20	20	NUM
dpc-4194	412	2	.	.	PUNCT
dpc-4194	413	1	warren	warren	PROPN
dpc-4194	413	2	rb	rb	PROPN
dpc-4194	413	3	,	,	PUNCT
dpc-4194	413	4	blauvelt	blauvelt	VERB
dpc-4194	413	5	a	a	DET
dpc-4194	413	6	,	,	PUNCT
dpc-4194	413	7	bagel	bagel	NOUN
dpc-4194	413	8	j	j	PROPN
dpc-4194	413	9	,	,	PUNCT
dpc-4194	413	10	et	et	PROPN
dpc-4194	413	11	al	al	PROPN
dpc-4194	413	12	.	.	PROPN
dpc-4194	413	13	bimekizumab	bimekizumab	PROPN
dpc-4194	413	14	versus	versus	ADP
dpc-4194	413	15	adalimumab	adalimumab	NOUN
dpc-4194	413	16	in	in	ADP
dpc-4194	413	17	plaque	plaque	NOUN
dpc-4194	413	18	psoriasis	psoriasis	NOUN
dpc-4194	413	19	.	.	PUNCT
dpc-4194	414	1	n	n	PROPN
dpc-4194	414	2	engl	engl	PROPN
dpc-4194	414	3	j	j	PROPN
dpc-4194	414	4	med	med	PROPN
dpc-4194	414	5	.	.	PUNCT
dpc-4194	415	1	2021;385(2	2021;385(2	NUM
dpc-4194	415	2	):	):	PUNCT
dpc-4194	415	3	130	130	NUM
dpc-4194	415	4	-	-	SYM
dpc-4194	415	5	141	141	NUM
dpc-4194	415	6	.	.	PUNCT
dpc-4194	416	1	doi	doi	NOUN
dpc-4194	416	2	:	:	PUNCT
dpc-4194	416	3	10.1056	10.1056	NUM
dpc-4194	416	4	/	/	SYM
dpc-4194	416	5	nejmoa2102388	nejmoa2102388	PROPN
dpc-4194	416	6	.	.	PUNCT
dpc-4194	417	1	pmid	pmid	NOUN
dpc-4194	417	2	:	:	PUNCT
dpc-4194	417	3	33891379	33891379	NUM
dpc-4194	417	4	.	.	PUNCT
dpc-4194	418	1	21	21	NUM
dpc-4194	418	2	.	.	PUNCT
dpc-4194	419	1	gordon	gordon	PROPN
dpc-4194	419	2	kb	kb	PROPN
dpc-4194	419	3	,	,	PUNCT
dpc-4194	419	4	foley	foley	PROPN
dpc-4194	419	5	p	p	PROPN
dpc-4194	419	6	,	,	PUNCT
dpc-4194	419	7	krueger	krueger	PROPN
dpc-4194	419	8	jg	jg	PROPN
dpc-4194	419	9	,	,	PUNCT
dpc-4194	419	10	et	et	PROPN
dpc-4194	419	11	al	al	PROPN
dpc-4194	419	12	.	.	PROPN
dpc-4194	419	13	bimekizumab	bimekizumab	PROPN
dpc-4194	419	14	efficacy	efficacy	PROPN
dpc-4194	419	15	and	and	CCONJ
dpc-4194	419	16	safety	safety	NOUN
dpc-4194	419	17	in	in	ADP
dpc-4194	419	18	moderate	moderate	ADJ
dpc-4194	419	19	to	to	ADP
dpc-4194	419	20	severe	severe	ADJ
dpc-4194	419	21	plaque	plaque	NOUN
dpc-4194	419	22	psoriasis	psoriasis	NOUN
dpc-4194	419	23	(	(	PUNCT
dpc-4194	419	24	be	be	AUX
dpc-4194	419	25	ready	ready	ADJ
dpc-4194	419	26	):	):	PUNCT
dpc-4194	419	27	a	a	DET
dpc-4194	419	28	multicentre	multicentre	NOUN
dpc-4194	419	29	,	,	PUNCT
dpc-4194	419	30	double	double	ADJ
dpc-4194	419	31	-	-	PUNCT
dpc-4194	419	32	blind	blind	ADJ
dpc-4194	419	33	,	,	PUNCT
dpc-4194	419	34	placebo	placebo	NOUN
dpc-4194	419	35	-	-	PUNCT
dpc-4194	419	36	controlled	control	VERB
dpc-4194	419	37	,	,	PUNCT
dpc-4194	419	38	randomised	randomise	VERB
dpc-4194	419	39	withdrawal	withdrawal	NOUN
dpc-4194	419	40	phase	phase	NOUN
dpc-4194	419	41	3	3	NUM
dpc-4194	419	42	trial	trial	NOUN
dpc-4194	419	43	.	.	PUNCT
dpc-4194	420	1	lancet	lancet	NOUN
dpc-4194	420	2	.	.	PUNCT
dpc-4194	421	1	2021;397(10273):475	2021;397(10273):475	NUM
dpc-4194	421	2	-	-	SYM
dpc-4194	421	3	486	486	NUM
dpc-4194	421	4	.	.	PUNCT
dpc-4194	422	1	doi	doi	NOUN
dpc-4194	422	2	:	:	PUNCT
dpc-4194	422	3	10.1016	10.1016	NUM
dpc-4194	422	4	/	/	SYM
dpc-4194	422	5	s0140	s0140	PROPN
dpc-4194	422	6	-	-	PUNCT
dpc-4194	422	7	6736(21)00126	6736(21)00126	NUM
dpc-4194	422	8	-	-	PUNCT
dpc-4194	422	9	4	4	NUM
dpc-4194	422	10	.	.	PUNCT
dpc-4194	423	1	pmid	pmid	NOUN
dpc-4194	423	2	:	:	PUNCT
dpc-4194	423	3	33549192	33549192	NUM
dpc-4194	423	4	.	.	PUNCT
dpc-4194	424	1	22	22	NUM
dpc-4194	424	2	.	.	PUNCT
dpc-4194	425	1	reich	reich	PROPN
dpc-4194	425	2	k	k	PROPN
dpc-4194	425	3	,	,	PUNCT
dpc-4194	425	4	papp	papp	PROPN
dpc-4194	425	5	ka	ka	PROPN
dpc-4194	425	6	,	,	PUNCT
dpc-4194	425	7	blauvelt	blauvelt	VERB
dpc-4194	425	8	a	a	PRON
dpc-4194	425	9	,	,	PUNCT
dpc-4194	425	10	et	et	PROPN
dpc-4194	425	11	al	al	PROPN
dpc-4194	425	12	.	.	PROPN
dpc-4194	425	13	bimekizumab	bimekizumab	PROPN
dpc-4194	425	14	versus	versus	ADP
dpc-4194	425	15	ustekinumab	ustekinumab	NOUN
dpc-4194	425	16	for	for	ADP
dpc-4194	425	17	the	the	DET
dpc-4194	425	18	treatment	treatment	NOUN
dpc-4194	425	19	of	of	ADP
dpc-4194	425	20	moderate	moderate	ADJ
dpc-4194	425	21	to	to	ADP
dpc-4194	425	22	severe	severe	ADJ
dpc-4194	425	23	plaque	plaque	NOUN
dpc-4194	425	24	psoriasis	psoriasis	NOUN
dpc-4194	425	25	(	(	PUNCT
dpc-4194	425	26	be	be	AUX
dpc-4194	425	27	vivid	vivid	ADJ
dpc-4194	425	28	):	):	PUNCT
dpc-4194	425	29	efficacy	efficacy	NOUN
dpc-4194	425	30	and	and	CCONJ
dpc-4194	425	31	safety	safety	NOUN
dpc-4194	425	32	from	from	ADP
dpc-4194	425	33	a	a	DET
dpc-4194	425	34	52	52	NUM
dpc-4194	425	35	-	-	PUNCT
dpc-4194	425	36	week	week	NOUN
dpc-4194	425	37	,	,	PUNCT
dpc-4194	425	38	multicentre	multicentre	NOUN
dpc-4194	425	39	,	,	PUNCT
dpc-4194	425	40	double	double	ADJ
dpc-4194	425	41	-	-	PUNCT
dpc-4194	425	42	blind	blind	ADJ
dpc-4194	425	43	,	,	PUNCT
dpc-4194	425	44	active	active	ADJ
dpc-4194	425	45	comparator	comparator	NOUN
dpc-4194	425	46	and	and	CCONJ
dpc-4194	425	47	placebo	placebo	NOUN
dpc-4194	425	48	controlled	control	VERB
dpc-4194	425	49	phase	phase	NOUN
dpc-4194	425	50	3	3	NUM
dpc-4194	425	51	trial	trial	NOUN
dpc-4194	425	52	.	.	PUNCT
dpc-4194	426	1	lancet	lancet	NOUN
dpc-4194	426	2	.	.	PUNCT
dpc-4194	427	1	2021;397(10273):487	2021;397(10273):487	NUM
dpc-4194	427	2	-	-	SYM
dpc-4194	427	3	498	498	NUM
dpc-4194	427	4	.	.	PUNCT
dpc-4194	428	1	doi	doi	NOUN
dpc-4194	428	2	:	:	PUNCT
dpc-4194	428	3	10.1016	10.1016	NUM
dpc-4194	428	4	/	/	SYM
dpc-4194	428	5	s0140	s0140	PROPN
dpc-4194	428	6	-6736(21)00125	-6736(21)00125	NOUN
dpc-4194	428	7	-	-	PUNCT
dpc-4194	428	8	2	2	NUM
dpc-4194	428	9	.	.	PUNCT
dpc-4194	429	1	pmid	pmid	NOUN
dpc-4194	429	2	:	:	PUNCT
dpc-4194	429	3	33549193	33549193	NUM
dpc-4194	429	4	.	.	PUNCT
dpc-4194	430	1	23	23	NUM
dpc-4194	430	2	.	.	PUNCT
dpc-4194	431	1	reich	reich	PROPN
dpc-4194	431	2	k	k	PROPN
dpc-4194	431	3	,	,	PUNCT
dpc-4194	431	4	warren	warren	PROPN
dpc-4194	431	5	rb	rb	PROPN
dpc-4194	431	6	,	,	PUNCT
dpc-4194	431	7	lebwohl	lebwohl	NOUN
dpc-4194	431	8	m	m	PROPN
dpc-4194	431	9	,	,	PUNCT
dpc-4194	431	10	et	et	PROPN
dpc-4194	431	11	al	al	PROPN
dpc-4194	431	12	.	.	PROPN
dpc-4194	431	13	bimekizumab	bimekizumab	PROPN
dpc-4194	431	14	versus	versus	ADP
dpc-4194	431	15	secukinumab	secukinumab	NOUN
dpc-4194	431	16	in	in	ADP
dpc-4194	431	17	plaque	plaque	NOUN
dpc-4194	431	18	psoriasis	psoriasis	NOUN
dpc-4194	431	19	.	.	PUNCT
dpc-4194	432	1	n	n	PROPN
dpc-4194	432	2	engl	engl	PROPN
dpc-4194	432	3	j	j	PROPN
dpc-4194	432	4	med	med	PROPN
dpc-4194	432	5	.	.	PUNCT
dpc-4194	433	1	2021;385(2	2021;385(2	NUM
dpc-4194	433	2	):	):	PUNCT
dpc-4194	433	3	142	142	NUM
dpc-4194	433	4	-	-	SYM
dpc-4194	433	5	152	152	NUM
dpc-4194	433	6	.	.	PUNCT
dpc-4194	434	1	doi	doi	NOUN
dpc-4194	434	2	:	:	PUNCT
dpc-4194	434	3	10.1056	10.1056	NUM
dpc-4194	434	4	/	/	SYM
dpc-4194	434	5	nejmoa2102383	nejmoa2102383	PROPN
dpc-4194	434	6	.	.	PUNCT
dpc-4194	435	1	pmid	pmid	NOUN
dpc-4194	435	2	:	:	PUNCT
dpc-4194	435	3	33891380	33891380	NUM
dpc-4194	435	4	.	.	PUNCT
dpc-4194	436	1	24	24	NUM
dpc-4194	436	2	.	.	PUNCT
dpc-4194	436	3	megna	megna	PROPN
dpc-4194	436	4	m	m	PROPN
dpc-4194	436	5	,	,	PUNCT
dpc-4194	436	6	battista	battista	PROPN
dpc-4194	436	7	t	t	PROPN
dpc-4194	436	8	,	,	PUNCT
dpc-4194	436	9	potestio	potestio	NOUN
dpc-4194	436	10	l	l	NOUN
dpc-4194	436	11	,	,	PUNCT
dpc-4194	436	12	et	et	PROPN
dpc-4194	436	13	al	al	PROPN
dpc-4194	436	14	.	.	PUNCT
dpc-4194	437	1	a	a	DET
dpc-4194	437	2	case	case	NOUN
dpc-4194	437	3	of	of	ADP
dpc-4194	437	4	erythrodermic	erythrodermic	ADJ
dpc-4194	437	5	psoriasis	psoriasis	NOUN
dpc-4194	437	6	rapidly	rapidly	ADV
dpc-4194	437	7	and	and	CCONJ
dpc-4194	437	8	successfully	successfully	ADV
dpc-4194	437	9	treated	treat	VERB
dpc-4194	437	10	with	with	ADP
dpc-4194	437	11	bimekizumab	bimekizumab	NOUN
dpc-4194	437	12	.	.	PUNCT
dpc-4194	438	1	j	j	PROPN
dpc-4194	438	2	cosmet	cosmet	PROPN
dpc-4194	438	3	dermatol	dermatol	NOUN
dpc-4194	438	4	.	.	PUNCT
dpc-4194	439	1	2023;22(3):1146	2023;22(3):1146	NUM
dpc-4194	439	2	-	-	SYM
dpc-4194	439	3	1148	1148	NUM
dpc-4194	439	4	.	.	PUNCT
dpc-4194	440	1	doi	doi	NOUN
dpc-4194	440	2	:	:	PUNCT
dpc-4194	440	3	10.1111	10.1111	NUM
dpc-4194	440	4	/	/	SYM
dpc-4194	440	5	jocd	jocd	ADJ
dpc-4194	440	6	.15543	.15543	PROPN
dpc-4194	440	7	.	.	PUNCT
dpc-4194	441	1	pmid	pmid	NOUN
dpc-4194	441	2	:	:	PUNCT
dpc-4194	441	3	36448190	36448190	NUM
dpc-4194	441	4	.	.	PUNCT
dpc-4194	442	1	25	25	NUM
dpc-4194	442	2	.	.	PUNCT
dpc-4194	443	1	valenti	valenti	PROPN
dpc-4194	443	2	m	m	PROPN
dpc-4194	443	3	,	,	PUNCT
dpc-4194	443	4	gargiulo	gargiulo	NOUN
dpc-4194	443	5	l	l	NOUN
dpc-4194	443	6	,	,	PUNCT
dpc-4194	443	7	ibba	ibba	ADJ
dpc-4194	443	8	l	l	NOUN
dpc-4194	443	9	,	,	PUNCT
dpc-4194	443	10	pavia	pavia	VERB
dpc-4194	443	11	g	g	NOUN
dpc-4194	443	12	,	,	PUNCT
dpc-4194	443	13	narcisi	narcisi	ADV
dpc-4194	443	14	a	a	PRON
dpc-4194	443	15	,	,	PUNCT
dpc-4194	443	16	costanzo	costanzo	PROPN
dpc-4194	443	17	a.	a.	PROPN
dpc-4194	443	18	sub	sub	PROPN
dpc-4194	443	19	-	-	ADJ
dpc-4194	443	20	erythrodermic	erythrodermic	ADJ
dpc-4194	443	21	psoriasis	psoriasis	NOUN
dpc-4194	443	22	successfully	successfully	ADV
dpc-4194	443	23	treated	treat	VERB
dpc-4194	443	24	with	with	ADP
dpc-4194	443	25	bimekizumab	bimekizumab	NOUN
dpc-4194	443	26	:	:	PUNCT
dpc-4194	443	27	a	a	DET
dpc-4194	443	28	case	case	NOUN
dpc-4194	443	29	report	report	NOUN
dpc-4194	443	30	.	.	PUNCT
dpc-4194	444	1	dermatol	dermatol	NOUN
dpc-4194	444	2	ther	ther	ADV
dpc-4194	444	3	.	.	PUNCT
dpc-4194	445	1	2022;35(12):e15952	2022;35(12):e15952	NOUN
dpc-4194	445	2	.	.	PUNCT
dpc-4194	446	1	doi	doi	NOUN
dpc-4194	446	2	:	:	PUNCT
dpc-4194	446	3	10.1111	10.1111	NUM
dpc-4194	446	4	/	/	SYM
dpc-4194	446	5	dth.15952	dth.15952	NOUN
dpc-4194	446	6	.	.	PUNCT
dpc-4194	447	1	pmid	pmid	NOUN
dpc-4194	447	2	:	:	PUNCT
dpc-4194	447	3	36269298	36269298	NUM
dpc-4194	447	4	.	.	PUNCT
dpc-4194	448	1	pmcid	pmcid	NOUN
dpc-4194	448	2	:	:	PUNCT
dpc-4194	448	3	pmc10078003	pmc10078003	ADJ
dpc-4194	448	4	.	.	PUNCT
dpc-4194	449	1	26	26	NUM
dpc-4194	449	2	.	.	PUNCT
dpc-4194	450	1	gargiulo	gargiulo	PROPN
dpc-4194	450	2	l	l	NOUN
dpc-4194	450	3	,	,	PUNCT
dpc-4194	450	4	narcisi	narcisi	ADV
dpc-4194	450	5	a	a	DET
dpc-4194	450	6	,	,	PUNCT
dpc-4194	450	7	ibba	ibba	ADJ
dpc-4194	450	8	l	l	NOUN
dpc-4194	450	9	,	,	PUNCT
dpc-4194	450	10	et	et	PROPN
dpc-4194	450	11	al	al	PROPN
dpc-4194	450	12	.	.	PROPN
dpc-4194	450	13	effectiveness	effectiveness	NOUN
dpc-4194	450	14	and	and	CCONJ
dpc-4194	450	15	safety	safety	NOUN
dpc-4194	450	16	of	of	ADP
dpc-4194	450	17	bimekizumab	bimekizumab	NOUN
dpc-4194	450	18	for	for	ADP
dpc-4194	450	19	the	the	DET
dpc-4194	450	20	treatment	treatment	NOUN
dpc-4194	450	21	of	of	ADP
dpc-4194	450	22	plaque	plaque	NOUN
dpc-4194	450	23	psoriasis	psoriasis	NOUN
dpc-4194	450	24	:	:	PUNCT
dpc-4194	450	25	a	a	DET
dpc-4194	450	26	real	real	ADJ
dpc-4194	450	27	life	life	NOUN
dpc-4194	450	28	multicenter	multicenter	NOUN
dpc-4194	450	29	study	study	NOUN
dpc-4194	450	30	-	-	PUNCT
dpc-4194	450	31	il	il	PROPN
dpc-4194	450	32	pso	pso	PROPN
dpc-4194	450	33	(	(	PUNCT
dpc-4194	450	34	italian	italian	ADJ
dpc-4194	450	35	landscape	landscape	NOUN
dpc-4194	450	36	psoriasis	psoriasis	NOUN
dpc-4194	450	37	)	)	PUNCT
dpc-4194	450	38	.	.	PUNCT
dpc-4194	451	1	front	front	PROPN
dpc-4194	451	2	med	med	PROPN
dpc-4194	451	3	(	(	PUNCT
dpc-4194	451	4	lausanne	lausanne	PROPN
dpc-4194	451	5	)	)	PUNCT
dpc-4194	451	6	.	.	PUNCT
dpc-4194	452	1	2023;10:1243843	2023;10:1243843	X
dpc-4194	452	2	.	.	PUNCT
dpc-4194	452	3	doi	doi	NOUN
dpc-4194	452	4	:	:	PUNCT
dpc-4194	452	5	10.3389	10.3389	NUM
dpc-4194	452	6	/	/	SYM
dpc-4194	452	7	fmed	fmed	ADJ
dpc-4194	452	8	.2023.1243843	.2023.1243843	PROPN
dpc-4194	452	9	.	.	PUNCT
dpc-4194	453	1	pmid	pmid	NOUN
dpc-4194	453	2	:	:	PUNCT
dpc-4194	453	3	37614958	37614958	NUM
dpc-4194	453	4	.	.	PUNCT
dpc-4194	454	1	pmcid	pmcid	NOUN
dpc-4194	454	2	:	:	PUNCT
dpc-4194	454	3	pmc10442506	pmc10442506	NOUN
dpc-4194	454	4	.	.	PUNCT
dpc-4194	455	1	27	27	NUM
dpc-4194	455	2	.	.	X
dpc-4194	456	1	piaserico	piaserico	PROPN
dpc-4194	456	2	s	s	PART
dpc-4194	456	3	,	,	PUNCT
dpc-4194	456	4	riedl	riedl	PROPN
dpc-4194	456	5	e	e	NOUN
dpc-4194	456	6	,	,	PUNCT
dpc-4194	456	7	pavlovsky	pavlovsky	PROPN
dpc-4194	456	8	l	l	NOUN
dpc-4194	456	9	,	,	PUNCT
dpc-4194	456	10	et	et	PROPN
dpc-4194	456	11	al	al	PROPN
dpc-4194	456	12	.	.	PROPN
dpc-4194	457	1	comparative	comparative	ADJ
dpc-4194	457	2	effectiveness	effectiveness	NOUN
dpc-4194	457	3	of	of	ADP
dpc-4194	457	4	biologics	biologic	NOUN
dpc-4194	457	5	for	for	ADP
dpc-4194	457	6	patients	patient	NOUN
dpc-4194	457	7	with	with	ADP
dpc-4194	457	8	moderate	moderate	ADJ
dpc-4194	457	9	-	-	PUNCT
dpc-4194	457	10	to	to	ADP
dpc-4194	457	11	-	-	PUNCT
dpc-4194	457	12	severe	severe	ADJ
dpc-4194	457	13	psoriasis	psoriasis	NOUN
dpc-4194	457	14	and	and	CCONJ
dpc-4194	457	15	special	special	ADJ
dpc-4194	457	16	area	area	NOUN
dpc-4194	457	17	involvement	involvement	NOUN
dpc-4194	457	18	:	:	PUNCT
dpc-4194	457	19	week	week	NOUN
dpc-4194	457	20	12	12	NUM
dpc-4194	457	21	results	result	NOUN
dpc-4194	457	22	from	from	ADP
dpc-4194	457	23	the	the	DET
dpc-4194	457	24	observational	observational	ADJ
dpc-4194	457	25	psoriasis	psoriasis	NOUN
dpc-4194	457	26	study	study	NOUN
dpc-4194	457	27	of	of	ADP
dpc-4194	457	28	health	health	NOUN
dpc-4194	457	29	outcomes	outcome	NOUN
dpc-4194	457	30	(	(	PUNCT
dpc-4194	457	31	psoho	psoho	NOUN
dpc-4194	457	32	)	)	PUNCT
dpc-4194	457	33	.	.	PUNCT
dpc-4194	458	1	front	front	PROPN
dpc-4194	458	2	med	med	PROPN
dpc-4194	458	3	(	(	PUNCT
dpc-4194	458	4	lausanne	lausanne	PROPN
dpc-4194	458	5	)	)	PUNCT
dpc-4194	458	6	.	.	PUNCT
dpc-4194	459	1	2023;10:1185523	2023;10:1185523	NUM
dpc-4194	459	2	.	.	PUNCT
dpc-4194	459	3	doi	doi	NOUN
dpc-4194	459	4	:	:	PUNCT
dpc-4194	459	5	10.3389	10.3389	NUM
dpc-4194	459	6	/	/	SYM
dpc-4194	459	7	fmed.2023.1185523	fmed.2023.1185523	NOUN
dpc-4194	459	8	.	.	PUNCT
dpc-4194	460	1	pmid	pmid	NOUN
dpc-4194	460	2	:	:	PUNCT
dpc-4194	460	3	37457564	37457564	NUM
dpc-4194	460	4	.	.	PUNCT
dpc-4194	461	1	pmcid	pmcid	NOUN
dpc-4194	461	2	:	:	PUNCT
dpc-4194	461	3	pmc10339811	pmc10339811	PROPN
dpc-4194	461	4	.	.	PUNCT
dpc-4194	462	1	28	28	NUM
dpc-4194	462	2	.	.	PUNCT
dpc-4194	463	1	gisondi	gisondi	PROPN
dpc-4194	463	2	p	p	NOUN
dpc-4194	463	3	,	,	PUNCT
dpc-4194	463	4	fargnoli	fargnoli	PROPN
dpc-4194	463	5	mc	mc	PROPN
dpc-4194	463	6	,	,	PUNCT
dpc-4194	463	7	amerio	amerio	ADP
dpc-4194	463	8	p	p	X
dpc-4194	463	9	,	,	PUNCT
dpc-4194	463	10	et	et	PROPN
dpc-4194	463	11	al	al	PROPN
dpc-4194	463	12	.	.	PUNCT
dpc-4194	464	1	italian	italian	ADJ
dpc-4194	464	2	adaptation	adaptation	NOUN
dpc-4194	464	3	of	of	ADP
dpc-4194	464	4	euroguiderm	euroguiderm	NOUN
dpc-4194	464	5	guideline	guideline	NOUN
dpc-4194	464	6	on	on	ADP
dpc-4194	464	7	the	the	DET
dpc-4194	464	8	systemic	systemic	ADJ
dpc-4194	464	9	treatment	treatment	NOUN
dpc-4194	464	10	of	of	ADP
dpc-4194	464	11	chronic	chronic	ADJ
dpc-4194	464	12	plaque	plaque	NOUN
dpc-4194	464	13	psoriasis	psoriasis	NOUN
dpc-4194	464	14	.	.	PUNCT
dpc-4194	465	1	ital	ital	PROPN
dpc-4194	465	2	j	j	PROPN
dpc-4194	465	3	dermatol	dermatol	PROPN
dpc-4194	465	4	venerol	venerol	PROPN
dpc-4194	465	5	.	.	PUNCT
dpc-4194	466	1	2022;157(suppl	2022;157(suppl	NUM
dpc-4194	466	2	.	.	NOUN
dpc-4194	466	3	1	1	NUM
dpc-4194	466	4	to	to	ADP
dpc-4194	466	5	no	no	NOUN
dpc-4194	466	6	.	.	NOUN
dpc-4194	466	7	1	1	NUM
dpc-4194	466	8	):	):	PUNCT
dpc-4194	466	9	1	1	NUM
dpc-4194	466	10	-	-	SYM
dpc-4194	466	11	78	78	NUM
dpc-4194	466	12	.	.	PUNCT
dpc-4194	467	1	doi	doi	NOUN
dpc-4194	467	2	:	:	PUNCT
dpc-4194	467	3	10.23736	10.23736	NUM
dpc-4194	467	4	/	/	SYM
dpc-4194	467	5	s2784	s2784	PROPN
dpc-4194	467	6	-	-	PUNCT
dpc-4194	467	7	8671.21.07132	8671.21.07132	NUM
dpc-4194	467	8	-	-	SYM
dpc-4194	467	9	2	2	NUM
dpc-4194	467	10	.	.	PUNCT
dpc-4194	468	1	pmid	pmid	NOUN
dpc-4194	468	2	:	:	PUNCT
dpc-4194	468	3	35262308	35262308	NUM
dpc-4194	468	4	.	.	PUNCT
dpc-4194	469	1	29	29	NUM
dpc-4194	469	2	.	.	PUNCT
dpc-4194	470	1	european	european	PROPN
dpc-4194	470	2	medicines	medicine	NOUN
dpc-4194	470	3	agency	agency	NOUN
dpc-4194	470	4	.	.	PUNCT
dpc-4194	471	1	bimzelx	bimzelx	PROPN
dpc-4194	471	2	(	(	PUNCT
dpc-4194	471	3	bimekizumab	bimekizumab	ADV
dpc-4194	471	4	):	):	PUNCT
dpc-4194	471	5	summary	summary	NOUN
dpc-4194	471	6	of	of	ADP
dpc-4194	471	7	product	product	NOUN
dpc-4194	471	8	characteristics	characteristic	NOUN
dpc-4194	471	9	.	.	PUNCT
dpc-4194	472	1	(	(	PUNCT
dpc-4194	472	2	2023	2023	NUM
dpc-4194	472	3	)	)	PUNCT
dpc-4194	472	4	.	.	PUNCT
dpc-4194	473	1	available	available	ADJ
dpc-4194	473	2	fromt	fromt	ADJ
dpc-4194	473	3	:	:	PUNCT
dpc-4194	473	4	https://www	https://www	PROPN
dpc-4194	473	5	.	.	PUNCT
dpc-4194	473	6	ema.europa.eu/en/documents/product-information/bimzelx	ema.europa.eu/en/documents/product-information/bimzelx	PROPN
dpc-4194	473	7	epar-product-information_it.pdf	epar-product-information_it.pdf	PROPN
dpc-4194	473	8	.	.	PUNCT
dpc-4194	474	1	accessed	access	VERB
dpc-4194	474	2	on	on	ADP
dpc-4194	474	3	september	september	PROPN
dpc-4194	474	4	6	6	NUM
dpc-4194	474	5	,	,	PUNCT
dpc-4194	474	6	2023	2023	NUM
dpc-4194	474	7	.	.	PUNCT
dpc-4194	475	1	30	30	NUM
dpc-4194	475	2	.	.	PUNCT
dpc-4194	476	1	orsini	orsini	PROPN
dpc-4194	476	2	d	d	PROPN
dpc-4194	476	3	,	,	PUNCT
dpc-4194	476	4	gargiulo	gargiulo	ADJ
dpc-4194	476	5	l	l	NOUN
dpc-4194	476	6	,	,	PUNCT
dpc-4194	476	7	ibba	ibba	ADJ
dpc-4194	476	8	l	l	NOUN
dpc-4194	476	9	,	,	PUNCT
dpc-4194	476	10	et	et	PROPN
dpc-4194	476	11	al	al	PROPN
dpc-4194	476	12	.	.	PROPN
dpc-4194	476	13	effectiveness	effectiveness	NOUN
dpc-4194	476	14	of	of	ADP
dpc-4194	476	15	risankizumab	risankizumab	NOUN
dpc-4194	476	16	in	in	ADP
dpc-4194	476	17	plaque	plaque	NOUN
dpc-4194	476	18	psoriasis	psoriasis	NOUN
dpc-4194	476	19	with	with	ADP
dpc-4194	476	20	involvement	involvement	NOUN
dpc-4194	476	21	of	of	ADP
dpc-4194	476	22	difficult	difficult	ADJ
dpc-4194	476	23	to	to	PART
dpc-4194	476	24	-	-	PUNCT
dpc-4194	476	25	treat	treat	VERB
dpc-4194	476	26	areas	area	NOUN
dpc-4194	476	27	:	:	PUNCT
dpc-4194	476	28	a	a	DET
dpc-4194	476	29	real	real	ADJ
dpc-4194	476	30	-	-	PUNCT
dpc-4194	476	31	world	world	NOUN
dpc-4194	476	32	experience	experience	NOUN
dpc-4194	476	33	from	from	ADP
dpc-4194	476	34	two	two	NUM
dpc-4194	476	35	referral	referral	ADJ
dpc-4194	476	36	centers	center	NOUN
dpc-4194	476	37	.	.	PUNCT
dpc-4194	477	1	j	j	PROPN
dpc-4194	477	2	dermatolog	dermatolog	PROPN
dpc-4194	477	3	treat	treat	NOUN
dpc-4194	477	4	.	.	PUNCT
dpc-4194	478	1	2023;34(1):2220849	2023;34(1):2220849	X
dpc-4194	478	2	.	.	X
dpc-4194	478	3	doi	doi	NOUN
dpc-4194	478	4	:	:	PUNCT
dpc-4194	478	5	10.1080	10.1080	NUM
dpc-4194	478	6	/09546634.2023.2220849	/09546634.2023.2220849	SYM
dpc-4194	478	7	.	.	PUNCT
dpc-4194	479	1	pmid	pmid	NOUN
dpc-4194	479	2	:	:	PUNCT
dpc-4194	479	3	37288760	37288760	NUM
dpc-4194	479	4	.	.	PUNCT
dpc-4194	480	1	31	31	NUM
dpc-4194	480	2	.	.	PUNCT
dpc-4194	481	1	european	european	PROPN
dpc-4194	481	2	medicines	medicine	NOUN
dpc-4194	481	3	agency	agency	NOUN
dpc-4194	481	4	.	.	PUNCT
dpc-4194	482	1	taltz	taltz	NOUN
dpc-4194	482	2	(	(	PUNCT
dpc-4194	482	3	ixekizumab	ixekizumab	NOUN
dpc-4194	482	4	):	):	PUNCT
dpc-4194	482	5	summary	summary	NOUN
dpc-4194	482	6	of	of	ADP
dpc-4194	482	7	product	product	NOUN
dpc-4194	482	8	characteristics	characteristic	NOUN
dpc-4194	482	9	.	.	PUNCT
dpc-4194	483	1	(	(	PUNCT
dpc-4194	483	2	2023	2023	NUM
dpc-4194	483	3	)	)	PUNCT
dpc-4194	483	4	.	.	PUNCT
dpc-4194	484	1	available	available	ADJ
dpc-4194	484	2	from	from	ADP
dpc-4194	484	3	:	:	PUNCT
dpc-4194	484	4	https://www.ema.europa	https://www.ema.europa	PROPN
dpc-4194	484	5	.eu	.eu	PUNCT
dpc-4194	484	6	/	/	SYM
dpc-4194	484	7	en	en	ADP
dpc-4194	484	8	/	/	SYM
dpc-4194	484	9	medicines	medicine	NOUN
dpc-4194	484	10	/	/	SYM
dpc-4194	484	11	human	human	NOUN
dpc-4194	484	12	/	/	SYM
dpc-4194	484	13	epar	epar	NOUN
dpc-4194	484	14	/	/	SYM
dpc-4194	484	15	taltz	taltz	NOUN
dpc-4194	484	16	.	.	PUNCT
dpc-4194	485	1	accessed	access	VERB
dpc-4194	485	2	on	on	ADP
dpc-4194	485	3	september	september	PROPN
dpc-4194	485	4	20	20	NUM
dpc-4194	485	5	,	,	PUNCT
dpc-4194	485	6	2023	2023	NUM
dpc-4194	485	7	.	.	PUNCT
dpc-4194	486	1	32	32	NUM
dpc-4194	486	2	.	.	PUNCT
dpc-4194	487	1	gargiulo	gargiulo	PROPN
dpc-4194	487	2	l	l	NOUN
dpc-4194	487	3	,	,	PUNCT
dpc-4194	487	4	ibba	ibba	ADJ
dpc-4194	487	5	l	l	NOUN
dpc-4194	487	6	,	,	PUNCT
dpc-4194	487	7	malagoli	malagoli	NOUN
dpc-4194	487	8	p	p	NOUN
dpc-4194	487	9	,	,	PUNCT
dpc-4194	487	10	et	et	PROPN
dpc-4194	487	11	al	al	PROPN
dpc-4194	487	12	.	.	PUNCT
dpc-4194	488	1	a	a	DET
dpc-4194	488	2	risankizumab	risankizumab	NOUN
dpc-4194	488	3	super	super	ADJ
dpc-4194	488	4	responder	responder	NOUN
dpc-4194	488	5	profile	profile	NOUN
dpc-4194	488	6	identified	identify	VERB
dpc-4194	488	7	by	by	ADP
dpc-4194	488	8	long	long	ADJ
dpc-4194	488	9	-	-	PUNCT
dpc-4194	488	10	term	term	NOUN
dpc-4194	488	11	real	real	ADJ
dpc-4194	488	12	-	-	PUNCT
dpc-4194	488	13	life	life	NOUN
dpc-4194	488	14	observation	observation	NOUN
dpc-4194	488	15	-	-	PUNCT
dpc-4194	488	16	il	il	NOUN